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Abstract
ABSTRACT
Astrocytomas are the most common variety of primary tumours of the central nervous system 
(CNS). The incidence increases with age, peaking in patients aged 65 -  75 years. They are 
generally unresponsive to treatment, and most patients die within one year o f diagnosis. Recent 
genetic studies o f astrocytoma susceptibility syndromes, familial- and sporadic astrocytomas 
have led to the discovery o f many genes and molecular mechanisms underlying astrocytoma 
oncogenesis. A few of the genes involved in inherited astrocytoma associated-syndromes (e.g., 
Cowden and Li-Fraumeni syndromes) are also strongly implicated in sporadic astrocytomas. 
However for several other well characterised genes i.e. those mutated in Tuberous sclerosis (TSC) 
and Neurofibromatosis (NF) any evidence for involvement in sporadic astrocytomas is much less 
clear. The objective of this study was to undertake a genome-wide survey of high malignancy 
grade astrocytomas with a view to ascertaining the distribution and prevalence o f copy number 
aberrations, search for associations with prognosis and outcomes to treatment, and to discover 
possible novel pathways o f oncogenesis.
Thirty-two high malignancy grade astrocytomas were investigated. Twenty were available as 
frozen biopsies and 12 as short-term cell cultures. Genomic profiling o f all 32, comprising 6 
tumours of WHO Grade III and 26 o f Grade IV, was achieved by the method o f Comparative 
Genomic Hybridisation onto metaphase chromosomes. 7 of the tumours were investigated by 
array CGH, with one further investigated by MFISH. Two tumours did not reveal aberrations. 
For the other 30 tumours, data pooled from a minimum of 10 profiles o f each tumour were 
analysed.
Recurrent DNA copy number gains and losses were detected across the genome. In a number of
tumours aberrations spanned loci o f established candidate genes previously associated with
sporadic astrocytomas, on chromosomes 7, 9p, lOq, I2q, I3q and I7p. In addition over 70% of
‘sporadic’ tumours appeared to have DNA-copy number aberrations implicating genes with
established roles in astrocytoma-susceptibility syndromes. The chromosomal region 9q34 (site of
TSCl) appeared to be under-represented in 25% of the tumours, while I6pI3 (site of TSC2) was
diminished in -38% . Similarly, loci for NFI and NF2 were involved in aberrations in -10%  and
38% o f the cases respectively, as were those of PMS2 (22%), ARC (19%) and a number of miss-
1
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match repair (MMR) genes. Eight tumours had probable loss at lp36. Several novel locations 
were also suggested
An attempt to correlate DNA copy number alterations with survival showed that among patients 
with grade IV tumours, there were on average far fewer chromosome aberrations per tumour in 
four of the five patients surviving longer than one year after diagnosis than in those who died 
before this. There was some suggestion of a worse prognosis in Grade IV tumours with a specific 
deletion of lp36, which would agree with a previous report.
The only Grade IV tumour that was studied by all three approaches showed good agreement 
between array and metaphase CGH. In addition, array CGH revealed small regions of loss in the 
region of PTEN (CHR lOq) and TP53 (CHR I7p) below the resolution o f the metaphase CGH. 
The M-FISH revealed very large numbers o f chromosomes and several translocations, and 
comparison o f the microarray data and the MFISH data suggests possible candidate regions for 
breakpoints. The data are discussed in the light of previous work and with a view to the 
possibility that there may be some diversity in the cellular origin o f astrocytomas and that 
haploinsufficiency may play some role in oncogenesis
II
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CHAPTER 1 INTRODUCTION
Brain tumours comprise approximately 5% of all human cancers (ENCR, 2001) of 
which ~ 70% arise from glial cells and are known as gliomas (Kleihues & Cavenee, 
2000). Diffuse astrocytomas, which are the major subset of gliomas derived from 
astrocytes, account for about 93 - 95% of astrocytomas (Garcia & Fulling, 1985; 
Forsyth et al., 1993; Szymas et al., 2000; Lewis et al., 2005) while the remaining 5 -  
7% constitute a predominantly benign category known as pilocytic astrocytomas 
(Kleihues & Cavenee, 2000). Based on histological appearances diffuse astrocytomas 
are graded as low grade (LGAs) (WHO malignancy grade II) or high-grade (HGAs) 
(WHO grades III & IV). The HGAs have a very poor prognosis, with most patients 
dying within a year of diagnosis (Sant et al., 2003). However, the biological behaviours 
of these tumours vary greatly and the rationale behind this thesis is the idea that 
understanding the genetic factors altered in the tumours may allow a more accurate 
assessment of prognosis and more effective management options.
1-1 Glial cells and the relationship to astrocytomas
Typically two main types of mature terminally differentiated glial cells, 
oligodendrocytes and type-1 astrocytes (TlAs), are identified in vivo in the adult CNS. 
Developmentally, they are thought to arise from different precursor cell populations, 
which define separate glial lineages (Figure 1), with T lA s presumed as the sole end­
point o f differentiation along the TIA  lineage. On the other hand, oligodendrocytes 
arise from precursor cells called perinatal oligodendrocyte type-2 astrocyte (0-2A) 
progenitor cells. In vitro, the 0-2A  precursor cell is bipotential, maintaining the 
capacity to differentiate into either oligodendrocytes or type-2 astrocytes (T2As) (Raff 
et al., 1983). Type-2 astrocytes are thought not to occur in vivo under normal conditions 
(Lemsky, 1997); thus it is generally assumed that astrocytomas arise from type-1 
astrocytes or their progenitors. However, since some oligodendrogliomas progress to 
glioblastomas (Kocaeli et al., 2006) the implication would be that aberrations in 
oligodendrocytes could cause glioblastomas.
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Astrocytomas are variable with respect to their morphology, therefore either they may 
arise from a similar population of cells which happen to sustain different initiating 
abnormalities, or there are already many heterogeneous types of astrocytes (Mayer- 
Proschel et al 1997, Rao 1999), astrocyte progenitors (Tole et al., 2000; Foley et al., 
2000; Acampora et al., 2001; McCarthy et al., 2001; Martinez-Barbera et al., 2001; 
Hiroshi et al., 2002; Kiecker & Lumsden, 2004, 2005; Puelles et al., 2004, 2006; 
Shimogori & Grove, 2005; Takahasi & Liu, 2006; Emsley & Macklis, 2006; Nickerson 
et al., 2007), or stem cells (Sohur et al., 2006), which may account for some molecular 
differences in tumours (Shapiro & Shapiro, 1985; Bigner, 1981; Yung et al., 1982; 
Shapiro et al., 1991; Saxena et al., 1999; Camby et al., 2000; Nishizaki et al., 2000; 
Rich et al., 2005).
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Figure 1-1 is a schematic diagram of neural stem cells (NSC) and their progeny in the 
developing forebrain. [The schema is reproduced from Merkle & Alvcarez-Buylla, 
2006]. See explanation below. [Stri, striatum; VZ, ventricular zone]
1 he NSCs (shown in blue) lining the walls of the lateral ventricle change shape and 
produce different progeny as the brain develops. They begin as neuroepithelial cells and 
transform into radial glial cells, which mature into astrocyte-like cells. Typically, NSCs 
maintain contact with the ventricle into which they project a primary cilium. The 
potential of an individual stem cell in vivo is not known, however, the progeny shown 
in the schema are cell types that are generated by NSC. Stem cells produce progeny 
either directly or via an intermediate progenitor (some of which are shown here in 
green). Different types of progeny may be produced by different intermediate 
progenitors, although just one is shown here:
(a) At early developmental stages the CNS is a tubular structure. It is made up of 
neuroepithelial cells, which divide symmetrically at the ventricular surface to expand 
the stem cell pool. At this time, some early-born neurons such as Cajal-Retzius cells are 
produced.
(b) Neuroepithelial cells probably differentiate into embryonic radial glial cells, 
which divide to generate striatal neurons and oligodendrocytes either directly or via 
an intermediate progenitor in the subventricular zone (SVZ). The radial processes of 
radial glial cells support the migration of neuroblasts (shown in red).
(c) Radial glial cells persist in the neonatal brain, where they generate 
oligodendrocytes, olfactory bulb interneurons, and ependymal cells. They also 
generate astrocytes, some o f which remain stem cells in the adult.
(d) In the adult brain, neurogenic astrocytes often retain a radial process and contact 
both the ventricle and the basal lamina of blood vessels. They generate 
oligodendrocytes and olfactory bulb interneurons.
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F igure 1-2
Neural Stem Cell [NSC]
Neuroepithelial Precursor [NEP]
Glial Restricted Precursors 
[GRPs]
A2B5+
PDGFRA- 
CSPG4+
Neuron Restricted Precursors [NRPs]
Motorneuron -O ligodendrocyte Precursors 
[M NOPs]
0LIG2+
Ependymal Restricted Precursors 
[ERPs]
01 igodendr oeyte/ Astrocyte 
Restricted Precursors [0 2 A ]
A strocyte Restricted Precursors 
[ARPs)
A2B5+, PDGFRA+, CSPG4 [NG2]+ 
O ligodendroeytes [types]
Type 2 A strocytes
ARP [spinal] 
A 2B 5-, C D 44+
ARP [optic] 
A 2B 5+ , PA X 2 +
Type-1 A strocytes
1. ARP Cerebral: Probably subgroups exi st, based on anatom ical/functional networks 
For exam ple: Radial glia: NRG1+, ERBB2+, ERBB4+, BLBP+
W hite Matter Precursor C ells (W M PCs): A2B5-
2. ARP C erebellar Location
E.g., Bergmann glia: NRG1+, ERBB4+, ERBB2-, BLBP-
3. ARP o f  other brain parts: M id-brain, Pons, etc.. E.g., Polyadenocytes: CSPG4+,
PDGFRA+
Figure 1-2 is a schem atic representation o f  neural cell lineages: a m odel o f  established cells  
o f  origin o f  astrocytes and other known gli al cell types. [M odified from M ayer-Proscel et al. 
1997; Richardson et al., 1997; Rao et al., 1999; M erkle & A lvarez-B uylla , 2006].
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1-2 Cellular com position and locations o f  intracranial gliomas
Gliomas, of which astrocytomas and oligodendrogliomas are the most prevalent, 
develop from glial cells. It is not certain what proportion of the various glial tumours 
are histologically homogeneous, however, a glioma with more than one cell type is 
classified as mixed only if the most prevalent cell type is estimated to occur in <70% of 
the tumour (Cillekens et al., 2000). This definition raises interesting questions, 
particularly when viewed in light of the concept that it takes one aberrant cell, with the 
combination o f mutations that confer a selective growth advantage, to trigger the 
formation of a clone that could result in a malignancy (Hanahan & Weinstein, 2000).
Approximately 94% of gliomas arise in intracranial sites (Brain Tumor Working Group: 
National Coordinating Council for Cancer Surveillance, USA, 1998), and the majority 
present in the supratentorial compartment in adults and the infratentorial in children.
1 -3 Astrocytomas
1-3-1 Classification, Clinical features and genetic Characteristics o f
Astrocytic Gliom as
The WHO Classification puts astrocytic gliomas into 4 grades, I -IV , on the basis of 
histological appearances and biological behaviours (Kleihues & Cavenee, 2000; 
McCarthy et al., 2002). Grade 1 is composed of Pilocytic astrocytoma (ICD-0 code 
9421/1). They are predominantly benign, are well circumscribed and arise in familial 
/hereditary syndromes with astrocytoma association such as tuberous sclerosis and 
neurofibromatosis. Except for a small percentage, estimated as -1.5% , pilocytic 
astrocytomas are surgically curable.
Grade II -  IV astrocytomas are infiltrating and have therefore no defined border, which 
makes it impossible to cure them surgically. They invariably recur, with a tendency to 
progress to higher grades. Grade II astrocytomas (also known as diffuse astrocytomas) 
are of two recognised histological cell-types (Protoplasmic astrocytoma (ICD-0 code 
9410/3) and Fibrillary (Fibrous) astrocytomas (ICD-O code 9420/3). Grade III 
astrocytomas are also made up of two recognised histological cell-types: anaplastic 
astrocytomas (AA) (ICD-O code 9401/3) and Gemistocytic astrocytoma
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(Gemistocytoma) (ICD-O code 9411/3). Grade IV is known as Glioblastoma, and is 
made up of astrocytic tumours constituting three separate lCD -0 histological codes. 
The first of three ICD-O codes (9440/3) is made up by glioblastoma multiforme, 
spongioblastoma multiforme and glioblastoma NOS (not otherwise specified), the 
second ICD-O code (9441/3) is made up by giant cell glioblastoma and monstrocellular 
sarcoma) and the third (9442/3) by gliosarcoma and glioblastoma with sarcomatous 
component (McCarthy et al., 2002).
The prognosis for GBM is very poor. A EUROCARE study which looked at survival 
data from population-based registries of 18 European countries, altogether involving 
6,513 adults diagnosed with GBM between 1990-1994, (followed-up until 1999), found 
relative survival rates of approximately 25% at one year, 5% at three years, and 3% at 
five years (Sant et al., 2003). The five-year relative survival decreased markedly with 
age from 11% in the younger (15-45 years) group to 2% in the group aged 75 years and 
over.
In the UK, the annual incidence of glioma is generally reported to be around 4 - 6  per 
100,000 of the population (Brain Tumour Working Party, 2001). Thus, approximately 
2,400 -  3,600 people develop glioma each year and most die within a year of the 
diagnosis (Maher et al., 2001; Sant et al., 2003; Ohgaki & Kleihues, 2005).
1 -4 Long-term survivors
Long-term survival is currently defined as survival lasting 3 or more years from time of 
diagnosis (Scott et al., 1998; Burton et al., 2002). In spite of the overwhelmingly poor 
prognosis for high-grade gliomas, which is attributable mostly to astrocytomas, there 
are reports of GBM patients surviving for long periods. The Brain Tumour Study Party 
(2001) in a series of 467 patients found that 15-20% of the patients survived longer than 
18 months. This survival was similar to that found by Lieberman and coworkers in a 
1982 report of a study involving fifty-seven patients with malignant astrocytoma. 
Lieberman’s group found a two-year survival of 14% (8 out of 57). As already reported, 
a more recent and larger study by ENCR (Sant et al., 2003) reported relative survival 
for patients with glioblastomas at 3 and 5 years, of 5% and 3%, respectively.
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1 -5 Risk factors
An increase in the incidence of brain tumours has been established definitively in 
association with advancing age; exposure to high doses of ionizing radiation, and in 
association with astrocytoma susceptibility- or familial/hereditary syndromes. Several 
epidemiological studies in addition to confirming the role of established risk factors as 
mentioned above, recently pointed to an association of glioma/astrocytoma with 
perinatal and late onset infections with the simian viruses (SV40 virus; Carbone et al., 
2003), and high intake of proteins (Kaplan et al., 1997). SV40 is a known tumour virus 
however, the association with protein possibly implicated N-nitroso compounds, which 
are commonly associated with cured meats. The association with proteins is interesting 
since other studies such as that by Preston-Martin & Mark (1991), which have 
previously investigated the possible role of high intake of N-nitroso compounds in brain 
tumours were unable to find evidence specifically implicating N-nitroso compounds as 
risk factor for brain tumours.
1-5-1 Ethnic differences
The role of interethnic differences in the development of astrocytomas has yet to be 
ascertained. Interethnic genetic differences are believed not to play a significant part in 
brain tumours (Ohgaki & Kleihues, 2005; Miller et al., 2005), however some studies 
suggest that ethnic differences may indeed be important (Chen et al., 2001; Wang et al., 
2004; Wiencke et al., 2005; Jemal et al., 2005). In 2001, Chen et al., reported findings 
o f a population based study conducted in California, which investigated the prevalence 
and types o f alterations in the p53 pathway genes in brain tumours. The study suggested 
that brain cancer incidence rates varied with race and ethnicity as well as gender. For 
example, Chen and colleagues found that non-Hispanic whites had brain tumour 
incidence rates 60-100% higher than in blacks, 10-90% higher than in Hispanics, and 
40-45% higher than in Chinese, Japanese, or Filipino ethnicities. Within ethnic groups, 
rates were 7%, 39%, 66%, 71%, and 73 percent higher in men than women of Chinese, 
white non-Hispanic, black, Hispanic, and Filipino ethnicities, respectively.
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1-5-2 A ge
The incidence of brain tumours is highly correlated with age (Batchelor et al., 2004), 
there being, in general, an increase from around 2 per 100,000 for population group 
aged less than 20 years, to 20 per 100,000 for those aged 70 years (Surveillance, 
Epidemiology and End Results (SEER) in the U.S.A for the period 1975-1995 (Legler 
et al., 1999). These incidence rates are considered similar in most industrialised
countries. The peak incidence in childhood, around ages 5-14 years (Legler et al. 1999),
is followed by a marked increase after age 45, which reaches a high plateau around 65- 
75 years. Incidence is then reported to gradually decline to a sharp drop after the age of 
80 years (Shugg et al., 1994), although this claim is disputed (Kleihues & Cavenee, 
2000).
1-5-3 Gender
Regarding gender distribution, there is some uncertainty on the actual figures, however 
males are generally reported more affected than females. The prevalence is reported to 
vary from the lower figure of 6.4 per 100,000 population for males and 4.6 per 100,000 
population for females (Shugg et al., 1994) to as high as 13.55 per 100,000 population 
compared to 12.25 per 100,000 population for males and females respectively (Ohgaki 
& Kleihues, 2005).
1-5-4 Environmental factors
Among several environmental factors implicated in human cancer in general, radiation 
has been convincingly implicated in the aetiology of gliomas. Therapeutic and 
prophylactic irradiation o f the CNS of children with acute lymphocytic leukaemia 
(ALL) and pituitary adenomas is associated with increased risk of developing gliomas 
(Brat et al., 1999). Based on this established link with brain cancers, it is suggested that 
the age-related increase in brain tumour may arise out of accumulated toxicity or that it 
could be the consequence of prolonged latency (Lewis, 2005).
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1-5-4-1 Exposure to electromagnetic fields
There is currently much concern about the effects of mobile phones, high-frequency 
radio transmitters and probable consequences of living near high power electric cables. 
In particular, considerable interest has focused on whether the use of mobile phones is 
associated with an increased risk of gliomas and other brain tumours, even though little 
is known about potential mechanisms (Sienkiewicz & Kowalczuk, 2005). The Advisory 
Group on non-ionizing Radiation iwww.hpa.org.uk/radiation/T accessed in May 2007, 
suggest that the energy of the radiofrequency fields emitted by mobile phones is 
insufficient to cause malignant transformation through direct damage to DNA. Most 
published epidemiological studies on mobile phone use and gliomas have not generally 
reported any increased risk either overall, or with long term use (Muscat et al., 2000; 
Inskip et al., 2001; Lonn et al., 2005; Christensen et al., 2005). However, some isolated 
studies have found positive associations between high-grade astrocytoma (glioma) and 
phone use ipsilateral to the side of the tumour (Hardel et al., 2003), brain tumours and 
phone use in rural areas (Auvinen et al., 2002), and use of analogue mobile phones 
(Auvinen et al., 2003, Hardel et al., 2003). A large population based case-control study 
of 966 patients with glioma in the United Kingdom, part of the Interphone project 
started in 1999 (Cardis & Kilkenny), as part of an international collaboration of 13 
countries investigating mobile phone use and the risk of intracranial tumours, reported 
in 2006 that use of a mobile phone, either in the short or medium term, is not associated 
with an increased risk of glioma. The authors of the report further concluded that the 
complementary positive and negative risks associated with ipsilateral and contralateral 
use of the phone in relation to the side of the tumour might be due to recall bias 
(Hepworth et al., 2006).
1-5-5 Exposure to viral infections
Three recent epidemiological studies (Fear et al. 2001; Dickinson et al 2002; McNally 
et al., 2004) investigated the role o f prenatal and neonatal factors in the aetiology of 
CNS tumours in the UK. They all found an increased risk of brain and spinal tumours, 
notably astrocytomas and ependymomas among children exposed soon after birth to 
higher levels of community infections in particular measles and influenza.
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1-5-5-1 SV40
There are many reports of detection of the simian virus 40 (SV40) DNA, and proteins, 
in human malignancies including brain cancers (Kouhata et al., 2001; Engel et al., 
2005). SV40 is a known tumour virus and induces malignancies in laboratory animals 
(such as hamsters) that are identical to those in which its DNA is associated in humans 
(Butel & Lednicky, 2000). Known exposure to the SV40 virus has recently been linked 
to cancer development in a laboratory researcher who had a probable direct exposure, 
and subsequently developed a tumour positive for viral DNA sequences 
indistinguishable from those of the laboratory source (Arrington et al, 2003). This 
evidence strongly suggests a causal link between exposure to SV40 and development of 
brain tumours in humans
1-5-5-2 HCMV
HCMV is a beta-herpes virus that persistently infects 50-90% of the adult human 
population (Fish et al., 1996). It is trophic for glial cells (Fritschy et al. 1996) and is 
reportedly re-activated by inflammatory (Fritschy et al., 1996) and immunosuppressive 
(Lokensgard et al., 2002; Andre, 2005) conditions in the host. Its gene products can 
deregulate cellular pathways involved in regulating the cell cycle (Salvant et al. 1998; 
McElroy et al., 2000), apoptosis (Murphy et al., 2000), angiogenesis (Cinatl et al. 1999; 
Hoever et al., 2005), cues for cellular invasion (Scholz et al. 1999), and host immune 
response (Ross et al., 1987; Cinatl et al., 2005). Thus, it is probable that HCMV is 
directly implicated in the pathogenesis of several human malignancies (Shen et al. 
1997), including glioma (Cobbs et al. 2002).
1-5-6 Probable aetiologic role o f  dietary/nutritional factors
N-nitroso compounds are implicated in carcinogenesis of the urogenital systems, and it 
appears that they may be involved in cancers of several other organs/systems (Okazaki 
et al., 2003). However, N-nitroso compounds and their precursors, nitrites and nitrates, 
have only been hypothesized as risk factors in brain tumours. Established inhibitors of 
N-nitroso compounds (e.g., vitamins C and E) are known anti cancer agents (Bunin et 
al., 1994). Several epidemiological studies have reported an association between
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consumption of cured meats (a known source of N-nitroso compounds like 
nitrosamines) and cancers of the CNS in children (Dietrich et ah, 2005; Kaplan et al., 
199TX
1-5-7 Exposure to chemical carcinogens
Epidemiological studies have associated certain occupations with increased risks of 
brain tumour. In particular, risk has been associated with occupations involving 
exposure to formaldehyde (Krishnan & Levy, 1994; Andersen, 2003), rubber and 
plastics- (polyvinyl chlorides (PVCs), or polyaromatic hydrocarbons (PAHs) industries 
(Zheng et al., 2001). Other studies have reported increased risk among employees in 
heavy metal industries such as those with exposure to mercury, arsenic and lead (Navas- 
Acien et al., 2002). However, it appears that most of these studies have not been 
confirmed by independent studies in other populations, and no environmental 
carcinogen has been identified that could be unequivocally linked to brain tumour 
development in adults (Ohgaki & Kleihues, 2005). However, an international 
population-based case-control study conducted in 7 countries found an increased risk of 
glioma and other brain tumours in children born to parents employed in agricultural and 
textile industries (Cordier et al., 2001). Large population-based case-control studies 
have been carried out in seven countries as part of the lARC SEARCH program. 
Several of these studies suggest that parental occupation may influence the development 
o f pediatric gliomas. http://monographs.iarc.fr/monoeval/crthall.htmlL The I ARC 
monograph identifies 66 chemicals classified as carcinogenic to humans, 66 in Group 
2A, that are categorized as probably carcinogenic, and 240 in Group 2B which are 
considered possibly carcinogenic to humans. In particular, the I ARC monogram has 
identified exposure to nine chemicals with ‘possible’ or ‘weak associations’ with CNS 
tumours in humans. These are beryllium, epichlorohydrin, chlordane/heptachlor, 
methylthiouracil, thiouracil, propylthiouracil, lead, diisopropyl sulfate, and 
dichloromethane. The I ARC monograph also contains various other chemicals that 
apparently increased the incidence of brain tumours (including gliomas) in experimental 
animals without concomitant evidence in humans. These included aflatoxin B l, diethyl 
sulfate, acrylamide, ethylnitrosourea, methylnitrosourea, procarbazine hydrochloride.
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methyl methanesulfonate, dimethyl sulfate, glycidol, dacarbazine, 1,3-propane sulfone, 
and acrylonitrile.
l -5-7-1 Exposure to tobacco smoke
Long-term exposure to tobacco smoke is known to play a significant role in the 
aetiology of many solid tumours although an association with gliomas has not been 
demonstrated previously (Zheng et al. 2001; Peters et al. 2001). A recent clinical study 
o f Efird et al., (2004), which investigated the association of tobacco smoking and other 
lifestyle behaviours and malignant primary adult-onset glioma (MPAG), reported 
increased risk among female smokers but not males. This study is significant in light of 
its unique design: it recruited a cohort of 133,811 adults aged at least 25 years, with no 
prior history of benign or malignant brain tumours, who were enrolled at the Medical 
Care Program of Northern California between 1977 and 1985. The average follow-up to 
the development of glioma was 21 years.
1-5-8 Genetic aetiology o f  cancer
Based on evidence gathered from observations going back over two centuries cancer 
was, until 2-3 decades back, viewed largely as an environmental problem. The 
observation by Percival Pott in the 19**^ century (Hall, 1998) that soot was a risk factor 
for scrotal cancer among chimney sweeps, and of a high incidence o f cancers in 
populations of immigrants (Kolonel et al., 2004; Marchand & Kolonel, 1992), partly 
contributed to this view. Immigrants, for example, were observed to manifest altered 
risk of developing cancer when compared with the indigenous ethnic population. 
Advances in genetics in the past 15-25 years have provided supplementary evidence, 
which ultimately implicates molecular and genetic factors in causation of malignancies. 
At the cytogenetic and molecular levels, it is now accepted that a cancerous cell is likely 
to have sustained multiple genetic aberrations (Hanahan & Weinberg, 2000). These may 
involve copy-number or structural changes, and that other genes may be differentially 
expressed (Pillai et al., 2004). Altered genetic expression is usually the result of 
aberrations such as point mutations, translocations, genomic deletions, insertions and / 
or epigenetic modifications (Hulsebos et al., 2004). These aberrations vary between
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tumour types, within the same type of tumour and grade in different people, and in 
different tumour grades in the same patient. Significantly, it is also known that there are 
intratumoural phenotypic differences, which are reflected in the histological 
appearances and malignancy grades in the same patient (Paulus & Peiffer, 1989; Coons 
& Johnson, 1993; Coons et al., 1997).
1-6 Initiation o f  the cancer process
Cancers arise from a complex multi-step process, resulting from accumulation of 
genetic aberrations, which confer a susceptible cell with properties that enable it to 
escape normal growth regulatory mechanisms. Once unregulated growth has been 
initiated, successive advantageous mutations then accumulate and promote clonal 
expansion of a malignant cell. Accumulation of mutations is vital for the acquisition of 
a genotype that allows the expression o f characteristics typical of malignancy such as 
invasion of adjacent tissue, breaching the limiting membranes to cause métastasés, and 
induction of malignant angiogenesis (Hanahan & Weinberg, 2000). Typically, it is 
estimated that the duration it takes from the time a cell sustains initial genetic damage to 
the appearance of manifest malignancy can be as long as several decades (Boehm & 
Hahn, 2005). Underlining the complexity of acquiring a malignant phenotype are 
thought to be essentially six transformations, 1) Self-sufficiency in growth signals, 2) 
Insensitivity to antigrowth signals, 3) Evading of apoptosis, 4) Unlimited replicative 
potential, 5) Sustained angiogenesis, and 6) Tissue invasion and metastasis (Hanahan & 
Weinberg, 2000; Gatenby & Vincent, 2002; Cristini et al., 2005). These genomic 
changes affect oncogenes, TSGs and DNA repair genes (Dunlop et al., 1997). Activated 
oncogenes are capable o f inducing and maintaining neoplastic cell proliferation and 
tissue growth (Collins, 1995), whereas TSGs are negative regulators of growth 
(Knudson, 2001; Iwasa et al., 2005). DNA repair genes (Bartek & Lukas, 2007) 
maintain the integrity of the genome; following inactivation, there is increased genetic 
instability (Duesberg et al., 1998; Bartek & Lukas, 2007), which promotes tumour 
formation and growth (Yarosh et al., 2005).
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1-6-1 Genetic aberrations: Tumour suppressor genes and O ncogenes
Although cancer genes are broadly classified as either TSGs or as oncogenes, by virtue 
of their specific roles/functions TSGs can be considered as concerned either with 1) 
maintaining the integrity of the genome, which includes control of entry into the cell 
cycle, 2) DNA repair, 3) mediating apoptosis, and 4) interaction/communication with 
the surrounding stromal tissues. TSGs are therefore further subdivided into roughly 
three categories, respectively, gatekeepers, caretakers, and landscapers (Kinzler & 
Vogelstein, 1998). Oncogenes, on the other hand, essentially promote growth as well as 
inhibiting differentiation and apoptosis. Uncontrolled expression of oncogenes and 
downregulation (or the complete inactivation) of TSGs leads to uncontrolled cell 
multiplication. In almost all cancers, abnormalities occur simultaneously in regulation 
of genes belonging to both classes.
1-6-2 M echanisms o f  inactivation o f  tumour suppressor genes (TSGs).
TSGs are defined as the genes inactivated in conformity to Knudson's ‘2-hif model; 
that is, both alleles of a gene are inactivated by genetic alterations such as chromosomal 
deletion and loss-of-function mutations. Typically, mutation or deletion is recessive at 
the cellular level since both alleles generally need to be inactivated to cause a 
tumourigenic effect (Knudson, 1971). In solid tumours such as astrocytomas, the first 
hit typically involves a small alteration while the second characteristically involves loss 
of large chromosome segments incorporating loci of many adjacent genes. Fully 
developed tumours may contain a heterogeneous collection of cells with so many 
chromosomal changes that it is difficult to extract clean patterns of loss specific to one 
small chromosome region using conventional LOH analysis. Because of this fact, the 
search for candidate TSGs using the traditional method of LOH analyses has quite often 
yielded disappointing results (Strachan & Read, 2007) considering that it involves 
looking at large areas of chromosomal changes, which could contain other probable 
candidate genes.
Once a candidate TSG has been identified, for example by LOH analyses or array CGH, 
further studies would follow to establish the expression profiles and functional 
relationship of the gene of interest. Gene expression studies, involving targeted
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inactivation/deletion of candidate TSG might demonstrate that loss of function allows 
tumours to grow.
Figure l-3a & b
Fig. 1-3 (a) (above) illustrates mechanisms o f loss o f wild-type allele in TSGs - Taking 
the example o f  retinoblastoma. (A) Loss o f a whole chromosome by mitotic 
nondisjunction. (B) Loss followed by reduplication to give (in this case) three copies o f  
the Rb chromosome. (C) Mitotic recombination proximal to the Rb locus (Ci), followed 
by segregation o f  both Rb-bearing chromosomes into one daughter cell (C2). (D) 
Deletion o f the wild-type allele. (E) Pathogenic point mutation o f the wild-type allele. 
Red mark on chromosomes represented the RBI locus on human CHR 13q.
(b) Shows results o f  typing normal (N) and tumour (T) DNA for the two markers A and 
B located as shown. (The figure is taken from Strachan & Read; Eds. Human Molecular 
Genetics 3, Chapter 17: Cancer genetics, pg. 495).
Cytogenetic Analysis o f DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
15
Introduction
1-6-3 D N A  méthylation in astrocytoma
More recently it has become clear that methylation-related ‘gene silencing’ of the 
promoter region of many genes, or even silencing of vital transactivation domains away 
from gene promoter regions, acts as an alternative mechanism for aberrant TSG gene 
expression in solid tumours including astrocytomas (Uhlmann et ah, 2003). Promoter 
hypermethylation and chromatin-structural-changes e.g., histone tail modifications 
(such as deactivation), cause transcriptional silence, and are important contributors to 
tumourigenesis (Costello et ah, 2000; Nakamura et ah, 2001; Jones & Baylin, 2002). 
DNA méthylation is mediated by a family of DNA-methyltransferases including 
DNMTl, DNMT3A, and DNMT3B, which regulate a potent, heritable gene silencing 
system that is critical for normal embryonic development. This system is thought to be 
deregulated in nearly all tumor cells (Jones & Baylin, 2002). DNA méthylation changes 
are thought to occur earlier and more frequently than individual genetic changes 
(Belinsky, 2004). Studies on the role o f epigenetic silencing in glioma have been carried 
out using either a candidate gene approach and/or by a genome-wide screening method. 
For example, the former revealed that genes, such as TIMP3 (Lindsey et ah, 2004; 
Martinez et ah, 2007), whose gene product inhibits the activity of matrix 
metalloproteinases, and epithelial membrane protein (EMP3), a myelin-related gene 
believed to be involved in cell proliferation and cell-cell interactions, and are located 
within the commonly deleted 19ql3.3 region, are frequently targeted for DNA 
methylation-mediated silencing in glioma (Alaminos et ah, 2005). A genome-wide 
screen for aberrant DNA méthylation events in glioma using restriction landmark 
genomic scanning revealed that 1,500 CpG islands may be subject to aberrant 
hypermethylation in low-grade gliomas, suggesting that epigenetic alterations are 
widespread and likely contribute significantly to gliomagenesis (Costello et ah, 2000).
Epigenetic silencing of the MGMT gene, which is involved in the repair of DNA 
damage due to alkylation of the 0 6  position of guanine, is also frequent in glioma 
(Esteller, 1999). Silencing of MGMT by DNA méthylation is associated with longer 
survival of newly diagnosed glioblastoma patients and is also an indicator of increased 
survival in patients treated with radiation plus the alkylating agent temozolomide (Hegi 
et ah, 2005). However, the impact of MGMT méthylation is much less clear and
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controversial in the other treatment modalities including radiotherapy (RT) plus 
nitrosourea-based adjuvant chemotherapy, RT alone, and chemotherapy alone (Silber et 
al., 1999; Esteller et al., 2000; Paz et al., 2004). It is also not clear whether MGMT is by 
itself a prognostic factor or only a predictor of response to treatment. It has been 
suggested that in untreated low-grade gliomas MGMT was associated with shortened 
progression free survival (PFS) (Komine et al., 2003), and is due to a higher rate of GC 
to AT transitions targeting critical genes such as p53 (Watanabe et al., 2003, 2005), as 
the 06-alkylguanine may preferentially misrepair with thymidine rather than cytosine 
during DNA replication.
1-6-4 M echanisms o f  oncogene activation
Unlike the classic TSGs, oncogenes require only one allele to be abnormal in order to
exert their tumourigenic effect; thus they act in a dominant fashion (Hemminki & Li,
2004). Typically, oncogene activation occurs in one of 4 ways. 1) Generation of
multiple gene copies (called amplification) (Kuttler & Mai, 2006) - sometimes in the
form of small extra chromosomes, sometimes as duplications within a chromosome -
often leading to overexpression. 2) A mutation may occur that alters the function of the
protein encoded by the gene (Nenutil et al., 2005). For example, the three human RAS
genes (KRAS, HRAS, NRAS) encode small GTPases, which activate an intracellular
signaling cascade (RAS->RAF->MEK->MAPK) that leads to changes in gene
expression. Gain o f function mutations produce a hyperactive version of the GTPase
that triggers excessive expression of the target genes. 3) A Chromosome rearrangement,
usually a translocation (Truong & Ben-David, 2000), can up-regulate expression of an
oncogene by moving it into a transcriptionally highly active region of chromatin where
it comes under the influence o f a strong regulatory promoter (Brake et al., 1998; 2002),
leading to an inappropriately increased expression. A classic case is Burkitfs
lymphoma in which the balanced reciprocal translocation - t(8;14)(q24;q32) -  moves
the MYC oncogene from CHR 8 to the neigbourhood of the IGH (immunoglobulin
heavy) chain gene on CHR 14 and leading to overexpression of MYC by the
cells/tissues (in the case of Burkitt’s lymphoma, lymphocytes) with the translocation. 4)
Finally, chromosome rearrangements can bring together exons of two distant genes to
make a chimeric gene (Qian et al., 2005) usually resulting from a chromosome
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translocation (Chernova et al., 2001), for example the BCR-ABL in CML, though it can 
sometimes follow an inversion or a deletion (Chernova et al., 2001).
1-7 Astrocytoma susceptibility [familial/hereditary] syndromes 
A number of glioma/astrocytoma susceptibility syndromes have been described and are 
estimated to account for approximately 5-7% of sporadic astrocytomas (Acqui et al., 
1989; Kleihues & Cavenee, 2000). The genes that are implicated in familial syndromes 
are 1) those for neurofibromatosis -  NFl (17qll.2), NF2 (22ql2.2) (Evans et al., 2000; 
Gutmann DH, 2001). 2) Tuberous sclerosis -  TSCl (9q34), TSC2 (16pl3.3) (Boesel et 
al., 1979; Arbiser et al., 2002). 3) Melanoma/ astrocytoma syndrome
(CDKN2AandCDKN2B; 9p21) (Kaufman et al. 1993; Randerson-Moor et al. 2001). 4) 
Nevoid basal cell syndrome (NBCCS) (or Gorlin syndrome - PTCH; 9q22.3) (Evans et 
al., 1991). 5) Hereditary nonpolyposis colorectal cancer type 1 (HNPCCl) MSH2; 
2p22-p21)) (Okamoto et al., 2004; Vasen et al., 1996). 6) Hereditary nonpolyposis 
colorectal cancer type 2 (FTNPCC2; 3p21.3) (Buerstedde et al., 1995). 7) Cowden 
syndrome, (PTEN; 10q23.3) (Zhang et al., 2000). 8) Turcot’s syndrome, or familial 
adenomatosis polyposis coli/glioma syndrome, (APC; 7q21) (Yong et al., 1995; 
Hamilton et al., 1995), and 9) Li-Fraumeni syndrome (TP53; 17pl3) (Tachibana et al., 
2000; Rieske et al., 2005). However familial clustering of gliomas has been observed in 
the absence of these tumour syndromes (Paunu et al. 2002). Apart from these 
established astrocytoma susceptibility syndromes, many instances of astrocytoma have 
been noted in association with other cancer susceptibility-syndromes, e.g., Fanconi 
anaemia and breast cancer (Offlt et al., 2003), Wilms tumour (Rainov et al., 1995; 
McNally et al., 2005) or other hereditary-disease syndromes, for example, ataxia- 
telangiectasia (Miyagi et al., 1995; Liang et al., 1995).
1-7-1 Germline mutations in astrocytoma susceptibility syndromes 
It has been observed that quite often genes that are responsible for familial cancer 
syndromes are also altered in corresponding sporadic tumours (Lau et al., 2000; Paunu 
et al., 2001). In some cases knowledge of germline alterations characterised in familial 
cancers has aided the identification of somatic alterations in sporadic tumours and vice
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versa (Kamb et al., 1994; Marsh et al., 1998; Paunu et al., 2001). Several alterations 
thought to be of critical significance for the development of sporadic gliomas have been 
identified including alterations of TP53, PTEN, CDKN2A and CDKN2B, and CDK4. 
In addition, the functional relevance of some of the implicated genes has been 
elucidated, and provides insights of pathogenesis of some tumours. For example, the 
TP53, CDKN2A and CDKN2B, and CDK4 genes are now known to serve as critical 
cell cycle regulators (Gemma et al., 1996; Fang et al., 2006). PTEN is a dual lipid and 
protein phosphatase associated with cell growth and migration (Kamb, 1995; Furnari et 
al., 1998). Thus, although this study is principally on sporadic high malignancy grade 
astrocytomas, it is relevant to provide a brief review of germline alterations that have 
been observed in some of the most common syndromes associated with susceptibility to 
astrocytomas.
1 -7-1 -1 M elanoma astrocytoma syndrome
The melanoma-astrocytoma syndrome is characterised by a dual predisposition to 
melanoma and tumours of the nervous system, in particular astrocytomas (Randerson- 
Moor et al., 2001). Germline deletions around 9p21 which involve the CDKN2A exon 
1(3, thought to implicate the coding region for the P I6 and P14ARF (alternative reading 
frame) genes (Stone et Al., 1995), have been reported in patients of 
melanoma/astrocytoma and their relatives (Kamb et al., 1994). These mutations alter the 
protein coded by the genes. Mutational analyses of the CDKN2A gene in small groups 
of healthy individuals in several countries have detected the prevalence of variants in 
frequencies ranging from 6-48% among the French (Soufir et al., 1998), USA 
(Fitzgerald et al., 1996), Australian (Walker et al., 1995), Dutch (Gruis et al., 1995), 
Italian (Ghiorzo et al., 1996), Swedish (Platz et al., 1997), British (Harland et al., 2000) 
and Polish (Lamperska et al., 2002; Debniak et al., 2004; and Debniak et al., 2005) 
populations. Since only a limited number of individuals have so far been analysed, the 
overall frequencies of the CDKN2A variants are not known. However there are 
currently 77 CDKN2A variants listed in the International Melanoma Mutation 
Database: https://biodesktop.uvm.edu/perl/pI 6. All 77 result in altered protein products 
and may account for rare familial forms of melanoma, thus are believed to be causative. 
Two common polymorphisms in the 3-prime untranslated region (3’ UTR) of CDKN2A
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involving transition (mutation) of nucleotide (Nt) 500 from c to g (Nt500c>g), and 
Nt540c>t, are implicated in modulating the risk. The former is rarely associated with 
simultaneous mutations in other pathway genes such as CDKN2B, CDKN2C, CDK4 
and P53 (Kumar et al., 2001). The latter is thought to modulate disease progression 
(Straume et al., 2002) because it has been observed to be frequently hypermethylated in 
melanomas of lower malignancy. The Polish studies found another common variant in 
which there is an alanine to threonine substitution at codon 148 (A148T), and is 
estimated to be present in approximately 3% to 3.5% of their population. It occurs more 
commonly in relatives of melanoma patients compared to the general population (3% vs 
1.8%; Aitken et al., 1999). However, large germline deletions at the CDKN2A and 
CDKN2B (P16INK4A) tumour suppressor region involving the p i6, p i 5, and p i4 
genes have been found in some families featuring both gliomas and cutaneous 
melanomas (Petronzelli et al., 2001; Debniak et al., 2004). It has not been established 
which, if any, of the above variants are associated with this predisposition.
1-7-1-2 PTEN hamartoma tumour syndromes
The PTEN hamartoma tumour syndrome, also known as Cowden syndrome, is a wide 
spectrum of disorders arising from germline mutations of PTEN of which familial 
glioblastomas is one possibility. Many malignant and benign lesions make up the 
syndrome: allelic variants constitute separate though related syndromes such as 
macrocephaly, lipomatosis, haemangiomatosis, and pigmented macules of the glans 
penis seen in the variant syndrome called Bannayan-Riley-Ruvalcaba (Marsh et al.,
1999). Mucocutaneous lymphangiomatosis is the main feature of the variant known as 
Proteus syndrome (Biesecker et al., 1998), while dysplastic gangliocytoma of the 
cerebellum characterizes the Proteus-like and Lhermitte-Duclos disease (Zhou et al.,
2000).
It has been suggested by Nelen and co-workers (1999) that the incidence of PTEN 
mutations, currently estimated to be 1 in 200,000, is at best a ‘conservative’ estimate. 
This view is based on the observation that penetrance is variable and age-related. Many 
others share this view, for example, Starink et al., (1986), Ohgaki et al., (2004). Thus,
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for example, as a result of variable penetrance, in the study of Starink et al., (1999) most 
patients with PTEN hamartoma syndrome who developed breast cancers did so at 
around 38-46 years. However, with regards to brain tumours the lifetime risk for 
patients developing them in Cowdens syndrome is not known. Germline PTEN 
deletions and promoter mutations for Cowden syndrome and Bannayan-Riley- 
Ruvalcaba syndrome are estimated at 85-90% and 65%, respectively (Pilarski et al.,
2004). Promoter mutations have only been noted in Cowden syndrome, while large 
deletions are observed only in Bannayan-Riley-Ruvalcaba syndrome and in patients 
with overlapping Cowden- and Bannayan-Riley-Ruvalcaba syndromes, but not Cowden 
syndrome (Zhou et al., 2003). Germline PTEN mutations are considered to be aetiologic 
for classic Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, but have been 
found to be responsible for an increasing spectrum of clinical disorders as well as 
accounting for the majority of patients with adult onset Lhermitte-Duclos disease. It 
seems that glioblastomas have been observed in association only with the latter variant 
of the PTEN hamartoma syndromes (Kwon et al., 2001 & 2003). This is if interest, 
since Lhermitte-Duclos disease is noted to frequently manifest with atypical features, 
i.e., without signs typical of Cowden syndrome (Delatycki et al., 2003).
1-7-1-3 Li Fraumeni syndrome
Li-Fraumeni syndrome is an autosomal dominant disorder arising from germline 
mutations of TP53 and is characterized by multiple early-onset primary malignant 
tumours in childhood. These include brain tumours, sarcomas, adrenal carcinomas and 
leukaemia. However, in adults, cancers of the breast, soft tissue sarcomas, brain, bone, 
adrenal, leukaemia/lymphoma, stomach, colorectal, ovary, skin and cancers of many 
other sites are among the most frequent encountered (Olivier et al., 2003). The 
transcription factor P53 exerts its tumour suppressor function by activating target genes 
in response to stress signals such as those relayed following DNA damage, triggering 
the initiation of downstream effects like DNA repair, cell-cycle arrest, and / or 
apoptosis (Vogelstein et al., 2000). The p53 protein, composed of 393-amino acid (393- 
aa), has an amino-terminal transactivation domain, a core domain of approximately 200 
amino acids (amino acids 96-292) that recognizes P53 DNA-binding sites (DBSs), and 
a carboxyl-terminal (C-terminal) tetramerisation domain. It is estimated that up to half
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of all human cancers carry P53 gene mutations, o f which many have been documented 
in large international databases (Beroud & Soussi, 2003). The International Agency for 
Research on Cancer (lARC) TP53 Mutation Database, www.iarc.fr/p53, for example, 
contains 264 rnutations described in 261 families and 19,809 somatic p53 mutations 
(lARC web, accessed in June 2005) of which approximately 71% result in full-length 
protein with only one amino acid substitution within the p53 core domain (Olivier et al., 
2003). In addition, p53 mutations are frequently found in solid tumours including 
astrocytomas, that are resistant to conventional therapies (Beroud & Soussi, 2003). 
Interestingly, 8 amino acid changes and 50 amino acid changes, respectively, account 
for 30% and 55% of all core domain mutants with a single amino acid change (Olivier 
et al., 2002).
I-7-1-4 Tuberous sclerosis
Tuberous sclerosis is characterized by development of tumour-like growths, called 
hamartomas in the skin and several other organs especially the brain and kidneys. It is 
associated with mental retardation and epilepsy. Hamartomata in the CNS are 
differentiated benign growths forming localised regions of disorganised cortical 
architecture comprising abnormally shaped neuronal cell body, dendrite processes, and 
spine density. Among CNS manifestations brain tumours, in particular subependymal 
giant cell astrocytomas (SEGA) and seizures (which occur in 80-90% of affected 
individuals) are a major cause of morbidity (Parry et al., 2000). Astrocytomas have also 
been described in association with TSC (Parry et al., 2000; Kwiatkowski et al., 2003). 
Germline mutations of two TSC genes, TSCI at 9q34 encoding a 130kDa protein 
named hamartin (The TSCI Consortium, 1997), and TSC2 (16pl3.3) encoding tuberin, 
which is a 200kDa protein (The European Chromosome 16 Tuberous Sclerosis 
Consortium, 1993), are transmitted in an autosomal dominant fashion. The prevalence is 
estimated to be 1 in 6,000-10,000 individuals, of which approximately two-thirds are 
sporadic. Among familial cases, linkage analysis suggests that about half of large 
families are linked to TSCI and half to TSC2, while sporadic cases are more commonly 
associated with mutations involving the TSC2 gene (Kwiatkowski et al., 2003). The 
range of mutations, which have been described for TSC2 is wide and heterogeneous and 
includes large deletions/rearrangements as well as insertions, deletions, nonsense,
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splicing and missense mutations. On the other hand, the vast majority of TSCI 
mutations are small missense or deletions, nonsense or splicing mutations 
(Kwiatkowski et ah, 2003).
In renal lesions the TSCI and TSC2 genes act as tumour suppressors and show LOH in 
lesions, which appear to be monoclonal in origin (Murthy et ah, 2000). In brain lesions, 
it is not quite so clear -  there are publications, which suggest that haploinsufficiency 
may be the underlying mechanism in some brain lesions (Goorden et ah, 2007; 
Wienecke et ah, 2002). Studies of CNS abnormalities and tumour predisposition in the 
Eker rat, a naturally occurring rat model with known TSC2 mutations (Yeung et ah, 
1994; Kobayashi et ah, 1995; Yeung RS, 2004), and studies of astrocyte-specific TSCI 
and TSC2 knockout models (Uhlmann et ah, 2002; Potter et ah, 2001) have revealed 
some ways in which TSCI and TSC2 genes might contribute to events in 
early/embryonic development (Yeung et ah, 1994). The TSC genes exert influence on 
the GO/Gl -  S transition (Soucek et ah, 1997; Uhlmann et ah, 2002) by regulating 
levels of the CDK inhibitor (CKl) p27 (Uhlmann et ah, 2002; Khare et ah, 2003). 
Deficient levels of TSC genes cause increase in cell cycle progression with 
corresponding increase in cell proliferation (Catania et ah, 2001). In addition, the TSC 
genes appear to regulate cell size (Cooper, 2004). This function is typically attributed to 
genes involved in the insulin-signalling pathway such as insulin growth factor (IGF) 
molecules and their receptors P13K, PKDl, AKT and TOR, and is normally regulated 
by PTEN (Potter et ah, 2001; Gao & Pan, 2001). The mechanism by which TSCs are 
able to control the growth of cells has recently been linked to regulation of the 
molecular pathways involving mammalian target of rapamycin (mTOR), which is 
negatively regulated (inhibited) by the TSC1/TSC2 complex, acting via a downstream 
inducible GTPase target o f TSC2 that is known as Rheb (Tee et ah, 2003; Smith et ah,
2005).
1-8 M odel for the molecular/genetic basis o f  astrocytomas 
Diffuse astrocytomas infiltrate throughout the brain making complete surgical removal 
virtually impossible (Frank et ah, 1988; Guyotat et ah, 2000) and, in addition, they are 
almost invariably resistant to radiation and chemotherapy (Lefrank & Kiss, 2005, 2006;
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Jagannathan et al., 2006). It is apparent from clinical characteristics of grade IV 
astrocytomas that gliomas are heterogeneous. Grade IV astrocytomas are divided into 
primary and secondary GBMs: the former arising de novo whereas secondary GBMs 
develop progressively from a low-grade astrocytoma (Kleihues & Cavenee, 2000; 
Maher et al., 2001; Holland, 2001). Cytogenetic studies of lesions followed up by 
molecular studies have suggested developmental pathways of gliomagenesis. Genetic 
studies, particularly of secondary GBMs, indicate that there are distinct genetic 
pathways involved in initiation and progression of astrocytic neoplasms
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Fig 1-4: Model of genetic pathways to primary and secondary glioblastomas (adapted from von Deimling et al., 1997; Reifenberger et al., 
1997; Hong-Xuang et al., 1998; Ohgaki et al., 2004; Ohgaki, 2005; Meyer-Pulitz et al., 1997; Martinez et al., 2(X)7
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Explanation o f  figure 1-4:
LOH lOq and 22q is frequent in both primary and secondary glioblastomas, but 
commonly deleted regions vary between the two subtypes. *, Genetic alterations that 
are significantly different in frequency between primary and secondary glioblastomas.
Continuation of text...
Molecular genetics investigations have highlighted common events that are involved in
some astrocytic tumours. Based on these, von Deimling, Louis & Wiester (von
Deimling et al., 1995), proposed a model for the pathogenesis of human gliomas, which
involves 3 distinct pathways. The first, which leads to pilocytic astrocytomas (WHO
grade I), is caused by loss of heterozygosity for chromosome 17q and is presumed to
result from mutations of NFl (neurofibromin). The second pathway is thought to start
with LOH at 17p, involving mutations in the p53 gene, and leads to astrocytoma (WHO
grade II). Further LOH at 9p and 13q, which are believed to unmask mutations in
CDKN2A/pl6 or CDKN2B/pl5 (at 9p) and RBI (13q), respectively, provide further
steps along this second pathway - leading to grade III astrocytomas. The final step on
this pathway is LOH on chromosome lOq, which is thought to involve the loss of
PTEN/MMAC1, culminating in GBM type 1. Other chromosomes, notably 14q and 19q
(Hu et al 2002), 6q, 22q (Tsuzuki et al 1996, Ino et al 1999, Miyakawa et al 2000), have
been observed to be fairly frequently deleted along this pathway, and may harbour
TSGs that contribute to this or alternative pathways. A third pathway, which leads to de
novo GBMs (GBM type 2; WHO grade IV) is considered to begin with LOH at
chromosomes 10 and 9p, which is followed by gene amplification of EGFR (7pl2),
CDK4 (12ql4), MDM2 (12ql4.3-ql5) (Karlbom et al 1993, Reifenberger et al. 1993,
Ueki et al 1996), and sarcoma amplified sequence (SAS; 12ql3.3) (Hu et al 2002).
These pathways are not representative of alterations in all astrocytic tumours. The study
by Hu and colleagues, which involved genome-wide allelic analysis of 17 fibrillary
astrocytomas and 21 primary GBMs, found common genetic changes that may be
shared by primary GBMs and low malignancy grade astrocytomas. This is significant
considering that these two types of tumours are believed to evolve along different
genetic pathways. Complete loss of chromosome 10 is observed in some patients with
GBM and it is generally accepted that PTEN / MMAC, which is mapped at lGq23.3 is
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critical in transformation of AAs to GBMs (Kotelevets et a!., 2001; Hu et al., 2002; 
Leuraud et al., 2003a). Partial losses involving at least 2 additional common regions of 
deletion (CRDs) on chromosome 10 are frequently observed at 10pl4-pl5.1 and lOq 
25.1-qter (Hu et al 2002). As yet it is not clear what genes, in these locations, are 
implicated or if they have critical roles in transforming astrocytes. However Nishimoto 
et al. (2001) mapped a repressor of telomerase expression to a 2.7-cM region on 
10pl5.1. This candidate gene is a tumour suppressor and was found inactivated in high- 
grade gliomas (Leuraud et al. 2003b).
1-8-1-1 Progression pathways o f  astrocytoma development 
Genetic pathways that are specifically disrupted in high-grade- but not in low-grade 
astrocytomas are considered to be involved in progression (Rickman et al., 2001; 
Markert et al., 2001). To maintain normal homeostasis cells have several mechanisms to 
regulate cell-cell progression, one of which takes place at the G l/S  checkpoint (Castro 
et al., 2005). This checkpoint is believed to be primarily under the control of the RB 
genes (Fang et al., 2006). A hallmark of high-grade astrocytomas is high mitotic activity 
(Coons & Pearl, 1998; Colman et al., 2006) and is believed to reflect the frequency of 
aberrations involving components of the RB-CDK-CKI (cyclin-dependent kinase 
inhibitor) pathway (Xiao et al., 1995; Yin et al., 2002).
Cytogenetic Analysis o f  DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
Introduction
Figure 1-5: G1-S checkpoint
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Figure 1-5 shows some of the controls and interactions governing G l-S progress. 
Shows inhibitory action, _^  Shows a stimulatory action.
Loss of CDKN2A is reported to occur in 40-57% of GBMs (Ichimura et al., 1996), 
CDK4 amplification is found in 12-14% of GBMs (Ichimura et al., 1996; Burns et al., 
1998), while loss of RB is identified in 14-33% of GBMs (Ichimura et al., 1996). These 
genetic alterations are found to be almost invariably mutually exclusive (Biernat et al., 
1997; Wilkman & Kettunen, 2006) which is believed to imply that mutation of any 
component of the CDKN2A-CDK4-RB pathway can have equivalent effects 
(Nakayama et al., 1996). From a histological point of view this may well be, however 
recent findings from a glioma model seem to suggest that there could be important 
differences, particularly as regards the biological behaviours (Hesselager et al., 2003). 
Mutation of components of the RB pathway combined (INK4A/CDK4/RB) are detected 
in >80% of GBMs and in -50%  of AAs (Biernat et al., 1997). It is thought that the 
remaining 20% of GBMs that lack detectable INK4A/CDK4/RB mutations could
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harbour mutations in other components of this pathway. Indeed, by way of 
substantiation, overexpression of CDK6 and cyclin D1 has been detected in a number of 
GBMs (Costello et al,, 1997) while in one study downregulation of E2F1 and 
overexpression of cyclin E were observed in some high-grade gliomas (Walter et al.,
2002). Data from mouse models support the idea that genes involved in RB-mediated 
cell-cycle progression checkpoint are important in progression but not initiation of 
astrocytoma (Sharpless et al., 2001). In their study on Ink4a-homozygous and Ink4a- 
heterozygous mice, Sharpless and colleagues, found that neither group of mice 
developed astrocytomas although they were considered cancer prone. Similarly, the 
study of Elolland et al., (2000) on Rb -/- astrocyte cultures, and that of Merlo et al., 
(2003) on mouse models with overexpression of Cdk4, both groups failed to develop 
astrocytomas. However, simultaneous inactivation of Rb protein pathway in mice and 
overexpression of a truncated SV40 T antigen led to development of high-grade 
astrocytomas (Xiao et al., 2002).
1-8-2 G enetic alterations with probable initiating roles for astrocytoma 
Cytogenetic profiles of astrocytomas of various tumour grades reveal alterations that are 
common to low-grade- and high-grade tumours, and others that are restricted to tumours 
of higher grades. This led to the hypothesis that mutations that are shared by tumours of 
low- and high grades may be involved in early phases of tumour formation (Vogelstein 
et al., 2000). So far, the TP53 TSG, the receptor tyrosine kinases (RTKs) and RAS are 
the leading candidates genes that are implicated in the initiation o f astrocytomas (Paulus 
et al., 1996; Nozaki et al., 1999).
1-8-2-1 The Role o f  TP53 Tumour Suppressor Gene 
TP53 is a transcription factor that regulates cell cycle progression and apoptosis in 
response to a variety of external insults, such as DNA damage and oncogenic mutations 
(Vogelstein et al., 2000). Germline mutations of the P53 gene cause the Li-Fraumeni 
Syndrome; a familial cancer syndrome that predisposed affected individuals to 
development of various brain tumours including astrocytomas (Malkin et al., 1990). 
Mutations of TP53 are found with equal frequency (estimated at >60%) in all grades of 
sporadic astrocytomas (Louis DN, et al., 1993; Ohgaki, et al., 1999). Since
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astrocytomas, including the well-differentiated ones, exhibit a unique tendency to 
infiltrate surrounding tissues, a trait that is not common in other neoplasms until they 
have attained advanced stages (Kinzler & Vogelstein, 1996), the association of this 
tendency with the high frequency of mutations of the TP53 is tempting. The early loss 
of TP53 is also implicated in the ability of astrocytomas to evade apoptosis, thereby 
continuing to migrate and survive in a microenvironment that would normally not 
provide adequate growth support (Rich et al., 2005). However, in spite of the evidence 
from genetic studies pointing to an association between TP53 mutations and initiation 
of astrocytomas, studies of mouse models have not demonstrated a causal link. Instead 
the mouse models demonstrate that loss of Tp53 alone is insufficient to initiate 
astrocytoma formation (Donehower et al., 1992; Jacks et al., 1994), which implies that 
additional genetic or epigenetic events are required (Watanabe et al., 2003; Ichimura et 
al., 2000).
1-8-2-2 The Role o f  Receptor Tyrosine Kinase (RTK) and RAS  
Normal cells require growth signals for survival and/or proliferation (Yu et al., 2002). 
Many growth signals are mediated by diffusible growth factors transmitted into the cell 
via transmembrane proteins with intrinsic RTK activity (Burdon et al., 1999). RTKs 
bind to growth factors resulting in receptor dimérisation, autophosphorylation and 
recruitment o f adaptor proteins such as growth factor receptor bound protein 2 (GRB2) 
and sarcoma (Src) homology 2 domain containing (SHC), which interact with and 
activate various downstream effectors. One example of downstream effectors of RTK 
signaling is the Ras oncogene, which codes for a small GTP-binding protein (Seger & 
Krebs, 1995). Ras can activate at least three downstream cascades: 1) RAF- (mitogen 
activated, extracellular signal regulated kinase) MEK -MAPK (mitogen-activated 
protein kinase), 2) phosphatidylinositol 3-kinase (PI3K)-AKT, and 3) CDC2-RAC- 
RHO (Seger & Krebs, 1995; Hunter, 1998). The growth factor-RTK-RAS signalling 
cascade is one of the most frequently targeted genetic pathways in human cancers 
(Takahashi et al., 1992; Weis et al., 1999), which could suggest that activating 
mutations of this pathway render cancer cells independent of exogenous growth factors 
(Yamaguchi et al., 1994; Guha et al., 1995; Parsa & Holland, 2004). Genetic analysis of 
astrocytomas reveals elevated expression of several growth factors and their RTK
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receptors, for example PDGFR, in all grades of astrocytoma (Hermanson et al., 1996), 
which could indicate that RAS-mediated signaling is involved in initiation of 
astrocytoma development (Parsa & Holland, 2004).
Growth factors e .g ., EOF, PDGF and VEGF
Cell membrane
o
PI3K
Ras-GTP PI C
PTEN
Raf
PKC Akt
mTORMEK-1/2
Cell survival
MAPK/ERK-1/2
Proliferation
Angiogenesis
Figure 1-6 shows the growth factor signaling pathways
The tyrosine kinase activity o f growth factors is stimulated after binding to the cognate 
growth factors, which results in the stimulation of multiple downstream signaling 
cascades. These pathways are important in various cellular functions, including cell 
survival, proliferation and angiogenesis. As a result, novel molecular therapies for high 
grade astrocytomas are being sought that target various factors in these pathways e.g., 
farnesyltransferase inhibitors RTK->Ras-GTP); Raf inhibitors (Raf); PKC-B2 inhibitors 
(PKC); RTK inhibitors (EGFR, PDGFR, VEGFR); mTOR inhibitors (mTOR).
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EOF, ep id erm a l g ro w th  fa c to r ;  EGFR, E O F  recep tor; PD G F, p la te le t d e r iv e d  g ro w th  fa c to r;  
PD G FR, P D G F  recep to r; M E K -1/2, m ito g en -a c tiva ted  p ro te in  k in a se -1/2; PLC, p h o sp h o lip a se  
C; PKC, p ro te in  kinase C; PI3K, ph osph o in osito l-3 -k in ase; mTOR, m am m alian  ta rg e t o f  
rapam ycin; Akt, p ro te in  kinase B; PTEN, p h o sp h a ta se  a n d  tensin h om ology d e le te d  on 
chrom osom e 10. The f ig u re  is a d a p te d  fro m  B randsm a & van den Bent, 2007.
PDGF and PDGFR in particular are often co-expressed in the same tumour cells, 
suggesting that astrocytoma cells establish an autocrine stimulatory loop (Nister et al., 
1988; Hermanson et al., 1992; Rajasekhar & Holland, 2004), and could therefore be 
involved in mediating astrocytoma development (Nister et al., 1988; Vogelstein et al.,
2000). This possibility is supported by experiments in mice in which Pdgf was 
expressed in the brains using a retrovirus vector (Uhrbom et al., 1998), resulting in 
development of astrocytomas in 40% of the mice. These tumours also expressed Pdgfr, 
thus supporting a model of autocrine stimulation (Hermanson et al., 1992; Uhrbom et 
al., 2002). However, these mice experiments also seem to suggest that co-expression of 
Pdgf/Pdgfr may be required for astrocytoma to develop only in certain situations, for 
example, astrocytoma models that have been developed by Pdgf overexpression are 
unable, so far, to develop low-grade astrocytomas (Uhrbom et al., 1998; Dai et al.,
2001) as might be expected in the early stages of tumour development. Perhaps the 
explanation lies in the stage of development of these mouse models, which are typically 
neonates (Oumesmar et al., 1997). Taken together with data from mouse experiments, it 
appears that since astrocytomas occur mainly in adulthood in humans (Kleihues & 
Cavenee, 2000) either co-expression of Pdgf/Pdgfr is a requirement for tumour 
initiation only in adult animals, including humans, or it may be that adult astrocytes are 
the more susceptible target for Pdgf signalling (Zhu & Parada, 2002). An additional 
issue concerning the role of PDGF/PDGFR as probable mitogens for initiation of 
astrocytomas is that no mutations have been detected in either PDGF or its receptor in 
astrocytomas (Saxena et al., 1999; Dai et al., 2001; Hasselager et al., 2003). Moreover 
no defects of astrocyte development have been reported in Pdgfa- or Pdgfb-null mice 
(Fruttiger et al., 1999), both o f which observations render uncertain the precise role of 
PDGF/PDGFR signalling in astrocyte in both initiating and/or promoting development 
of astrocytic tumours.
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Furthermore, PDGF/PDGFR signaling is typically thought to be mitogenic (Saxena et 
al., 1999; Dai et al., 2001; Hasselager et al., 2003) which is also the primary basis for 
implicating these genes in astrocytoma oncogenesis. However, low-grade infiltrating 
astrocytomas typically have low mitotic activity despite being invasive (Johannessen & 
Forp, 2006). This would appear to suggest that mitogenic factors by themselves are not 
a critical requirement for development of low-grade astrocytomas (Hasselarger et al.,
2003). If PDGF/PDGFR signalling is involved in astrocyte development it could 
possibly be involved in functions other than or in conjunction with proliferation: for 
example, a PDGF/PDGFR could be involved in regulating cellular migration as 
demonstrated for a Drosophila PDGFR homologue by Duchek et al. (2001).
RAS mutations are found in -30%  of human cancers in general (Rushworth et al.,
2006), but, apparently, have not been detected in astrocytomas (Maltzman et al., 1997; 
Knobbe et al., 2004) although Sharma et al., (2005) have reported finding what they 
believe to be an oncogenetic mutation in one out of 21 (4.8%) pilocytic astrocytoma in 
their study. More commonly, RAS appears to be activated indirectly by upregulation of 
growth factor-RTK pathways (for example PDGF/PDGFR), through the loss of the NFl 
gene (Cickowski et al., 2003) or via other RAS-pathway-activating mechanisms 
(Kaplan & Stephens, 1994; Nakamura, 1995). The NFl gene encodes the protein 
neurofibromin, which shares homology with the RAS GTPase-activating protein (GAP) 
family (Oguzkan et al., 2006). RAS-GAPs catalyse conversion of activated RAS-GTP 
to RAS-GDP, thereby downregulating RAS activity (Oguzkan et al., 2006). Patients 
with neurofibromatosis type 1 are predisposed to developing astrocytomas (Cickowski 
et al., 2003), which are mostly believed to be of the pilocytic type (Kleihues and 
Cavenee, 2000). Homozygous deletion of the NFl alleles has been demonstrated in 
these tumours (Tada et al., 2003). However, activation of RAS-mediated MAPK and 
PI3K cascades are found in both NF 1-mutant-associated and sporadic astrocytomas 
(Lau et al., 2000). Although no mutations of Ras have been observed in astrocytomas, 
direct evidence implicating Ras in astrocytoma oncogenesis was provided by a mouse 
transgenic model (Bajenaru et al., 2002) in which overexpression of oncogenic Ras in 
astrocytes led to the development of astrocytomas.
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1-9 The pathogenesis & biological characteristics of primary GBMs
Although primary and secondary GBMs have similar histopathological characteristics 
and apparently clinical outcomes (Kleihues & Cavenee, 2000) the kinetics of tumour 
development in these two subgroups are strikingly different (Kleihues et ah, 2000). 
Primary GBMs arise rapidly, typically in <3 months, and without clinical or 
histological evidence of pre-existing low-grade lesions (Kleihues & Cavenee, 2000; 
Maher et ah, 2001). For this reason, it is difficult to distinguish between genetic 
alterations that contribute to their initiation and those associated with progression (Mao 
& Hamoudi, 2000; Weinberg, 2005). However, mutational analysis indicates that some 
of the genetic pathways that are disrupted in secondary GBMs are also altered in 
primary GBMs (Kleihues & Cavenee, 2000). A question thus arises regarding what 
mechanisms might explain the differences between the rapid- versus slow-progression 
in glial tumours (Kleihues & Cavenee, 2000). Certain genetic alterations have been 
observed that could separate primary from secondary GBMs.
1-9-1 INK4A/ARF/TP53 mutations
Mutations in 1NK4A, which are found in -40%  of GBMs, most of which are 
homozygous deletions (Labuhn et al., 2001; Houillier et al., 2006), are common in 
primary GBMs as compared to secondary GBMs, of which only -4%  have INK4A 
mutations (Biernat et al., 1997). TP53 mutations are more frequently detected in 
secondary GBMs (-60% ) but are found in -10%  of primary GBMs (Lang et al., 1994). 
In these tumours, mutations of TP53 and INK4A are mutually exclusive (Fulci et al.,
2000) and are believed to be due to a shift in the INK4A reading frame at the CDKN2A 
locus leading to a coding of the CDKN2B (P14ARF) gene in GBMs without INK4A 
mutations (Sherr et al., 2001; Bruggeman et al., 2005). ARF stabilizes p53 proteins 
through binding to MDM2, which normally targets p53 for ubiquitin-mediated 
degradation (Sherr et al., 2001). Thus, in secondary GBMs, TP53 pathway is directly 
mutated whereas in primary GBMs the p53 pathway is altered resulting either in loss of 
ARF or upregulation of MDM2. Homozygous deletion of the CDKN2A locus ablates 
both INK4A and ARF function (Labhun et al., 2001), simultaneously affecting the RB 
and p53 pathways (Labhun et al., 2001; Uhrbom et al., 2005). It has been suggested, for 
example, by Miao et al., (2001) and Weinberg, (2005) that homozygous inactivation of
3 4
Cytogenetic Analysis o f  DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
Introduction
the INK4A locus might explain why primary GBMs manifest so rapidly (Bruggeman et 
al., 2005). If this is the case, it could suggest that simultaneous loss o f two key growth- 
regulatory pathways in a cell might expose it to more favourable conditions for 
development of cancer (Miao et al., 2001; Weinberg, 2005). This concept is supported 
by studies in mouse models of astrocytoma in which simultaneous disruption of Nfl 
and Tp53 genes results in development of high-grade astrocytomas whereas a step-wise 
loss of the same genes does not (Reilly et al., 2001).
1-9-2 EGF/EGFR
Amplification of EGFR is found in -40%  of primary GBMs but rarely in secondary 
GBMs (Lang et al., 1994). EGFR amplification is associated with mutations in the 
genes for 1NK4A and is mutually exclusive with mutations of TP53 (Simmons et al.,
2001). Most astrocytomas with EGFR amplifications (estimated to be -77% ) have 
additional genetic alterations (Frederick et al., 2000) most of which are intragenic 
rearrangements that lead to truncated and constitutively active EGFR (Sugawa et al., 
1990; Frederick et al., 2000). Overexpression of truncated EGFR alleles confers a 
growth advantage and tumourigenic properties in glioma cell lines (Nishikawa et al., 
1994). In vitro administration of dozes of Egfr to brains of neonatal mice, in amounts 
equivalent to overexpression, failed to induce tumour formation in normal mice while 
those with mutations of Ink4a-Arf developed brain tumours (Holland et al., 1998). This 
seems to provide proof that EGFR activation in the background of Ink4a-Arf deficiency 
in some ways corporate to cause development of astrocytic tumour (Holland et al., 
1998).
1-9-3 PTEN
Loss of the lOq arm is the most common genetic alteration associated with GBMs (Fults 
et al., 1993; von Deimling et al., 1993), and several GBM-associated genetic loci, 
among them loss of PTEN (Li et al., 1997) have been identified (Fults et al., 1998). 
Alterations of PTEN occur in 30% of primary GBMs but only -4%  in secondary GBMs 
(Tohma et al., 1998). The PTEN protein can function as both a Serine/threonine 
/tyrosine protein-kinase and as a lipid phosphatase, with the phosphatase activity
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seeming to be of primary importance in tumour suppression since many mutations have 
been found in this domain (Tamura et al., 1998; Maehama & Dixon, 1998). 
Phosphatidylinositol (3,4,5)-triphosphate (PIP3, a PI3K product) is a substrate of PTEN 
(Maehama & Dixon, 1998) and is activated in GBMs with PTEN deletions, which 
supports the view that PTEN could function as a TSG as well as a regulator of the 
PI3K-AKT pathway (Leevers et al., 1999; Newton, 2004). Enhanced AKT activity has 
been detected in PTEN-deficient tumours and cell lines from both humans and mice 
(Holland et al. 2000; Kondo et al., 2004). Overexpression of Akt as well as oncogenic 
Ras in mouse neural stem cells (NSC) leads to development of GBMs. Together, these 
observations suggest that the PI 3K-AKT pathway is important in the aetiology of 
GBMs (Mischel & Cloughesy, 2003; Ghosh et al., 2005).
1 -9-4 Candidate genes at other loci in 1 Oq
Several candidate genes have been investigated in lOq in glioblastomas. ST AM binding 
protein-like 1 (STAMBPLl), which is a cell surface receptor that transduces apoptotic 
death signals and is mapped in the same region as PTEN (10q23.3), and MXIl MAX 
Interactor 1, which is a myc-C associated factor X (MAX) at I0q24-q25, appear to have 
been ruled out (Fults et al., 1998). Two candidates both mapped around 10q26-q27 are 
DMBTl (deleted in multiple brain tumours) and MGMT. The MGMT gene is of 
particular interest. It encodes the DNA repair enzyme O-6-alkyIguanine-DNA- 
alkyltransferase, which is responsible for protecting cells from alkylating agents. The 
enzyme efficiently removes methyl adducts at the O-6-position of guanine, which is an 
important target of alkylating agents (Pegg, 1990). It has been shown that the sensitivity 
to alkylating agents like BCNU correlates inversely with MGMT activity (Stupp et al., 
2001; Gerson, 2002). The response of patients to BCNU is associated with an increase 
in overall survival rate (Esteller et al., 2000). Further more, aberrant hypermethylation 
of MGMT promoter is associated with loss of the MGMT protein, which is in contrast 
to retention of protein seen in the majority of tumours without hypermethylation 
(Esteller et al., 1999). Clinical trials have suggested that méthylation of the MGMT 
promoter is predictive for better outcome in patients with malignant gliomas treated 
with alkylating agents such as temozolomide (Paz et al., 2004; Hegi et al., 2004), ail
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appearing to support the possibility of MGMT being a candidate TSG located at distal 
lOq.
1-10 The NSCs as probable cell o f  origin o f  primary GBM s 
As shown by Holland et al., (2000), NSCs develop primary GBMs when subjected to 
overexpression of Akt and Ras oncogene. Other studies have subsequently shown that 
in vitro EGF but not PDGF can stimulate proliferation of neural stem cells (Miao et al., 
2001; Mondai et al., 2004) while specific inactivation of Pten in mouse stem cells 
causes increased proliferation (Xiao et al., 2002; Fraser et al., 2004; Simin et al., 2006), 
which is thought to be as a result of shortening of the cell cycle of neural stem cells 
(Groszer et al., 2001). This effect of EGF signalling and PTEN in neural stem cell 
proliferation raises the possibility that primary GBMs might arise from neural stem cells 
(Ehtesham et al., 2004). Adult stem cells have been identified in humans (Temple et al., 
1999; Rakic, 2002) and have been shown to express GFAP, which is a marker of 
astrocytes (Doetsch et al., 1999; Seri et al., 2001). This finding suggests that a close link 
might exist between the astrocytic lineage and adult neural stem cells (Quinn et al., 
1999; Steindler & Lay well, 2002; Seidenfaden et al., 2006). Radial glia, which are 
traditionally considered to be astrocyte precursors, show characteristics of neural stem 
cells both in vitro and in vivo (Noctor et al., 2001). In mice it has been shown that 
neural stem cells are more susceptible to transformation than differentiated astrocytes 
(Holland et al., 1998; Holland et al., 2000). These observations are consistent with the 
view that the rapid growth of primary GBMs might be a consequence of transformation 
of neural stem cells (Miao et al., 2001). However primary GBMs arise mainly in 
patients who are older than 55 years of age (Kleihues et al., 2000; Maher et al., 2001), 
and neural stem cell-activity reduces with age (Gage et al., 2000). Both factors would 
appear to contradict the findings in mice. However, these apparently contradictory 
observations could be reconciled by several studies, one of which reported that 
oligodendrocyte precursors acquired characteristics of neural stem cells in response to 
certain exogenous stimuli (Kondo et al., 2000, 2004). Another study in which Ink4a/Arf 
''' astrocytes as well as Ink4a/Arf ''' NSCs were transplanted into neonatal brains 
demonstrated that homozygous deletion of both lnk4a and Arf, but not of lnk4a, Arf, or 
p53 alone, results in “de-differentiation” of neonatal mouse astrocytes into neural stem
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cells in response to Egf signalling (Bachoo et al., 2002). Overall, these observations 
support a model in which primary GBMs can arise from NSCs, which either exist in the 
adult brain, or can be generated from more differentiated, though perhaps not terminally 
differentiated cell types in response to oncogenic mutations (Sell, 1993, 2004; Scott et 
al., 2005).
1-11 Clinical features o f  astrocytomas
Several clinical and histological criteria are in use for classifying and grading malignant 
brain tumours, however, the one preferred by the majority of pathologists, and 
recommended by the World Health Organisation is known as the WHO grading system 
(Kleihues & Cavenee 2000). The WHO classification grades astrocytomas into 4 
categories. Grades 1 -  IV, in the order of increasing malignancy. WHO grade Is, are 
pilocytic astrocytomas, and are considered to be largely non-infiltrating and as such 
circumscribed. Tumours of this grade can therefore be cured by surgical resection 
(Szymas et al., 2000). Grades Il-lV are collectively known as diffuse astrocytomas. 
Tumours of malignancy grade 11 are known as fibrillary astrocytoma, grade III as 
anaplastic astrocytoma (AA), and grade IV as glioblastoma multiforme (GBM). WHO 
Grade 1 and II astrocytomas are considered as low-grade astrocytomas (LGAs) while 
Grades III and IV are high-grade astrocytomas (HGAs).
Fibrillary astrocytomas have a high tendency for malignant progression to higher grade, 
with the GBM as the most malignant phenotype-endpoint. Glioblastomas arising as a 
result of stepwise progression are termed as secondary GBMs as opposed to de novo 
GBMs that arise rapidly with no clinical history suggestive of a prior low-grade 
astrocytic tumour. These two broad subgroups of GBMs are associated with clinical 
manifestations and genetic profiles that appear to support the separation. The majority 
of secondary GBMs harbour alterations of TP53 and PDGFA, while most primary 
GBMs tend to have alteration of EGF and PTEN (Ohgaki, 2005). Evidence from both 
histological and molecular studies suggests the presence of intermediate categories of 
GBM, such as the giant cell and gliosarcoma types. While several histological
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manifestations of glial tumour aberration, such as gliosarcoma, have been described, 
these are not specifically covered in this thesis.
1-11-1 A etiology, Gender and A ge distribution o f  HGAs
1-11-1-1 WHO Grade III astrocytomas
Little is known about their aetiology, but astrocytomas arising from inherited/familial 
syndromes appear to progress mostly from lower to higher grades (Arruda et al., 1995). 
WHO grade III astrocytomas typically affect young adults (Hirose et al., 2003), with a 
peak around age 45 years, but are very occasionally encountered in older patients. The 
ratio of males and females appears to be similar (Collins, 1995).
1-11-1-2 WHO Grade IV astrocytomas
GBMs predominantly affect adults with the peak incidence between 45 and 70 years 
(Ohgaki & Kleihues, 2005). However, interestingly, numerous cases of congenital 
GBM have been reported in the literature (for example, Lee et al., 1999; Castellano- 
Sanchez et al., 2005; Brat et al., 2007). Patients with secondary GBM are on average 
much younger than those of primary GBM (Ohgaki, 2005). Over 90% of GBMs are
thought to be of the primary type (Ohgaki & Kleihues, 2007). Males appear to be
affected more commonly than females, with male to female ration of 1.2:1 (Collins,
2004).
Presenting clinical features of a GBM vary with location in the cranial cavity and the
stage of development. The usual presenting complaints are a history of epileptic seizure,
often with non-specific neurological symptoms and no focal neurological abnormalities,
headache and personality changes. Raised intracranial pressure may signify a larger
space occupying lesion, a location in the vicinity of the brain stem or the posterior
cranial fossa. It could signify imminent danger to life and constitutes a surgical
emergency. In over 50% of the cases, patients present with a short duration of
symptoms, typically lasting less than 3 months. Clinical suspicion of the diagnosis of
glioma is confirmed by neuroimaging, with both CT and MRI providing useful clues.
On CT scans, GBMs present as irregularly shaped lesions with an area of central
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necrosis, which is surrounded by a contrast enhancing area corresponding to the highly 
vascuiarised zone. This rim is invariably infiltrated by tumour tissue (Thomas, 1998; 
Mitchell et al., 2005) and does not represent the outer limits of the tumour. A zone of 
vasogenic oedema may be present for a distanee of two or more centimeters beyond this 
rim.
1-11-2 Locations o f  cerebral astrocytomas
Most supratentorial astrocytomas are located in the subcortical white matter, commonly 
in the frontal and temporal lobes. Tumours may infiltrate the adjacent cortex and basal 
ganglia. It is estimated that -15%  of GBMs spread via the corpus callosum to infiltrate 
the contralateral hemisphere. Imaging of such lesions usually shows the characteristic 
appearance of bilateral glioma that has been likened to the shape of a butterfly 
(Shimauchi & Kinoshita, 1989; Zakrzewska et al., 2007). GBMs do not commonly 
infiltrate the dura, however it does occasionally happen, in which case the result is 
widespread intracranial dissemination, which is known as gliomatosis cerebri (Marwin 
et al., 2005).
1-11-3 M acroscopic and microscopic features
The definitive diagnosis is made on examination of the tumour biopsy specimen, in 
which tumours appear pale yellow in contrast to the gray whitish normal appearance of 
the brain. Some areas may demonstrate signs of more recent (pink/bright red) or older 
(browning) haemorrhage. The histological diagnosis is based on recognition of the 
presence, or absence, of 4 morphologic criteria, namely: cellular and nuclear atypia 
(pleiomorphism), mitoses, endothelial proliferation and necrosis. Light microscopy of 
tumour sections stained in haematoxyline and eosin (H & E) usually show more 
intensely stained tumour tissue comprising a higher density of astrocytes of varying 
shapes and sizes (Revesz, personal communication).
In addition to the pleiomorphic appearance in the histology, AAs are distinguished from 
the LGAs by the presence of cells undergoing mitosis, and usually the astrocytes are far
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less differentiated. On the other hand, a diagnosis of GBM is made if haemorrhagic and 
necrotic areas or evidence of formation of new vessels is found. Sometimes the 
histology is of a highly anaplastic cellular architecture, in which case, by accepted 
convention a tissue testing positive for GFAP is considered as of astrocyte origins 
(Johnson, 2002).
1-12 Clinical management
Conventional treatment of patients with high malignancy grade astrocytoma consists of 
surgery and radiotherapy (RT), while the standard treatment for recurrent tumours is 
chemotherapy (CT) with either lomustine alone, or in combination with procarbazine 
and vincristine (NHS Northern and Yorkshire, 2000). Although there are reports of 
benefits derived from adjuvant chemotherapy for patients with high malignancy grade 
gliomas, its role remains uncertain (MRC Brain Tumour Working Party, 2001).
1-12-1 Role o f  surgery
The invasive and widely infiltrative nature of high-grade astrocytomas makes curative 
resection impossible (Kelly et al., 1987. Thus, the impact of surgery is compromised 
because of the lack of a defined tumour edge and the close proximity of vital anatomical 
structures. Still, surgery has a vital role as the means for obtaining the biopsy specimen 
needed to establish the diagnosis, administering intratumoural wafers, as an aid to 
investigative procedures such as functional magnetic resonance imaging (fMRI) 
(Mueller et al., 1996; Nimsky et al., 2006), and may be employed in managing raised 
intracranial pressure arising from CSF circulatory block when surgical bypass 
procedures may offer temporary improvement in the quality of life for the patient 
(Thomas, 1998). Likewise, patients with large tumours in surgically accessible locations 
may derive temporary benefits from surgical tumour reduction (Mueller et al., 1996; 
Thomas, 1998; Nimsky et al., 2006).
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1 -12-2 Radiotherapy
Radiotherapy currently serves as adjunct to surgery in the treatment of high-grade 
astrocytomas. Normal CNS tissue can tolerate up to 60 Gy of radiation, which is below 
the threshold required to kill malignant glioma cells. Consequently, the risk of residual 
tumours remains high (Burnet et al., 2006). Stereotactic radiosurgery or radiotherapy, 
interstitial radiotherapy, boron neutron-capture therapy (Andrews et al., 2006), and 
several techniques that attempt to enhance the effect of radiotherapy, such as hypoxia- 
targeting pharmacoradiotherapy (Shibamoto et al., 2004), have so far provided only 
marginal improvements in survival.
1-12-3 Chemotherapy
The goal of chemotherapy is mainly to control tumour growth and to maintain, for as 
long as possible, a satisfactory quality of life of the patients (Castro et al., 2003). 
However malignant gliomas, in particular those of astrocytic origins, tend to be either 
initially or gradually chemoresistant (Shapiro et al., 1991). In part, the failure of 
chemotherapy may be due to the presence of the blood-brain barrier (Signer, 1981), 
which may act as a physical barrier or operate different efflux pumps (Tamai et al., 
2005; Girardin F, 2006) and so hinder the transport of chemotherapeutic agents into the 
CNS. Several chemotherapeutic agents are used alone, or in combination, as standard 
first-line drug treatments for primary malignant astrocytic tumours. The combinations 
of procarbazine, lomustine, and vincristine (Levin et al., 1995), or procarabazine, 
cisplatin, and vincristine (PCV) (Souhami et al., 2004), or carmustine (a DNA 
alkylating agent) alone, have demonstrated a significant prolongation of survival. All 
three have been found in several large randomised clinical trials to confer comparable 
levels of efficacy (Levin et al., 1995; Prados et al., 1999; Parney & Chang, 2003). 
However, recently, it has been shown that temozolomide (TMZ), when used as adjuvant 
chemotherapy in the prophylactic treatment of non-responsive, and inoperable primary 
as well as recurrent tumours, resulted in significant improvements in the symptoms and 
quality of life (Teixeira et al., 2003; Stupp et al., 2005), making this approach the new 
standard of care for GBM (Stupp et al., 2005).
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1 -12-4 M anagement o f  recurrent tumours
Recurrences of tumour in the same location are common and may be managed by re­
operation where possible, additional radiotherapy and/or chemotherapy. Retinoic acid 
(Defer et al., 1997; Phuphanich et al., 1997; Wismeth et al., 2004; Parney and Chang,
2003) and interleukins (Kahlon et al., 2004) have demonstrated some benefits; the 
former promotes cellular differentiation in proliferating tissue (Parney et al., 2005) 
while the latter enhances immune response to tumour antigens (Kahlon et al., 2004).
1-12-5 Predictors o f  response to radiotherapy/chemotherapy
The two factors, namely the méthylation status of the MGMT promoter, and the status 
of Ip and 19q in the tumour, in particular, combined deletion (codeletion), have recently 
emerged at important predictors of chemotherapy in some gliomas.
1-12-5-1 The role o f  M GM T in resistance to alkylating chemotherapy 
Epigenetic silencing of the 06-methylguanine-DNA methyltransferase (MGMT) gene 
by promoter méthylation has been recognized as an important factor for predicting 
outcome in GBM patients treated with alkylating agents such as TMZ and carmustine 
(BCNU) (Esteller et al., 1998; Hegi et al., 2004). The MGMT gene is located on CHR 
10q26 and codes for an excision repair enzyme that removes alkyl-groups from 0-6- 
position of guanine, one of the targets of alkylating agents. The alkyl-group is 
transferred to the active site of the MGMT protein that thereby becomes irreversibly 
inactivated and subsequently degraded, requiring resynthesis. Although 06- 
methylguanine accounts for <10% of the lesions triggered by alkylating agents, it plays 
a major role as a trigger for cytotoxicity and apoptosis (Ochs & Kaina, 2000). If left 
unrepaired, e.g., due to epigenetic silencing of the MGMT gene or depletion of the 
MGMT protein by saturation of the process, 06-methylguanine forms mispairs with 
thymidine after replication that are recognized by the mismatch repair (MMR) system. 
However, since MMR is directed to the newly synthesised strand while the 06-MG 
resides in the template strand, the lesion is not repaired, but engages MMR in what is 
called futile repair cycle that eventually leads to cell death (Karran, 2001). Thus, 
suggesting that in addition to an inactivated MGMT gene, MMR-proficiency is an
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important factor for response. Indeed, it has been reported cells deficient for MMR are 
100 times more resistant to alkylating drugs even in the absence of MGMT (Stojic et 
al., 2004).
1-12-5-2 M GM T Promoter M éthylation & Chemosensitivity o f  
Gliomas
Méthylation of the MGMT was found to have strong prognostic effect in a 
homogeneous cohort o f patients treated with combination of radiotherapy and TMZ 
(Hegi et al., 2005). The impact of MGMT méthylation is dependent on therapeutic 
modalities, for example, benefits were more apparent for patients treated with RT plus 
chemotherapy (CT), particularly when CT is administered during the cause of the RT 
(Criniere et al., 2007). In the absence of any treatment, MGMT méthylation has no 
impact or may have a negative impact on survival (Komine et al., 2003; Criniere et al., 
2007) while the impact on RT alone is less than that in patients receiving RT and TMZ 
(Stupp et al., 2005). The synergistic effect of RT + TMZ for patients with MGMT 
méthylation is not clearly understood. CT is presumed to consume MGMT (Tolcher et 
al., 2003), whereas several in vitro studies suggested that RT upregulates MGMT 
(Grombcher et al., 1998) though this has not been confirmed by others (Hermisson et 
al., 2006). Older patients tend to have a higher rate of MGMT méthylation (Rolhion et 
al., 1999). Since age is a very strong negative prognostic factor in GBM (Houilliet et al., 
2006; Curran et al., 1993), it could mask the apparent positive effect of MGMT 
méthylation in patients treated with alkylating agents, and it appears that the impact of 
MGMT méthylation probably depends on type of alkylating drugs used for example, 
TMX vs. nitrosourea vs. other alkylating agents. The degree of méthylation may also 
have a differential impact on chemosensitivity, while this is also dependent on the 
mismatch repair (MMR) system.
1-12-5-3 D eletion o f  Ip & 19q in the tumour
Chromosome lp/19q codeletion as a predictor of chemosensitivity has mainly been 
studied in oligodendroglioma tumours and low-grade gliomas (LGGs) (e.g.. Levin et al., 
2006; Kaloshi et al., 2007; Kouwenhoven et al., 2006; Brandes et al., 2006; Walker et 
al., 2006). The survival of patients of anaplastic astrocytomas is dependent on the status
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of lp/19q in the tumour. Randomized studies carried out by the Radiation Therapy 
Oncology Group (RTOG) and the European Organization for Research and Treatment 
of Cancer (EORTC) were the first to reveal that tumours with the codeletion of Ip and 
19q are more sensitive to chemotherapy, with 90-100% of the patients responding 
(Caincross et al., 1998; Van den Bent et al., 2003). Survival was also better in patients 
with tumours showing combined lp/19q loss (Bauman et al., 2000; Smith et al., 2000). 
In Oligodendrogliomas, it was found that this lp/19q codeletion is an early event in the 
tumourigenesis, which is mediated by an unbalanced translocation of 19p to Iq: 
der(l;19)(pl0;ql0) (Griffin et al., 2006; Jenkins et al., 2006). Patients with AAs (and 
OAs) having normal lp/19q status survived ~ 2-3years, while patients whose tumours 
showed codeletion of lp/19q survived 6-7years. Interestingly, the MGMT promoter 
méthylation seems more frequent in tumours with combined lp/19q combined loss, 
with 80% of tumours showing méthylation (Mollemann et al., 2004).
1-13 M olecular Targeted Therapies
From a molecular perspective, malignant gliomas are extremely heterogeneous. Despite
this variability, common alterations in specific cellular signal transduction pathways
occur in most malignant gliomas. These include alterations in the p53 protein, the
retinoblastoma susceptible protein (pRb), the Ras-Raf pathway and the
phosphoinisitide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)
pathway (Rich et al., 2004). Mutations within the p53 and pRb pathway lead to an
inhibition of apoptosis and cell cycle arrest, and thereby remove the restrictions to
proliferation (Vogelstein et al., 2000; Sherr, 1996). Alterations in the growth factor
pathways, mediated by Ras and P13K, are mostly responsible for proliferation of
malignant gliomas (Wang et al., 1997). For example, an important signaling pathway in
the development of malignant gliomas is mediated via the epidermal growth factor
receptor (EGFR)/P13K7Akt/mTOR pathway. This pathway is normally inhibited by
PTEN, which is mutated in 30-40% of GBM (Wang et al., 1997; Stambolic et al.,
1998). Another important signaling cascade, having a key role in angiogenesis, is the
vascular endothelial growth factor (VEGF)-A pathway. The main receptors involved in
VEGF-A signaling are VEGF receptor (VEGFR)-l (Flt-1) and VEGFR-2 (KDR, Flk-1).
VEGFR-2 is a potent tyrosine kinase, which mediates endothelial cell signaling through
activation of Ras, P13K-and-protein kinase C-b pathways (Petrova et al., 1999). These
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signalling pathways are responsible for the high vascularity of glial tumors, often with 
overexpression of VEGF-A (Plate et al., 1992; Chaudhry et al., 2001). For a number of 
these pathways, there are now available specific inhibiting agents (Rich et al., 2004), 
and clinical trials have focused mainly on the EGFR/PI3K, Ras and VEGF signaling 
cascades.
1-13-1 Epidermal growth factor receptor
EGFR is amplified in 40-50% and overexpressed in up to 60% of GBM (Ekstrand et 
al., 1992; Watanabe et al., 1996; Ohgaki et al., 2004). EGFR mutations occur in about 
50% of EGFR-amplified GBM, most frequently affecting the extracellular domain with 
a deletion of exons 2-7 (EGFRvIII mutation) (Huang et al., 1997). The resulting variant 
receptor, EGFRvIII, is constitutively activated with continuously downstream signaling 
(Frederick et al., 2000; Aldape et al., 2004). This made the EGFR a logical target for 
clinical trials. The majority o f these trials focus on targeting EGFR by small molecule 
tyrosine kinase inhibitors (TKIs) that act as competitive antagonists of the intracellular 
EGFR domain. ZD 1839 (gefmitib/Iressa) and OSI774 (erlotinib/Tarceva), which both 
have specificity for EGFR/ HERl, are two EGFR TKIs currently under investigation 
(Prados et al., 2006; Reardon et al., 2006). Unfortunately, phase II data show that the 
overall efficacy of these agents in unselected patients with newly diagnosed or recurrent 
GBM is minimal (Rich et al., 2004; Raizer et al., 2004; Quan et al., 2005). The first 
correlative studies linked to these trials demonstrated that EGFR-expression, 
amplification or mutation does not predict response to EGFR TKIs (Lassman et al., 
2005). A large study using two independent datasets suggested that coexpression of 
EGFRvIII and PTEN was statistically significantly associated with response to EGFR 
TKIs, with 60-80% o f patients with this combination responding (Mellinghoff et al.,
2005). However, a recent randomized European Organization for Research and 
Treatment of Cancer phase II study failed to establish clinically significant activity of 
erlotinib in unselected patients, and could also not confirm the responsiveness of GBM 
with combined EGFRvIII mutation and PTEN expression (Van den Brent et al., 2007).
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1.13.2 Mammalian target o f  rapamycin (mTOR)
mTOR is a key downstream kinase in the P13K/Akt/ mTOR pathway (Vivanco et ai.,
2002). PTEN gene mutations/deletions, occurring in 30-40% of patients with GBM, 
result in activation of the PI3K pathway (Wang et al., 1997). In preclinical models an 
enhanced sensitivity to mTOR inhibition was found in PTEN-deficient tumors (Neshat 
et al., 2001). Phase II results of two studies on the mTOR inhibitor CCI-79 
(temsirolimus) in unselected recurrent glioma patients showed no significant efficacy 
(Galanis et al., 2005; Chang et al., 2005). In-vitro evidence of synergism between 
mTOR inhibitors and EGFR TKIs has resulted in concentrating efforts in clinical trials 
on combining these agents.
1-13-3 Platelet-derived growth factor receptor
Overexpression and activation of platelet-derived growth factor receptors (PDGFRs) 
play a role in cancer through autocrine stimulation, angiogenesis and control of tumor 
interstitial pressure (Ostman et al., 2004). PDGFR pathways promote glioma 
transformation and many gliomas show upregulation of PDGF (Lokker et al., 2002; 
Clarke ID, Dirks PB, 2003). Despite the rarity of PDGFR mutations in gliomas, these 
observations have prompted trials on PDGFR inhibition in malignant gliomas. The most 
frequently studied drug is imatinib (STI571), a small-molecule that is an inhibitor of 
PDGFR-a and b, c-kit, and the Bcl-Abl fusion protein. Phase II results of studies on 
imatinib monotherapy have so far showed no significant activity in recurrent gliomas 
(Raymond et al., 2003; Wen et al., 2006). However, interesting results were observed in 
initial studies on the combination of imatinib and hydroxyurea, resulting in 10-20% of 
patients responding, and 24-30% 6-month PFS (Dresemann G, 2005; Reardon et al., 
2005; Desjardins et al., 2007).
1-13-4 Vascular endothelial growth factor receptor
Current strategies for targeting VEGF in malignant gliomas are directed to design and 
application of VEGFR-TKIs, VEGF antibodies and protein kinase-C-beta (PKC-b) 
inhibitors. Treatment of recurrent GBM with vatalanib (PTK787/ZK222584), a 
VEGFR-1 and VEGFR-2-TK1, showed disappointing results in two Phase I/II studies 
(Conrad et al., 2004; Reardon et al., 2004). In contrast, a recent study on the
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combination of bevacizumab (Avastin), a VEGF-A monoclonal antibody, and 
irinotecan demonstrated activity in recurrent high-grade gliomas. In a group of 23 
patients, a 63% response rate was found, with a median PFS of 23 weeks, whereas the 
6-month PFS in GBM without this treatment was 38% (Vredenburgh et al., 2007). 
Finally, enzastaurin (LY317615), an inhibitor of activated protein kinase C-b2, is 
currently being tested in phase II studies in recurrent malignant gliomas. Preliminary 
results of a phase II study showed a 22% response rate but the 6-month PFS is still not 
reported. A randomized phase III study comparing enzastaurin to single-agent 
lomustine was prematurely closed due to expected failure to meet its endpoint, but 
combination studies of enzastaurin with TMZ and radiotherapy are ongoing.
1-13-5 Famesyltransferase inhibitors
Farnesyl transferases are involved in signal transduction in the Ras pathway (Newton et
al., 2003). The inhibitor, tipifarnib, had only limited activity as a single agent in 
recurrent gliomas, however, trials combining it with radiotherapy, TMZ and other 
targeted agents are underway (Cloughesy et al., 2005; 2006).
1-14 Prognostic factors
It is generally accepted that important prognostic factors in brain tumours are. I) the age
of the patient, 2) degree of neurological impairment (Karnofsky performance score, 
KPS), 3) extent o f surgical resection of the tumour, 4) tumour type, 5) grade and 6) 
intracranial location (Rich et al., 2005). However regarding high-grade astrocytomas 
prognostic factors are as yet not clearly defined. The survival of patients with anaplastic 
astrocytomas, whose median survival is 3-5 years (Surawicz et al., 1998), is 
considerably better when compared with that of glioblastoma patients that on average is 
below 12 months. The mean survival times for GBM in the absence of treatment is 
around 17 weeks, 30 weeks following biopsy and radiotherapy, 37 weeks following 
partial surgical removal and radiotherapy, and 51 weeks following more extensive 
volumetric reduction procedure and radiotherapy (MRC Brain Tumour Working Party, 
2001)
Some GBM patients are known to survive for longer periods, and are categorized as
long-term survivors. In the context of GBM, survival of 3 or more years is considered to
. . . .  . . .  . . .
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constitute long-term survival (Burton et al., 2002). There is considerable uncertainty 
and disagreement among researchers on the proportion of GBM patients attaining long­
term survival. More optimistic estimates have put the figure around 15 - 20% (Sant et 
al., 2003); others estimate it to be 2 -  5% (McLendon & Halperin, 2003; Senger, 
Caineross & Forsyth, 2003). Long-term survivors appear to have certain characteristies 
in common among which are, 1 ) the younger age and 2) favourable tumour indicators, 
such as less dedifferentiated tumours and tumours showing limited areas of neerosis, 
which may both be related to, 3) a favourable initial KPS (MRC Brain Tumour working 
Party, 2001).
There is significant genetic heterogeneity among tumour specimens from different 
patients with glioblastoma (von Deimling et al., 1993; Schmidt et al., 2002; Nutt et al.,
2003), as there are intratumoural genetic differences (Burger Kleihues, 1989; Jung et 
al., 1999; Liang et al., 2005). There are suggestions that intratumoural genetic 
heterogeneities may contribute to differences in response to therapy (Hamstra et al.,
2004). Mutations of the TP53 gene, and amplification, and rearrangement of the EGFR 
gene are common genetic alterations in patients with glioblastoma (Louis and Cavenee,
2001). Studies of their relationship with prognosis have yielded inconsistent results, 
which have been attributed to several eauses, for instance, small sample sizes, inclusion 
of different tumour histologies, and lack of uniform treatment (Kraus et al., 2000). 
Nevertheless, in general, the prevailing view appears to be that the relationship of 
genetic alterations and prognosis in patients with GBM is complex and may be a 
function of the age of the patient (Simmons et al., 2001).
TP53 mutations, allelic loss of Ip (Caincross et al., 1998) and CDKN2A7pl6 
homozygous deletion (Ushio et al., 2003), which, previously, had either not been 
reported as having a prognostic value in astrocytomas (LOH Ip, CDKN2A (9p21), or 
over which there has continued to be a controversy (LOH TP53 (17pl3) (Batchelor et 
al., 2004), and EGFR amplification (Barker et al., 2001), have each, individually, 
recently been reported to influence prognosis in high grade astrocytomas. However, as 
yet a consensus appears to exist only regarding the influence of TP53 mutations and
LOH at lOq. Survival of patients with secondary glioblastoma is significantly longer
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than that of those with primary glioblastoma. Absence of TP53 mutations and presence 
of LOH lOq are predictive of shorter survival. EGFR amplification, p i6 INK4a 
homozygous deletion, and PTEN mutations are not associated with prognosis of 
glioblastoma patients (Ohgaki et al., 2004).
In some tumours, biological markers have been found that appear to be associated with 
age. For example, Ki-67 (MIB) labelling index and oestrogen receptor status, as well as 
the expression levels of EGFR, ERBB2, BRCAl and BRCA2 in cancers of the breast 
(Garvin et al., 1997; Bogdani et al., 2002; Ito et al., 2001; Iwase et al., 2001), and 
thyroid (van Toi et al., 2001). Some studies have attempted to correlate age with 
biological markers in high-grade astrocytomas. For example, Kunwar et al., (2001) 
investigated 80 tumours of patients with anaplastic astrocytoma using comparative 
genomic hybridization, with the aim of assessing the relationship between cytogenetic 
alterations and clinical parameters. They observed cytogenetic alterations such as gain 
of 7p, and 19, and loss of 4q, to occur more commonly in older patients while loss of
11 p was seen frequently in younger patients. In their study, the gain of 7p in older
patients with AAs was a poor prognostic indicator.
1-14-1 Prognostic factors for glioblastomas
1-14-1-1 Small neoplastic cells
On the basis of 71 cases of glioblastomas. Burger PC & Green SB, in 1987, showed that 
patients with glioblastomas composed of homogeneous small neoplastic cells had 
shorter survival. However, in 2002, Schmidt et al., (2002), in a study of 97 
glioblastomas, did not find differences in the survival of patients with glioblastoma with 
or without areas of better differentiation. This was supported in 2006 by the study of 
Homma et al., in which both univariate and multivariate analyses showed that small 
cells as the major cell type in glioblastomas were not predictive of survival. Burger et 
al., (2001) reported an association between the small-cell-phenotype, in glioblastomas, 
with EGFR amplification. They found that -67%  of exclusively small cell neoplasms, 
32% of glioblastomas with both small and non-small cell areas, and 9% of non-small 
cell glioblastomas, had EGFR amplification. In 2004, Perry et al. also reported that
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small cell glioblastomas showed frequent EGFR amplification (72%), as well as LOH 
lOq (100%), whereas none of the tumours (with small cells) showed loss of lp/19q. The 
larger study of Homma et al., in 2006 subsequently confirmed the association of small 
cell phenotype and higher rate of EGFR amplification. In addition, they found that 
tumours with small cell glioblastomas had significantly more homozygous deletion of 
CDKN2A, but infrequent PTEN mutations, suggesting that their genetic basis may 
differ from that of other glioblastomas (Homma et al., 2006).
1-14-1-2 Oligodendroglial component
Homma et al., in 2006, also found that 20% of 403 glioblastomas investigated, showed 
focal areas composed of oligodendroglial cells. This result is similar to that of He et al., 
who, in 2001, found 17% of 142 GBMs contained foci of oligodendroglial cells. In the 
context of the oligodendroglial phenotype, several studies have reported longer survival 
of GBM patients with areas containing an oligodendroglial component (Nelson et al., 
1996; Hilton et al., 1996). Hilton et al., in a study with 107 patients, showed that 
glioblastomas with an oligodendroglial component were associated with longer survival 
(median survival of 70 weeks) than those without (27 weeks). Similarly, Kraus et al., in 
2001, reported the median survival of 12 patients with glioblastoma with an 
oligodendroglial component as 104 weeks, suggesting that these tumours are associated 
with better prognosis. This was contradicted by He et al., also in 2001, who reported 
that the age (median, 54 years) and survival (median, 11.5 months) of 25 patients with 
glioblastoma containing an oligodendroglial component, did not differ from those of 
patients with ordinary glioblastoma. Some studies reported that patients with 
glioblastoma having oligodendroglial features were younger than those with ordinary 
glioblastoma (Baker et al., 1996), but other studies failed to confirm this difference 
(Nelson et al., 1996; Kraus et al., 2001). The more recent and larger study of Homma et 
al., found that glioblastomas containing an oligodendroglial component developed in 
significantly younger patients. Univariate analysis revealed a tendency for longer 
survival of patients with glioblastoma containing an oligodendroglial component, and 
also showed that oligodendroglial components were significantly more frequent in 
glioblastomas that developed in long-term survivors (>18 months) than in short-term 
survivors (<6 months). On the other hand, multivariate analyses with adjustment for age
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and gender did not show the presence of an oligodendroglial component as predictive of 
longer survival (Homma et al., 2006).
A related finding is the association between deletions of lp/19q and the 
oligodendroglial cell type. Genetic analyses in 13 GBMs with an oligodendroglial 
component found LOH Ip in 3 (23%) with only one (8%) of these showing codeletion 
of 19q (Kraus et al., 2001) although He et al., in a study of 25 GBMs, reported a 
deletion of 1 p and 19q in 40% and 60% of tumours with oligodendroglial cell type. The 
larger study (comprising 97 glioblastomas) by Schmidt et al., in 2002 found that some 
glioblastomas without oligodendroglial components also had LOH lp/19q. However, 
the larger study of Homma et al., in 2006, found no correlation between 
oligodendroglial components and the presence of LOH lp/19q in glioblastomas in both 
univariate and multivariate analyses.
1-14-1-3 M ultinucleated giant cells
Multinucleated giant cells are frequently encountered in glioblastomas, with 
glioblastomas characterized by predominance of large, bizarre, multinucleated giant 
cells, being termed as giant cell glioblastomas (Peraud et al., 1999: Reis et al., 2001). 
These are rare variant, and are genetically characterized by frequent TP53 mutations 
(78%) and infrequent EGFR amplification (6%), (Peraud et al., 1999). The study of 
Homma et al., confirmed, in multivariate analyses, that the presence of >5% 
multinucleated giant cells was associated with frequent TP53 mutations and infrequent 
EGFR amplification.
1-14-1-4 The presence o f  necrosis
Patients with glioblastomas showing necrosis are significantly at higher risk of death 
than those without necrosis (Burger et al., 1987; Hammoud et al., 1996; Pierallini et al.,
1998). The study, in 1996, by Hammoud et al., showed that the strongest prognostic 
variable was the amount of tumour necrosis on a preoperative scan. They found median 
survivals of 42, 24, 15, and 12 months, respectively for tumour-necrosis grades 0 (7
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patients), I (11 patients), Il (9 patients), and III (21 patients). Barker et al., in 1996, 
reported that 80% of patients in their study (275) who had supratentorial glioblastoma 
containing endothelial proliferation had tumour necrosis. Pierallini et al., found that 
patients with necrosis affecting >35% of the tumour had a significantly shorter survival 
time (Pierallini et al., 1998). The presence of necrosis was correlated with older age of 
patients and was associated with significantly shorter survival (Hammoud et al., 1996). 
The recent study of Homma et al., reported that the mean age of patients with 
glioblastoma with necrosis was 59.2 years, significantly older than those without 
necrosis (51.6 years), and survival of patients with glioblastoma with necrosis was 7.9 
months, significantly shorter than those without necrosis (12.9 months). Multivariate 
analyses with adjustment for age and gender also indicated that the presence of necrosis 
is a significant predictive factor for poor survival of patients with glioblastoma.
1-14-1-5. Glioblastoma sub-type
These glioblastoma subtypes constitute distinct disease entities that affect patients at 
different ages, and evolve through different genetic pathways. Primary glioblastomas 
develop in older patients and typically show LOH on the entire chromosome 10, EGFR 
amplification /overexpression, and PTEN mutations (Burger et al., 2001; Ohgaki & 
Kleihues, 2005). Secondary glioblastomas develop in younger patients and typically 
contain TP53 mutations as an early alteration, and LOH 1 Oq as a late event (Burger et 
al., 2001; Ohgaki & Kleihues, 2005). Histological features may also differ between 
primary and secondary glioblastomas. Large ischemic necrosis is significantly more 
frequent in primary glioblastomas than secondary glioblastomas (Tohma et al., 1998). 
The study of Homma et al., confirmed these results, and further showed a tendency for a 
more frequent oligodendroglial component in secondary than in primary glioblastomas, 
whereas small cell phenotypes were observed at similar frequency in both glioblastoma 
subtypes. In addition, they observed a significant association between the presence of 
necrosis and absence of TP53 mutations in glioblastomas. This can probably be 
explained at in part by the infrequent occurrence of TP53 mutations in primary 
glioblastomas that more frequently show necrosis.
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1-14-2 Long-term survival o f  patients with glioblastoma 
Survival is still extremely poor despite advances in surgical and clinical neurooncology. 
In a meta-analysis of 12 randomised clinical trials, the overall survival rate of patients 
with high-grade glioma was 40% at 1 year (Stewart, 2002). At the population level, 
survival of patients with glioblastoma was even worse, observed survival rates were 
42.6% at 6 months and 17.7% at lyear (Burger et al., 2001). However, some patients 
survive longer, and several studies have focused on identification of histological and 
genetic features of glioblastomas from long-term glioblastoma survivors. Scott et al 
(1998) reported that 5 glioblastomas in patients who survived for >3 years after 
diagnosis did not show differences with respect to the presence of necrosis, vascular 
proliferation, lymphocytic infiltration, nuclear pleiomorphism, and nuclear size 
compared with 286 cases of all glioblastomas. Burton et al (2002) reported that the 
presence of necrosis or microvascular proliferation was not different between long-term 
(>3years) and short-term glioblastoma survivors (<1.5 years). McLendon et al (2003) 
reported that intermediate fibrillary components were more frequent and small cell 
components less frequent in 17 cases of glioblastoma from patients who survived for 
more than 5 years.
Burton et al., (2002) compared genetic alterations in glioblastomas from long-term 
survivors (>3 years; 41 patients) and those from short-term survivors (<1.5 years; 48 
patients). Nuclear p53 expression was significantly more frequent in the long-term 
survivor group (85% vs 56%). Kraus et al (2000) showed no differences in TP53 
mutation, PTEN mutation, CDKN2A deletion, EGFR overexpression among 21 long­
term (>24 months), and 21 short-term (<6months) survivors of glioblastoma. Homma et 
al., in their study of 2006, found that patients with glioblastoma who survived more 
than 18 months were younger (mean, 50 years) and their tumours contained 
oligodendroglial components more frequently (27% vs 14%). However, LOH lOq was 
the only genetic alteration that tended to be less frequent in glioblastomas from long­
term survivors (Homma et al., 2006).
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1-15 Cytogenetic detection o f  aberrations in astrocytomas
Cytogenetic techniques, designed for studying gross structural alterations in cancer
chromosomes have been applied with improvements over the past thirty-five years to a
level where they are now very sensitive (Kearney, 2001; Subramonia-Iyer, 2007). The
original cytogenetic technique was called karyotyping (Wahl et al., 1982), and required
culturing cells. ‘Chromosome spreads’ prepared from cells that are induced to undergo
mitotic arrested at metaphase were examined visually. This procedure was initially
applied to the study of chromosomal abnormalities in haematological malignancies
(Kallioniemi et al., 1995) and was instrumental in revealing many alterations that
identified candidate genes implicated in these malignancies. While karyotyping was
generally successful in haematological malignancies, in which cells can be grown with
relative ease, it proved difficult to apply to solid tumours. Astrocytomas are far more
difficult to grow, and are often unable to yield cells with adequate metaphase spreads
for analysis by conventional banding techniques. An improvement from karyotyping led
to fluorescence in situ hybridisation (FISH) techniques (Nacheva et al., 1998). FISH
techniques require the use of specific genetic markers (chromosome probes) to map
chromosome regions that are altered in tumour cells. FISH procedures are currently
available in a number of refinements that may require the use of metaphase or
interphase nuclei (Jacobsen et al., 2000). The use of interphase nuclei is intended to
overcome the difficulties encountered in growing cells from some tumour. More recent
refinements of the FISH techniques have enabled painting of whole chromosomes,
allowing easy identification (Kubota et al., 2001), which has made it even easier to
detect balanced translocations in chromosomes (Youings et al., 2004). However, in
general, the growing of cells outside the body is associated with several potential
drawbacks. In addition to difficulties encountered in growing cells from some solid
tumours, a major drawback is the uncertainty about the true representation of original
tumour in cell cultures. It is possible in some instances that the clone of cells that may
grow might not be representative of the original tumour. In addition FISH procedures
require specific genetic markers (probes) to map aberrant chromosome regions.
Furthermore, both karyotyping and FISH procedures are unsuitable for studying the
entire genomes of cancer cells. Two derivations of the conventional FISH procedure
that are termed as Multi colour Fluorescence In situ Hybridisation (M-FISH) and
comparative genomic hybridisation (CGH) have made it possible to study the entire
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genome in a single hybridisation experiment (Mohapatra et al., 1997; Kearney L, 2006), 
which has singled them our as invaluable procedures for whole genome analyses.
Figure 1-7 (taken from Kearney L, 2006) shows the combination-labelling scheme for 
the M-FISH procedure using five spectrally separable fluorochromes. Each 
chromosome is labelled with a unique combination of fluorochromes: five 
chromosomes are labelled with a single fluorochrome, ten chromosomes with two 
fluorochromes, and nine chromosomes with three fluorochromes, respectively. The 
'Colour' column shows the pseudocolour assigned to each unique colour combination.
1-15-1 Comparative genomic hybridisation (CGH)
CGH was developed by Kallioniemi et al., in 1992, and has since contributed a great 
deal to genome-wide investigation of solid tumours. The CGH method involves 
simultaneous hybridisation, onto a slide containing normal male lymphocyte metaphase 
chromosomes, separately labelled DNAs from two sources, one from a patient and the 
other, normal DNA, serving as reference. Unlike karyotyping, CGH requires only 
genomic DNA from a tumour and therefore has a wider application. For example, it can 
be applied to both fresh and paraffin-embedded tissue specimen (Kallioniemi et al.
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1992, Speicher et al. 1993, Isola et al. 1994). Furthermore, even very small tumour 
samples can be studied by the CGH technique after amplification of the tumour material 
using any of the available whole genome amplification procedures such as multiple 
displacement amplification (MDA) (Dickson et al., 2005), or degenerate 
oligonucleotide primed polymerase chain reaction (DOP-PCR) (Speicher et al 1993, 
Hirose et al.2001). On the downside, the CGH method only detects chromosomal 
imbalance, missing out balanced chromosomal translocations, inversions, or small 
intragenic rearrangements (Kallioniemi et al, 1994). An additional limitation of the 
CGH procedure is the narrow range of sensitivity. It can only reliably detect large-sized 
structural alterations, those estimated to be in the order of 10 to 20 million bases (MB). 
Aberrations smaller than 10 MB easily escape detection. In particular, chromosomal 
aberrations that are present in low frequency, amplifications smaller than 2 megabases 
(Mb) and deletions smaller than 5 MB are easily missed by the CGH method (Forozan 
et al. 1997).
CGH has been widely used to investigate chromosomal aberrations associated with 
progression and clonal expansion in a variety of tumours including astrocytomas 
(Bigner et al. 1999), and has been successfully used in identifying novel genes involved 
in tumourigenesis (Hemmilinki et al., 1997). Some CGH studies focus on identifying 
recurring chromosomal aberrations and associations with clinical, pathological or 
prognostic factors (Vettenranta et al. 2001). A typical cytogenetic pattern observed in 
astrocytic tumours has been a direct correlation of the number of chromosomal 
abnormalities with increasing histopathological malignancy (Goussia et al., 2000).
1-15-2 M ETAPHASE CGH: BRIEF HISTORY OF THE
PROCEDURE
Comparative genomic hybridisation is used to examine an entire genome for changes in 
DNA sequence copy number - gains (e.g., amplification) and losses (e.g., deletions) - 
using extracted tumour DNA or other specimen DNA as a probe. Unlike conventional 
cytogenetic analysis, such as metaphase FISH, CGH does not require a previous 
knowledge of genetic aberrations or require a complex and extensive series of
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chromosome-/ or loci-specific probes to fully evaluate the extent of genetic gains or 
losses in a genome. CGH has been used to examine chromosomal aberrations in several 
types of solid tumours including brain tumours. The results from these studies were in 
agreement with previously reported genetic aberrations or were verified using 
procedures such as FISH, karyotyping or PGR analysis. Additionally, CGH analysis has 
highlighted several unreported aberrations (Kallioniemi et al., 1995). Used to detect 
numerical chromosomal aberrations in prenatal samples, CGH identified the origins of 
extra and missing chromosomes in cases that could not have been resolved by 
karyotyping (Bryndorf et al., 1993). Classical cytogenetics is limited in the analysis of 
solid tumours because of the technical difficulties in obtaining metaphases and in 
interpreting karyotypes that are often complex. Furthermore, cells that proceed to 
mitosis may not be representative of the tumour. On the other hand comparative 
genomic hybridization uses the genomic DNA directly extracted from the tumour 
samples containing >50% tumour cells, ideally eliminating the need for cell culture. 
CGH has been successfully used to examine formalin-fixed tumour samples (Burger et 
al., 2001). This opens to analysis a variety of archival material that could not be 
examined by other cytogenetic methods. The technique of CGH is based on a two- 
colour competitive fluorescence in situ hybridisation of differentially labelled tumour 
and reference DNA to normal metaphase chromosomes (Kallioniemi et al., 1995), see 
illustrated below. The ratio of fluorescence intensities reflects the relative copy number 
in the tumour DNA compared to the normal DNA. Amplifications and deletions in the 
tumour will give distinct signals, therefore revealing the chromosomal positions of 
specific alterations (Schlegel, 1996).
In order to determine chromosomal location of copy number alterations (CNA) that may 
contribute to development of astrocytomas, CGH was performed on DNA extracted 
from various sources as already stated. The CGH procedure involved simultaneous 
hybridization of two genomic samples to normal metaphase chromosomes in the 
presence of Cot-1 DNA, which serves to block the repetitive sequences (Traut et al.,
1999). Tumour DNA (alternatively referred to as test DNA) was usually labelled with 
Spectrum Green dUTP (e.g., fluorescein) and the normal (reference DNA) is then 
labelled with SpectrumRed dUTP (e.g., Texas Red). The basic assumption in CGH is 
that the hybridisation kinetics of the test and the reference DNA are independent, so the
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ratio of binding of the DNA to ‘target’ (metaphase) chromosomes is proportional to the 
ratio of the copy numbers of the sequences in the DNA samples at a specific locus 
(Piper et al., 1995). The relative fluorescence intensities of the test DNA to the 
reference DNA, hybridized onto normal metaphase chromosomes, were used to 
determine the regions of changed copy number. At least 10 metaphases were analysed 
in each experiment as recommended by du Manoir et al., (1995)
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1-15-2-1 Typical CGH findings in astrocytomas
Most grade 11 and 111 astrocytomas have been reported to have a few aberrations on 
CGH examination. Typically, biopsies show losses on the X chromosome (Schrock et 
ah, 1996), while cell cultures of the majority of tumours may have additional alterations 
(Magnani et ah 1994). A few cases of grade 111 astrocytomas have been noted to have 
trisomy of chromosome 7 and losses on chromosomes 6, 10, 22, X and Y as well as 
structural abnormalities involving the short (p-) arm of chromosomes 1 and 9 (Goussia 
et ah, 2000; Ueki et ah, 2002).
The number of chromosomal aberrations typically accumulates with increasing 
malignancy grade of astrocytomas. The mean number of chromosomal changes per 
tumour is roughly two in Grade II astrocytomas, and five in Grades III and IV 
astrocytomas (Goussia et ah, 2000). In Grade II astrocytomas, or generally in LGAs, it 
appears that chromosomal gains tend to outnumber chromosomal losses, while in Grade 
III and IV astrocytomas losses tend to predominate (Wiltshire et ah, 2004). The most 
common chromosomal alterations in Grade II astrocytomas have been gains on 
chromosomes 7, 8q, 12p and losses on chromosomes 19q and X (Hirose et ah, 2003). 
Regarding Grades III-IV astrocytomas, the most frequent alterations have been gains on 
chromosomes 1, 19,20 and losses on chromosomes 9p, 10, 13, 14 and 22 (Nishizaki et 
ah, 1998).
Two relatively recent studies combined CGH analyses and MFISH (Kubota et ah 2001, 
Squire et ah 2001). Kubota and colleagues studied nine GBM cell lines using CGH and 
spectral karyotyping (SKY; MFISH) analyses, and found many instances of recurrent 
chromosomal rearrangements. O f particular interest was the observation that several cell 
lines of different origin showed very similar karyotypes. From CGH data, the most 
commonly lost chromosomal regions were found on chromosomes 4q, lOp, 13q, 14q 
and 18q, and gains were detected most often on chromosomes 7 and X. In addition, 
frequent amplifications on chromosomal loci lp l3 , 4ql2 and 16ql3 were demonstrated. 
Notably, data from SKY analysis demonstrated that regions of low-level DNA 
amplification tended to harbour translocations and/or insertions at a high rate (Kubota et 
ah 2001). The study o f Squire and colleagues, on the other hand, which utilized 16 cell-
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lines, of which ten were of glial tumours, showed that the chromosomes affected most 
often by translocation events were 1 and 10. Other chromosomes that were less 
implicated in translocations were chromosomes 3, 5, 7 and 11. The most common 
alteration detected by CGH was gain on chromosome 7.
1-16 D N A  microarrays
Following the introduction of DNA microarrays approximately 10 years ago several 
versions have come into use and have provided a rapid method for exploring the tumour 
genome. Arrays are designed to act as gene-specific hybridisation targets which has 
made it possible, in the course of a single hybridisation experiment, for clones 
representing thousands of genes to be assessed for copy number aberrations in the same 
tumour sample (Ramsay, 1998; Fiegler et al., 2007). In addition, it is possible to 
compare two biological samples by simultaneously hybridising a mixture of two 
independently labelled probes to the same microarray (Schena et al. 1996). Most 
experiments have utilised arrays of DNA fragments or large genomic clones (Solinas- 
Toldo et al., 1997; Ekong et al., 2004; Fiegler et al., 2006). Microarray-based CGH has 
~ 20-fold higher mapping resolution than conventional metaphase CGH (Pollack et al.
1999), depending on spacing of clones on the array.
From the point of view of clinical application, a potentially important adaptation of 
array technology is the incorporation of whole tissue into what has been termed as 
“tissue microarray”, which is intended to achieve parallel detection of DNA, RNA and 
protein targets in multiple tumours (estimated in hundreds) in a single hybridisation 
procedure (Kallioniemi et al. 2001). Tissue arrays are constructed by bringing small 
circular tissue biopsies from different tumours into a single paraffin block. So far up to 
1000 samples can be applied to one tissue-array-block (Hocquette, 2005). However, the 
high-throughput nature of microarray experiments imposes numerous limitations, which 
apply to simple issues such as sample acquisition and data mining, to more complex 
issues that relate to the methods of biostatistical analysis required to analyze the 
enormous quantities o f data obtained. Furthermore, genomic arrays for detection of 
DNA copy number aberrations are also unable to detect aberrations resulting in
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balanced rearrangements, and are as yet unable to identify aberrations in chromosomal 
regions that are enriched in highly repetitive DNA sequences, duplications, 
polymorphisms and copy number variations (CNV) (Carter et al., 2002; Ekong et al., 
2004; Redon et al., 2006; Fiegler et al., 2007).
1-17-1 Use o f  microarrays to detect gene expression 
The use of microarray techniques, especially cDNA microarray, for gene expression 
profiling of various cancers (for example, Mischel et al., 2004; Neben et al., 2004; Ge et 
al., 2005), have yielded valuable results, demonstrating the potential for their clinical 
usefulness. A study of expression profiles of tumours of the breast (van Veer et al.,
2002) and gliomas (Mischel et al., 2003) using cDNA arrays found a correlation with 
the clinical outcome of patients, thus demonstrating the clinical utility of cDNA 
microarrays. A number of studies of microarray-based analyses of astrocytomas have 
been reported. In a 1999 study by Fuller et al., cDNA microarray analysis of 588 known 
genes revealed the expression of insulin-like growth factor receptor binding protein 2 
(IGFBP2; 7pl3-12) in GBMs, but not in anaplastic astrocytomas. Another study of the 
gene expression profile of 1176 known cancer-associated genes in 11 Grade 11 
astrocytomas, by Huang and colleagues, in 2000, demonstrated significant expression 
changes in 24 genes. The expressions of tissue inhibitors of metal 1 oproteinase 3 
(T1MP3; 22ql2.1-13.2), cellular MYC (C-MYC; 8q24), epidermal growth factor 
receptor (EGFR; 7pl2), non-metastatic cell 3 (NME3; 16ql3.3), 2-4-dienoyl CoA 
reductase 2 (NME4; 16pl3.3) and serine (or cysteine) proteinase inhibitor, clade E 
(nexin, plasminogen activator inhibitor type 1), member 2, or glial-derived neurite 
promoting factor, protease inhibitor 7 (SERPINE; 7q21.3-22) were detected in the 
majority of Grade 11 astrocytomas but not in normal brain tissue. In addition, the 
AADH, secreted protein, acidic, cysteine-rich (SPARC; 5q31-33), low density 
lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) (LRP; 12ql3-14), 
platelet derived growth factor receptor-a (PDGFRA; 4ql2), 60S ribosomal protein L5, 
pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) 
(PTN; 7q33), dehex 3-like or B-lymphoma- and BAL-associated protein (DTX3L; 
3q21.1) were demonstrated to be upregulated more than 2-fold in 20-60% of Grade 11 
astrocytomas. Meanwhile, interferon induced transmembrane protein 1 (IFlTM l;
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llp l5 .5 ), CDC-like kinase 1 (protein kinase CLK), teratocarcinoma-derived growth 
factor 1 (TDGFl; 3p21-31), bridging interactor 1 (BINl; 2ql4), G-protein receptor 
binding 2 associated (GRB2-associated) binding protein 1 (GABl; 4q31.1), tyrosine- 
protein kinase receptor TYR03 precursor (TYR03; 15ql5.1-21.1), lactate
dehydrogenase A (LDHA; 1 lpl5.1), adducing 3, guanylate kinase 1 (GUKl; lq32-41), 
cell division cycle 10 (CDCIO), and keratin 8 (KRT8; 12ql3) were down-regulated 
more than 50% in the majority of the tumours (Huang et al. 2000).
Similarly, distinctive molecular profiles of low-grade and high-grade astrocytomas 
were demonstrated using oligonucleotide-based microarray analysis of approximately 
6800 genes (Rickman et al. 2001). Out of the above panel, a total of 378 genes differed 
in their expression patterns between Grade II astrocytomas and normal brain samples, 
while 1305 genes had differences in expression levels between GBMs and normal brain 
tissue samples. A comparison of the expression profiles of GBMs with Grade II 
astrocytomas, found 183 genes expressed at a higher level and 149 genes at a lower 
level. Many of the genes found upregulated in GBMs encoded proteins that are involved 
in cell proliferation or cell migration (Rickman et al. 2001). A second study of 
oligonucleotide-based microarray on four GBMs identified several downregulated ion 
and solute transport-related genes (Markert et al. 2001), while several others: aquaporin- 
I, solute carrier family 2 (facilitated glucose transporter), member 3 (SLC2A3; 
I2pI3.I), tumour necrosis factor (ligand) superfamily, member II or osteoporin 
(TNFSFII; I3qI4), nicotinamide N-methyltransferase (NNMT; I Iq23.I), murine 
double minute 2 (MDM2; I2qI3-I4), granulin (GRN; I7q21.32), tumour protein p53 
binding protein, I or cytokine and P53 binding protein (TP53BPI; 15q15-21), and 
macrophage migration inhibitory factor (MIF; 22ql 1.23) were found to be upregulated.
Several GBM short-term cell cultures (STCC) and solids tumour samples (biopsies) 
were analysed by array CGH to determine expression levels of 58 target oncogenes 
(Hui et al. 2001). Their study revealed high-level amplification of CDK4 (I2qI3), 
glioma-associated oncogene homolog I (GLI; I2qI3.3-I4.I), MYCN (2p24.3), MYC 
(8q24), MDM2 (I2qI3-I4) and PDGFRA (4qI2), and frequent gains of 
phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA; 3q26.3), EGFR 
(7pI2), chromosome segregation I-like (CSEIL; 20qI3), NRAS (Ipi  3.2), MYCN
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(2p24.3), Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog (FOR; 
lp36.2-36.1), estrogen receptor 1 (ESR; 6q24-27), ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 (ABCBl; 7q21.12). This suggests involvement of these genes 
in GBM tumourigenesis.
1-18 W hole Genome Amplification (W GA)
Metaphase CGH requires large amounts of starting DNA (typically 0.2-lug; Wells et 
al., 1999) for the labeling (nick-translation) reaction. However, several tumour samples 
for this study had small amounts of starting DNA and therefore required amplification 
by a procedure capable of achieving uniform whole genome replication. The concept of 
whole genome amplification (WGA) arose as the polymerase chain reaction (PCR) was 
adopted to replicate regions of genomes that are of biological interest (Telenius et al., 
1992; Zhang et al., 1992) and has been successfully used to amplify minute amounts of 
DNA (for example, from a single cell (i.e., ~6pg) for CGH to assay chromosomal 
mosaicism in preimplantation embryos (Wells et al., 1999; Wells & Delhanty, 2000).
Several approaches are used to achieve WGA, among them in vivo amplification in 
Escherichia coli hosts, polymerase chain reaction (PCR), and isothermal rolling circle 
DNA replication. Ideally, a WGA procedure should avoid bias (i.e., preferential 
amplification of parts o f the target genome) while achieving accurate replication of the 
original genome sequence. A number of studies have demonstrated that both DOP 
(degenerate oligonucleotide-primed) PCR (DOP-PCR) and MDA (multiple 
displacement amplification), an isothermal (non-PCR) strand-displacement 
amplification procedure) meet these criteria (for example. Wells et al., 1999; Wells & 
Delhanty 2000; Detter et al., 2002; Hawking et al., 2002; Hughes et al., 2005). 
Amplification products obtained using DOP-PCR are typically between 300bp-3Kb and 
therefore can be labelled without enzyme digestion prior to use in metaphase CGH. On 
the other hand, rolling cycle amplification such as MDA produce DNA of ~10Kb, 
which has to undergo enzyme digestion during labelling to produce fragments suitable 
for hybridization.
■ ■ ■ . . . .  
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One immediate advantage of MDA results from the o29 DNA polymerase error rate, 
which is reported to be ~1 in 10^-10^ (Esteban et ah, 1993) in contrast to Taq DNA 
polymerase (used in DOP-PCR), which has an error rate of 3 in 10"* (Eckert & Kunkel, 
1991) or 1.6 in 10  ^ for Pyrococcus furiosus (Pfu) DNA polymerase (Lundberg et ah, 
1991). Thus, although both DOP-PCR and MDA are generally considered suitable for 
generating products that are non-biased and an accurate replication of the original 
genome sequence, for this study, the need to generate DNA of a higher size as well as 
consideration of the slight advantage of lower error rate reported by earlier studies, led 
us to choose the MDA procedure over DOP-PCR for amplifying samples with 
inadequate DNA.
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1-19 Aim s o f  this thesis
High-grade astrocytomas, in particular glioblastoma multiforme (GBM), which is the 
most common primary tumour of the brain, continue to present challenges in their 
management. Primarily due to the infiltrating nature, there is no effective treatment for 
glioblastomas, while on the other hand, relatively little is known about the processes by 
which they develop. The way forward appears to be in the design of effective novel 
therapies and treatments for GBM, which requires research, to identify cellular and 
molecular mechanisms that cause GBMs. Modelling of astrocytomas by genetic 
manipulation of mice suggests that deregulation of pathways that control gliogenesis 
during normal brain development, such as the differentiation of neural stem cells 
(NSCs) into astrocytes, might contribute to GBM formation. These pathways include 
growth factor-induced signal transduction routes, and processes that control cell cycle 
progression such as the pl6-CDK4-RB and the ARF-MDM2-p53 pathways. The 
expression of several components of these signaling cascades has been found altered in 
GBM, and recent data indicate that combinations of mutations in these pathways may 
contribute to GBM formation, although the exact mechanisms are still uncertain. High 
malignancy grade astrocytomas typically display a wide variety of molecular 
aberrations and biological behaviours, which have been used to classify them as 
primary (de novo) or secondary (progressive). The assumption seems to be that 
astrocytes from which the tumours originate are homogeneous. However individual 
tumours within the two established categories are known to display a wide range of 
molecular differences as well as intratumoural heterogeneity. Several possibilities could 
account for this phenomenon; for example, a straightforward possibility could be the 
random genomic rearrangements that arise as tumours evolve. An alternative possibility 
is the likelihood that certain aberrations could be associated with molecular 
heterogeneity in astrocyte subpopulations from which tumours originate. This view is 
supported by findings of various investigators, showing that there is regional restriction 
of astrocyte progenitors in the CNS. In order to shed light on this matter the objective of 
this project was to establish the frequency of copy number alterations, and their extent 
and chromosomal locations in a group of relatively young adults diagnosed with high 
malignancy grade astrocytomas. In the longer term, it is hoped this data can be used as a 
framework for investigating a relationship of various copy number alterations and 
prognosis.
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CHAPTER 2 MATERIALS AND METHODS
2-1 THE RESEARCH PROPOSAL
This study involves 32 tumours of 31 patients (table 2-1) diagnosed and treated for high 
malignancy grade astrocytomas.
Table 2-1
1 Anaplastic astrocytomas (A A ) -  W HO Grade 3
1.1 Solid tumour samples (biopsies) (A S)
ID Gender Age (Yrs)
l . l A S24 F 48
1.2 AS2641 F 40
1.3 A S 2 7 0 6 F 38
1.4 A S 272I M 46
1.5 A S2745 M 31
1.2 A A  Short-term cell cultures (STCC) (A C )
1.2.1 A C 545  Male 38
Glioblastom a multiforme (G B M s) -  WHO Grade 4 
2 . 1 Solid tissues (biopsies) (G B S)
2 . 1.1 G B S l l M 53
2 . 1.2 G B S1575 F 61
2.1.3 G B S1625 M 60
2.1.4 GBS2051 M 44
2.1.5 G B S2093 M 53
2 . 1.6 G B S 2126 M 41
2.1.7 G B S 2409 F 41
2 . 1.8 G B S 2532 M 50
2.1.9 G B S 2858 M 54
2 . 1.10 G B S 3044 M 56
2.2 D N A  o f  G BM  biopsies amplified by Multiple Displacement  
Amplification (M D A )
2.3
2 .2.1 G B S 1595m F 67
2 .2.2 G B S  1926m M N /A
2.2.3 G B S 2650m M 44
2.2.4 G B S 2687m M 48
2.2.5 G B S 2848m M 46
D N A from G BM  Short-term Cell Cultures (S
2.3.1 G B C 160 M 40
2.3 .2 G B C 1397 M 38
2.3.3 G B C 1510 M 50
2.3.4 G B C 1706 M 47
96+2 .3.5 G B C 1724 M 44
2.3.6 G B C 1752 M 44
2.3.7 G B C 2394 M 47
2.3.8 G BC 2685 M 48
■ ‘ . ..........
Cytogenetic A nalysis o f  D N A  Copy Number Aberrations in High Malignancy Grade Astrocytomas
Chapter 2 Materials and Methods
2.4 D N A  from G BC amplified by M DA
9^2.4.1 G B C 1612m M 44
2.4.2 G B C 1719m F 69
2.4.3 GBC 1760m F 57
^*2.4.4 GBC 1724m M 44
Explanation for table 2-1
List o f  tumour samples and patients investigated in this study. There was no constitutional 
blood or normal DNA to serve as a match for the tumour. F, Female, M, Male, N/A not 
available, *, same tumour sample, same patient
Continuation o f  text...
Laboratory data were acquired from 19 frozen biopsies and 14 short-term cell cultures 
obtained from the tumour archive held at the Institute of Neurology’s Department of 
Neurosurgery. The Institute of Neurology is a department of University College London 
and is affiliated to the National Hospital for Neurology and Neurosurgery. A number of 
tumour samples were of patients previously enrolled in the MRC-BR05 multi-centre 
Clinical Trial (MRC Brain Tumour Working Party, 1990; 2001), which was conducted 
between 1985 and 1997. Additional specimens were from patients managed in the 
period after the clinical trial, and were provided by several previously participating 
hospitals, such as the Preston NHS Trust, Addenbrooke, and several other hospitals. 
The research proposal was reviewed and approved by the Education Sub-committee of 
the Academic Board of the Institute of Neurology.
2-1-1 BAC K G RO UN D
This study investigated chromosomal copy number abnormalities (CNAs) in 33 high 
malignancy grade astrocytomas, primarily using the method of comparative genomic 
hybridisation (CGH). Seven tumour specimens were investigated further by array CGH, 
however one particular glioblastoma was investigated more extensively, largely for 
purposes of optimizing the various experimental procedures and also to illustrate 
several other fluorescence in situ (FISH) procedures, such as multicolour FISH 
(MFISH), and microarray CGH. Each tumour specimen was assessed for chromosomal 
copy number alterations. Survival data were compared in patients with and without 
losses and gains in chromosomal material, stratifying for only age, sex and grade, which 
were the clinical variables for which data were available.
68
Cytogenetic Analysis o f DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
Chapter 2 Materials and Methods
2-1-2 CONFIRM ATION OF HISTOLOGICAL DIAGNOSIS  
Although the tumour classification and grades at the time of recruitment into the BR05 
trial were determined by a Pathology Reference Panel comprising three pathologists 
(MRC Brain Tumour Working Party, 2001), in the course of this study each specimen 
(histology slide from previous biopsies) of patients recruited into the study was 
reviewed by Professor Tamas Revesz and myself. Our objective was to identify the 
blocks with sufficient amount of tumour, and to reconfirmation the diagnosis. Professor 
Revesz of the Department of Neuropathology at the Institute of Neurology is a 
consultant neuropathologist and was previously one of three members constituting the 
Pathology Reference Panel for the BR05 Clinical Trial.
2-1-3 PATIENTS A N D  SAM PLES
The study involved 31 patients with high-grade astrocytomas. Two tumour samples 
(GBM/C1612, GBM/C1724) were from one patient. Tumour DNA was available as 
frozen solids in 19 cases and as short-term cell cultures in 14. The solids comprised 5 
A As and 15 GBMs. Nine starting DNA samples were inadequate and needed to be 
amplified in order to generate sufficient amounts of “representative DNA” for CGH, 
and other experimental procedures. Five of these DNAs were originally from biopsies 
and 4 from cell cultures. For whole genome DNA amplification we used the method of 
multiple displacement amplification (MDA) (Dickson et al., 2005).
2-1-4 GENDER A N D  AGE DISTRIBUTION
There were 8 females, three of them with the diagnosis of AA. Of the 23 males 20 had 
GBMs. The patients’ ages ranged from 31 to 69 years, with the mean of 46.4 years. 
Only 6 patients were aged over 55 years, four of them females.
2-2 M ETHODS 
2-2-1 M ETAPHASE CGH
An investigation of the genome-wide copy number alterations for each of the 33 
tumours was performed using CGH. Tumours GBM/C1724 was subjected both to 
reverse hybridisation and to MDA to compare results with those obtained by the
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conventional labelling procedure (details follow). This tumour was in addition 
investigated by the methods of array CGH and MFISH.
2-2-2 CELL CULTURES
Patients with insufficient or with no remaining frozen biopsy tissues but who had frozen 
cells had their DNA prepared from this source. Other than the consideration for tumour 
grade, the selection of cell lines for culture was relatively random. However, the 
prevailing tendency was to select cell-lines of lower passage (p) times, commonly p2 -  
p6 although several cultures were of higher passage. For example, GBM/C1724, used 
for array CGH and MFISH, was of passage number 12.
2-2-3 RE-ESTABLISHING CELL CULTURES FROM FROZEN  
ALIQUOTS
Aliquots of one milliliter (1 ml) comprising a suspension of ~10^ astrocytes in a mixture 
of fetal calf serum (FCS) with 10% dimethyl sulfoxide (DMSO) which serves as a 
cryopreservative protecting cells from structural damage during deep freezing in liquid 
nitrogen at temperatures of ~ minus 196C, were recovered from liquid nitrogen, thawed 
at room temperature and transferred into a 25ml sterile universal container where cells 
were washed in 9mls Hank’s balanced salts solution (HBSS). The cells were then 
pelleted from solution by centrifugation at 1000 rpm for 5 minutes and the pellet of 
cells resuspended in 10 mis of the Nutrient Mixture F-10 (HAM), which contained 25 
mm Hepes Buffer, fetal calf serum (FCS), L-Glutamine, penicillin and streptomycin 
(GPS) and NaHCOS (Invitrogen/Gibco, Paisley, Scotland). The cell suspension in the
nutrient mixture was transferred to a 75 cm^ culture flask and volume made up to 20ml 
with additional nutrient mixture. Cell culture flasks from Bibby Sterilin (European 
distributor for the Iwaki range of cell biology plastic-ware) were used for cell cultures. 
These flasks have a special surface treatment to ensure optimum attachment of 
anchorage-dependent cells. The flasks were incubated in a chamber of 5% CO2, at 37^C 
throughout the period of cell growth. All procedures involving exposure of the cells to 
the outside were carried out in the safety of the laminar airflow cabinets (Gelaire, INC 
Biochemicals, Basingstoke, Hampshire).
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2-2-3-1 M AINTAINING CELLS IN CULTURE
Cells were inspected on average two to three times each week. This enables early 
detection and disposal of the occasional infected cultures and feeding the cultures with 
rapid doubling times. On average cells were fed once a week or when the nutrients were 
depleted from the medium depending on which came first. When the medium is 
depleted of nutrients and the amount of metabolic waste predominates, the medium 
becomes acidic and assumes an increasing bright yellow and pale colour. A flask due 
for replenishment of nutrients was transferred to the laminar airflow cabinet from where 
the old media was aspirated and replaced with equal amount of HAM’s FIO (Sigma- 
Aldrich).
2-2-S-2 PASSAGING OF CELL CULTURES
In order to obtain sufficient cell numbers for a high yield of DNA (averaging 10 -  
20X10^ cells) cells were harvested and passaged three times. Cultures were initially 
established in one medium (25 ml) flask which, when confluent, was passaged into 
three flasks of the same size. In the second passage, one of the three was in turn 
passaged into one large (75 ml) flask while the two remaining were maintained as 
backup in case of contamination. Subsequently, they were frozen if there was no 
immediate need. Once confluent, the large flask was passaged into three flasks of the 
same size. The passage process involved aspirating or draining the nutrient media from 
confluent monolayer, flask rinsed with 1.0 ml trypsin EOT A (Life Technologies), which 
was drained and the cells incubated in 3-5 mis of trypsin for 2-3 minutes or until the 
cells are fully detached. Caution was taken not to over expose the cells to trypsin 
treatment for fear of inducing damage to the cell membrane. Cells were assisted to 
detach by intermittently striking the lower edge of the flask against the palm of one 
hand and gently swirling contents. When a majority of cells were detached and freely 
floating about, an equal amount of nutrient medium containing fetal calf serum, which 
naturally contains the enzyme antitrypsin, was added to stop the digestive activity of 
trypsin. The cell suspension was then pipetted into a 25ml universal container 
(collecting tube) and cells pelleted by centrifugation at 1000 rpm for 5 minutes. The 
liquid phase was aspirated and the cells resuspended in 10 mis of HAM’s F-10 nutrient 
medium. This suspension was divided equally between the required culture flasks. The 
nutrient medium in each flask was adjusted to 20.Omis and 30.0 mis respectively for the
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medium and large flasks. The number of times the cell line was passaged was updated 
from the previous passage number by a factor of one.
2 -2-S -2-1 PROCEDURES FOR CONFLUENT CELL CULTURES
When the cells in the large flasks are confluent they are detached with trypsin as 
previously described. To the trypsin - cell suspension is added 5 mis PBS buffer and 
cells pelleted by centrifugation at 3000 rpm for 5 minutes. The cells are washed a 
second time by resuspending in 10 mis PBS buffer from which the cells are pelleted and 
the media discarded before the cells are resuspended in 10 mis of fresh PBS and the cell
counted. A cell suspension containing approximately 2x10^ cells is pelleted and 
resuspended in 2.0 mis PBS buffer and DNA extracted following the QIAgen protocol 
for DNA extraction from cell cultures. Any surplus cells from back up flasks and in 
excess of the 2x10^ needed for DNA extraction are frozen by resuspending the detached 
cells in 10.0 mis of nutrient mixture and the cell count determined. The cells are 
pelleted and resuspended in an appropriate amount of FCS containing 10% DMSO
(Sigma Aldrich) to a final concentration of 1x10^ cells per ml. Aliquots of 1.0 ml cell 
suspension are stored in appropriately labelled cryotube vials which are frozen down 
progressively first to -70®C for the first 24 hours after which the vials are considered 
safe for transfer to LN2 tanks for long-term storage.
2-2-3-3 EXTRACTION OF TUM OUR DN A  FROM CELL CULTURES
Genomic DNA was extracted from LN2 frozen-biopsies and short-term cell cultures 
using respectively the QIAGEN tissue protocols [DNA Mini Kit] for solid (biopsy) 
tissues, and for cultured cells (QIAamp DNA Blood Mini Kit Handbook, January 1999) 
(QIAGEN Ltd, Crawley, Sussex). After elution DNA was stored at -20^C until needed. 
DNA purified by the DNA Mini Kits ranges in size up to 50 Kb, with fragments of 
approximately 20-30 kb predominating. This is an optimal size for preparation of the 
probe required for CGH by Nick translation and, in addition, DNA of this length is 
denatured completely during thermal cycling and can be amplified with the highest 
efficiency.
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2-2-3-4 MEASUMENT OF DNA CONCENTRATIONS 
After DNA extraction the assay of DNA concentration was done with the DyNAQuant 
200 fluorometer (Amersham Pharmacia Biotech, Little Chalfont, Burkinghamshire) 
using the DyNAquant Capillary Cuvette kit. The DyNAQuant 200 fluorometer is a filter 
fluorescence photometer for accurate measurement of low DNA concentrations using 
Hoechst 33258 dye (Sigma, St. Louis, USA for Amersham Pharmacia Biotech). The 
DyNAQuant 130 kit includes a capillary cuvette and capillary tubes which hold up to 9 
pi of solution.
2-3 MULTIPLE DISPLACEMENT AMPLIFICATION (MDA)
The MDA-protocol used in this experiment required the concentration of DNA to be 
approximately ~10ng/ul. This would yield 5ng of DNA in 0.5ul, which was the initial 
volume that went into the reaction tube. Other reagents were added to the tube to make 
up 5Oui reaction volume, in the following order: 26.5ul ddHiO, 12.5ul of dNTP mix and 
0.5ul DNA polymerase (table 2-2).
DNA
sam ple ID
Starting
Cone.
(ng/ui)
Dilution
Ratio
Post­
dilution
Cone.
DNA
Cone.
O.Sul
Reaction
Buffer
(ul)
ddHîO
(ul)
dNTP
mix
(ul)
0 2 9
(ul)
Total 
Reaetion 
Vol (ul)
AS2721 93 1:9 9.3 4.7 10 26.5 12.5 0.5 50
GBC 1724 670 1:99 6.7 3.4 10 26.5 12.5 0.5 50
EF 665 1:99 6.65 3.4 10 26.5 12.5 0.5 50
MPE 112 1:9 11.2 5.6 10 26.5 12.5 0.5 50
Control 10 - - 5 10 26.5 12.5 0.5 50
Table 2-2 shows the work-up of some of the DNA samples used in this study. Shaded 
boxes indicate components that constitute the total reaction mixture for each sample.
Into each of the tubes containing 0.5ul aliquots of each sample (in the above example,
ranging in concentration from 3.4-5.6 ng of DNA) were added lOul of reaction buffer,
and the tubes were then vortexed briefly, spun down, and samples denatured at 95C for
3 minutes, before returning to ice buckets for addition of the remaining reagents. Each
tube of denatured-DNA-samples/buffer mix was made up with 26.5 pi of ddH20, 12.5ul
of dNTPs and 0.5ul Phi29 DNA-polymerase (with reagents added in that order), and
immediately transferred to a circulating waterbath, which regulated at 30C, and left to 
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incubate for 16-18 hours (overnight) (alternatively a thermocycler may be used). After 
the incubation period tubes were heated at 65C for 10 minutes, to stop the reactions, and 
samples were then stored at -20C until required. DNA concentration was quantitated 
with Picogreen Fluorimeter (Invitrogen) following which approximately lug of the 
reaction mix was purified by phenol/chloroform isopropanol precipitation. The pellet 
was resuspended in 5 pi of Elution Buffer (Qiagen) and a small sample (containing 
~50ng) was run on 1% agarose gel to determine the size of DNA fragments.
2-4 LABELLING OF TUM OUR DN A
Tumour DNA was labelled using SpectrumGreen-dUTP (Vysis, Downers Grove, IL). 
The reagents were mixed in chilled sterile 0.5 ml eppendorf (PCR) tubes, which were 
wrapped in aluminum foil to protect the reagents from direct light and kept in buckets 
of ice. Initially, approximately 1 ug of genomic DNA from each tumour was aliquoted 
into two separate eppendorf tubes and mixed with 2.5pl of 0.2 mM SpectrumGreen, 5pi
0.1 mM dTTP, 10 ml 0.1 dNTP mix (dATP, dCTP, dGTP), 5pl 10 X nick translation 
buffer. Then 5pl and lOpl nick translation enzyme was introduced into either of the 
tubes, respectively. The final volume was adjusted to 50pl with nuclease-free water. 
The tubes containing the mixtures were vortexed briefly and incubated at 15°C for 2 
hours. The reaction was stopped by heating at 70°C for 10 minutes in the thermocycler 
and the samples transferred to ice or stored in refrigerator at -20°C while the probe size 
was being determined, or until the needed for hybridisation. The optimum probe size for 
CGH analysis is in the range of 300-3000 bp. As the quality of starting DNA varies 
greatly between different samples, two volumes of enzyme were routinely used for each 
sample during the first labelling reaction to ensure that the appropriate sized smear was 
obtained. After optimizing the labelling protocol we routinely labelled DNA in only one 
tube, usually digesting lug of DNA for 2 hours with lOuL of nick translation enzyme in 
a 50uL reaction mix, which resulted in an optimum probe size whose length ranged 
between 500 bp and 3 Kb.
2-4-1 DETBRMINIG THE PROBE SIZE
The size of the labelled DNA was estimated by running 5 0 -  100 ng of the reaction mix 
from each tube, mixed with 2pl PCR loading buffer on a 1% agarose gel (dissolved in 
tris-acetate-EDTA buffer (TAE), stained in ethidium bromide (0.5 mg/ml) to aid with
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the visualization of DNA under UV light. The 1 KB marker DNA, EcoRI 911 was used 
to provide the size ladder for estimating the size of the probe. The electrophoresis was 
carried out with the gel immersed in 1 % TAE, at lOOV for 60 minutes; at other times, 
60V, or alternatively 50 ma, for 60 minutes, which produced similar outcomes.
2-4-2 PREPARING THE PROBEMIX
CGH was performed according to Mohapatra (1998) with some modifications. For 
standard CGH experiments, test DNA and normal DNA was labelled by nick translation 
using DNA Taq polymerase (Life Technologies) with SpectrumGreen and 
SpectrumRed respectively. In order to produce a hybridisation signal with equivalent 
intensities various amounts of test and normal DNA were hybridised in a ratio of 2:1 
SpectrumGreen to SpectrumRed labelled DNA. For most experiments, four hundred 
nanograms ((400ng) of SpectrumGreen tumour probe was combined with 200 ng of 
SpectrumRed total genomic reference DNA (Vysis) and 10 mg Cot-1 human DNA 
(Vysis) in 0.5 ml eppendorf tubes. To each tube was added 0.1 volumes of 3M sodium 
acetate and 2.5 volumes of 100% ice-cold ethanol to precipitate the DNA. However, at 
other times lug/0.5ug of test to normal DNA with 20 ng of human Cot-1 were ethanol- 
pelleted in 0.5ml eppendorf tubes using 0.1 volumes of 3M sodium acetate and 2.5 
volumes of ice-cold (-20°C) 100% Et OH.
Samples were vortexed briefly and placed at -20°C for 1 hour or in dry ice or -75°C for 
15 minutes, followed by centrifugation at 13,000 rpm for 30 minutes to pellet the DNA. 
After the supernatant was removed the and the sides of the tube blotted dry pellet was 
dried for less than 1 minute under vacuum and was then resuspended in lOpl of 
hybridisation mixture, and dissolved in CGH hybridiation buffer containing 50% 
formamide, 10% dextran sulfate. The probe mixture was denatured in a water bath at 
73°C for 5 minutes immediately prior to hybridisation, and hybridised to normal 
metaphase spreads (Vysis Inc., Downers Grove, IL) for 72 hours. Control experiments 
using Vysis-labelled SpectrumGreen and SpectrumRed normal DNAs (for negative 
controls) and Vysis-labelled MPE600 (for positive controls) were performed at each 
hybridisation experiment.
. . . . .
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2-4-3 HYBRIDISATION TO M ETAPHASE SPREADS 
Normal metaphase slides made from phytohaemaglutin-stimulated lymphocytes derived 
from a karyotypically normal male donor were procured from Vysis. The factory 
process involved culturing lymphocytes for 48-72 hours prior to synchronisation with 
thymidine to produce chromosomes with lengths of 400-550 bands. Hybridisation areas 
were marked with a diamond pen and the identity of the tumour indicated at the label 
end of the slides using a sharp pointed lead pencil. The metaphases were denatured for 5 
minutes at 73°C by immersing in 50ml jar of denaturing solution containing formamide, 
20xSSC and nuclease-free water, then dehydrated serially by immersion for 3 minutes 
in ice-cold 70% ethyl alcohol, followed by 2 minutes’ duration each in 85%, and 100% 
ethanol.
While the slides were drying, the probe was similarly denatured for 5 minutes at 73°C 
waterbath, following which the tubes containing the probe were kept in a warm 
environment (waterbath at 50°C) until time of hybridisation. After air-drying the 
metaphase slides, 10 pil of the denatured probemix from two different tumours was 
applied to previously designated hybridisation sites on the normal metaphases slides, 
which were immediately covered with coverslip and sealed with cow gum prior to 
incubation in a sealed (+/- humidified) container for 72 hours, at 37°C.
2-4-4 POST-HYBRIDISATION W ASHES A N D  COUNTERSTAINING  
WITH DAPI
The cow gum seal and coverslip were removed on the third day. Slides incubated in a 
dry chamber needed immersion in cool room temperature (RT) 0.4xSSC/0.3% NP-40 to 
loosen the gum so that the slide covers can be removed. Otherwise, the slides are 
normally washed by immersion in warmed 0.4x SSC/0.3% NP-40 at 74°C for 2 
minutes, which is followed by immersion in 2x SSC/0.1% NP-40 at room temperature 
for 1 minute, prior to air-drying in darkness. Hybridisation sites on the dry slides were 
counterstained with 4,6-diamidino-phenylindole (DAPI) in antifade solution (Vysis).
2-4-5 DIGITAL IM AGING A N D  ANALYSIS
Metaphase images with uniform hybridisation were acquired with a Quantitative Image
Processing System (QUIPS) software using a Zeiss Axioscope epifluorescent
- - . . . . . .  . . . .  -  .
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microscope equipped with a triple band pass filter (Vysis) designed to simultaneously 
excite and emit light specific for DAPI, SpectrumGreen and SpectrumRed, and a cooled 
charge-coupled device camera (Photometries, Tuscon, AZ). The hybridisations were 
evaluated by visual inspection in the course of image acquisition, and during digital 
image analysis. A hybridisation of good quality is easier to karyotype and results in 
accurate interpretations of the data within and across experiments. Metaphases were 
selected for CGH analyses if they had minimum or negligible background fluorescence, 
(that which was low and uniform around each chromosome) with minimal surrounding 
cytoplasm and balanced red and green fluorescence. It is essential that the chromosomes 
are well developed, with an average length of 400 -  550 band, adequately separated 
from each other and should preferably be free from overlapping. It is preferable to have 
all the chromosomes of a metaphase accessible in the X I00 magnification microscope- 
objective so as to capture all of them in a single digital image during acquisition.
2-4-6 CAPTURING M ETAPHASE IMAGES
Chromosome images from hybridised metaphases were captured using SmartCapture 
softwares, and the features of this program are described briefly here. The SmartCapture 
program has several features for capturing multicolour images of metaphases resulting 
from hybridisation. The camera settings are configured to enable the condenser on the 
microscope to give the best illumination and duration of exposure to light. A binning of 
2 X 2 is usually set for a lOOx objective. Once the capture settings have been verified, 
the rest of the capture procedure is automated through a series of dialogue boxes, which 
allow the operator to decide whether to save or discard images that have been acquired. 
Suitable images are exported and saved in an ICS format (described below). When the 
file is saved in the ICS format, two files are automatically created; one “.ics”, the other, 
an “.ids.” The “.ics” file contains a text description of the image while the “.ids” file 
contains the image data. Both of these files were required to analyse the image using the 
Quips program.
2-4-7 EDITING THE M ETAPHASE AN D  KARYOTYPE  
The process of editing the metaphase karyotype was done in the main window, which is 
displayed on the computer screen. The CGH/Karyyotyper program provides for 
multiple metaphase image analysis to generate a single karyotype. Each window also
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displays a selection of command options and tools used to edit the metaphase, such as 
tools for separating a touching pair, overlapping or cluster of chromosomes, and it also 
allows the operator to include/exclude unsuitable chromosomes from a karyotype or 
from a CGH profile, as well as repositioning those that are inverted and for classifying 
or declassifying chromosomes.
2-4-8 CLASSIFIYNG CHROMOSOMES
There are several methods for classifying chromosomes using the Quips software. The 
software will automatically classify the chromosomes by size, using the banding- 
specific classifier. Generally, there will be one or more errors in the computer-generated 
karyotype, and the operator then manually edits the results to complete the karyotype. 
The chromosomes are organized in a standard human karyotype format to facilitate 
examination. Several features are available for evaluating and editing a karyotype, for 
example, the “Reference window”, which is used for examining a metaphase image in 
the original form. To facilitate a review of the classification, several features of the 
chromosome can be selected for the computer to display automatically, such as the 
centromere and axis of symmetry, or an option can be selected to show an ideogram and 
how to align the chromosomes. A set of tools is included that can be used to reposition a 
centromere, rotate and straighten chromosomes and exclude objects from the karyotype. 
A good knowledge of distinguishing characteristics and normal alignment of the entire 
chromosome complement is necessary for the operator to be able to recognize, identify, 
separate and match closely resembling chromosome sets and groups. On the basis of 
size, the chromosomes and classes into which they fall are ordered in decreasing length: 
typically 1 -  7, X, 8 -  22 and Y. The Quips CGH/Karyotyper program has classifiers 
for use with DAPI-, G- and R-banded chromosomes.
2-4-9 EXAM ING A  CGH RATIO PROFILE
A ratio profile of the fluorescence intensities is measured along each chromosome. To 
facilitate review of the profile data, it is possible to select various features, such as 
ideograms, to display in the main window, or to show the grid lines on the profile and 
the gain/loss bars. It is possible to exclude ratio profiles from profile analysis.
. . . .  . . . .    . . . . . .
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2-4-10 INTERPRETING CGH PROFILES
The interpretation editor of the Quips Interpreter program is used to select and evaluate 
the profile data from several metaphases in a single experiment. By combining the ratio 
profiles of homologous chromosomes from several metaphases, a reliable identification 
of likely areas of change in the sequence copy number is possible. The Interpreter 
program calculates the mean ratio and determines the standard deviation, confidence 
interval, and range for the data.
The ratios of fluorescence intensity along the chromosomes were quantitated as 
described by Piper et al (1995). The mean ratios of SpectrumGreen to SpectrumRed 
signal intensities were calculated with SmartCapture software (Vysis). On average 
between 10 and 20 metaphases were analysed and averaged to yield CGH profiles for 
each tumour. A relative gain was scored when the mean green:red ratio was above 1.2 
and relative loss, when the mean green:red ratio was below 0.8. CNAs were not scored 
at or near the centromeres. Gains were scored only when visual inspection revealed a 
bright and discrete signal confined to a subchromosomal region. If signals were too 
dim, the hybridisation was repeated. Similarly, if ratios were simultaneously altered at 
chromosomes Ip, 19, and 22, the experiment was repeated as recommended in 
Mohapatra et al., (1998).
2-5 A R R A Y -BA SED  COM PARATIVE GENOMIC HYBDRID- 
ISATION (arrayCGH)
Array CGH was performed using the Sanger Centre slides: numbers 11174, and 1309-42 
-  1309-47 (Sanger Centre Cambridge, UK), which were kindly provided respectively 
by Professor Ian Tomlinson of Cancer Research UK, and Dr Maria Bitner-Glindzicz of 
the Institute of Child Health (ICH), Great Ormond Street Hospital for Children, UCL. 
All 7 were 1Mb genomic arrays. The hybridisation experiments were performed by Dr 
Rosemary Ekong of the Galton Laboratory, UCL, at the genetics laboratory of the 
Institute of Child Health (ICH; UCL), where Rosemary was involved in conducting 
other genetic studies using micro arrays. In addition the ICH has an established platform 
for microarray analyses.
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2-5-1 LABELLING OF TARGET DN A
A total of 10 pg of genomic DNA from test samples and normal controls was first 
digested with M bol, then purified using the QIAquick® PCR purification kit (Qiagen, 
www.qiagen.com). A total of 2 pg of Mho 1-digested genomic DNA was then labelled 
by random priming with dCTP-Cy3 or dCTP-Cy5 (Amersham Biosciences, 
www.amershambiosciences.com). The reaction contained 300 pg/ml random octamers 
(BioPrime kit, 18094-011; Life Technologies), 0.5 mM dATP, 0.5 mM dTTP, 0.5 m 
dGTP, 0.2 mM dCTP, 80 U Klenow (Life Technologies, www.lifetech.com or NEB, 
www.neb.com) and 2 ml dCTP-Cy 3 or dCTP-Cy5 in a total reaction volume of 50 pi. 
Purifications were on Centri-Sep columns (Princeton Separations, www.prinsep.com) 
and storage was at -  20°C. Estimates of the amount of purified labelled DNA were 
obtained from ethidium bromide-stained gels of 1 pi of the Cy5-labelled DNA.
2-5-2 PREHYBRIDISATION A N D  HYBRIDISATION
Denatured slides were prehybridised with 10 pi of preheated (100°C for 3 min) 50% 
formamide, 5 x SSPE, 0.5% SDS, 5 x Denhardts, 100 pg/ml herring sperm DNA, 1 
pg/ml human COTl DNA, and an ethanol-cleaned 22x22-mm glass coverslip was 
placed over the arrayed area. The slide and coverslip assembly was placed in a humid 
box for 30 min at 37°C. Cy3- and Cy5-labelled test and reference DNA (3-4 mg of 
each) were combined in a microcentrifuge tube and spin dried under vacuum at room 
temperature, then suspended in 10 ml of hybridisation buffer (50% formamide, 5 x 
SSPE, 0.5% SDS, 60-80 pg human COT-1 DNA). This mix was denatured at 100°C for 
3 min and the DNA was preannealed at 37°C for 30 min. For hybridisation, the mix was 
placed on a new coverslip, which was overturned onto the slide to allow the DNA-hyb 
mixture to spread evenly before the coverslip was gently slid off to remove as much 
prehybridisation mix as possible without scratching the array. The slide was inverted so 
that the array side was facing down and the hybridisation mix on the new coverslip was 
immediately picked up and allowed to spread over the array area. The slide/coverslip 
assembly was placed in a humidified sealed Perspex slide chamber and incubated at 
42"C for 16 hr.
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2-5-3 POSTHYBRIDISATION
Washes were performed at 45°C using 50 ml prewarmed solutions and gentle agitation. 
Coverslips were floated off with 2 x SSC/0.1% SDS. Washes were 4 x8 min in 50% 
Formamide/2 x SSC/0.1% SDS, 4 x5 min in 2 x SSC/0.1% SDS, 1 x5 min in 0.2 x 
SSC/0.1% SDS, 1 x5 min in 0.02 x SSC/0.1% SDS, and a final rinse in sterile distilled 
water. Slides were dried by centrifugation at 1000 rpm for 3 min then stored in the dark.
2-5-4 SCANNING A N D  NORM ALIZATION
The arrays contained -3000 clones, covering the entire genome, most of them in 
duplicate although a small number were in quadruplicate sets. A rapid scan (40 mm 
resolution) of the microarray was performed with the Cyclone Gene Array Scanner 
(Scan Array®) using QuantArray image analysis software (Perkin Elmer: 
www://las.perkinelmer.com/). An area judged to be representative of the maximum 
signal was rescanned at higher resolution (10 mm) to minimize exposure of the 
microarray to the scanner’s lasers thus avoid significant photobleaching of the dyes. 
The software can save the image analysis data in a tab-delimited text file and 
automatically export the file to an Excel spreadsheet for spot-by-spot examination of the 
data.
2-5-5 A N ALYSIS OF AR R A Y  DATA
Despite experimental caution, variations occur within and between experiments. These 
variations, which result from random and systematic errors, affect measurements and, in 
turn, decrease accuracy. While random errors can be minimized through replicate 
measurements, systematic errors (biases) need to be controlled experimentally and 
require statistical correction (Nadon and Shoemaker, 2002). Systematic errors, 
associated with the properties of the different dyes, spotting, labelling strategy, 
hybridisation and posthybridisation conditions, quality of DNA samples, and scanner 
settings during data collection, result in variations (Nadon & Shoemaker, 2002; 
Quackenbush, 2002; Yang et al., 2002). Those biases associated with dyes include 
differing rates of incorporation of the different dyes during labelling, signal intensity of 
the different dye complexes, differing background noise, and the physical properties 
such as half-life and light sensitivity (Ekong et al., 2004). Therefore, before comparing
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the copy number of DNA sequences, data needs to be transformed so that 1) 
measurements due to artifacts are removed, 2) measured intensities are adjusted, and 3) 
the relative ratios (copy numbers) of the genomic sequences determined. Normalization 
is the initial transformation applied to microarray data, and balancing the data sets by 
normalizing with a set of appropriate control samples should minimize variations 
(Nadon & Shoemaker, 2002; Yang et al., 2002). Due to the presence of systematic 
variations in array experiments, each slide was normalized separately, using a set of 
controls (Ekong et al., 2004). Data acquired from the Cyclone Gene Array Scanner were 
analyzed with the QuantArray image analysis software (Perkin Elmer). For each spot, 
the software gave values for the red signal, the green signal, the local background, and 
the signal intensity after subtraction of the local background. Results were presented as 
ratios of red:green. In addition, the software generates whole chromosome and 
individual chromosome plots. In the array experiments no matching blood or normal 
DNA were available for comparative analysis with the patients’ tumour samples.
2-6 MFISH
2-6-1 TISSUE CULTURE A N D  HARVESTING
Passage 12 (p i2) short-term culture of GBC1724 was established as described in 
section 2-2-3. When the cultures were >70% confluent (average 48-72 hours) colchicine 
(Colcemid, Life Technologies, Gaithersburg, MD, USA) was added into culture and left 
for 40 minutes to synchronise the cells in metaphase. The cells were then harvested, 
washed, and resuspended in 0.075M KCL (hypotonic buffer) at 37C for 15 minutes. A 
small volume of 3:1 methanol:acetic acid fixative was added to the cell suspension and 
3 more fixative washes were subsequently performed. Cell pellet(s) were stored at -20C 
in fixative, until required for metaphase spreads preparation.
2-6-2 SLIDE PREPARATION
The equipment required for this step included a waterbath in which the water 
temperature was maintained at 75-80C. Although any waterbath would work, a 
waterbath with re-circulating capabilities close to the water surface was preferable, 
since the amount of steam produced is higher. The water level was brought to within I- 
2 cm from the top to allow heating of a flat metal surface (the lid of any metal plate) 
close to the temperature of the water. The metal plate was placed on top of the
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waterbath, covering it only partially, leaving an opening of about 5-10 cm through 
which hot steam could escape. At the other end of the metal plate, an area -10  cm wide 
was allowed to project ("hang out") in the air and not be in contact with the steam. A 2- 
3mm thick metal plate was used, which allowed a smooth temperature gradient across 
the metal plate surface, from ~70C at the "hot" end (facing the water) to about room 
temperature at the "cold" end of the plate.
2-6-2-1 M OUNTING M ETAPHASES ONTO SLIDES 
Using a common dropper, or an automatic pipette, 20-25 ul cell suspension was placed 
on a slide taken directly from its original package. Dropping from a height was not 
necessary. The suspension was spread evenly by moving the pipette tip gently across 
the slide surface. Excess liquid was drained on a paper towel. When the surface of the 
slide became grainy (as the fixative evaporated), the slide was placed facedown for 1-3 
seconds in the line of steam escaping from a hot waterbath, then it was dried by placing 
on the metal plate carrying a gradient of temperature across its surface, as described 
already. The hot steam is intended to overcome any potential influence of the 
atmospheric humidity, while the drying-temperature was varied depending on the 
positions on the metal plate where slides were placed to dry out.
Dried-out metaphase-mounted slides were examined, to determine the quality of the 
metaphase spreads, under the xlO or x20 objective (lens) of an Olympus microscope 
equipped with a charged coupled device (CCD) camera (Carl Zeiss, Welwyn Garden 
City, UK).
2-6-2-2 CHEMICAL AGEING OF SLIDES
Ethanol was used to achieve fixation and shape-preservation of the nuclei/chromosomes 
on the slide. The slide was place on the metal block of a thermocycler and 150-200 pi of 
ethanol pipetted onto the slide, which was then covered with a coverslip. The 
slide/coverslip assembly was in turn covered with ethanol-soaked gauze to prevent 
ethanol evaporation. The thermocycler block was programmed to increase its 
temperature to 94C, and to hold it there for 10-20 seconds before gradually cooling 
down towards room temperature. Depending on the machine, the heating and cooling 
speed is 1 -2C/second.
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An alternative method was to incubate the slide for 10-15 seconds each, in jars with 
ethanol at 50C, 75C, 94C, 75C and 50C, followed by drying at room temperature. 
Gradual thermal treatment works better than sudden temperature changes for 
chromosome shape preservation. To harden the chromosomes more and ensure sharper 
subsequent DAPI banding, the time the slides are incubated at 94C in ethanol can be 
increased up to 2 minutes.
2-Ô-2-3 PEPSIN TREATM ENT OF M ETAPHASE M OUNTED SLIDES 
Slides chemically aged for 10-15 seconds at 94C were incubated in 20-30ul of a 10% 
(w/v) solution of pepsin in HCL (0.5ml) made up with 49.5 ml distilled water, for 30-60 
seconds, rinsed briefly in PBS and incubated for 5 minutes each in 70% and 100% 
ethanol, followed by air-drying. Slides that were aged longer (i.e., for 2 minutes at 94C) 
were subjected to 1-2 minute pepsin pretreatment.
2-6-3 SLIDES & DNA-PROBE DENATURATION &
HYBRIDISATION
Slides were treated with 150ul of 70%formamide/2xSSC and cover with a 50x22mm 
coverslip, place slide on the metal block of the thermocycler and denature as described 
under chemical ageing. Once the thermocycler has cooled down to safe temperatures, 
slides are removed, the coverslip taken off and slides place for 3 minutes duration, each 
time, in 70% and 100% ethanol at room temperature, and then air-dried.
The MFISH chromosome probe (SpectraVysion, Vysis, Richmond, Surrey, UK) was 
suspended in 50ul of formamide hybridisation buffer and denatured by heating the vial 
for 5 minutes in a thermocycler at 75C and then cooling down to room temperature. The 
probe was left to re-anneal for ~ 30 minutes, then it was placed on the warmed slide, 
covered with coverslip and sealed with rubber cement and incubated for -24  hrs 
(overnight) in a moist chamber at 37C.
2-6-4 POST-HYBRIDISATION W ASHES AN D  DETECTION
Slides are washing serially in Detergent Mix solution made from 2:1 parts of 4XSSC
and Detergent DT solutions, respectively, followed by further washes in Stringency was
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solution, made from equal volumes of IxSSC and Deionised formamide (50 mis of 
each). The solutions, placed in Coplin jars (i.e.. Stringency wash solution (2 jars), 
IxSSC (2 jars), and Detergent wash solution (1 jar)) are prewarmed to 45C in a 
waterbath for at least 30 minutes before starting. Slides are removed from the 
incubation chamber and left in IXSSC for 5 minutes. The rubber cement is then taken 
off and slides left in the solution to remove the coverslip. The stringency wash is then 
done twice, each time incubating slides for 5 minutes, in separate jars of Stringency 
wash solution. In the final wash, the slides are incubated in the Detergent wash solution 
for 4 minutes. Taking precautions not to allow the slide to dry, 125ul of Detection 
Reagent, constituted by mixing Detection Reagent (MDA) and Detergent Wash 
Solution in a ratio of 1:9, was applied onto the slide and covered with paraffin 
immediately. Slides were then incubated in a humidified chamber for 15-20 minutes, 
paraffin removed and slides washed 3 times, for 4 minutes each, in Detergent wash 
solution at room temperature by emptying and refilling the Coplin jar. The slides were 
then drained well, and mounted with 5Oui of DAPI II®
The MFISH slides were viewed using a fluorescent microscope fitted with 
epifluorescence filters specific for Cy3, Cy3.5, Cy5, Cy5.5 and FTIC (Carl Zeiss, 
Welwyn Garden City, UK), imaged using a CCD camera, and karyotyping was 
performed using Quips SpectraVysion software (Applied Imaging, Newcastle, UK).
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3 CHAPTERS RESULTS o f METAPHASE CGH 
ANALYSES
3-1 Sample size
CGH data were obtained from brain tumour samples taken from 32 high-grade 
astrocytomas, six AAs and 27 OEMs. The patient from whom biopsy number GBC1612 
was obtained had tumour recurrence following initial treatment and underwent re­
operation, and biopsy RGBC1724 was taken. RGBC1724 was investigated to a greater 
extent in the course of this study. Its images and other data from various laboratory 
procedures undertaken throughout the study are presented in Chapter 4 to illustrate 
outcomes of CGH, MFISH and micro-array CGH procedures.
3-2 Validation o f  metaphase CGH Procedures
Validation experiments were designed to serve as controls, to validate the outcomes of 
the Nick-translation steps of the CGH procedure. This is the enzyme digestion of 
genomic DNA intended to produce smaller-sized DNA fragments that are 
simultaneously tagged with reporter / fluorescent molecules called the probe. In 
addition, validation procedures were used to test the quality of probe hybridisation to 
normal metaphases chromosomes mounted to a microscope slide. Trial experiments and 
various forms of internal controls were performed at key stages of the experimental 
procedures. The labelling steps of the CGH procedures were validated through 
simultaneous but separately labelling (different reaction mixtures/tubes) of test DNA 
and the unlabelled positive control DNA in the same experiment. This permits 
assessment of enzyme digestion that is simultaneous with the incorporation of the 
fluorescent label onto control and test DNAs under similar experimental conditions. The 
sizes of labelled genomic DNA probes that result from this process were determined by 
gel electrophoresis (see sample images below). Similarly, the conditions of a 
subsequent step, the hybridisation experiment, were monitored by simultaneously 
hybridising factory labelled control DNAs, the negative (normal DNA) or positive 
(MPE600, a breast cancer cell line with known chromosomal aberrations) controls at 
the same time as the test tumour probes are being hybridised. Thus the figures that 
follow illustrate the following sets of sample images.
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1) Several photographs of 1% agarose gel electrophoreses of DNA extracts and 
labelled probes. Samples of PGBS1625 (a solid), RGBC1724) (taken from cell 
culture and MDA-amplified DNA (RGbCl724mda)), originally unlabelled Vysis 
positive control (MPE600), Galton negative (normal) control (identified as Galton 
EF) as well as labelled probes thereof are highlighted.
2) A series of CGH images in the form of metaphase spreads, karyotypes and 
profiles, the results of trial experiments to validate the MDA-amplified DNA for use 
in metaphase comparative genomic hybridisation. The images are subdivided and 
arranged in the following order: images of hybridisation of the DNA of RGBC1724 
prior to MDA amplification (1) when the CGH experiment was performed with the 
test probe and reference labelled conventionally, i.e., green and red for test and 
reference DNAs respectively, (2) the CGH experiment done with the test probe and 
controls labelled in reverse order, and (3) the CGH experiment performed using the 
DNA of RGBC1724 that has been subjected to MDA amplification procedure. 
However, so as to illustrate other aspects of the CGH procedures, such as an initial 
general assessment of the success of the extraction procedure, and in order to 
roughly estimate the average size of the fragments making up the DNA extract, 
sample images of photographs taken following gel electrophoresis of genomic DNA 
extracts and probes are included.
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3-2-1 Figure 3-1 Gel photograph o f  a sample o f  genomic DNA extracts. 
Uncut and unlabelled genomic DNA from tumour samples run in 1% agarose gel and 
compared with separation of 1 Kb ladder. Lanes: 1=PGBS2051, 2=PGBS2126, 
3=AS2614, 4=AS2706, 5=AS2721, and 7=AS2745. All the samples show DNA with 
fragments sizes around 12 Kb and also showing lack of degradation. The gel was 
stained with ethidium bromide.
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3-2-2 Figure 3-2 Samples o f  genomic extracts o f  solids/biopsy tissues.
1% agarose gel stained with ethidium bromide, showing 3 uncut, unlabelled samples 1, 
2, and 3 respectively of AS2706 (subsequently excluded from the study), AS2721, and 
RGBS 1625. In lanes 1, n, and o are probes made from samples 1, 2 and 3 respectively. 
All the probes are labelled with Spectrum Green dUTP. The results of the gel 
electrophoresis of Spectrum Red dUTP labelled samples are shown in lanes m, o, and p. 
The unincorporated Spectrum Green and Spectrum Red are shown with sharp flare of 
fluorescence at the ends of lanes 1, n, q (unincorporated Spectrum Green dUTP), and in 
the middle of the DNA smears in lanes m, o, and q (unincorporated Spectrum Red 
dUTP). Comparison of the smears of labelled probes with the markers suggests 
fragment sizes in the region of about 200 -  1000 base pairs.
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3-2-3 Figure 3-3 - Gel photograph o f  MDA amplified DNA o f  RGBC1724 
and negative (normal) control DNAs 
Lanes numbered 1 and 2 are, respectively, those for DNAs of Galton normal (negative) 
control identified simply as EF, and RGBC1724. These DNAs have been 
cleaned/purified by phenol/chloroform method and then ethanol pelleted. Lane 3 is of 
the Spectrum Green-labelled probe of RGBC1724. The MDA-amplified DNAs of EF 
and RGBC1724 prior to PCI ‘cleaning’ are in lanes 4 and 5 respectively. The lane 
immediately before lane 4 contains the control DNA that was supplied with the MDA 
Kit.
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3-2-4 Figure 3-4 Sample genomic probes, r -  x.
Probe (r) was Galton normal (control) DNA, simply identified as EF. This sample is 
labelled with Rodamine. Lanes s -  x were of probes prepared from genomic DNA, 
respectively, of GBM/C2227, GBM/S2495, AS2614, GBM/C2410, GBS2867, and 
GBM/S1830, following MDA amplification. The average probe sizes are in the range of 
700-1000Bp, which is somehow over-digested (borderline?). Due to the fact that the 
starting amounts of DNAs were low, that combined with overdigestion may have 
contributed to poor hybridisation of most of these tumours. With the exception of 
AS2614 and GBS2867 the rest were excluded from the study for reason of failure to 
produce good quality hybridisations.
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3-2-5 Figure 3-5 CGH images o f  the negative control experiment (3-5 A -  
5D).
3-2-5-1 Figure (3-5 A) Sample metaphase spread o f negative control CGH 
experiment.
The negative control DNAs used were factory-supplied, labelled reference DNAs, one 
of them labelled green with fluorescein isothiocyanate and the other labelled red with 
Rodamine.
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3-2-5-2 Figure (3-5B) Karyotype o f the metaphase in (A)
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3-2-5-3 Figure (3-5C) Profile o f  fluorescence ratios for each
chromosome-set in the metaphase shown in 3-5A, generated from 
its karyotype (3-5B).
In this single metaphase, the average fluorescence ratio profiles for each pair of the 
autosomes, except CHR 3 where only one chromosome was available for analysis, are 
basically normal. But, there is a loss in 16q-ter, which may be due to an experimental 
artifact. It is partly for this reason that it is necessary, for a reliable outcome to take the 
average of individual ratio profiles from a minimum 5 chromosomes (Kallioniemi et al., 
1995) in a single experiment. In practice most investigators currently recommend 
analysing a minimum of 10 metaphases in a single CGH experiment. Both the X-, and 
Y-CHRs are depicted as being deleted. When this experiment was performed the gender 
of the control DNAs used was not observed, which would have aided interpretation of 
this CGH result. However, the metaphase spread used is from a normal male source. 
Since the X-CHR is shown as deleted, it suggests that the Rhodamine labelled control 
was female and the Sp Green labelled control was male. The concurrent loss in the Y- 
CHR contradicts this view. However, on account of its vast heterochromatin content,
i.e., rich content of repetitive DNA sequences, it is generally difficult to interpret 
ordinary CGH data on this chromosome.
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3-2-S-4 Figure (3-5D) Combined ratio profile o f  22 metaphases analysed 
in the negative control experiment.
This figure shows the combined fluorescence profiles for 22 metaphases, with an 
average of roughly 40 chromosomes anaylsed for each autosome. Note that, unlike in 
the single metaphase seen earlier, the ratio profiles are now within normal range. The 
alterations seen in the sex chromosomes, which has been discussed is confirmed.
3-2-6 Figure 3-6 - (6A -  6C): CGH images o f  the positive control 
(MPE600 (Vysis) v Ref. (Vysis).
aê ê
3-2-6-1 (3:6A) Karyotype set o f a metaphase captured from the positive
control hybridisation
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3-2-Ô-2 (3-6B) Profiles o f fluorescence ratios o f a single metaphase
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3-2-Ô-3 (3-6C ) C om bined  ratio  profile  o f  11 m etaphases analysed  
The alterations revealed included gains at Iq, proximal llq , distal 13q, and 17q; and 
deletions at 9p, llq , and 16q. Most of these agree with results provided by Vysis (the 
supplier of the control DNA). According to Vysis, the cell line may change over time 
and could show additional aberrations. However, the cell line is expected to show 1) a 
small deletion near Ipter; gain of Iq, 2) loss of 9p, 3) distal deletion on llq , and 4) loss
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of 16q. Chromosomes 2 and X are expected to be normal. Thus, cytogenetic findings in 
this experiment are in agreement with Vysis data on their MPE600 cell line.
3-2-7 Figure 3-7 Sample o f a solid (RGBS 1625) - representative o f  
“solids’” (tumour) images
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3-2-7-1 (3-7A) Metaphase spread o f RGBS 1625
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3-2-7-2 (3-7B) Karyotype o f  the metaphase in 3A
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3-2-7-3 (3-7C) Fluorescence ratio profiles o f the metaphase in 3-7A, 
generated from its karyotype (3-7B)
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3-2-7-4 (3-7D) Combined fluorescence ratio profiles o f  19 metaphases 
analysed for PGBS1625 in this experiment.
Gains (Green) were observed at I p l l - q l l ,  7p22-q36, and 12ql3-ql5, while losses 
occurred at 2q35-q37, 10pl5-q24, and 13q33-q34
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Figure 3-8 - CGH images o f  a representative cell culture: RGBC1724, 
showing CGH images for conventionally labelled (3-8A (i -  iv), inverse labelling (3-8B 
(i -  iv), and MDA experiments (3-8C (i -  iv)) experiments
a
S-2-7-5 Figure 3-8A (i) Metaphase spread taken from the RGBC1724 
conventional labelling experiment
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3-2-7-Ô Figure 3-8A (ii) Karyotype o f  the metaphase in 3-8A (i)
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3-2-7-7 Figure 3-8A (iii) Fluorescence ratio profiles o f  a single 
metaphase, same one in 3-8A (i)
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3-2-7-S Figure 3-8A (iv) Combined fluorescence ratio profiles o f  33 
metaphases analysed
In figure 3-8A (iv) 33 metaphases with a total of 1246 chromosomes have being 
analysed. There are gains at lp22, 4pl5 .3-pll, 5pl4-pl2, 8pll.2 , 8qll.l-q24.3, 9pl2-
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q33, 21ql l-q22, and Ypl3.3-Yql2, while losses are observed at 2q35-q37, 1 Iq22-q25, 
13q32-q34, 14q24-q31, 16pl3.3-q24.
3-2-8 Figure 3-8B RGBC1724 Reverse labelling experiment
3-2-8-1 3-8B(i): Metaphase image
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3-2-8-3 Figure 3-8B (iii) Profile o f the metaphase in 3-8B (i)
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3-2-S-4 Figure 3-8B (iv) Combined fluorescence ratio profiles for 
The reverse labelling experiment o f RGBC1724
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Figure 3-8C CGH images o f RGBC1724 using MDA-amplified DNA
3-2-S-5 Figure 3-8C (i) Metaphase image
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3-2-S-7 Figure 3-8C (iii) Fluorescence ratio profiles for a single 
metaphase
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In this MDA experiment on RGBC1724, 14 metaphases and 566 chromosomes have 
been analysed. It shows alterations, most of which are seen both in the normal labelling 
and in the inverse/reverse labelling experiments. There are gains at Ip31-pl3, lq22- 
q23, 4pl5.3-pl2, 8pll.2-q24.3, 9p l3 -q ll, 9ql3-q34, 21ql 1.2-q22, and 
Ypll.3-q22; and losses at l ip  11.2-q 11, Hq22-q25, 13ql3-ql4, 13q33-q34, 14q21-q24, 
and 16pl3.3-q23
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3-3 Conclusions From Control Experiments
The control experiments were successful in validating the results expected from 
normal/normal hybridisation and in a sample with known abnormalities. Using the usual 
labelling protocol (with Spectrum Green dUTP for the test DNA and Spectrum Red 
dUTP for the controls), similar results were obtained for the tumour RGBC1724 as 
directly labelled original DNA extract and for the very tiny amount of that tumour DNA 
subjected to whole genome amplification. Thus, gains on 4p, 8q, 9q, and 21q, and losses 
on l lq , 16p and 16q were seen by both methods. However, there were some 
differences, mostly relating to the extents of the regions gained and lost, and also, in 
some cases, (especially so for the two results in chromosomes 1) changes which were 
invisible in the analysis in both experiments but were revealed when the cut-off limits 
were narrowed. Both the direct and the MDA results from this tumour are shown in the 
subsequent analysis, emphasizing the somewhat arbitrary nature of the cutoff values, 
which have been used. The reverse labelling experiment proved less sensitive although 
the major changes were still seen. All subsequent experiments were carried out with the 
conventional labelling.
3-4 Overall CGH Results
The complete listing of changes seen in each tumour is presented in table 6-1 (Chapter 
6). However, in this section I consider the results for each chromosome in turn. Copy 
number aberrations observed for each tumour are plotted in the excel chart which shows 
accurate band regions of aberrations but is not proportional to the actual band sizes in a 
chromosome. For this reason, each figure in addition contains the respective 
chromosome ideogram, to give a sense of the relative sizes of aberrant chromosome 
regions.
j Qq,
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3-4-1 Figure 3-9 - Chromosome 1: Ideogram and Excel chart showing 
CNAs for 16 high-grade astrocytomas (HGAs).
(Losses and gains are represented in red and green respectively).
Deletions in the Ip -arm : Chromosome 1 was deleted in the distal p-arm between 
lp31.1 and lp36.33 in 9 out of 16 (60%) informative cases, of which one (6.7%) was
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histologically an anaplastic astrocytoma, AS2745 (Ip36.3-p36.3), and eight, 
glioblastomas: U G BSll (Ip36.13-p36.33), PGBS2051 (Ip33-p36.33), GBM/S2621 
(Ip31.3-p36.33), PGBS2409 (lp36.33), UGBS3044 (Ip33-p36.11 ; Ip36.12-p36.33), 
GBM/S1595 (Ip33-p36.33), and UGBC1397 (Ip32.3-p36.31). The most frequently 
deleted region was Ip34.1-lp36.23, which was deleted in 5 informative cases (38.46%), 
but the most commonly deleted bands, lost by 6 of 13 tumours (46.15%) were lp35.1- 
p35.3. Two (15.38%) tumours with DNA copy number alterations were deleted at lp l2
Deletions in the Iq-arm: Five (38.46%) tumours with DNA copy number alterations 
were deleted in the noncentromere heterochromatin band lq l2 , but one of them, 
PGBS 1926m, was deleted at Ipl2-q22.
Genes of interest (GOIs) located in the most frequently deleted regions include the ones 
for cell division cycle 42 (CDC42 (lp36.1)), ephrin receptor A2 (EPHB2 (Ip36.1-p35)), 
and paired box 7 (PAX7 (Ip36.2-p36.12)), while the 4.9 Kb locus of nascient helix- 
loop-helix (NHLH) is at lp l2 -p ll .
Gains in the 1 p-arm: Gains on chromosome 1 occurred in 10 (76.92%) informative 
cases. Several bands deleted in the p-arm, notably lp32.3, lp34.1 and Ip36.32-p36.3, 
are gained in a different set of tumours, RGBC1724 and PGBC 1760m respectively. 
Gains in 8 out of 10 tumours (80%) were clustered at Ipl3.2-lp31.2. The most 
commonly gained region is lp22, which was gained in 7 (53.84) cases, i.e., PGBS 1625 
(Ip22.2-p31.1), PGBS2051 (lp22.3), PGBS2126 (Ipl3.2-p31.2), UGBS3044 (lp l3 .2- 
p31.2), UGBC1397 (lp22.3) and RGBC1724 (Ipl3.2-p31.3).
The gene for the transcription factor wingless-type MMTV integration site, member 2B 
(WNT2B) is mapped to a 54.47 Kb locus at lp l3 , while genes for bone morphogenetic 
protein, member 8B (BMP8B), paired box 7 (PAX 7), E2F transcription factor 2 
(E2F2), natriuretic peptide precursor B (NPPB), and mitogen-activated protein kinase 
kinase kinase 6 (MAP3K6) are respectively mapped to loci at Ip35-p32, Ip36.2-p36.12, 
lp36, lp36.2 and lp36.11.
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Gains in the Iq-arm: Four tumours gained genetic material in the q-arm with two of 
them, UGBS3044 (Iq24-q31) and PGBS2126 (lq31) sharing the gain at lq31. The third 
and fourth tumour each had one isolated gain (7.69%), at Iq22-q23 for RGBC 1724m, 
and at Iq43-q44 for RGBS 1926m. The 305.09 Kb locus of astrotactin (ASTNl (lq25.2) 
gene is mapped to lq25.2, while the 89.68 Kb locus of the entactin or nidogen (NIDI) 
gene is at lq43.
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3-4-2 Figure 3-10 - CHR 2: Ideogram and Excel chart o f CNAs for 15 
HGAs.
Fifteen tumours are informative for CNAs on this chromosome. One of them,
RGBS 1612m lost the entire chromosome 2, a finding that was confirmed in a repeat
CGH experiment. This biopsy was taken at the initial operation, which was followed by
recurrence and re-operation, when a second biopsy identified as RGBC 1724
(RGBC 1724m) was taken.
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Deletions in the 2p-arm: Only one tumour, PGBC1612, lost the p-arm as part of an 
entire deletion of chromosome 2. The DNA mismatch repair gene, MutS homolog 2 
(MSH2), which is believed to be involved in early stages of glioblastoma development 
(Wei et al., 1997), and in other solid tumours (Wei et al., 1997; Falkenback et al., 2005), 
is mapped to the 159.34 Kb locus at 2p22-p21.
Deletion in the 2q-arm: Six (40%) tumours with DNA copy number alterations lost 
genetic material; all but PGBC1612, which lost the entire chromosome (2p25-q37), 
were deleted only at the distal q-arm between 2q35-q37.3 - PGBS1625 (2q35-q37), 
RGBC 1724 (2q35-q37), UGBS3044 (2q37), PGBC160 (2q37) and AS2706 (2q37) - 
making 2q37 the most frequently lost region in chromosome 2. The genes for insulin­
like growth factor binding protein 5 (IGFBP5 (2q33-q36; 23.46 Kb)) and the paired box 
gene 3 (2q35-q37; 99.1Kb)) are located in the deleted region.
Gains in the 2p-arm: Six tumours (40%) gained material at the distal p-arm between 
2p24.3 and 2p25.3, three were WHO malignancy grade 3 tumours, AS2614 (2p25), 
AS2745 (2p21-p24) and AC545 (2p25), the other three GBMs, UGBC1719m (2p24- 
p25), GBS2650 (2p25) and GBC 1760m (2p24-p25); making 2p25 - pter the most 
commonly gained region in chromosome 2. The DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 1 (DDXl (2p24; 39.93 Kb)) and the N-myc and ST AT interactor (NMI 
(2p24-q21.3)) genes are mapped within the amplified region. One tumour, 
UGBC1719m, gained genetic material across the centromere, at 2pl 1.2-2ql 1.
Gains in the 2q-arm: Five tumours with DNA copy number alterations (33.3%)
gained genetic material over large segments in the middle of the q-arm between 2q21.1
and 2q33.3, creating peaks in 2 regions - 2q22-q23 (33.3%) and 2q31.2-q31.3 (33.3%).
Two of these tumours were WHO malignancy grade 3, AS2721 and AS2745, and the
other 3 were GBMs, PGBS1575, GBS2126, and UGBS3044. PGBS1575 also had a
gain around 2qter (2q37). The genes for v-erb-a erythroblastic viral oncogene, homolog
4 (ERBB4; 2q33.3), postmeiotic segregation increased 1 (PMSl; 2q31-q33), neurogenin
differentiation 1 (NEURODl; 2q32) and paired box 3 (PAX3; 2q27) are mapped within
the deleted region.
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Losses at 3p- and q-arms: Only one of 12 (8%) tumours (AS2706) that were 
informative for this chromosome was deleted in both the p- (3pl4-p21) and q-arms 
(3q26.3). The deletion in the p-arm spans the locus for the fragile site 3B (FRA3B), 
which contains the 333.85 Kb locus for the fragile histidine triad (FHIT.l) gene, which 
is mapped to 3pl4.2, while, respectively, the 31.23 Kb and 60.66 Kb loci for the genes 
for cell division cycle 25 A (CDC25A) and (CTNNBl) are mapped to 3p21.
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Gains in the 3p-arm: 10 out of 11 (90.9%) tumours with DNA copy number alterations 
gained genetic material in this chromosome, 6 of them (54.54%) gaining in the distal p- 
arm from 3p25.3-p26.3. Two of these were anaplastic astrocytomas, AS2614 and 
AS2721, the other four GBMs, GBS2650m (3p26), GBC1612 (3p24-p26) GBC1719 
(3p25-p26) and GBC 1760m (3p26). The 171.4 Kb locus for retinoic acid receptor, beta 
(RARB) is located at 3p24. The gene for mismatch repair (MSHl) that codes for the 
protein MutL homolog 1, which is implicated in glioblastoma arise in association with 
Turcot’s syndrome (Madhuri et al., 2005), is mapped to the 58.14 Kb locus at 3p21.3. 
The 3pl2 region was gained in 5 (45.45%) tumours with DNA copy number alterations, 
one of them an anaplastic astrocytoma, AS2745, the others GBMs, GBS2126 (3pl2), 
GBS2532 (3pl2), GBC1397 (3 p ll-p l2 ), and GBC1719 (3p ll-p l2 ). GBC1612 gained 
at a region, which spans the centromere proximally, at 3pl2-ql 1.2. The 422.23 Kb axon 
guidance receptor, roundabout, homolog 1 (ROBOl) is mapped to 3pl2.
Gains in the 3q-arm: Five tumours (45.45%) gained in the q-arm, forming a minor 
peak at 3ql3.1 l-ql3.12, which involved one anaplastic astrocytoma (AAS/2721) and 
two GBMs, GBS2126 (3 q ll .l-q l3 )  and GBS2532 (3ql4-q31). Two GBMs, GBS2532 
and GBS3044 (3q24-q25) gained material at 3q25.31-q25.33. Only GBC 1760 gained at 
3qter (3q29). This region contains the genes for ephrin receptor 3 (EPH3; 3q21-qter), 
eukaryotic translation initiation factor 4 (EIF4 (DE AD/DE AH box helicase, N-terminal 
motif isoform 2B, containing (3q28)) and tumour protein p73-like (3q27-q29).
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Chromosome 4 showed more gains than losses, with 7 out of (12 ~58%) informative 
cases gaining and only one (8.33%), PGBS2126 was deleted in the p-arm. Large gains 
occurred in the q-arm in 9 out of 12 (75%) informative cases; only one tumour (8.33%) 
was deleted extensive in the q-arm.
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Losses in the 4p-arm: One GBM, PGBS2126 was deleted at 4pl6. The genes for the 
fibroblast growth factor receptor 3 (FGFR3, 4pl6.3), muscle segment homeobox 1 
homolog (MSXl; 4pl6.3-pl6.1), and NK3 transcription factor related, locus 2 (NKX3- 
2; 4pl6.1), are mapped to this region.
Losses in the 4q-arm: One of the 12 informative cases for this chromosome (8.33%), 
PGBC1612, was extensively deleted at 4 regions in the q-arm, namely 4q21-q22, 4q28- 
q31.2, 4q31.3 and 4q32-q35. The genes of interest in the deleted regions include those 
for the NK6 transcription factor related, locus 1 (NKX6-1; 4q21.2-q22), platelet derived 
growth factor C (PDGFC; 4q32), vascular endothelial growth factor (VEGF; 4q34.1- 
q34.3) and mothers against decapentaplegic homolog 1 (SMADl; 4q31).
Gains in the 4p-arm: Three samples from the same patient, RGBC 1724 (4p ll- 
pl5.3), RGBC 1724m (4pl2-pl5.3) and GBC1612 (4pl3-pl5.2) gained extensively in 
the p-arm. Along with two others, AS2721 (4pl4) and UGBS3044 (4pl4-pl5.1), the 
above three tumours shared a common region of gain at 4pl4-pl5.1, making this the 
most gained (41.66%) in the p-arm of chromosome 4. The 367.3 Kb locus for the gene 
for slit homolog 2 (SLIT2; 4pl5.2), and one, of 116.14 Kb, for prominin 1 
(PROM 1/CD 133 (4pl5.32) gene, are located in the gained region.
Gains in the 4q-arm: All 12 tumours that gained in the q-arm either had single 
extensive gains o f genetic material, GBS1926 (4q34), UGBC1719m (4q34-q36) 
GBC 1760 (4q34), PGBS2858 (4q26-q31.1) or had multiple gains along the length of 
the chromosome arm: UGBC1397 (4q22-q24; 4q26-q27), PGBS2126 (4ql3-q28; 
4q31.3-q32), and UGBS3044 (4ql2-q21; 4q21-q28; 4q31.2-q32). Two out of 12 
tumours that are informative for this chromosome arm (16.66%), AS2721 (4q21-q28; 
4q31.2-q3L3) and AS2745 (4ql3-q21; 4q22-q27) are anaplastic astrocytomas, while 
nine (75%) are GBMs. The gains span respectively the 83.25 and 47.45 Kb loci of 
genes for CKIT, the human homolog of the proto-oncogene c-kit (v-kit Hardy- 
Zuckerman 4 feline sarcoma viral oncogene homolog) and vascular endothelial growth 
factor receptor or kinase insert domain receptor (VEGFR/KDR), which are both 
mapped to 4q 11 -q 12.
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The two most frequently gained regions in the q-arm were 4q22-q24 (41.66%) and 
4q26-q27 (58.33%). These regions span the loci for endomucin (EMCN, 4q24) and 
epidermal growth factor (EOF; epidermal growth factor (beta-urogastrone); 4q25)) 
genes.
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Chromosome 5 had more gains than losses among 14 informative cases for this 
chromosome. There was one prominent region of gain at the distal p-arm and one 
located midway along the q-arm
Losses in the 5p: Two GBMs were deleted, one, PGBS2126, at 5p 15.33 and 
PGBS2858 at 5q35.2. The muscle segment homeobox homolog 2 (MSH2, 5q34-q35) 
and the slit 3 (SL1T3; 5q35) genes are located within the q-arm deleted region.
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Gains in the 5p-arm: GBS1595 (5pl5.2-pl5.3) and GBC 1724 (5pl5.2-pl5.3) gained 
genetic material between 5pl 1 and 5pl4.3 while 6 tumours (50%) gained at a common 
region between 5pl5.2 and 5pl5.33. One of these was an anaplastic astrocytoma, 
AS2614 (5pl5.3) while 5 were GBMs, RGBS 1595m (5pl5.2-pl5.3), GBS2650 
(5pl5.2-pl5.3), RGBS2687m (5pl5.3), UGBC 1719m (5pl5.3), and GBC 1760 
(5pl5.3). The gene for activated RNA polymerase II transcription factor 4 (PC4) is 
mapped to a 72,29 Kb locus at 5pl3.3, while SEMA5A, a member of the samaphorin 
gene family whose protein products serve as cues for axon guidance in early 
neurogenesis (Adams et al. 1996), is mapped to a 511.75 Kb locus at 15pl2.
Gains in the 5q-arm: Nine of 12 tumours with DNA copy number alterations gained 
material in the q-arms, three of them, AC545 (5ql 1-ql 1.2), GBS2650 (5q35-q35.3), 
GBC 1760 (5q35) gained across small stretches of the chromosome. Six tumours, the 
first three of them, AS2721 (5ql4-q21), AS2745 (5ql4-q23) UGBC1397 (5ql4-q22) 
each had a single large gain, whereas the others, PGBS2126 (5ql2-q23; 5q31-q32), 
UGBS3044 (5ql3; 5ql4-q23) and GBS1595 (5qll.2-q l3 ; 5ql4-q23) gained in more 
than one region of the chromosome arm. However, most gains in the q-arm aggregated 
at 5ql4-q21.2 (50%), followed by 5q21.2-q22.2 (41.66%) and 5q23.3 (25%). The 
proximal q-arm gains involves loci for several genes of interest, among them three 
isoforms of the general transcription factor II, polypeptide 2: GTF2H2, GTF2H2.2 and 
GTF2H2.1 - all of which are clustered at 5ql2.2-ql3.3; follistatin (FST; 5ql 1.2); islet-1 
transcription factor, LIM/homeo domain (ISLl; 5ql 1.2) and cyclin H (CCNH; 5ql3.3- 
ql4). Five tumours have gains, which span the 185.81 Kb locus at 5q22, for the 
adenomatosis polyposis coli gene (APC), which is implicated in colon cancer (Sarova et 
al., 1998). The locus for the cell division cycle 25C (CDC25C) is mapped to distal q- 
arm at 5q31, and is gained in PGBS2126.
Other genes of interest located in the 5q-arm are, the genes for ephrin-A5 (EFNA5; 
5q21), neurogenin 1 (NEUROGl; 5q23-q31), fibroblast growth factor (FGF; 5q31), and 
platelet derived growth factor receptor (PDGFR; 5q31-q32).
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Nine tumours (31.25%) showed DNA copy number changes on this chromosome with 
all except PGBC1612 gaining genetic material, 5 of them in the p-arm, and 7 in the q- 
arm. PGBC1612 gained nearly the entire chromosome 6 (6p25-6q25 and 6q26).
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Losses in the 6q-ami: One tumour, RGBC 1724m, the only recurrent tumour in the 
study, had extensive loss in the q-arm at 6ql 1.1-q22. The genes of interest in this region 
include those for vascular endothelial growth factor, alpha (VEGF, 6ql2), ephrin A7 
(EPHA7; 6ql6.1), single-minded homolog 1 (SIMl; 6ql6.1), fused in glioma (FIG; 
6q21), cyclin C (CCNC; 6q21), peroxismal biogenesis factor 7 (PER7, 6q21-q22.2), 
cyclin dependent kinase (CDC2-like) 11 (C D K ll; 6q21) and hairy/enhancer of split 
related with YRPW motif 2 (HEY2; 6q22.2-q22.3).
Gains in the 6p-arm: Five tumours gained in the p-arm: PGBC1612 gained the entire 
chromosome, while AS2614 gained in the distal half of the p-arm, at 6p22.3-6p25.3, as 
did PGBS1625, at 6p25.1-6p25.3. AC545 and UGBC1719m each also gained the 6pter 
band, 6p25.3. The region most commonly gained, in 5 of 12 (41.66%) tumours is 
6p25.1-p25.3. The spinocerebellar ataxia/ataxin (SCAl/ATXN; 6p23) and genes for 
several tumour necrosis factor induced proteins, and receptors, including TNF alpha- 
induced protein 3 (TNFAIP3; 6p23), and others in loci clustered around 6p25.2, map 
within the gained chromosome region.
Gains in the 6q-arm: Seven of 9 tumours gained in the q-arm, with gains aggregating 
in three regions, 6ql2 (41.7%), 6ql5-6ql6.2 (33.4%) and 6q22 (41.7%). The genes for 
vascular endothelial growth factor (VEGF, 6ql2), ephrin, A7 (EPHA7, 6ql6.1), 
mitogen-activated protein kinase kinase kinase 5 (MAP3K5, 6q22.33), neuromedin B 
receptor (NMBR, 6q21-qter), peroxisomal biogenesis factor 7 (PEX7, 6q21-q22.2) and 
brain lipid binding protein (BLBP, 6q22-q23) are mapped in the regions that have 
gained. Three tumours gained genetic material in the q-arm region, which spans the 
locus for the oligodendrocyte transcription factor 3 (OL1G3) at 6q23.3, which is also the 
location of the transcription factor 21 gene (TCF21) that codes a protein with DNA 
dependent transcription- and RNA 11 transcription factor activity (Hidai et al., 1998) and 
has a role in lineage specific differentiation early in embryonic development (Hidai et 
al., 1998; Funato et al. 2003).
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16 tumours (51.5%) are informative for CNAs on this chromosome; all are gains in one 
or both chromosome arms. Except for AS2721, all informative samples showed 
extensive gains covering large portions of the chromosome arms. In most cases, the 
entire length of an arm and the entire chromosome gained genetic material. 
Remarkably, this chromosome did not show any loss of genetic material.
Gains in the 7p-arm : 11 out of 16 tumours (68.8%) gained material along the entire 
p-arm except at p-ter bands (7p22.1-p22.3) where the average gain was 29.4%. Two 
regions, 7pl3-pl4.1 and 7pl5.1-pl5.3, were gained in 70.5% of the tumours. One of the 
five anaplastic astrocytomas in the study (20%), AS2614, gained genetic material in the 
entire p-arm. A number of genes of interest are located in the gained regions, among 
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them those for the homeobox A1 (HOXAl; 7pl5.3) and homeobox A13 (H0XA13; 
7pl5-pl4) that map to the 7pl5 region, and platelet-derived growth factor, alpha 
polypeptide (PDGF, 7p22), ras-related C3 botulinum toxin substrate 1 (rho family, 
small GTP binding protein Racl) (RACl, 7p22) and the postmeiotic segregation 
increased 2 (PMS2) gene (located in a 38.18 Kb locus) are mapped at 7p21. Other p- 
arm genes include the epidermal growth factor receptor (EGFR, 7pl2), glioblastoma 
amplified sequence (GBAS, 7pl2) and phosphorylase kinase gamma 1 (PHKGl, 7pl2- 
q21).
Gains in the 7q-arm: The q-arm was gained in 15 of 16 informative cases with an 
average gain across the chromosome of 58.8%. Like in the p-arm, most tumours had 
massive gains along the q-arm, often covering the entire length. Three regions, centered 
at 7q21, 7q22 and 7q31 had gain-peaks in the range 64.7 - 70.5 %.
Three anaplastic astrocytomas, AS2614 (7q21; 7q22-q27), AS2706 (7qll.2-q36) and 
AS2721 (7q31) gained in the q-arm, with the first two gaining as extensively as did 
GBMs. Several genes of interest map to these regions, among them ones for hepatocyte 
growth factor/scatter factor (HGF/SF; 7q21.1) and its receptor, the met proto-oncogene 
(hepatocyte growth factor receptor (HGFR/MET/CMET; 7q31)), phosphoinisitide-3- 
kinase, catalytic gamma polypeptide (PI3K; 7q22.3), fragile site 7G (FRA7G; 7q31.2) 
and Wiscott-Aldrich syndrome-like (N-WASPAVASL; 7q31.3). The CHR region 
7q32.3 is gained in 12 out of 17 tumours with DNA copy number alterations. This 
region is known to harbour locus for SMO (Smothered), a receptor for Patched (PTH), 
which is implicated in the oncogenesis of ependymomas.
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3-4-14 Figure 3-16 -  CHR 8: Ideogram and Excel graph o f  CNAs for 
10 HGAs.
Nine tumour samples were informative for this chromosome. Except for three tumours 
from the same patient, the other five samples had small gains in a corresponding region 
at the distal portion of the p-arm in 4 out of 5 cases, and in the region 8q22 in 3 of 5 
cases. Only one sample out of nine had a deletion, which was in the p-arm.
Losses in the 8p-arm : PGBS2126 lost a large portion of the p-arm at 8pl2-p23. The 
genes for scleraxis, the basic helix loop helix dimérisation region 2 (SCX/bHLH.2;
Cytogenetic Analysis o f DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
121
Chapter 3 Results o f metaphase CGH analysis
8q24.3), neuregulin 1 (NRGI; 8p21-p22) and NK3 transcription factor related, locus 1 
(NKX3-1; 8p21), are located within the deleted region.
Gains in the  8 p-arm : Six tumours gained in the p-arm forming a peak at 8p23.3 in 
which four of them - 2 anaplastic astrocytomas, AS2614 (8p23.3), AC545 (8p23.3) and 
2 GBMs, PGBS2650 (8p22-8p23.3) and UGBC1719m (8p23.2-p23.3), are involved. 
RGBC 1724 (8 pl 1.21) and PGBC1612 (8p23.3 ->q-arm) also gained in the p-arm.
Gains in the 8q-arm: Three samples from the same patient who has previously been 
referred to, and four others: two anaplastic astrocytomas AS2721 (8q22-q23), AS2745 
(8q22), and glioblastomas PGBS2126 (8q22) and UGBC1719m (8q24.2-q24.3) were 
among seven tumours that gained in the q-arm, all the gains clustering at 8q22-q23. The 
genes of interest that map to this region include cyclin E 2 (CCNE2; 8q22.1), NK3 
transcription initiation factor, locus 1 (NKX3-1; 8q21.2), E2F5 transcription factor 
(E2F5; 8q21.2) and neuregulin 1 (NRGl; 8q21-q22).
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Twenty-two tumours showed DNA copy number changes in this chromosome, a 
number of them have losses or gains in either arm.
Losses in the 9p-arm: Three GBMs, PGBS2858 (9p24-ql2), GBS1595 (9pl2-p21) 
and GBC1760 (9pl2-p23) had deletions spanning the centromere and adjacent 
heterochromatin band, which extend to involve large parts of the p-arm. Genes of 
interest include those for cyclin dependent kinase 2A  (p i6 ) / cyclin dependent kinase 
2B/(pl4ARF) / pl5 / inhibitor of CDK4 (CDKN2A/CDKN2B); 9p21); interferon, beta
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polypeptide 1 (IFNBl, 9p21), methylthioadenosine phosphorylase (MTAP; 9p21) and 
vesicular glutamate transporter (9p24).
Losses in the 9q-arm: Only PGBS 1926m was deleted in the proximal part of the q- 
arm (at 9ql l-q21) whereas 7 of the 10 tumours that are informative for the q-arm, AS24 
(9q34), PGBS2126 (9q34), PGBS2532 (9q34), UGBS3044 (9q34), GBS1595 (9q34), 
PGBC1510 (9q34), UGBC1719m (9q33-q34), incurred discrete deletions in the distal q- 
arm encompassing the loci of chromosome 9 open reading frame 96 and -197 (C9orf96 
and C9orfl57) at 9q34.11 and 9q34.3 respectively, creating a peak at 9q34.1 l-q34.2. 
Other genes include those for fibrinogen C domain containing 1 (FIBCDl; 9q34.2), 
death associated protein kinase 1 (DAPKl; 9q34.1), oncogene v-abl, Abel son murine 
leukaemia viral oncogene homolog 1 (ABLl; 9q34.1), and the tumour suppressor for 
tuberous sclerosis, type 1 (TSCl) both of which have well established associations with 
malignancies that include gliomas (Kim et al., 2004).
Gains in the 9p-arm : Ten out of 17 tumours, which are informative of CNAs in the 
p-arm gained genetic material. Two of these, AS2706 (9p l2 -q ll), RGBC 1724 (9pl3- 
q l l )  gained at p 11.1-p i2, while three, PGBS2126 (9p21), PGBS2409 (9p21-p23) and 
RGBC 1724m (9pl3-p21) gained in the middle of the p-arm, resulting in a peak at 
9p21.1-9p21.3. However, 5 tumours, AS2614 (9p24), AC545 (9p24), PGBS2051 
(9p24), UGBC 1397 (9p24) and UGBC1719M (9p23-p24) gained in the distal p-arm- 
bands, forming a prominent peak at 9p24.2-p24.3. The genes for CDKN2A/CDKN2B, 
interferon beta 1 (IFNBl), methylthioadenosine phosphorylase (MTAP) and DBRT-like 
family 1 (DMRTAl; 9p21.1) are located at 9p21, whereas the gene for solute carrier 
family 1, member 1 (SLClA l), the neuronal/epithelial high affinity glutamate 
transporter, maps to the 97.26 Kb locus at 9p24.
Gains in the 9q-arm: Two of the three tumours that gained in the q-arm, AS2706 
(9q21-q34), RGBC 1724 (9pl2-q33), RGBC 1724m (9ql3-q34) are from the same 
patient. All but RGBC 1724m gained the entire q-arm from the centromere downwards, 
truncating at 9q33.3. The gained region contains the genes for the human homolog of
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patched (PTCH; 9q22), which is a receptor for sonic hedgehog, astrotactin 2 (ASTN2; 
9p33.1) and fibrinogen C domain containing 1 (FIBCDl; 9p34.2).
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Figure 3 -1 8 - CHR 10: Ideogram & Excel graph o f  CNAs for 14 HGAs
Fourteen tumours showed DNA copy number changes in this chromosome. Except for 
two, AS2614 (lOplS) and UGBC1719m (10pl5), which gained genetic material at the 
distal p-arm, and four, PGBS2409 (10pl5; lGq26), PGBS2532 (lOpl 1.2-ql 1.2; lGq25- 
q26) UGBS3G44 (lGq25-q26) GBS1595 (lGq24-q25) that were deleted in relatively 
shorter stretches of the chromosome, the rest namely GBS1575, PGBS 1625, 
PGBS2126, PGBS2858, GBS256Gm, RGBS2687m, PGBC1612, PGBC176Gm had 
multiple patchy losses over long sections, and whole chromosome arms or the entire
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chromosome. The average loss across the length of chromosome 10 in the informative 
group is approximately 70%.
Losses in the lOp-arm: There are two deletion peaks in the p-arm, located at 
1 Op 11.21 and lOpl 1.22-pl 1.23. The proximal peak spans the regional loci of the genes 
for zinc finger protein 33A (ZNF33A; lOpll.2), neuropilin 1 (NRPl; 10pl2) and Abl- 
interactor 1 (ABIl; 1 Op 11.2).
Losses in the lOq-arm: The q-arm has three peaks around 10q21.2-q21.3, 10q23.1- 
q23.3, and 10q25.1-q26.12. The phosphatase and tensin homolog (PTEN)/mutated in 
multiple carcinomas (MMCAl) (PTEN/MMCAl; 10q23.3), slit homolog 1 (SLITl; 
10q23.3-q24), paired box 2 (PAX2; 10q24), O-6 -methylguanine DNA methyl 
transferase (MGMT; 10q26), NK6  transcription factor related, locus 2 (NKX6.2; 
10q26), ventral anterior homeobox 1 (VAXl; 10q26.1) and suppressor of fused (SUFU; 
10q24.32) homolog, a component of the sonic hedgehog/patched pathway and is 
associated with cancer predisposing syndromes (Borycki et al., 2000), are some of the 
genes of interest in the deleted q-arm of chromosome 1 0 .
Gains in the 10-arm: Two tumours gained genetic material in the distal p-arm; one 
was an anaplastic astrocytoma (AS2614) and the other a GBM (UGBC1719m) both of 
which gained at 10pl5.
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12 tumours are informative for CNAs in this chromosome, but only 5 of them were 
highlighted in the p-arm.
Gains in the 11 p-arm : A minor peak of gain was formed at 11 p i5.5, arising from 
gains in one anaplastic astrocytoma, AS2614 ( llp l5 )  and two glioblastomas, 
UGBC1719m (11 p i5) and PGBC1760m (11 p i5), while another glioblastoma, 
PGBS2126, gained genetic material proximally, at 1 lp l2 -l lpl4.2. The genes for 
transcription factor 2H, member 1 (TFIIHI; llp l5 .3), achaete-scute complex like 3 
(ASCL3), myogenic factor 3 (MYODl; llp l5 .4), hypothetical protein LOC441583.1 
(similar to radixin (ESP 10; llp l5 .4), that codes for a member of the ERM protein 
family, a E2F-related hypothetical protein, FLJ23311 (1 lp l5 ,l)  and the proto-oncogene
Cytogenetic Analysis o f DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
127
Chapter 3 Results o f metaphase CGH analysis
v-Ha-ras, Harvey rat sarcoma viral oncogene homolog (HRAS; 1 lpl5.4) are mapped in 
this region.
Gains in the 11 q-arm: Two peaks appear in the q-arm one at 1 Iq l4 .1 -q l4.3, caused 
by three GBMs: PGBS2051 ( llq l4 ) ,  PGBS2126 (H ql4-q22), UGBS3044 (llq l4 )), 
while a broader peak is at 1 lq23.2-l lq24.3. Genes of interest include those for 
mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2; llq l3 ) , vascular 
endothelial growth factor beta (VEGFB; llq l3 ) , paired box 6  (PAX6 ; llq l3 ) , cell 
adhesion molecule CD44 (CD44; 1 Iq l3), cyclin D (CCND; 1 I q l3).
Losses in the 11 p-arm: Two tumours lost genetic material at the centromeres, 
PGBS2532 (1 Ip l l.l-q l3 )  and RGBC 1724m (1 lp l2 -q l 1), with the latter extending for 
two bands above the heterochromatin region. These losses span the loci for cyclin D 
(CCND), vascular endothelial growth factor, beta (VEGFB) and mitogen-activated 
protein kinase kinase kinase kinase 2 (MAP4K2)(already mentioned). In addition, the 
gene for proteoglycan 2 and solute carrier 43 alpha, member 3 polypeptide, 
(PRG2andSLC43A3) that has structural similarities with bone morphogenetic protein 4, 
(BMP4) is mapped to 1 I q l l .  Two tumours, AS2706 and PGBS2532, were deleted at 
1 Ip 15.2-1 I p l5.5, which includes the loci for TFIIHI and ASCL3 genes.
Losses in the 11 q-arm: A common region lost in 3 tumours, GBS2126 (1 lq l2), 
PGBS2532 (1 Ip ll-q l3 ) , and PGBS 1595m (1 Iql2-ql3), is located in the proximal q- 
arm at 1 Iq l2.2-1 I q l3.1. RGBC 1724 and RGBC 1724m are both deleted at 1 lq22.1- 
1 lq24.3. The common deleted regions span the loci for CCND, VEGFB, MAP4K2, 
PRG2andSLC43A3 and CTNNDl (1 lql2).
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for 12 HGAs.
12 tumours are informative for CNAs in this chromosome, all of them gaining with the 
exception of UGBS3044 (12q24.1-q24.3) and PGBS2126 (12q24.3), which were 
deleted in a corresponding region of the q-arm, making the 12q24.3 the only common 
region to be deleted in chromosome 12. A gene of interest in this region is that of 
general transcription factor 2H, polypeptide 3 (GTF2H3; 12q24.31)
Gains in the 12p-arm : Two common regions of gain occur, one at 12pl3.32- 
12p 13.33 caused by 4 tumours, AS2614 (12pl2-pl3) and three GBMs (GBS1926 
(12pl3), UGBC 1719m (12pl3), PGBC 1760m (12pl3), and a second at 12pll.pl2,
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arising from gains in two glioblastomas, PGBS2126 (1 2 p ll.l-p ll) , and GBS1595 
(12pl l.l-p l2 ). The genes of interest in this region include those for the microsomal 
glutathione S-transferase 1 (MGSTl; 12pl2.3-pl2.1), neurotrophin 3 (NTF3; 12pl3), 
glyceraldehydes-3-phosphate dehydrogenase (GAPD; 12pl3), cyclin dependent kinase 
lB/p27/KIPl (CDKNIB; 12pl3.1) and neural enolase 2 gamma (EN02; 12pl3).
Gains in the 12q-arm: There is a major cluster of CNAs around the middle of the 
12q-arm involving 8  tumours with a peak at 12ql4.3-12q21.2. One of the tumours that 
gained is an astrocytoma, AS2745 (12ql5-q31), and the others are GBMs, GBS1575 
(12ql3-q21), PGBS 1625 (12ql3-ql5), PGBS2051 (12ql5-q21), PGBS2126 (12ql3.3- 
q21.32), PGBS2858 (12ql4-ql5), UGBS3044 (12ql5-q21) and GBS1595 (12ql4-q21). 
Several genes of interest are mapped to the listed 12q-arm regions, among them those 
for Cyclin dependent kinase 2 (CDK2; 12ql3), cyclin dependent kinase 4 (CDK4, 
12ql4), the MDM2-transformed 3T3 cell double minute 2, a p53 binding protein 
(MDM2, 12ql4.3-ql5), BRCAl associated protein (BRAP, 12q24) and mitogen- 
activated protein kinase-activated protein kinase 5 (MAPKAPK5, 12q24.12). One 
tumour, UGBC1719m (12q24.3) gained genetic material further down the chromosome, 
at bands 12q24.31-q24.32, which spans the 28.83 Kb locus of the general transcription 
factor 2 H, polypeptide 3 (GTF2H3, 12q24.31).
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3-4-18 Figure 3-21 -  CHR 13: Ideogram and Excel graph o f  CNAs in 
17 HGAs
Seventeen tumours (69.7%) showed DNA copy number changes in CHRl 3, with 5 out 
of the only 6  anaplastic astrocytomas showing alterations in DNA copy number. Two 
tumours, PGBC1612 (13qll-q34, and RGBC 1724 (13ql3-ql4; 13q21-q22; 13q33-q34) 
had extensive losses or loss of the entire q-arm while 15 others had alterations limited to 
a single band or moderate lengths.
Loss in the 13q-arm: Three tumours were jointly deleted around 13ql3-ql4 resulting 
in a peak at 13ql3.2-ql4.12 made by AS2706 (13ql3-ql4) and two related 
glioblastomas, GBC 1612, which lost the entire q-arm (13qll-q34) and RGBC 1724 
(13ql3-ql4). RGBC 1724 has other losses distal to this peak, at 13q21-q22 and 13q33-
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q34. A second peak is situated at 13q33.1-q33.3 and is formed by 5 GBMs, PGBS1625 
(13q33-q34), UGBS3044 (13q34), RGBC1724 (13q32-q34), GBC1612 (13qll-q34), 
and RGBC 1724m (13q33-q34). The last three tumours are from the same patient, taken 
at two separate operations. The homeodomain transcription factor, insulin promoter 
factor 1 (IPFl) and the cyclin dependent kinase 6  (CDK6 ), are located in loci around 
13ql2.1 and 13ql2 respectively, while the retinoblastoma (RBI) and the gene that 
induces the DEAD box protein, DDX26, a translation initiation factor, are located 
respectively at 13ql4.2 and 13ql4.12-ql4.2. The gene for large tumour suppressor, 
homolog 2 (LATS 2) that induces a polypeptide product similar to cyclin E (CCNE), 
maps proximally to a 12.32 KB locus at 13qll-q l2 .
Gains in the 13q-arm: Two peaks are formed in the q-arm by clustering of gains in 9 
tumours at 13q21.l-q21.33. Three of these are anaplastic astrocytomas (AS2721 
(13q21-q22), AS2745 (13q21-q31), AC545 (13q21)), the other 6  are glioblastomas, 
(PGBS2501 (13q21-q22), PGBS2126 (13q21-q22), PGBS2532 (13qll-q31),
PGBS2650 (13q32-q34), UGBC1397 (13q21-q31) and PGBC1706 (13q21)). The 
second peak is located at 13q33.1-q33.3, and is formed by one anaplastie astrocytoma 
(AS2614 (13q33-q34)) and three GBMs (GBS2650 (13q32-q34), UGBC1719m (13q34) 
and PGBC1760m(13q33).
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3-4-19 Figure 3-22 -  CHR 14: Ideogram and Excel graph o f  CNAs 
for 7 HGAs
Losses in the 14q-arm: One tumour, PGB1612 (14q ll.l-q l2 ; 14ql3-q32), almost 
completely lost the entire q-arm, while the related tumour (RGBC 1724m) lost a large 
segment (14q24-q31). Five other glioblastomas, PGBS2126 (14q31-q32), PGBS2409 
(14q31-q32), PGBS2532 (14pl3-q31), UGBS3044 (14q31-q32) and RGBC 1724 
(14q24-q31) have deletions that cluster around 14q24.2-q32.32, forming a peak at 
14q31.2-q32.13, which includes PGBC2685. The genes of interest in the proximal and 
middle portions of the q-arm include those for thyroid nuclear factor / thyroid 
transcription factor 1 (TIFl (47.01 Kb)) and NK2 transcription factor related, locus 9 
(NKX2-9 (2.58 Kb)), both located at 14ql3.3, mitogen-activated protein kinase kinase 
kinase kinase 5 (MAP4K5) at 14ql4.2-q21, bone morphogenetic protein 5 
(BMP5/BMP5.1) at 14q23-q24, V-AKT/AKTl, the human homolog of the murine 
thymoma viral oncogene, which is located at 14q23.32 and the mismatch repair gene
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MUTL homolog 3 (MLH3) which is located at a 37.74 Kb locus at 14q24. However, the 
most commonly deleted peak (on average deleted in 6  of 7 tumours with DNA copy 
number alterations for the q-arm of chromosome 14) is located at the 14q31-q32. This 
region spans the locus for the gene for CDC42 binding protein B (CDC42BPB) at 
14q32 and that of protein tyrosine phosphatase, non-receptor type 1 (PTPNl) which has 
been found to associate with sarcoma viral antigens (Yonemoko et al., 1987) and is a 
regulator of the Tec family kinases (Aoki et al., 2004) as well as containing an ezrin- 
like domain (Koyano et al., 1997).
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3-4-20 Figure 3-23 -  CHR 15: Ideogram & Excel graph o f  CNAs for 
11 HGAs
The 15q-arm CNAs: 9 tumours had aberrations in the q-arm of CHR15. One tumour, 
RGBS2687m lost material in the middle of the q-arm at 15q21.2-q22.32, spanning the
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79.79 Kb locus of the gene for mothers against decapentaplegic homolog 6  (SMAD6 ), 
located at 15q21-q23. The 15q26 region is deleted in 4 tumours -  one an anaplastic 
astrocytoma, AS2614 (15p26), and 3 GBMs, PGBS 1926m (15q26), RGBS2687m 
(15q21-q23), PGBS 1760m (15q26) and GBS2650 (15q26). The neogenin homolog 1 
(NEOl), which has homology with deleted in colon cancer (DCC.l), and could be 
implicated in familial gliomas (Latil et al., 2003), is mapped to a 2562.65 Kb locus 
atl5q22.3-q23 (Vielmetter et al., 1997). Several genes of interest (GOIs) are mapped to 
the most commonly gained region of chromosome 15 among them, the feline sarcoma 
viral homolog (FES; 15q26.1) and the mesodermal posterior 1 (MESPl) also at 15q26.1
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Figure 3-24- CHR 16: Ideogram and Excel graph o f  CNAs for 19 HGAs 
Nineteen tumours showed DNA copy number changes in this chromosome, and all of 
them were deleted predominantly in the p-arm and at the pericentromeric 
heterochromatin (in the proximal q-arm). Two peaks can be made out in the p-arm, one 
located at 16pl3.2-pl3.3, involves 12 tumours, while the second one, with a broader 
base, is at 16pl2.3-pl3.12 and includes 9 tumours. The 34.52 Kb and 65.33 Kb loci of 
the genes for mitochondrial ribosomal protein L28 (MRPL28), axinl (AXINl) protein,
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which functions as a negative regulator of the wingless-type MMTV integration site 
family, member 1 (WNT) signaling pathway (Salahshor and Woodget, 2005) and can 
induce apoptosis (Rui et al., 2004); and tuberous sclerosis type 2 (TSC2), are all 
mapped to loci around 16pl3.1-13.3
16 tumours, 3 of them A As are deleted in the centromere and noncentromeric 
heterochromatin region where a sharp peak is evident at 16pl 1.1-ql 1.2. The Ib p ll .l  
band is involved in 8  tumours while the 16ql 1.2 is involved in 13 (38.3%). The gene 
for myosin light chain kinase (MLCK; 16ql 1.2), which is involved in Ca2+/CaM 
mediated (Fajmut et al., 2005) and ATP-mediated P2X1-dependent ERK2 pathways 
(Mongin and Kimelbergh, 2005), and LOC440374, the gene encoding Similar to 
RAB43, a member of the Ras oncogene family (16ql 1.2), are among GOIs mapped to 
loci around 16ql 1 . 2
The q-arm is deleted commonly in two regions that peak at 16ql 1.2-ql2.2 and 16q23.3- 
q24.1 involving 6  and 5 tumours respectively. Two tumours from the same patient 
(RGBC 1724 and RGBC 1724m) had comparable deletions in different experiments. The 
genes of interest in the deleted regions include those for retinoblastoma-like 2  protein 
(RBL2; 16ql2.2), mitogen-activated protein kinase kinase kinase 7 (MAP3K7 
(16ql 6.1-16.3), AT rich interactive domain 3A BRlGHT-like (AR1D3A (16q21-q22), 
fragile site 16D (FRA16D; 16q23.3) and cyclin-dependent kinase (CDC2-like) 10 
(CDKIO; 16q24).
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3-4-21 Figure 3-25 -  CHR 17: Ideogram & Excel graph o f  CNAs for 
10 HGAs
Ten tumours were altered in this chromosome, with only one, PGBS 1926m (1 p i3.3), 
showing a gain. Nine tumours were deleted in the p-arm, forming a peak a broad-based 
peak at 17pl2-pl3.3 in which 7 of the 9 tumours are involved. 9 tumours were deleted 
in the q-arm, 4 of them at 17q21.1 while 6  were jointly deleted at 17q24.1-q25.1. Three 
tumours, PGBS2126 (17pll.l-p l3), PGB1595 (17pl 1.2-q21) and UGBC1719m 
(17pl 1.2-pl3) lost the entire p-arm as well as large sections or the entire q-arm. Genes 
of interest at 17pl3 are TP53 that encodes tumour protein p53, located at 17pl3.1, 
transcription regulator eukaryotic initiation factor 4, A1 (EIF4A1), which is located at 
17pl3 and two genes with roles in neurogenesis: hairy/enhancer of split, homolog 7 
(HES7) and neurogenic differentiation factor 2 (NEUROD2) both located in loci at 
17pl3.1.
The deleted regions in the q-arm harbour several GOIs among them, the v-erb-b 
erythroblastic leukaemia viral oncogene homolog 2 (ERBB2), which is located at 
17qll.2-ql2 and the genes for glial fibrillary acidic protein (GFAP), breast cancer 1, 
early onset (BRCAl), interferon induced protein 35 (1FI35), keratin 25 C (17q21.2), 
and all 11 homeobox class B genes (HOXB; 17q21.3-q22), are mapped in loci clustered 
around the 17q21-q22 chromosome region. The noggin-related symphalangism 1
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(SYMl) and synostoses 1 (SYNSl) genes are located at 17q22, while those for cyclin 
dependent kinase 3 (CDK3) and mitogen-activated protein kinase kinase 6  (MAP2K6) 
are respectively located at 17q22-qter and 17q24.1
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Figure 3-26 -  CHR 18: Ideogram and Excel graph o f CNAs from 8 HGAs 
Eight tumours were informative for copy number aberrations on chromosome 18 and all 
were gains involving the telomere ends of the p-arm in 5 tumours: 2 anaplastic 
astrocytomas, AS2614 (18pll.3), AC545 (18pll.3) and 3 GBMs, PGBS1575 
(18pll.3), UGBC1719m (18pll.3) GBC1760 (18pll.3), making 18pll.3 the only band 
gained in the p-arm. The ribonucleic acid (RNA) guanine-7-methyItransferase gene is 
located at 18pl 1.22-pl 1.23
Six tumours gained genetic material in the q-arm, PGBS2093 (18q23), PGBS2532 
(18qll.2-q22), UGBS3044 (18ql 1.2-ql2; 18q21.2-q22.2), GBS2650 (18q22-q23), 
UGBC1719m (18q22-q23) and PGBC 1760m (18q22-q23). Two of them, PGBS2532 
and UGBS3044 gained nearly the entire q-arm. A peak was formed at chromosome 
band 18q22.2 in which 5 out of six tumours with DNA copy number alterations were 
involved. The 30.86 Kb locus of the gene for mothers against decapentaplegic (DPP) 
homolog 7 (SMAD7) is located at 18q21.1, while the deleted in colon cancer genes 
(DCC and DCC.l) are mapped to loci at 18q21.3.
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3-4-22 Figure 3-27 -  Ideogram & Excel chart for CNAs on CHR 19: 
Fifteen tumours showed DNA copy number changes in this chromosome, which was 
almost exclusively deleted, to a similar extent in both arms, except for the gains in the 
q-arm of GBC1760, at 19qll and 19ql3.31-ql3.33. Three anaplastic astrocytomas lost 
the entire arm or large portions of both the p- and q-arms: AS2706 (19ql l-ql3.3), 
AS2721 (19pl3.3-ql3.2), AS2745 (19pl3.3-ql3.4)), as did 7 glioblastomas, UGBSll 
(19pl2-pl3.3; 19ql3.2-ql3.3), PGBS2126 (19pl3.3-ql3.43), PGBS2532 (19pl3.3-ql 1; 
19ql3.11-ql3.41), UGBS3044 (19pl3.3-ql3.3), PGBS 1595 (19pll-pl3.3; 19ql3.2- 
ql3.3), UGBC1397 (19pl3.3-ql3.4), PGBC1510 (19pl2-pl3.3) and UGBC1719m 
(19pl2-pl3.3; 19ql2-ql3.3).
Pattern o f  deletions in the p-arm: Ten of the 13 tumours showing deletions
of this arm lost the entire arm or major portions of it. However, the loss slightly peaked 
at 19pl3.2-pl9.3 where three tumours, AS24 (19pl3.2-pl3.3), PGBC1510 (19pl2- 
pl3.3) and GBC1612 (19pl3.2; 19pl3.3)) were deleted similarly. Eleven of 15 tumours 
with DNA copy number alterations lost significantly larger sections or entire p-arms: 
AS2721 (19pl3.3-ql3.2), AS2745 (19pl3.3-ql3.4), UGBSll (19pl2-pl3.3),
PGBS 1575 (19pl3.1-ql2), PGBS2126 (19pl3.3-ql3.43), PGBS2532 (19pl3.3-ql 1), 
UGBS3044 (19pl3.3-ql3.3), PGBS 1595 (19pll-pl3.3), UGBC1397 (19pl3.3-ql3),
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PGBC1510 (19pl2-pl3.3) and UGBC1719m (19pl2-pl3.3). The gene for nascient 
helix-loop-helix 2 (NHLH2) is located at 19qll-p l2 , while several GOIs are located at 
the 19pl3 region, among them cyclin dependent kinase 2D (CDKN2D; 19pl3), 
embryonic lethal, abnormal vision 2 (ELAV2; 19pl3.2) and ephrin-A2 (EFNA2; 
19pl3.3)
Losses in the q-arm: Eight out of 11 tumours that were deleted in the q-arm
lost large sections or the entire q-arm: AS2721, UGBSll, PGBS2126, PGBS2532, 
UGBS3044, PGBS 1595, UGBC1719m and UGBC1397. A deletion in a similar region 
of AS2706 (19ql 1-13.3), has added to the peak at I9ql3.2-ql3.33 in which 10 tumours 
are involved. The gene for cyclin E is located at 19ql2 while the SERTA domain 
containing 1 (SERTADl), transforming growth factor, beta 1 (TGFBl) and 
neurotrophin 5 (NTF5) are located respectively at loci around 19ql3.1-ql3.2, 19ql3.2 
and 19ql3.3
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3-4-23 Figure 3-28 -  CHR 20: Ideogram & Excel graph o f  CNAs for 
10 HGAs
Ten tumours, one of which is an anaplastic astrocytoma, are informative for copy 
number aberrations on chromosome 20. Of these, six have CNAs in the P-arm. The six 
tumours, AS2614 (20pl3), PGBS2051 (20pl 1.2-pl2), PGBS2858 (20pl l.l-p l3), 
PGBS 1926m (20pl2-pl3), UGBC 1719m (20pl3), and PGBC 1760m (20pl2-pl3; 
20pl 1.2-ql 1.2), all showed gains which form two peaks, one at 20pl2.1-pl2.3 and 
another at 20pl3.
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Several GOIs map to loci around 20p-arm. These include the neurotrophin factor 2 
(NFT2) -  like export factor 1 (NXTl) and DNA-binding and chromodomain-regulatory 
gene, SRY-BOX 12 (SOX12/SOX20; 20pter-ql 1.23) at 20pl2-pl 1.2, and the genes for 
NK2 transcription factor related, locus 2 (NKXX2.2), cell division cycle 25B and 
chromosome 20 open reading frame 29 (CDC25BandC20orf29), and SMOX, a 
hypothetical gene which codes for polyamide oxidases (Wang et al., 2003) that may 
have roles in cell proliferation and survival (Murray-Stewart et al., 2002), map to 
respective loci of 3.14 Kb, 38.32 Kb and 68.81 Kb, all located around 20pl3.
Six tumours are informative for CNAs in the q-arm, four are deleted, three of them at 
band 20ql3.2 while two others share a broader deletion spanning the region 2 0 q l2 - 
q 13.11. The genes for E2F transcription factor (E2F; 20ql 1.2), chromodomain DNA 
binding protein 6  (CHD6/CHD5; 20ql2), breast carcinoma amplified sequence 4 
(BCAS4; 20ql3.1) and v-myb, the myeloblastosis viral oncogene homolog (avian)-like 
2 (MYBL2; 20ql3.1), map to respective loci in the q-arm.
Gains in chromosome 20: Two tumours gained genetic material in different
regions of the q-arm, PGB2585 at 20ql 1.3-ql2 and PGBC 1760m at 20ql3.2, as well as 
the extensive gains both have in the p-arms. The q-arm gains span the locus for 
MYBL2.
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3-4-24 Figure 3-29 -  CHR 21: Ideogram and Excel graph o f CNAs 
for 7 HGAs
Seven tumours showed DNA copy number changes in this chromosome, but most were 
clustered within the region of the acrocentromere (data not shown). 7 tumours had 
CNAs in the euchromatin region of the q-arm, of which only one (PGBS2126; 
21q22.12-q22.13) was a deletion. Three tumours gained throughout most of the q-arm, 
PGBS2532 (21pll.2-q22), RGBC 1724 (21pll.l-q22), RGBC 1724m (21pl 1.2-q22) 
and formed two peaks at 2 1 q l l .2 -q2 1 . 2  and at 21q22.13-q22.2, which involved three 
other tumours, GBC1612 (21qll.2-q21), UGBC 1719m (21q22), GBM1760m (21q22). 
The S I00 calcium binding protein, beta (neural) (S-lOOb) is mapped to 21ql2.2.
The genes for oligodendrocyte lineage transcription factor 2 (OLIG2) and glutamate 
receptor, ionotrophic, kinase 1 (GRIKl) are located at loci around 21q22.1, while loci 
for several genes of interest, e.g., the genes for H2B histone family, member S (H2B), 
SH3 domain binding glutamic acid rich protein (WRDandSH3BGR) and runt-related 
transcription factor 1 (acute myeloid leukaemia 1 (amll oncogene (RUNXl and 
RUNXl.l) are located at 21q22.3.
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3-4-25 Figure 3-30 -  CHR 22: Ideogram & Excel graph o f CNAs for 12 
HGAs
Twelve tumours were informative of CNAs in CHR22. The distribution of CNAs 
created two peaks, one, with a very broad base at 2 2 q l l .2 1 -2 2 q l2 .1, was formed by 7  
tumours each of which lost large or complete stretches of the q-arm. A distal peak is 
located at 22ql2.3-22q 13.32 and is made up of losses from all 12 tumours with DNA 
copy number alterations. The genes for neurofibromin (bilateral acoustic neuroma; 
22ql2.2), hepatocyte growth factor-like (MGC17330; 22ql2.2), kringle containing 
transmembrane protein 1 (KREMENl; 22ql2.1), that encodes receptors which 
cooperate in blocking WNT/catenin-signaling pathways, LIM kinase 2 (LIMK2; 
22ql2), checkpoint homolog 2 (CHEK2; 22ql 1) and Chromosome 22 breakpoint 
cluster region (BCR; 22qll), are among the GOIs mapped to respective loci in the q- 
arm.
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Chapter 4: Results o f Array CGH experiments
Supplementary investigations using array CGH were performed on seven out of 32 
(-21%) tumours eonstituting this study. Two of these tumours (PGBC 1612 & 
RGBC 1724) were of the same patient, while the other five were PGBC 160, PGBC1510, 
PGBC 1706, PGBC 1752 and PGBS2093. The first two tumours were selected because 
we wanted to compare their array and metaphase CGH profiles to determine if any 
differences in their CNAs profiles might be construed to be informative in 
differentiating the two tumour samples with respect to tumour recurrence. The other 
four tumours had few or no detectable alterations in autosomes that could be revealed 
by metaphase CGH. This factor made these tumours suitable candidates for further 
investigation using array CGH, to determine if there might be subtle copy number 
alterations below the resolution of metaphase CGH, that could account for the advanced 
histologically grade of the respective tumours.
This chapter of the thesis discusses the results of these 7 array CGH experiments for the 
purpose of gaining additional information from these tumours. Together with Chapter 5 
(results of the MFISH experiment), which follows, this chapter also serves to illustrate 
the diagnostic potentials of various in-situ hybridisation (ISH) techniques, thus 
highlighting some of the experimental procedures that could form part of methodologies 
needed to carry forward some of the results obtained from the metaphase CGH 
experiments, in the hope that information gained from such studies could improve 
understanding of the oncopathogenesis of astrocytomas.
Array CGH experiments were performed using 1-mega-base (Mb) genomic chips 
produced at the Sanger Centre Cambridge, UK and the same DNA [taken from a normal 
male (ECACC Number: CBF 0008 HD03/01/176]) was used as a control in all 
microarray experiments.
The array CGH results of these seven tumours are shown alongside metaphase images 
in figures 4 (1-7). The results are directly produced respectively by the metaphase- 
CGH, and microarray CGH-analysis software. The metaphase and array data of tumours 
1612 and 1724, which are from the same patient, are discussed in detail for each
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chromosome, in sections 4, 7 1  (CHRl) to 7 24 (CHR-Y). Associated tables containing 
detailed genetic information on some of the outlying clones in all seven tumours, 
including the comparison of array and metaphase CGH for PGBC1612 and RDBC1724, 
are presented in Appendix 4. While these tables are referred to in the text, to avoid 
monotony, with a few exceptions no further reference to the appendix is made.
The normal range of fluorescence ratios between test and normal (also known as 
reference) DNAs, which is the reference point for interpreting outcomes of both 
metaphase and array-CGH experiments, has been taken as 1.0 +/- 0.2. The software for 
interpretation of the metaphase experiments generates graphs, which demonstrate their 
limits directly. Although the fluorescence intensities are presented in a standard 
numerical format, in the microarray Excel charts (data not shown on account of 
enormous size) the graphs of fluorescence intensities are generated on a log2 ratio. To 
convert fluorescence values represented in log2  to normal numerical equivalents, the 
following formula is applied: logy ( / )  = jc. “y” is the base of the logarithm, and x 
represents any value of fluorescence ratio in logarithm to base y (logy). For example, the 
normal numerical equivalent of the fluorescence ratio, which appears as 0.5 in log2, = 
log2 (2® )^ = 1.41 while that of the log2 on the negative side of the Y-ordinate, (i.e., log2 
of -0.5) is -0.71 (actual value, 0.7070).
4-1 Polymorphic and “problem” clones
In interpreting data generated by the arrays, consideration was taken of known 
polymorphic (those that were previously shown to be common non-pathogenic 
polymorphisms) and problem clones (clones with sequences matching those of 
chromosomes other than the ones which the clone is primarily associated) are listed in 
Appendix 5
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4-2 Metaphase and array CGH data
4-2-1 Tumour GBM /Cl 60
(la): The gain reported at 13p is in the heterochromatin region; Losses (Red) are reported at 2q37 and 
Y ql2.
(lb)
Figure 4-la  & b: Metaphase and array CGH images of GBM/C160
Metaphase CGH revealed one apparent CNA, a deletion at 2q37, while the rest of the 
genome was apparently normal. The whole genome array-CGH plot shows the majority 
of the clones have normal Test/Ref DNA ratios, which validates the metaphase 
experiment. However, the array plot revealed several clusters of clones that gained 
material in CHRs 5 and 19, and a number of scattered ones on chromosomes Ip, 2q, 6 q, 
1 Iq, 12q and Xp. One clone is underrepresented in CHR 15q and another in CHR 16q. 
Detailed information on the altered clones, sourced from the NCBI Clone Registry 
database (www.ncbi.nlm.nih.gov/genome/clone/), is presented in Appendix 4.
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4-2-2 Tumour G BM /C l510
(2a): Gains are reported at 7pl3, 7pl5, 7q21, and 7q22-q23; and Losses at 9q34, 16ql l-ql2, 19pl2- 
pl3.3,and Ypl3.3-ql2.
W h o l e  G e n o m e  A r r a y  P l o t  B l o c k  N o r m a l i s a t i o n
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FIG 4-2a & b: M etaphase CGH and Array CGH whole genome plot o f GBM /C1510.
Metaphase CGH detected gain of material in chromosome 7 in 4 regions, and loss of 
material at CHR 9q34, 16qll.2, (heterochromatin), 19pl2-pl3.2 and 22pll.2-pl2 
(heterochromatin). CHR 15p (Heterochromatin) was underrepresented both on 
metaphase and microarray. The remainder of the genome was essentially normal. The 
loss on 19p, reported in the metaphase is not evident in the microarray. The whole of 
CHR 7 is slightly overrepresented, which is also in agreement with the graph of average 
fluorescence ratios on metaphase chart. A number of scattered clones were deleted at 
2p, 5p, 6 p, 15, 16q, and 17. One clone each showed gain of material on 1 Iq and 12q. in 
Appendix 4, shows data on genes located in regions that are altered in the array CGH 
plots.
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4-2-3 Tumour G BM /C l706
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(3a): Gains were reported at 13q21 and Ypl3,3-ql2; and Losses at Xp22-q28
W h o l e  G e n o m e  A r r a y  P l o t  B l o c k  N o r m a l i s a t i o n
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Figure 4-3a & b: Metaphase and array CGH data for GBM/C1706 
The two graphs revealed contradictory profiles, which is evident both in the X- and the 
Y-CHRs. Metaphase CGH showed copy number alterations at two regions: a gain at 
13q21 and loss of the whole X-chromosome (Xp22.1-q28). The loss reported in the X- 
chromosome may represent an experimental artifact. It is likely due to differences in 
gender origins of reference DNA used in hybridized probe. GBM/Cl706 was from a 
male patient, however, female reference DNA was used in the metaphase CGH 
experiment, which could explain the apparent gains in the Y-CHR.
Array CGH mostly showed a normal genomic profile. CHRs 5 and 19 were slightly 
overrepresented in some regions. A sample list of the most altered clones is presented in 
Appendix 4.
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4-2-4 Tumour G BM /C l752
I
2
1 1 1 11
« n-337 n-2^
t
__ L. I 1
■ 1Y
i i
)>
@ C 3 C : 8 0
(4a): Gain was reported in the pericentromere heterochromatin at 9ql2, and a loss at Xp22.33-q28
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Figure 4-4a & b: Metaphase and Array CGH for GBM /Cl752
Metaphase CGH of GBM/Cl 752 showed a gain at 9pl2, a known polymorphic region, 
and may reflect normal variation. The loss of genetic material on CHR X and gain on Y 
are likely due to gender differences in the source of DNAs used in the hybridization 
probe. The whole genome array plot shows the genome as mostly normal with a few 
scattered clones having gained on CHRs 11, 12, 15, 16 and 19, while several were 
deleted on CHRs 1, 2, 3, 12 and 16. Data on some of the altered clones are presented in 
Appendix 4.
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4-2-5 Tumour GBM/S2093
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(5a): Gains are reported at 18q23, and Yql 1.1-ql2; Loss is reported at 21pl l . l -p l3 .
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Figure 4-5a & b: Metaphase and Array CGH data for GBM/S2093 
Metaphase CGH did not reveal a significant copy number alteration in this tumour 
sample; all those revealed are in heterochromatin regions, which are characterized by 
highly repetitive DNA sequences. The whole chromosome plot showed most of the 
genome as normal. There were 3 significantly overrepresented clones on CHR 7p while 
elsewhere in the genome a few showed gains or losses that were close to the cutoff 
limits for reporting CNAs. Two of the three contiguous clones that are overrepresented 
in 7p, RPl 1-1091E12 (at 54.85 MB CHR position) and RPl 1-339F13 (at the 55.01 MB 
CHR-position) both contain EGFR sequences. The EGFR is the most commonly 
amplified gene in high malignancy grade astrocytic tumours, thus gain of EGFR would 
confirm that the original tissue sample contained tumour material. Details of some of 
the most altered clones are presented in Appendix 4.
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4-2-6 Tumour G BM /Cl612
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(6a) Gains were reported at 3pl2-q l 1.2, 3p l4 ,  3p21-p24, 3p24-p26, 3q21-q26, 4p l3-p l5 .2 , 6p25-q25, 
6q27, 7p22-q35, 8p22-q24.2, 8q24, 21q ll .2 -q 21 ,  Xp22.3-Xql2, Xql3-q28; while Losses occurred at 
2p25-2q37, 4q21-q22, 4q28-q31.2, 4q31.3, 4q32-q35, 10pl5-10q25, 13qll-q34, 16pl3.3, 17p ll.2 ,  
19pl3.2, 19pl3.3
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Figure 4-6a & b: Metaphase and Array CGH data for GBM/C1612
The whole genome array plot of PGBC 1612 shows widespread copy number alterations 
in most of the chromosomes. Details of some prominent alterations reported by the 
software on CHRs 1612 and 1724 are discussed under individual chromosomes in the 
section that follows.
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4-2-7 Tumour G BM /Cl724
>
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(7a): Gains were reported at lp22, 4pl l-p l5 .3 ,  5p l2 -p l4 ,  8pl 1.2, 8q ll . l -q 24 .3 ,  9pl2-9q33, 2 1 p l l . l -  i 
21q22, Y p l l .3 -q l2 ;  and Losses at 2q35-q37, Hq22-q26, 13q32-q34, 14q24-q31, 1 6 p ll . l -p l3 .3 ,  and , 
I6p ll . l -16q 24
C « n o m «  A rra y  P lo t  B lo c k  N o r m a l i s a t io n
Figure 4-7a & b: Metaphase and Array CGH for GBM/C1724
The tumour RGBC 1724, like its counterpart, 1612, also shows widespread copy number 
alterations in many chromosomes, but to a lesser degree. Metaphase CGH showed 
overrepresentation of CHRl, 4p, 5p, 6, 8, 9, and 21. On the other hand, several 
chromosomes were generally underrepresented, e.g., CHR 4q, lOq, 1 Iq, 12q, 13q, 14q, 
15q, and 16. These findings are validated by the array. Details of these alterations are 
presented with those of PGBC 1612 in the following section.
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4-3 Comparison o f metaphase and array CGH data o f GBMs/1612 and 
1724
This section compares the results of metaphase and array CGH based on alterations 
revealed for each chromosome in the two tumours, 1612, which was the primary, and its 
recurrent counterpart RGBC 1724.
4-3-1 CHROMOSOME 1
1612
1724
0.5
100 tso-0.5i
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distance In tip
Chromosome 1
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Figure 4-7 1: Metaphase and array profiles of CHR 1 in 1612 and 1724
Both metaphase- and array CGH techniques show a shift towards gain for much of the 
p-arm and the proximal q-arm of CHR 1, but a larger region of overrepresentation of 
copy number across the threshold is revealed by the arrays.
The array graph of PGBC 1612 shows that most of the chromosome has balanced copy 
number except for several scattered clones that have either gained or lost copy number. 
Four prominently gained clones and a similar number that are lost on tumour 1612 are 
presented in Appendix 4.
CHR 1 of GBM/Cl 724 appears to have sustained three possible breakpoints, one on the 
p-arm whose boundaries are formed by clones RP4-731G4 (CHR1 36.32; fluorescence 
ratio (PR) 0.98) and RP11-204L3 (CHR1_39.81; PR 1.21). The two probable 
breakpoints in the q-arm are bordered by clones RPl 1-422P24 (CHR1 150.75; PR
  _____________    153
Cytogenetic Analysis o f DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
Chapter 4 Results o f Array CGH experiments
1.05) and RPl 1-17216 (CHR1_152.88; FR 1.38) - for the proximal breakpoint -  and, 
the distal breakpoint, by clones RPl 1-541J2 (CHR1_160.96; FR 1.25) and RP4-702J19 
(CHR1_164.73;FR 1.17).
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Figure 4-7_2: Metaphase and array of profiles of CHR 2 in 1612 and 1724
Metaphase CGH of 1612 shows under representation of the entire CHR, and is validated 
by the array. A few clones have maintained balanced copy number and can be seen 
straddling the ordinate position with the exception of clone RP11-299H21, which has 
apparently gained copy number. The entire CHR is similarly underrepresented, but to a 
lesser degree in tumour 1724 than in 1612. The details of eight clones that are 
prominently altered in both tumours are presented in Appendix 4.
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4-3-3 CHROMOSOME 3
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Figure 4-7_3: Metaphase and array of CHR 3 in 1612 and 1724
Both techniques show that CHR 3 in PGBC1612 is generally overrepresented. But there 
are three sections in the p-arm and the proximal 1/3 of the q-arm that are normal. Array 
CGH revealed a small segment of normal clones in the distal part of the q-arm, which is 
not seen in the metaphase CGH image. Three clones are shown deleted in the array. 
However, both techniques revealed no copy number alterations in this chromosome in 
1724. Table 4-7 3 shows details of clones that are most prominently altered in 1612.
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Figure 4-7 4: Metaphase and array of CHR 4 in 1612 and 1724
The metaphase CGH of both PGBC 1612 and RGBC 1724 show a region that has gained 
prominently for a distance of -40Mb in the middle of the p-arm of CHR 4, which is 
validated in both cases by the array CGH. Both techniques also reveal loss of copy 
number throughout the q-arm. Although metaphase CGH shows three regions to be
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deleted in 1612, the fluorescence ratio profiles are underrepresented for the entire length 
of the q-arm. This is validated by the array, which, in addition, revealed several clones 
that have gained, flanked by RP11-338K13 (8.1 Mb CHR position) and RP11-362J17 
(around 20.51 Mb CHR position. Array of 1724 shows a similar pattern to that of 1612; 
equally clones in similar locations as in 1612 are moderately overrepresented. Several 
genes, including LOC389199 (4pl6.1), AFAP (Actin Filament Associated Protein 1) 
(4pl6), ABLIM2 (Actin Binding LIM Protein Family, Member 2) (4pl6-pl5) and 
KCNIP4 (Kv Channel Interacting Protein 4) (4pl5.31) are mapped to this region.
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Figure 4-7_5: Metaphase and array of CHR 5 in 1612 and 1724
Metaphase CGH of 1724 shows a definite gain in the middle portion of 5p, which is not 
supported by the array. In light of the very convincing gain in 4p, this might suggest 
wrong identification, and assignment, of some chromosomes. However, in most 
metaphases analysed in this experiment all 4 CHR 4 and 5 show gain. Array showed 
that most of the clones have normal copy number throughout the length of the 
chromosome, both in 1612 and 1724. Two clones are shown prominently deleted in the 
p-arm of CHR 5 in both tumours while there are three prominently gained clones, 2 
immediately proximal to the centromere in 1612, and the other more distal in the q-arm, 
around the 180Mb position. Several clones are moderately underrepresented in similar
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locations in both tumours with no evidence shown in metaphase CGH. Details of some 
of the outlying clones are presented in Appending 4.
4-3-6 CHROMOSOME 6
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Figure 4-7 6: Metaphase and array of CHR 6 in 1612 and 1724
Both techniques show marked overrepresentation of copy number for the whole of CHR 
6 in 1612, the average fluorescence ratio on the array falling between 1.33-1.39. Array 
CGH revealed 2 underrepresented clones. In 1724, the whole of chromosome 6 is 
slightly overrepresented especially so in the q-arm, which appears very close to the cut­
off limit for a definite gain in metaphase CGH but is not so convincing in array CGH 
except for several scattered clones. One clone in the distal q-arm is lost in the array 
chip. Details of outlying clones are in Appendix 4.
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4-3-7 CHROMOSOME 7
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Figure 4-7 7: Metaphase and array of CHR 7 in 1612 and 1724 
CHR 7 of 1612 is overrepresented throughout most of its length, which is apparent from 
both techniques, but array revealed a few scattered normal clones and one, located 
around 45Mb position, which is deleted. However, in 1724 both techniques revealed an 
underrepresented segment in the proximal q-arm that is roughly 40 MB. The same 
clone, located around 140 Mb, which is one of several that are underrepresented relative 
to the rest in chromosome 1612, is shown apparently deleted in 1724. Details of some 
of the most altered clones in CHR 7 are shown in Appendix 4.
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4-3-8 CHROMOSOME 8
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Figure 4-7_8: Metaphase and array of CHR 8 in 1612 and 1724
Both techniques are in agreement; in each case CHR 8 is shown overrepresented 
throughout almost the entire length in 1612 and the q-arm in 1724. There is a sharp rise 
in fluorescence around the 35.02 MB position, between clone RP1-144M5 
(fluorescence ratio of 1.05) and RP1-155L11 (fluorescence ratio of 1.29), which is 
sustained in 22 contiguous clones for a distance of 7.1 MB. The demarcation between 
RP1-144M5 and RP1-155L11 may represent a possible translocation breakpoint in this 
CHR 8. This possibility is supported by results of MFISH analysis on RGBC1724, 
which found that CHR 8 was frequently involved in translocations. For example, 
der(8)t(8;22) was observed in 83% (5 out of 6) of the cells analysed, while der(8)t(8;12) 
occurred in 50% (3 out of 6) cells analysed. Other less frequent translocations involving 
CHR 8 were der(8)t(8;17) and der(8)t(8;19)t(19;21), each observed only in 1 out of 6 
cells analysed (-17%).
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Figure 4-7 9: Metaphase and array of CHR 9 in 1612 and 1724
Both techniques agree in each case, showing normal CHR 9 in 1612 and 
overrepresented q-arm in 1724
4-3-10 CHROMOSOME 10
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Figure 4-7 10: Metaphase and array of CHR 10 in 1612 and 1724
In 1612 both techniques show marked underrepresentation of the entire CHR 10, but 
with a couple of prominently deleted clones lying between 85-90 Mb. 1724 shows CHR 
10 as generally normal except for several clones that are prominently deleted in the 
array chip. Three of these are located around 85-90 Mb, corresponding to the 10q23 
region, and a fourth around 115-120 Mb region of the chromosome that corresponds to 
the coordinate 10q24-q25. Table 4 -710  shows details of the most prominently deleted 
clones.
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Table 4-7 10
CHR position Clone Fluorescence Matching genes (locus)
(Mb) ratio
1612 1724
CHRIO 49.26 RP11-13E1 0.58 0.84 FRMPD2(10q 11.22)
CHRIO 74.10 RP11-326F3 0.67 1.12 N/a
CHRIO 85.79 RP11-219F10 0.54 0.78 N/a
CHR10_ 89.83 RP11-380G5 0.02* 0.32* PTEN (10q23.3)
CHRIO 89.75 RP11-165M8 0.11* 0.32* 2 clones both mapped to 
10q23.31 (CFLPl, ATADl)
CHRIO 90.66 RPl 1-30415 0.33 0.54 2 genes both mapped to 
10q23.31 (ANKRD22, 
LIPL3)
CHR10_ 117.10 RP1 1-338L11 0.09* 0.33* ATRNLl (10q26)
*, The fluorescence ratio of these clones is so low that they do not appear on figure 4- 
7 1 0  but their positions can be seen on the whole-genome plot in figures 4-6b and 4-7b
All of these prominently deleted clones at distal lOq are part of the CHR 10 NT 030059 
contig that includes 5 clones with sequence similarity to genes clustered around 10q23. 
Clone RP11-380G5, which codes for the gene phosphatase and tensin homolog 
(mutated in advanced cancers 1) (PTEN), is mapped to 10q23.3, while RP11-165M8 
which contains parts of sequences of cofilin pseudogene (CFLPl) and Atpase family 
AAA domain containing 1 (ATADl) both of which are mapped to loci around 
10q23.31. Clone RP11-30415 corresponds to sequences for ankyrin repeat domain 
containing 22 (ANKRD22) and lipase-like, ab-hydrolase domain containing 3 (LIPL3), 
both also mapped at 10q23.31. The sixth’ clone, RPl 1-338L11, contains sequences of 
the attractin-like 1 (ATRNLl) or melanocortin 4 receptor (MC4-R) that is thought to 
have critical roles in regulating glucose homeostasis (Haqq et a l, 2003).
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Figure 4-7 11 : Metaphase and array of CHR 11 in 1612 and 1724
For tumour 1612, both techniques show mostly normal profiles, however array shows 
one prominently gained clone in the mid p-arm region and a deleted one in the 
heterochromatin region immediately above the centromere. In 1724 on the other hand, 
CHR 11 is generally underrepresented throughout most of its length except the upper 
half of lip,  which both techniques report as normal. The sharp break in continuity of 
the fluorescence ratio profiles seen in the middle of the p-arm could represent a 
translocation breakpoint. The probable translocation breakpoint is flanked proximally 
by clone RPl 1-34N19 (CHRl 1 22.56; mean fluorescence ratio of 1.02) and distally by 
RP11-72C9 (CHRl 1 24.54; mean fluorescence 0.89). The MFISH experiment of 
GBM/C1724 found der(9)t(9;l 1) translocations in 3 out of 6 (50%) cells analysed, 
which is a fairly a frequent occurrence that would warrant further study to establish 
genetic associations and their probable roles in the pathogenesis of this tumour. RPl 1- 
72C9 has sequences corresponding to those of the gene, leucine zipper protein 2 
(LUZP2) that is mapped to 11 p i4.3. It is a chromosome segregation ATPase, thought to 
have roles in cell division and chromosome partitioning. As yet there are no known 
genes associated with sequences for clone RP11-34N19. There is a definite loss 
reported by both techniques around Hq24-q25. Table 4-7_l 1 contains details of some 
of the most altered clones
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4-3-12 CHROMOSOME 12
1
s
n “ 50
1724
Chromoeome 12
«0-0.5 20 - 40 + 0
0.5
-0 5 20
distance in t>p
Figure 4-712:  Metaphase and array of CHR 12 in 1612 and 1724 
Metaphase and array CGH are in agreement in both tumours. The profiles of 1612 are 
shown as mostly normal, with two slightly overrepresented clones (one around 75 MB 
and one telomeric) and one deleted (at approximately 112 Mb position). Meanwhile, 
1724 shows underrepresentation of the whole chromosome in both techniques. Several 
deleted clones are clustered around 95-100 Mb. Table 4-712,  in Appendix 2, shows 
their details.
4-3-13 CHROMOSOME 13
n = 28
1612
n = 59
1724
Figure 4-7 13: Metaphase and array of CHR 13 in 1612 and 1724
The whole of CHR 13 is shown deleted in metaphase CGH profile, which is supported 
by markedly underrepresented array profile of log2 T/N ratios. A few clones are shown
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to have maintained balanced copy number while one at ~120 MB gained. The whole of 
CHR 13 of 1724 is similarly underrepresented but with a definite loss shown at 13q22- 
q24. Details of the most altered clones are presented in Table 4-713.
4-3-14 CHROMOSOME 14
r'
1612
1724
Figure 4-7 14: Metaphase and array of CHR 14 in 1612 and 1724
Like CHR 13, CHR 14 is also deleted across the entire length in 1612, which is 
confirmed by the array. A couple of clones are normal and one is shown to have gained. 
The whole chromosome 14 is similarly underrepresented in 1724 but only a short 
segment is reported deleted by the metaphase CGH. Some of the most altered clones are 
presented in Table -714.
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4-3-15 CHROMOSOME 15
n = 29
1612
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Figure 4-7 15: Metaphase and array of CHR 15 in 1612 and 1724
Both procedures are in agreement, each case showing under representation of the whole 
CHR 15 in both metaphase and array profiles. Several clones are shown deleted or 
amplified. Details of some o f  the altered clones are presented in Table 4-715.
4-3-16 CHROMOSOME 16
1612
n = 58
1724
Figure 4-7 16: Metaphase and array of CHR 16 in 1612 and 1724
Both techniques show slight-to-moderate under representation of chromosome 16 in 
1612, with a couple of clones shown deleted in the q-arm. However, the whole CHR 16 
is shown deleted and prominently underrepresented, respectively, in metaphase and 
array profiles of 1724. A sample of the most altered clones in 1612 and corresponding 
fluorescence ratios of 1724 are shown in Table 4-7 16
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4-3-17 CHROMOSOME 17
1612
1724
Figure 4-7 17: Metaphase and array of CHR 17 in 1612 and 1724
Both metaphase profiles show much of chromosome 17 to be within normal 
fluorescence cutoff range. However, the array shows that over 50 % of the clones in 
both tumours are overrepresented, with fluorescence ratios ranging between 1.25-1.36 
on average. A few clones are underrepresented, the most prominent being around the 10 
Mb position in both tumours, corresponding to the location of TP53 and several other 
genes. Table 4-717  shown details of clones altered in this the deleted cluster on the p- 
arm of CHR 17.
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Table 4-7_17
CHR position 
(Mb)
*CHR17_7.518 
'CHRH 7.52 ' ^
CHR17_7.65 
CHR17 8.49
Clone Fluorescence
ratio
161*2 Î724
Matching genes (locus)
RPl 1-31 (Dll
- 4-
RP11-404G1
RP11-12H18
0.42
0.39
0.39
0.58
0.49
0.55
Location of TP53 in relation 
to clones found in this array 
slide (plate)
N/a; Problem clone -  all 
STSs mapped to CHR 5 and 
none to this chromosome 
FLJ46675 (17pl3.1)
RP11-208F13
RPfwOlOO'
RP11-471L13
0.52
, _ L _ .
0.39
'T
0.65
0.61
2 genes: FLJ32734
(17pl3.1)and MYHIO 
(17pl3)
N/a
2 genes: MYH8 (17pl3.1)
and MYH13
(17pl3)
I 0.44 |~0.60 j MAP2K4(17pll.2)
*The shaded row shows the CHR position of TP53 in relation to clones that are present 
in this array slide.
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4-3-18 CHROMOSOME 18
n = 30
1612
n = 55
1724
CKrorr>o«om« ia
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(Nmtanc# tn bp
Figure 4-7 18: Metaphase and array of CHR 18 in 1612 and 1724
Metaphase and array experiments are in agreement, showing normal profiles in both 
1612 and 1724. However, there are several outlying clones, most in similar positions in 
the two tumours. Details of these are shown in table 4, 7 18.
4-3-19 CHROMOSOME 19
n = 29
1612
n = 61
1724
Figure 4-7 19: Metaphase and array of CHR 19 in 1612 and 1724
Metaphase CGH of 1612 showed deletion of 19p at 19pl3.2 and 19pl3.3 with an 
underrepresented fluorescence profile. The array log2 plot is slightly underrepresented 
in the distal V2 of the p-arm, while the remainder is normal except the distal % of the q- 
arm where several clones are overrepresented. In addition, the array revealed 3 isolated 
clones that are deleted. The one in the p-arm appears to correspond to the deletion at 
19pl3.2; the other two deleted clones are located around 37 Mb and 53 Mb 
respectively. In 1724, both techniques showed normal fluorescence ratio profiles, 
except that the array revealed overrepresentation of the same set of clones seen in 1612.
Details of these prominently altered clones are presented in Table 4, 7 1 9
— . — - — — ., - . - — 1 ^ ) 8  
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4-3-20 CHROMOSOME 20
J!
n = 27
1612
Chromosome 20
distancs In bp
1724
Chromosome 20
Hr; '
f  0.5
Ï § °
A 1  ^■".1
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dlstanc* In bp
Figure 4-7 20: Metaphase and array of CHR 20 in 1612 and 1724
Both techniques show normal CHR 20 profiles in 1612, but with the array showing a 
couple of underrepresented clones in the distal q-arm. However, both metaphase and 
array plots reveal overrepresentation of the p-arm and proximal of the q-arm; the 
distal V2 is normal except for a couple of overrepresented clones at the very end.
4-3-21 CHROMOSOME 21
I f
n = 29
1612
Crtromosom* 21
n = 51
1724 a*# Urn mom »o bp
Figure 4-7 21: Metaphase and array of CHR 21 in 1612 and 1724
CHR 21, both in 1612 and 1724, were generally overrepresented, with gains in the q-
arm.
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4-3-22 CHROMOSOME 22
n = 27
1612
Z
n = 58
1724 m tx»
Figure 4-7_22: Metaphase and array of CHR 22 in 1612 and 1724
There is generally no change in this chromosome in both tumours, however two clones 
may be deleted in the proximal q-arm. Details of the underrepresented clones are 
presented in Table 4, 7 22.
4-3-23 CHROMOSOME
« 0  eo 100 170
distance in  bp
Figure4-7 23: Metaphase and array of CHR X in 1612 and 1724
The entire X-chromosome is gained in the metaphase and is overrepresented throughout 
in the array. In 1724, the metaphase only shows overrepresentation in the long-arm, 
while the chip shows the entire chromosome to be overrepresented and is clearly 
gained.
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4-3-24 Y-CHROMOSOME
n = 14
1612
n = 30
1724
Figure 4-7 24: Metaphase and array of CHR-Y in 1612 and 1724
In both tumours, metaphase and array techniques show this chromosome to be generally 
overrepresented and gained entirely.
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4-4 Summary on comparisons data o f  metaphase and array data for 
GBMs /C 1612& /C 1724
In general, for each of the 7 tumours investigated by both metaphase and array CGH, it 
was observed that the data for the two experimental approaches were well correlated. 
Detailed analysis of alterations reported by both metaphase and array CGH on tumours 
1612 and 1724 showed that there were several important alterations that were common 
to the two tumours. Thus, in addition to validating the metaphase CGH experiments, 
this would in deed confirm that the two tumours could have originated from the same 
individual. Metaphase CGH of 1612 and 1724 revealed a large number of alterations in 
both tumours. Table 4 8 is a diagrammatical representation of alterations in both 
tumours.
4-4-1 Table 4 8: Comparison o f  CNAs revealed by metaphase CGH in 
G BM S/1612& /1724
1612 Gain 1612 Loss
CHRlp
CHRlq"
CHR2p'
"CHR2q
CHR3p
CHR3q
2p26-q37
2p26-q37
3pl2-ql.2 ,3pl4 ,
3p24-p26
3q21-q28
1724_Gain 1724 Loss 
i _ -  _ _ _ _ _ _
f ' P 2 2  i
1
i  _______
[  !
j
maim 2q35-q37
' j 
1
t
1
1
CHR4p
CHR4q
4pl3-pl5.2
4q21-q22,
, 4q28-q31.2, 
' 4q3L3, 
i 4q32-q35
4pll-pl5.3
CHRSp 11 - .
5pl2-pl4
CHR5q 1
CHR6p 6p25-q25 i
CHR6q 6p25-q25, 6q27 !
CHR7p 7p22-q35 1
!
CHR7q 7p22-q35,
1 iL
CHRSp 8p22-q24.2 8pll.2-q24.3 5
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8pll.2-q24.3 
9pl2-q33 "
CHR9q
CHRlOp
CHRlOq
CHRl Ip'
CHRMq
CHR12p
CHR12q
CHRÏ3q
CHRUq
CHRlSq
CHR16p
CHR16q
CHR17p
9pl2-q33
—i- 10pl5-q26
10pl5-q26
T
Uq22-q25 ■H
13qll-q34
14qll .l-q l2 ,
14ql3-q32
- I
16pl3.3
17pll.2
CHR17q
CHRT8p
chrT ^
'~CHR19q I
13q32-q34
14q24-q31
16pll.2-pl3.3  
16ql 1.2-24
19pl3.2, 19pl3.3 j
CHR20p
CHR20q
CHR21q 21qll.2-q21 21qll.l-q22
CHR22q
CHR-Xp
CHR-Xq
Xp22.3-ql2
Xp22.3-ql2,
Xql3-q28
CHR-Yp
CHR-Yq
Ypll.3-q34
Ypll.3-q34
Table 4 8: Metaphase CGH data on alterations in 1612 and 1724. Shaded 
rows show regions of common alterations in the 2 tumours. Green represents gain of 
DNA copy number while orange /brown represents regions that were shown as deleted.
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4-5 Array CGH data showing DNA copy number alterations at 19 loci o f  
some o f  the genes associated with development o f  astrocytomas - 
both hereditary and sporadic.
As mentioned in the introductory chapter, ~5% of astrocytomas arise in association with 
hereditary syndromes (e.g., neurofibromatosis or tuberous sclerosis), as a result of 
germline mutations in the TSGs that cause the syndromes. However, the majority of 
astrocytomas appear to arise spontaneously, following somatic mutations of other 
cancer predisposing genes. Thus, some cancer-associated genes are believed to cause 
only hereditary astrocytomas, while others appear to have roles in both hereditary and 
spontaneous astrocytomas. At least 19 loci harbour genes implicated in development of 
astrocytomas in general. Table 4 9, shows the fluorescence ratios of clones (from array- 
CGH) that are mapped within these loci, or in their vicinity, in the 7 tumours further 
investigated by this method.
174
Cytogenetic Analysis of DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
Chapter 4 Results of Array CGH experiments
T able 4 9: A rray CG H  data on clones m atched to genes that F luorescence rations (M ean) 
are im plicated in astrocytom a developm ent
Gene/Locus Clones <& Nucleotide coordinates €1752 C l 706 C1510 C160 S2093 C1612 C172
PDGFA; 7p22 
NC.503423-526007
CTB-164D18 7_2546G9.5 1.G2 1.02 1.14 1.08 1.23 1.27 1.03
PMS2: 7p22 
NC.5979396-6015263
RP11-449P15 7_727G16.5 0.98 1.05 1.03 1.07 1.08 1.21 1.06
EGFR: 7pl2  
NC.7518224-7531642
RP4-733B9 7_6978224.5 1.05 1.09 1.16 1.06 1.27 1.35 1.07
RP11-5G5D17 7_778G751 1.00 1.09 1.19 1.03 1.18 1.34 1.02
CDKN2A/2B:9p21 
NC.5979396-6015263
RP11-5G9D8 9_5G1649 1.00 1.07 1.09 1.08 0.83 1.07 1.07
RPl 1-21817 7_6G7GG88.5 1.04 1.04 1.03 1.03 0.82 1.03 1.00
PTEN: lGq23.3 
NC.89613175-89718512
RP11-165M8 1G_89754667 0.91 0.94 1.00 0.96 0.85 0.11 0.33
RP11-38GG5 1G_89838961.5 1.03 1.02 1.00 0.97 0.91 0.6 0.32
RP11-765C1G 1G_89938145.5 1.00 1.01 1.03 0.96 0.86 0.02 0.14
RP11-3G415 1G_9G6664G5.5 - 0.94 0.99 1.02 0.90 0.33 0.55
DMBTl: lGq26.13 
NC.12431G171-124393242
RPl 1-436019 1G_124317277 1.34 1.00 0.93 1.13 0.84 0.6 0.92
CDK4: I2ql4.3 RP11-183H16 12_5635412G.5 0.98 0.99 0.98 0.94 0.85 0.9 0.96
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NC.56428270-56432431 
Gene/Locus 
MDM2(PAP1B): 12ql5  
NC.67489255-67520481
RBI: 13ql4.2 
NC.47775884-47954027
TP53: 17pl3.1 
N C .7518224-7531642
Clones 4& Nucleotide coordinates 
RP11-328H16 12_67031985.5
RP11-542B15 12_67594405 
RP11-305D15 13_47867886.5
RPl 1-174110 13_47917948.5 
RP11-199F11 17_7520901.5
RP11-404G1 17 7650784
C1752
0.99
0.98
1.14
0.97
0.94
Cl 706 
1.03
0.99
1.05
1.06 
0.92
0.93 0.94
C1510
1.01
0.99
1.06
1.07
0.97
0.92
C160
1.05
0.96
1.13
0.90
0.86
0.94
S2093 C1612 C1724
1.06 1.04 0.86
1.03
1.10
0.98
0.74
0.99
0.75
0.70
0.99
0.91
0.89
0.88
0.58
0.82 0.40 0.50
TP73: lp36.32  
NC.3597096-3639716
19q
RP4-785P20 1 2868729.5
RP1-37J18 1 4103538
1.14
.06
0.96 0.94
0.96 0.94
0.98
0.96
1.01 0.92 0.93
0.98 0.94 0.90
MSH2:2p21-22
NC.47483767-47760014
RP11-436K12 2 47690350.5 1.02 0.96 0.95 0.99 0.93 0.71 0.91
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RP5-960D23 2_47939947 0.96 0.97 0.94 0.99 0.77 0.69 0.90
Gene/Locus Clones & Nucleotide coordinates C1752 C1706 C1510 C160 S2093 C1612 €1724
PM Sl:2q31-q33
NC. 190426900-190437086
CTC-444N24 2_190075192 1.26 1.31 1.21 1.44 1.23 0.90 0.96
RP11-455J20 2_190621121 1.02 1.09 1.07 0.99 0.99 0.79 « 5 0.97
MLHl:3p21.3
NC.37020896-37028594
RPl 1-491D6 3_36887415 1.06 1.03 1.01 1.00 0.96 1.04
RP11-331G2 3_39061581.5 0.99 0.99 0.96 1.03 0.99 1.27 1.04
APC:5q21-22
NC.l 12101483-112209835
RPl 1-3B10 5 _112080205.5 0.97 1.04 0.98 1.04 1.02 1.00 1.12
CTC-1554D6 5_112161361 1.04 1.09 1.05 1.17 1.07 0.99 1.28
PTCH: 9q22.3 
NC.97283932-97319160
RP11-80H12 9_97251057 1.01 0.96 1.00 0.93 1.08 1.06 1.31
RP11-75J9 9_97978853 1.01 0.97 1.00 0.92 1.06 1.00 1.36
T SC l:9q34
NC.134771939-134809841
GS1-135117 9_134247737 0.96 0.97 0.98 0.99 0.88 1.01 1.37
MLH3: 14q24 
NC.74550220-74587988
RP11-368K8 14_74223867.5 0.99 0.99 0.96 1.07 0.99 0.71 0.78
RPl 1-361HIO 14_74663588.5 0.99 0.96 0.98 1.01 0.94 0.69 0.81
TSC2: 16pl3.3  
NC.2037991-2078714
RP11-161M6 16_1008467.5 0.99 0.92 0.95 0.91 0.95 1.00 1.05
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RP11-304L19 16_2167457 0.94 0.94 0.92 0.93 0.83 0.92 0.81
Gene/Locus Clones & Nucleotide coordinates C1752 C l 706 C1510 C l 60 S2093 C1612 C1724
N F l: 17qlL 2 RP11-138P22 17_26048765 0.99 0.94 0.99 0.91 0.89 1.25 1.12
NC.26470278-26670503
RP11-192H23 17_26744090.5 0.94 0.93 0.94 0.95 0.84 1.28 1.33
RP11-229K15 17_29200556 0.95 0.95 0.98 0.94 0.78 1.27 1.36
RPl 1-104120 17_27994182 0.94 1.02 0.94 0.76 0.92 1.13 1.23
N F 2:22q l2 .2 RP1-329J7 22_205047 1.03 1.04 0.95 1.13 0.98 1.01 1.02
NC.28329565-28424585
CTA-57G9 17 27894024.5 0.94 0.91 0.95 0.93 0.8 0.96 1.03
C aption for table 4 9:
Light-green shading represents gains, beige shading represents loss, and Red font shows borderline fluorescence ratios - on the lower side of 
normal.
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5 CHAPTERS: Results o f MFISH Analysis o f
GBM/Cl 724
Multicolour fluorescent-m situ hybridisation (MFISH) was performed on chromosome 
spreads made from RGBC1724, which was a high malignancy grade astrocytoma 
(WHO Grade 4). The M-FISH was kindly carried out and analysed in Dr Denise Sheer’s 
lab by Radost Vatcheva, primarily because the software for manipulating the images 
was not available at the Galton lab. However, I was present at the experiments and 
participated in the analysis.
The point of doing this experiment was to see how the results related to the CGH 
experiments, and also to determine the number of chromosomes in each cell and see if 
any translocations of potential interest could be observed. It was also hoped to 
determine whether the gain on 4p was present on double minutes (DMs) or an obvious 
homogeneous staining region (HSR), which are believed to signify gene amplification 
(Bigner et al., 1987; Kleinschmidt-DeMasters et al., 2004; Arjona et al., 2005).
5-1 MFISH findings
The data presented here include one metaphase spread (fig 5:1 (a)), one karyotype from 
a different cell (fig. 5:1 (b)) and a summary table of the overall findings (Table 5:1). 
The major finding was the very large number of chromosomes in each cell and the 
heterogeneity between the six cells examined. The number of chromosomes could 
certainly explain the general slight over- or under-representation of particular 
chromosomes noted by CGH, but the heterogeneity makes comparison of copy number 
impossible. It was frustrating that no explanation for the clear gain of 4p material 
previously seen could be found. Simple chromosomal alterations in the form of 
deletions were noted to occur less frequently in chromosomes 1 (Ip), 3, 4, 6, 7, 8, 9, 10, 
11, 12 (12p), 16, 18 and the X-chromosome, while simple gains, in comparison to 
losses, were much less commonly encountered. For example simple gains were seen in 
chromosome 10, 16 and 20. More common, however, and potentially of great interest, 
was the occurrence of simple rearrangements (involving two chromosomes) and some 
more complex rearrangements (involving three or more chromosomes). Of particular
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note were two translocations seen in several cells. One of them was a translocation 
between chromosomes 8 and 22, where the former was the recipient in der(8)t(8;22) 
which was observed in 5 out of 6 (83%) cells analysed. The other was 
der(X)t(16;X)t(17;X), which was observed in 4 cells (67%). Thus, in decreasing 
frequency rearrangements found in two or more of the six cells analysed were: 
der(8)t(8.22) (83%), der(X)t(16;X)t(17;X) (67%), der(8)t(8;12) (50%), der(9)t(9;ll) 
(50%), der(l)t(l;8), (33%), der(5)t(5;22) (33%), der(6)t(6;13) (33%), der(7)t(7;10) 
(33%), der(7)t(7;X) (33%), der(9)t(6;9) (33%), der(10)t(10;15) (33%), der(20)t(7;20) 
(33%). These and other rearrangements/alterations observed only in six cells of the 
same tumour are shown in Table 5-1 (page 181).
Explanation fo r  table 5:1
The column o f  frequency indicates the number o f  times an aberration was observed in 
the six cells analysed. Where no figure is given, the aberration was observed just once. 
T & t: translocation; Del, deletion; Der, derived/(indicating the recipient chromosome 
o f an additional copy or chromosome segment).
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5-1-1 Table 5-1: List of cytogenetic aberrations revealed by MFISH on GBM/C1724
T(3;16)t(3;5) 2
T(7;10;3) Der(9)t(9;18)
T(3;g) 5
Del(lX-p) Der(9)t(9;10)
Der(l)t(l;3) 3
Der(l)t(l;12) Der(9)t(9;18)
Der(l)t(3;20) Del(IO) 6
D er(l)t(l;15) Der(10)t(10;15) 2
Der(l)t(l;16)t(l;10) Add(lO)
D er(l)t(l;8) 2 D er(ll)t(10 ;ll)
Der(l)t(l;9) D e l(ll)
D el(l) 2
Der(l)t(l;18) Del(12)(-p)
Der(l)t(l;5) Der(13)t(10;13)
Der(2)t(2;5) Der(14)(l;14)
Der(2)t(2;6) Der(14;15)
Der(2)t(2;X) Der(14)t(10;14)t(10;17)
De/rj; 2 Add(16)
Der(3)del(3)9q?)t(3;14) Der(16)t(6;16)
Del(4) 2 Der(16)t(6;X)
Del(4)t(4;10) Dmin(17) 2
Der(4)t(4;17) Der(17)t(4;17)
Der(5)del(5)(q?)t(5;10) Del(I8) 2
Der(5)t(5;10) Der(18)t(18;X)
2 2
2 Add(20)
2 Der(20)t(18;20)
Der(7)t(7; 10) 2 4
2 4
Der(7)t(7;20) Der(X)t(16;X)
Der(7)t(7;21) Der(Y)t(16;Y)
Del(7)
Del(8)
Der(8)t(8;17)
5
3
Der(8)t(8;19)t(19;21)
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5-1-1 Figure 5 -1(a) Image o f a single metaphase spread
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5-1-2 Figure 5 -1(b) Karyotype image o f a different metaphase spread
The total number of ehromosomal aberrations found in the six cells that were analysed 
by MFISH was approximately 120, of whieh simple chromosomal alterations were in 
the form of deletions, and were most eommonly encountered in chromosome 10, which 
was deleted in all six (100%) eells analysed. This was followed, in the order of 
deseending frequency, by chromosome 9, which was deleted in 5 out of six (83%) cells,
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X-chromosome, 4 out of six (67%), chromosome 3, 2 out of six (33%), chromosome 4 
(33%), chromosome 6 (33%), chromosome 12 (33%), and chromosome 18 (33%).
On the other hand, recurrent simple gains were observed only in chromosome 17, 
which, interestingly, had double minutes in two cells. In addition, three simple gains 
were observed, occurring only once in each case in chromosomes 10, 16 and 20.
The region on the array CGH of CHR 8, at approximately 38 Mb from p-ter, where the 
signal suddenly increases and continues to q-ter could possibly correspond to one of the 
breakpoints in the t(8;22) seen in the MFISH. Closer inspection suggests the boundary 
clones to be RP1-144M5 (at around the 34Mb position), RP11-155L11 (35Mb), R P ll- 
98112 (36Mb), RP1-197P20 (37Mb), (RP11-350N15 (38Mb), and RP11-44K6 (39Mb), 
so that genes within this region might possibly be contributory to a fusion protein with 
oncogenic potential. Although in such a very abnormal karyotype this must be a very 
tentative conclusion, it does illustrate a possible method to combine CGH microarray to 
MFISH results.
It was not possible in most cases to ascertain in more specific terms the chromosome 
arm of the donated segment in the region of translocation revealed by MFISH. 
Additional investigations would be required to characterise the breakpoints in both 
CHR 8 and 22 that are translocated and might possibly contribute to a fusion protein. 
Thus, at this stage of the study it is not possible to discuss the translocations in more 
specific detail with reference to genes that might be implicated. However it is of interest 
to notice that numerous translocations between chromosomes 8 and 22 have been 
reported in medical literature. A PubMed search found 242 entries (hits) although not 
all of them are limited strictly to the two chromosomes. Various combinations of 
translocation involving both arms of chromosome 8 and parts of chromosome 22 have 
been reported in association with a wide range of medical conditions. In some the 
diseases associated with various t(8;22) were not of the malignant kind, as for example, 
the association of constitutional t(8;22) with myasthenia gravis, leucocytosis and 
thrombocytosis (Keung et al., 2004). Other diseases associated with t(8:22) were related 
to haematopoietic and lymphopoietic-type malignancies (Demiroglu et al., 2001; 
Tasaka et al., 2002; Reid et al., 2003; Gupta et al., 2004) and solid lymphomas, in 
particular variants of Burkitt’s lymphoma (Gerbitz et al., 1999; Yamamoto et al., 1998;
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Rickert et al., 1999). In addition, there are occasional reports of translocations involving 
chromosomes 8 and 22 in solid tumours of other systems such as cardiac lymphoma 
(Klopfenstein et al., 1997), epithelioid sarcoma (Cordoba et al., 1994) and mixed 
mullerian tumour of the uterus (Sreekantaiah et al., 1999).
Probably the most characterised and documented t(8;22) is one involving 8q24 and 
22qll, der(8)t(8;22)(q24;ql 1) whieh is observed in variant forms of Burkitt’s 
lymphoma. This translocation is thought to implicate the C-MYC gene on 8q24 and 
immunoglobulin light chain, lambda, gene (IgX) at 22ql 1 (Zeidler et al., 1994; Calasanz 
et al., 1997(a); Calasanz et al., 1997(b); Yamamoto et al., 1998). Another t(8;22) 
translocation that has been characterised involved fusion of the genes for breakpoint 
cluster region (BCR; 22ql 1.23) and epidermal growth factor receptor 1 (FGFRl; 
8ql 1.2) in patients with chronic myeloid leukaemia (CML) (Demiroglu et al., 2001; 
Fioretos et al., 2001). It has been suggested that the t(8;22) in which the CMYC and 
light chain genes are fused, may contribute to oncogenesis in acute, mostly paediatric 
type malignancies (Gupta et al., 2004), while primarily promoting malignant 
progression in chronic haematogeneous malignancies (Yin et al., 2004). Thus, the 
translocation t(8;22)(q24;qll) is regarded as a marker of poor prognosis (Voorhees et 
al., 2004; Tones et al., 2004). Whether these various previously described translocations 
have any relationship to the translocations seen in the GBM/C1724 remains to be 
determined.
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DISCUSSION 
6-1 Overall aims
This thesis has been concerned with the detection and interpretation of copy number 
changes of the genetic material in astrocytomas. In general there are three types of 
large-scale chromosomal changes, which may provide useful clues to the mechanism 
of origin of a tumour and might also provide some indication of likely outcome. 
These include increase of material in a specific region, which might indicate 
amplification of an oncogene. Loss of a specific region may suggest the existence of a 
tumour suppressor gene. A truly balanced translocation between two chromosomes, 
which may for example result in the activation of an oncogene by the generation of a 
fusion protein will not be detectable as loss or gain of material. However, many 
translocations are not balanced (Krex et al., 2001; Jenkins et al., 2006; Mulholland et 
al., 2006) and in some instances, in theory copy number changes are detectable on one 
side of a translocation, delimiting a breakpoint. The changes which influence origin or 
progression of the tumour presumably arise as random events which confer some 
proliferative advantage and thus are selected and may come to dominate the tumour. 
However, some tumours develop genomic instability with each cell division 
generating new gross variation. It is not clear if the details of such variation can 
provide specific clues about origin or progression, but even in such situations an 
approach such as CGH will detect any copy number change present in the majority of 
tumour cells.
In this discussion I will assess the reliability of data obtained and consider the
technical limitations of the metaphase approach. For the limited number of tumours
further investigated by microarray, I will compare data obtained using the two
approaches. I will then summarize, in table and diagrammatic form, the mass of data
generated by this project and will attempt to relate the findings to previous work and
to consider whether previous hypotheses are supported. Any relationship of CGH
findings to age at diagnosis or length of survival after diagnosis will also be
considered. It is not practical to assess the possible significance of all possible
combinations of aberrations seen in the 32 tumours studied. I have therefore chosen to
consider in some detail changes in chromosomal regions known to harbour genes
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implicated in hereditary syndromes with which astrocytomas or other 
neurodevelopmental tumours are closely associated. I shall then consider genes 
known to be involved in astrocytoma progression (TSGs and oncogenes). Thereafter, 
I shall consider changes not previously reported but which are found in at least three 
independent tumours in this series. The discussion at this point will attempt to 
highlight genes with roles in neural development and established mutator phenotypes 
(caused by aberrations in genes for MMR).
The aim of this analysis is to generate additional hypotheses of pathways, genes and, 
indeed, different cell types which may be involved in the development of 
astrocytomas. These hypotheses might then suggest further work, which could 
identify biological features distinguishing different tumours and eventually provide 
tools for better prediction or treatment.
6-2 Reliability o f  metaphase CGH Results
The control experiments (reported in chapter 3) and the good agreement between the 
metaphase and microarray CGH results (excluding heterochromatic regions) on the 
seven tumours further investigated by this approach (chapter 4) give confidence that 
within the limits of the techniques used most of the results reported here are reliable. 
A discrepancy was the convincing loss of 16p in GBM/C1724, reported on metaphase 
but less convincing on microarray, and also 19p in /C l510, which is cytogenetically 
deleted in metaphase but not at all in array. Another small region of gain observed at 
13q21 in the metaphase of tumour 1706 could not be seen on microarray.
Distal Ip, 19q, and 22, the three other GC-rich regions in which spurious profiles are 
known to occur due to labelling artifacts (Kallioniemi et al., 1994), could not be 
compared in the 7 tumours investigated by microarray CGH in my series since none 
had alterations in these regions in the metaphases. While these discrepancies are 
clearly important, at this level of the analysis their significance remains uncertain. It is 
interesting that a rather similar genomic microarray previously failed to detect known 
deletions in the TSC2 region, at 16pl3, in two samples evaluated by this method 
(Ekong et al., 2004; Michalet et al., 1997; Sue Povey, personal communication).
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Therefore, while the metaphase and array CGH data are discussed as such, in the 
thesis, the discrepancies and uncertainties have been kept in mind.
One finding, which needs further consideration is that metaphase CGH of two 
tumours did not reveal any chromosomal alterations in any of the autosomes, while 5 
others revealed only one or two aberrations each, which is perhaps surprising for high 
malignancy grade astrocytomas. Possible explanations include failure to find small 
changes because of lack of sensitivity of the metaphase CGH technique, inappropriate 
choice of cut-off limits for reporting abnormalities, contamination of the sample by 
large proportions of normal DNA, and some genuine explanation such as méthylation 
of critical genes, or oncogene activation by balanced translocations.
6-2-1 Limitations o f the metaphase CGH Procedure
As mentioned in the introduction, metaphase CGH has a low resolution, capable of 
reliably detecting hemizygosity in deletions above 5-10 million bases (MB) (Van Roy 
et al 1997; Squire et al, 2001; Lupski, 2001). The threshold for detection of high copy 
number amplifications is better, estimated to be around 2.5 MB (Kearney, 2001). In 
terms of the procedures, CGH is technically demanding, requiring metaphase spreads 
of good quality, carefully controlled conditions for storage & handling of slides and 
adherence to optimum conditions during the labelling and hybridisation steps of the 
procedure (Karhu et al., 1997; Breen et al., 1999). Although computerized acquisition 
of images and karyotyping are facilitated by automated software packages, manual 
intervention is inevitable at various stages of the procedure. Manual intervention 
underscores the need for expert knowledge in the procedures in general, and 
introduces the possibility of human error especially at the level of karyotyping. Thus, 
technical issues can affect the outcomes of CGH though they cannot directly account 
for the absence of CNAs on chromosomes following a successful hybridisation.
The choice of the detection range, i.e., the cut-off limits used to generate ratio profiles
of gain/loss across the axis of symmetry for the entire length of each chromosome,
may be important. In this study the cut-off range for detection of loss and gain
respectively was set at 0.8 -  1.2, and between 10 and 33 metaphases were examined
for each sample. In some cases there were sections of borderline ratio profiles, i.e., the
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situation when the ratio profiles are shifted so that the graph of ratio profiles and the 
cut-off limits are close but not actually intersecting so that copy number changes were 
not reported. In cases where large numbers of cells are examined, it might be 
reasonable to narrow the ‘normal range’, which increases the number of abnormalities 
reported. This approach was tested in several of the tumours with ‘borderline’ 
fluorescence graphs in this study. Narrowing the detection range to between 0.85 -  
1.15 for tumours that did not show CNAs with initial cut-off limits, but demonstrated 
borderline ratio profiles, resulted in reporting of CNAs in previously borderline 
regions (see figure 6-1). However, data resulting from this alteration are not included 
in the overall results since ideally it would require adjusting the detection limits for 
the rest of the tumours as well. This would result in an enormous number of apparent 
CNAs of unknown significance. However for the detailed study of a particular 
tumour, or to answer a specific question especially if there is a possibility of 
contamination by normal cells, this could be very valuable.
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Figure: 6-1 Fluorescence ratio profile o f AS24 (an anaplastic 
astrocytoma) with cutoff range set at 0.8-1.2.
In this CGH experiment 24 metaphases with a total o f 881 chromosomes were analysed. There was one 
gain in the Y-CHR (Ypl l.l-q l2 ) , and three losses located respectively at 9q34, 19pl3.2-pl3.3, and 
22ql2-ql3. Although a candidate gene(s) at 19p has not been identified each of these chromosome 
regions is thought to harbour a gene or genes implicated in astrocytoma oncogenesis.
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Figure 6-2: shows the difference in pick-up rate for CNAS caused by 
altering the cutoff range.
Figure 6-1 is generated from the same data as the one in figure 4 -1(A) except that the cutoff range was 
narrowed down to 0.85-1.15, which increases the probability o f detecting CNAs. As a result alterations 
have emerged in regions that were previously borderline, i.e., shifted in the direction o f gain or loss 
without actually attaining the limits set for reporting aberrations. Thus, gains have now emerged at 
3pl2, 4ql2-ql3, 4q25-q28, 7q21, 7q31, 13q21, in addition to the original one at Ypl 1.12 (revealed 
under previous settings). Similarly, losses are clearly highlighted at Ip34.3-p36.3, 2q37, 3q26.2-q27, 
4pl6, 9q33-p34, lCq25-q26, 16pll.2-pl3.3, 16q22-q24, 19pl3.1-pl3, and 22qll.2-q l3
A quite probable reason for a lower-detection rate of CNAs in some of these tumours
could be due to a relatively high proportion of normal - non-tumour tissue - in the
biopsy sample. In order to gain meaningful information CGH requires at least 35% of
tumour cells in the sample (Lichter et al. 2000). Although histological sections of all
the samples were reviewed with a senior pathologist with the objective of confirming
the diagnosis prior to DNA extraction, we relied on slides of previous histology
sections because the majority of biopsy samples that were available for extraction
were very small and could not be spared for a repeat, confirmatory, diagnostic
procedure. Although clearly useful for ascertaining the original histological diagnosis,
in reality archived histology sections do not necessarily reflect the status of the
remaining ‘tumour’ specimen. After the original histology sections were taken,
further sections of any remaining biopsy materials would normally have been taken
for other investigative procedures such as immunohistochemical analyses etc. Thus, it
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was not possible to ascertain the relative amounts of tumour verses normal tissue in 
all the biopsies extracted for this CGH study.
Due to insufficient availability of solid biopsy materials, CGH of 12 out of 32 
tumours were done on DNA taken from cell cultures. Five of the 7 tumours in which 
low counts of CNAs (0-3) were reported in the autosomes were cell cultures; the other 
two were frozen biopsies. Both biopsy samples did not have any CNAs in the 
autosomes, which might suggest that the DNAs were taken from part of the original 
tumour biopsies that largely contained normal brain tissue. The cell cultures are likely 
to have grown clones composed predominantly of normal tissue or ones of lower 
malignancy grades than that indicated by the original histologies. This would account 
for the paucity of CNAs in the GBM solid biopsies UGBS2848m and PGBS2093, and 
the cell cultures PGBCl60, PGBCl706, PGBCl752, PGBC2394 and PGBC2685. In 
three of the cell-lines cases PGBCl60, PGBCl752 and PGBCl706) microarray 
analysis was possible and in all 3 cell-lines no clearly significant changes were found 
although there was some suggestion of increased overall signal for CHRs 5 and 19 in 
two of them. The existence of balanced translocations cannot of course be ruled out in 
these cases. In 3 of the other samples (/S2848, /C2394, and /C2685) there was 
insufficient material for microarray experiment. The array result on /S2093 and 
/C l510 are discussed below.
Microarrays of the tumours showing minimal changes on metaphase CGH indicated 
that 2 DNA sample had tumour material. PGBCl510, in whieh metaphase CGH 
showed apparent gains in 4 regions of CHR 7, was found by the array to have an 
increased signal all the way along chromosome 7. PGBS2093 revealed a strong signal 
of gain in the EGFR region and underrepresentation of CHR 10, both of which were 
undetected by metaphase CGH. These array findings suggest that unlike the first 
three, which may have grown a disproportionate amount of normal tissue, PGBCl 510 
and PGBS2093 certainly had some amount of tumour DNA.
Finally, it could be argued that tumours, from the low-CNA-count experiments,
originated from epigenetic mechanisms such as altered promoter méthylation rather
than other conventional mechanisms like loss of heterozygosity (LOH), which would
be characterized by deletions and amplifieations. Epigenetic events are elearly
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important in astrocytomas of low- and high malignancy grades (Costello et ah, 2000; 
Debinski et ah, 2003; Nakamura et ah, 2005). In addition, there are reports in the 
literature of findings of high-level chromosomal instability in the absence of structural 
alteration (Doneda et ah, 1998). Presumably, epigenetic mechanisms, acting as the 
primary cause to the exclusion of other mutational mechanisms, would be highly 
unlikely in astrocytomas that have attained a high malignancy grade such as the ones 
in this study. Therefore, finding normal CGH in astrocytomas of a high malignancy 
grade would be highly suspicious (Denise Sheer, personal communication). In this 
study, it seems most likely that the cells of three tumours examined were not entirely 
representative of the original tumours, and although these tumours have been kept in 
the analysis, where appropriate, this doubt has to be kept in mind.
6-3 Overall results
This study, which looked at 32 high malignancy grade astrocytomas using 
comparative genomic hybridisation found DNA sequence eopy number alterations in 
30 of them. Figure 6-3 gives a visual overview of the locations of the entire panel of 
DNA sequence CNAs in eaeh arm of the chromosomes, while Table 6-1 gives a 
numerical view of the distribution of CNAs in 26 informative tumours, providing, in 
digestible form, the relative copy number changes on each arm of the chromosomes. 
A detailed list of all CNAs revealed in eaeh tumour is presented in Appendix 1.
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Caption o f  Figure 6-3:
The shaded boxes represent the arms of chromosomes that are aberrant in high 
malignancy grade astrocytomas in this series. Sea-green shading indicates gains 
covering the entire arm, or a major portion of it (aberrations involving more than of 
CHR arm). Light green shading represents more discrete gains (or gains spanning 
limited number of segments) of a chromosome arm. Red shading on the other hand 
represents parts of the chromosome that are lost entirely or over large portions, while 
the colour “tan” marks the arm of a chromosome that is lost over smaller and discrete 
portions only. Gray-scale shading shows chromosome-arms that gained genetic 
material in some bands while incurring deletion(s) in other areas within the same 
chromosome arm. In a fairly large number of cases discrete aberrations were observed 
which involved a band, small segments of it, or, at most, a couple of bands.
Broken lines identify tumours that were further investigated by microarray CGH. 
Green and red triangles respectively show a sample of genes whose clones were found 
altered in the microarrays. /§, Shows regions where a discrepancy occurred in 
findings revealed by metaphase and array CGH.
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Table 6-1: Distribution o f DNA Copy Number Aberrations in metaphase CGH o f 26 informative tumours
CNAs (Whole) Number o f  CH R bands in CNAs
Chr. No
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
17
18
19
20 
21 
22
p-arm
10
6
10
7
7
5
14
6 
10 
2
4 
6
Aero
Aero
Aero
0
1
5 
0
6
Aero
Aero
Gains
q-arm
4 
6
5 
9 
9 
7
16 I
7 ' 
3
0
8 
9 
2 
0
5 
0 
0
6 
1 
2 
6 
0
Total
14 
12
15
16 
16 
12 
30
13
13
2
12
15
12
0
5 
0 
1 
11 
1 
8
6 
0
p-arm
Losses
q-arm Total
Total No o f  
CNAs Gains Losses Total
11 1 12 26 55 103 158
1 6 7 23 84 76 160
1 1 2 27 117 6 124
1 1 2 26 123 20 143
1 1 2 22 105 2 107
0 1 1 16 148 15 163
0 0 0 24 319 0 319
1 0 1 12 102 8 110
3 11 14 26 97 68 165
10 12 22 24 4 156 160
3 5 8 20 36 46 82
0 2 4 14 68 11 68
Aero 6 6 21 65 61 126
Aero 7 7 8 0 71 71
Aero 4 4 5 2 13 15
14 10 24 21 0 112 112
8 8 16 21 1 80 81
0 0 0 12 32 0 32
13 10 23 21 4 145 149
0 4 4 13 25 12 37
Aero 1 1 7 30 2 32
Aero 12 12 12 0 80 80
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Explanation for Table 6-1
The columns labelled ‘CNAs (Whole) ’ in table 6-1 show the total number o f  discrete 
abnormalities recorded by the software in each composite metaphase images for the 
26 informative tumours. They range in size from one band (or less in some cases) to a 
whole chromosome. The columns for ‘number o f CHR bands in CNAs ’ show the total 
number o f bands (G-banding pattern at the 850 band resolution (NCBI map viewer)) 
altered. The abbreviations: Aero, acrocentromere region
Continuation o f  text...
From table 6-1, the pattern of CNAs observed in chromosomes known to harbour 
genes with roles in pathogenesis of astrocytomas, for example gains of 7 and 12, and 
loss of 10, is confirmed. Both arms of CHR 7 were only gained, with no losses 
detected by metaphase CGH, while CHR 10 was predominantly lost, with only two 
instance of gain on lOp. The not-so-well described alterations such as gain of 18, 4 
and 5, and loss of 16, 19, and Ip are reported with relatively high frequencies in this 
study. Interestingly, based on the metaphase data alone, CHRs 9, 13 and 17, with 
well-described deletions at 9p21, 13ql4 and 17pl3.1, respectively, are apparently 
altered with much lower frequencies in this series.
However microarrays of one tumour in which metaphase CGH reported no alteration 
in regions of lOq and 17p, revealed alterations of clones with sequences matching 
those of PTEN and TP53 respectively, while another tumour had amplification of 
EGFR. This clearly demonstrates the limitations of the metaphase CGH approach for 
detecting subtle DNA sequence copy number alteration that may be involved in 
pathogenesis of astrocytic tumours. However the high resolution of microarrays does 
also bring problems (especially in the absence of blood DNA from the patient) 
because of the very large number of ‘normal’ copy number variants now known to be 
present in the human genome (see for example Redon et al 2006) which are much 
more likely to be detected by this approach. This is not such a difficulty when there is 
a strong prior hypothesis (as in the cases above) but for any new findings, the 
possibility of normal polymorphism has been kept constantly in mind in this study
. ' — '  1 5^
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The number of chromosomal abnormalities that have been detected by CGH in 
astrocytomas shows a progressive increase with the malignancy-grade of a tumour 
(Kleihues and Cavenee, 2000), and certain alterations occur more frequently in 
association with tumour-grade (Von Deimling et al., 1995; Ohgaki, 2005). This 
observation formed the basis for the prevailing models for astrocytoma progression 
pathways. In this study (see table 6-1 and figure 6-3) the CGH data of 26 informative 
tumours found DNA copy number alterations in all chromosomes although this was 
variable, with some more affeted than others. In general the number of aberrations 
observed in cell lines tended to be more than in solids. Aberrations, which are well 
established for astrocytomas and where at least some of the responsible genes have 
been identified, were frequently seen in this series (see figure 6-4) and will be 
discussed later. Deletions at Ip and 19q, which occur more frequently, and are of 
prognostic significance in oligodendrogliomas (Caimcross et al., 1998) and some 
astrocytomas (Reifenberger G and Louis DN, 2003), were also observed in this study 
and are also recorded in figure 6-4. The aberrations in loci implicated in syndromes 
with susceptibility to astrocytomas are shown in fig 6-5.
In addition, the study revealed novel locations of recurrent copy number aberrations 
(defined as occurring at least three times in this series). Some of the affected regions 
were found to harbour loci of genes with roles in CNS development, some of which 
are implicated in malignancies of other systems, and some involved loci of genes 
known to be responsible for established mutator phenotypes. However, in most cases 
the aberrant regions are gene-rich, which, given the limits of CGH, makes it difficult 
to implicate a particular gene, or conversely to eliminate other probable genes of 
interest (GOIs) without supplementary investigations.
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Figure 6-5 Distribution of CNAs at loci implicating genes with established roles in astrocytoma-associated syndromes, but not 
established in sporadic astrocytomas
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Interpretation o f figure 6-4 & figure 6-5
The figure 6-4, which shows distribution o f CNAs at loci containing genes with 
established roles in sporadic astrocytomas, also includes loci at Ip and 19q that are 
thought to harbour important candidate genes for glioma development. Figure 6-5, 
showing CNAs at loci o f genes with established roles in hereditary syndromes with 
astrocytoma association, shows combinations that would contradict current thinking. 
Aberrations o f  TSCl and TSC2 and o f NFl and NF2 are respectively thought to be 
mutually exclusive. The concurrent occurrence o f aberrations implicating both 
TSCl/2 in 4 tumours and NFl/2 in 2, clearly contradict the popular view. Thus, these 
curious findings would require further investigation.
Continuation o f  text...
TP73, a close homolog of TP53, is one of several genes that have been proposed as 
possible candidate located at lp36.3. The candidate gene at 19q is as yet unidentified. 
In the case of the region 12ql3-ql5, although only two candidate genes are shown 
here it is known to contain a cluster of 12 oncogenes that are implicated in gliomas.
Although a wide spectrum of changes is seen there is no doubt that changes which 
must include genes already recognised as relevant to astrocytomas occur with greater 
than random frequency in this series of 26 tumours analysed. Apart from the 
overwhelming visual impression from the chromosome specific diagrams in the 
results section a very rough numerical estimate may be obtained. From the summary 
table 6-1 it is clear that a total of 2494 autosomal bands have been recorded as altered 
in these tumours. Since the number of autosomal bands on the 850-band karyotype is 
799 the average number of alterations per band would be about 3 if they were evenly 
distributed. However this is far from the case
From figure 6-4 one can see that gain of EGFR occurs at least 13 times, loss of TP53 
at least 9 times, gain of PDGFA and of CDK4 each at least 8 times, and loss of PTEN 
also 8 times. The loss of CDKN2A /B was less striking at 5 times. The reason for 
mentioning these numbers is apparent when looking at figure 6-5, which records the 
alterations in loci which contain genes implicated in syndromes which included 
astrocytomas, excluding those already reported to be important in sporadic
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astrocytoma, such as TP53. A conservative interpretation obtained by combining 
information from fig 6.5 and the detailed table of karyotypes shows some loss of 
TSC2 in at least 12 tumours, NF2 in at least 12 tumours, TSCl in at least 7 tumours 
and APC in at least 6 tumours. The frequency with which loci of astrocytoma 
susceptibility genes are implicated would suggest the probable involvement of several 
of them in the pathogenesis of sporadic astrocytomas. In addition, altogether 25 out of 
32 tumours in the study (GBM/C1724 and GBM/C1724/mda are the same tumour) 
had aberrations implicating at least one of the 19 loci considered in figure 6-4 and 6-5
6-4 Conclusions from overall preliminary analysis
These data have led to several observations a number of which are in agreement with 
previous studies while others apparently do not. For example,
1. The frequent gains in copy number at CHRs7p and 12q, possibly implicating 
EGFR at 7pl2 in 13 tumours, PDGFA at 7p22 (in 7 tumours) and MDM2 at 
12ql4-15 (in 9 tumours; 28%), would be in agreement with other studies that 
have found these to be the oncogenes most commonly amplified in 
astrocytomas. The relatively high frequency of copy number losses in lOq 
(>70%) is also in agreement with other studies
2. The copy number losses at Ip and 19q, and the correlation between the two in 
a number of the tumours, are also in agreement with other studies.
3. Although DNA copy number losses in several tumours implicated 
CDKN2AandCDKN2B (9p21), RBI (13ql4) and TP53 (17pl3), respectively, 
the relative frequencies observed in this study appear lower than reported by 
other studies
4. Several uncharacteristic alterations were recorded in a significant number of 
the tumours. In particular, amplifications occurred at several loci implicating 
established TSGs at 9p21, 9q34, 13ql4, 17pl3, and at a number of loci 
implicating MMR genes.
5. A major difference with other studies seems to be in the distribution of DNA 
copy number alterations at loci implicating genes with established roles in 
syndromes with astrocytoma associations. Approximately 80% of the tumours
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(26 out of 33) had copy number aberrations involving loci of one or more of 
the 14 syndrome-associated genes.
Thus, these data appear to suggest that some of these genes could influence 
development of sporadic astrocytomas. This is surprising, and could be highly 
controversial in view of past evidence against them (for example, Rey et al., 1992; 
Green et al., 1994; Rubio et al., 1994; von Deimling et al., 1994; Hoang-Xuan et al., 
1995; Ng et al., 1995; Henske et al., 1996; Wienecke et al., 1997; Parry et al., 2000; 
Wimmer et al., 2002; Lau et al., 2003). Although several of these authors found LOH 
in some astrocytomas, they were unable to find mutations to confirm their findings. 
Hence, the need to explain the findings in this current study inevitably dominates 
parts of this discussion.
To answer the issues raised, I will discuss the findings under several subheadings. 1) 
First, an attempt will be made to correlate the findings with pathways that have been 
proposed for oncogenesis and progression of astrocytomas. Bearing in mind the 
limitations of the technique, this will give an idea whether the cytogenetic data for 
each tumour support the clinical category (whether a primary (de novo) or secondary 
glioblastoma) of the respective tumour. 2), A discussion of aberrations at Ip, 19q, the 
two established loci for which no genes have as yet been confirmed, will then follow. 
Studies, especially of oligodendrogliomas and low-grade astrocytomas (Buckner et 
al., 2003; Jenkins et al., 2006), have established associations between CNAs at these 
two regions with patients’ response to therapy and prognosis in general. Any possible 
correlation between CNAs in these regions with survival in this series will be 
considered here. The last part of the discussion in this section will address issues 
underlying CNAs at loci implicating syndromes with astrocytoma associations.
6-5 Correlation o f  DNA copy number alterations with prevailing 
tumorigenetic pathways
Tumours investigated in this study will be divided into several categories based on the 
number of aberrations implicating 7 genes known to be involved in the pathogenesis 
of sporadic astrocytomas, starting with those with few (or no) alterations, and ending 
with the ones in which the most number of alterations (per tumour) were recorded.
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6-5-1 Tumours with apparently no CNAs implicating genes with 
established roles in sporadic astrocytomas.
Ten (31%) tumours did not reveal CNAs in any of the 7 loci of genes with established 
roles in development of sporadic astrocytomas. Five of these had no CNAs on 
metaphase and the concerns about the amount of DNA present have already been 
noted. Still, the isolated CNAs revealed by the metaphase in /C l706 and /C l60 are of 
interest as several other tumours showed discrete alterations at similar loci. For 
example, the discrete copy number gains at 13q21, in /1706, was also observed in 8 
other tumours in this series, while the equally discrete loss at 2q37 found in /C l60 
was shared by 6 other tumours. However these aberrations (in the metaphases) were 
both not corroborated by the microarrays, so the possibility that these are artifacts 
cannot be excluded. However, the roles of potential candidate genes mapped to these 
aberrant loci are discussed in detail later under “novel alterations”.
The other 5 tumours in this group, which were thought to be genuine tumour material 
each had between 3-18 CNAs. Of the five, only GBM/C545, remarkably, had all 16 
CNAs at novel loci, while the other 4 had between 1-3 CNAs at loci implicating 
genes with established roles in syndromes with astrocytoma associations. For example 
two of the tumours apparently lost in the region of TSCl (AA/S24 and GBM1510), 
and one at TSC2 (GBM 1397). This group is potentially of great interest but would 
need much more investigation before any firm hypothesis could be proposed, 
especially as some of the findings were not confirmed on microarray.
6-5-2 Tumours with CNAs implicating genes with established roles in 
development o f  sporadic astrocytomas.
22 tumours had CNAs at one or more of seven loci implicating genes with established 
roles in development of sporadic astrocytomas (DSA), i.e., EGFR, PDGFA, 
CDKN2AandCDKN2B, PTEN, CDK4/MDM2, RBI and TP53. In 3 of these tumours 
(GBMs /C l752, /S2093, and /C l724) the only CNAs implicating these genes were 
revealed by array, which metaphase CGH had failed to detect. DNA copy number 
gains were revealed at loci of CDK4/MDM2 and EGFR, in /C l752 and /S2093
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respectively, while losses of PTEN and TP53 were found in /C l724. This clearly 
demonstrates the superiority of the array over metaphase CGH method, a fact that has 
been kept in mind throughout the discussion of these data. In this small group of 
tumours, except for these alterations the tumours might not have fitted in the category 
of sporadic astrocytomas. The first two of these tumours, along with several others in 
which fewer than 3 CNAs were found in the autosomes, have already been discussed 
In the section that follows, each of the other tumours is discussed separately.
6-5-2.1 GBMs/C1612 and 1724
GBMl612 and GBM/C 1724 are both from the same patient, 1612 being the first 
biopsy and 1724 being a recurrence after an unknown time. Since the patient only 
lived eight months after the diagnosis it could not have been longer than this. 1612 
did not survive as a cell-line and the amount of DNA available was small, so whole 
genome amplification was used. 1724 was studied as a cell-line. Both tumours were 
studied by microarray and 1724 also by M-FISH. Both lines showed extensive 
changes with some features in common, in particular a substantial gain in signal from 
a 4 MB region on 4p, which was also seen to a lesser extent in 5 other samples
Most CNAs in PGBMC1612m involved extensive segments, for example, the whole 
of CHR 2, 10, 13q and 14q were under-represented while 3q, 6, 7, and 8 were gained. 
However, 3 regions of discrete gains were at 3q28, 4pl5.2-13 and 21ql 1.2-21 while 
discrete losses were located at 4q21-22, 4q28-35, llq22-25, 13q32-34 and 14q24-31 
and 17pl3. The losses in the loci of RBI, PTEN and TP53, and gains corresponding 
to EGFR would fit in the category of primary GBM - based on existing pathway 
models, and is in agreement with clinical data on this patient. However the additional 
gain corresponding to PDGFA (or PMS2) and MLHl, as well as deletions 
corresponding to MSH2 and TSC2 would point to a possibility of PGBCl 612 being a 
secondary GBM while a probable role of these genes in sporadic primary GBMs 
would raise issues about the role of genes hitherto not believed to have roles in this 
category of tumours. The microarray data on 1612 in general showed good agreement 
with the metaphase data, although the specific clones containing the PTEN gene were 
seen on the microarray to be virtually totally deleted, with much less signal than the 
rest of CHR 10.
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RGBC1724 was shown by microarrays to have striking loss of PTEN and the region 
of TP53 on chromosome 17p. Other features of 1724 showed some similarity to 1612, 
such as the identical gain on 4p already mentioned, and losses on 13q and 14q, but 
also some differences in whole chromosome balance such as the lack of gain of 
chromosome 7. In at least two cases (chromosome 8 and chromosome 11) the 
microarray data on 1724 but not on 1612 showed a discontinuity suggesting a possible 
breakpoint. Examination of the M-FISH results on the 1724 cell-line provided a rather 
startling explanation for the probably non-stability of the whole chromosome balance, 
as the karyotype showed approximately 300 chromosomes per cell and the six cells 
examined were all so different. It was interesting that there was an 8;22 translocation 
in five of the six cells, which might well have reflected the possible breakpoint in the 
region of uncoordinated centrosome (movement)-5D (UNC5D) between clone R P ll- 
144M5 and RP11-155L11 seen on the microarray. Another translocation seen in 4 
cells could have implicated the possible break on chromosome 11 in the region of 
Fanconi anaemia, complementation group F (FANCF) (postulated to be a pseudo 
gene -  NCBI Aceview) between clones RP11-34N19 and RPl 1-72C9.
It was impossible to see the position of the extra 4p material on the MFISH, which 
was rather surprising. Although it would be of interest to clone the breakpoint on the 
8;22 translocation the very large number of chromosomes make further study and 
interpretation of this line quite challenging
Of the 3 tumours found to have only one aberration at loci implicating established 
genes with roles in development of sporadic astrocytomas, AA/S2706 had loss at the 
locus of the RBI gene; GBM/S2051 had gains implicating CDK4/MDM2, while 
GBM/Sl 1 had deletion implicating the TP53 gene. GBM/S2051 was a primary GBM, 
but no data were available on the category of GBM/Sl 1.
6-5-2.2 AA/S2706
AA/S2706, showing loss in the region of RBI was additionally deleted at 7 novel loci 
with 22ql3 and 19q 13.3-13.1, (respectively deleted in 12 and 10 other tumours) being
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the most frequently deleted in the study. The loss of copy number at 2q37, shared by 
5 other tumours, has already been highlighted. This tumour was also deleted at 
20ql3.2, which it shares with 3 others in this series. These frequently deleted novel 
loci may harbour important TSGs. In addition, AA/S2706 had 5 regions of novel 
gains; the large gain spanning 7qll.2-q26 was common to 9 other tumours, while 5 
others had discrete amplieons at 7q22, q23, and q31, which might point to loci of 
important oncogenes in the long-arm of chromosome 7. Another frequent region 
gained by AA/S2706 was 1 lq23-24, a discrete region of novel gain, shared by 7 other 
tumours in this series.
6-5-2.3 GBM/S2051
In addition to the gain at 12ql2-14, GBM/S2051 lost at lp36.3-33 (whieh was also 
observed in one other tumour) with 7 other tumours sharing the discrete loss of lp36. 
This tumour additionally lost at 2 of the most frequently deleted loci in this study, 
16qll.2 and 22ql 1-13. Although the 16qll.2 region is heterochromatic and 
polymorphic, this finding is recorded here and in other tumours because there are 
genes of possible significance (e.g., RBL2). There were additional gains in 10 novel 
regions, the 2 most frequent discrete regions gained being lp31-22 and 13q21-22 that 
are shared by 8 other tumours. Other discrete regions of novel gains were at 12ql5- 
21, which was shared by 6 tumours, while 6p25 and 9p24 were each shared by 4 
tumours. Losses at Ip and NF2 do not fit the pattern for primary GBMs as proposed 
in existing pathways model. Although the clinical data indicated that GBM/S2051 
was a primary GBM, the cytogenetic data suggest that this tumour could pass for a 
secondary GBM, an optic pathway- (Dasgupta et al., 2005) or other glioma in another 
cerebral location, typically arising in association with neurofibromatosis type 2. 
Otherwise, like in 1724 the data raise issues concerning the probable roles of CNAs at 
loci of genes implicated in syndromes with astrocytoma association, in development 
of sporadic primary glioblastomas.
6-5-2.4 G B M /S ll
GBM/Sl 1 (with the loss implicating the TP53 gene) additionally had losses at loci 
implicating the TSC2 (in common with 11 other tumours), lp36 (shared by 7 others) 
and 19ql3.2-13.3, which was deleted in 10 other tumours, 5 of them deleted in the
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entire q-arm. Remarkably, there were no gains revealed in UGBCl 1, but there were 5 
regions of novel deletions, with 4 of them being among the most altered in this series. 
The deletions of 16qll.2 and 19pl3.3-12 have already been highlighted in other 
tumours. Other novel deletions were at 16q24 (shared by 4 other tumours), 17q24-25 
(by 7 others) and 22ql3 (distal to the NF2 locus) (shared by 12 other tumours, of 
which 9 had deletions spanning the entire 22q-arm). These novel regions could 
harbour important TSGs. There was no clinical data on the category of this tumour 
however the pattern of CNAs at established loci would fit the pathway to secondary 
GBM. This combination of CNAs is shared by GBMs of oligodendroglial origins 
(Caimcross et al., 1998).
6-5-3 Tumours with 2 CNAs at loci o f genes for development o f sporadic 
astrocytomas
6-5-3-1 AA/S2745
This tumour had increased copy number at the CDK3/MDM2 locus and loss at the 
locus of TP53, which fit in with the secondary pathway to GBM. In addition, there 
were loss of copy numbers at the loci of NFl and TSC2, genes with important roles in 
astrocytoma-associated syndromes, and combined loss of lp36 and 19q. The gains at 
2q31-q33 and 5ql4-q23 could imply that the usual mismatch repair genes located in 
the respective loci might be involved through somewhat different mechanisms in the 
pathogenesis of AA/S2745. Alternatively there could be different oncogenes mapped 
in these regions that may have contributed to pathogenesis of this anaplastic 
astrocytoma. This tumour also had 7 regions of novel copy number gain, and a similar 
number with loss. Novel gains were at 2q21-22 (shared by 4 other tumours), 3pl2 (5 
others), 4q (with discrete gains at q 13-21 and q22-27, respectively shared by 5 
others), 6q (with discrete gains at ql2, q 15-21 and q21-22, respectively shared by 5 
tumours) and 8q22 (5 others). However, the 2 regions that were most frequently 
gained were at 12ql5-21 (distal to the CDK4/MDM2 locus) and 13q21-q23, which 
were respectively shared by 7 and 8 other tumours in this series. Any of them could 
harbour important oncogenes. Novel losses were at lq l2  (lost in 3 other tumours), 
9qll-13 (lost in 6 others), 16ql 1-12.2, 17qll.2 (3 others), 17q24 (6 others), 19pl3.3- 
11, and 19ql 1-13.4, most of which have already been highlighted.
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Ô-5-3-2 AA/S2614
This AA gained at 2 regions implicating genes with established roles in sporadic 
astrocytomas, and at the same time there was one gain at the MLHl locus. There were 
no losses at any of the regions of a TSG with established roles in sporadic 
astrocytomas or syndromes with astrocytoma associations. The only losses were at 
novel loci: the pericentromere heterochromatin region, 16qll-12 (lost in 12 other 
tumours), 21pll-q l2  (only loss in the study) and 22ql 1.2. There were 14 regions of 
novel gain a number of which were also frequently gained in other tumours. However, 
gains at 7pl2 and 7p22 suggest involvement of EGFR, at the former locus, and either 
PMS2 or PDGFA (or both?) at the latter locus. Although EGFR and PDGFA have 
both been found amplified in glioblastomas, it is believed that EGFR is predominantly 
amplified in primary as opposed to secondary glioblastomas in which PDGFA is 
thought to be the more likely to be amplified (Reifenberger et ah, 1996; Weber et ah, 
1996). The gain of the locus for EGFR in AA/S2614 suggests that both genes may be 
amplified in a subgroup of secondary glioblastomas. Alternatively, it might be PMS2 
rather than PDGFA that is amplified at 7p22.
6-S-3-3 GBM/S2650
PGBS2650 had CNAs at 2 loci of known astrocytoma genes -  a gain of 7pl2 
(EGFR), and deletion of lOq, corresponding to the locus of PTEN. This combination 
is considered as the classical representation of the route/pathway to primary or de 
novo glioblastomas (Kleihues and Cavenee, 2000). Indeed, GBM/S2650 was one of 
only 6 tumours (of which 5 were due to insufficient tumour-DNA in study samples) in 
this study that did not have alterations in any of the loci implicating genes typically 
associated with astroeytomas-related syndromes. This tumour, in addition, had 9 
regions of novel gains and 2 of loss. The gains were at 2p25 (seen in 4 other tumours), 
3p26, 5pl5 and 13q32-34 (each gained in 5 others), 8p22-23, 15q26, 18q22-23 (each 
gained in 4 other tumours), 5q35 (3 others), but the most frequently gained region was 
13q21 (already highlighted) that was shared by 8 other tumours in this study. The 2 
regions of novel loss were lOp (lost in 8 tumours -  with 2 tumours showing discrete 
losses respectively at 1 Op 11.2 and 10pl5), and 17q21 in which 3 other tumours were 
also deleted. These novel regions of copy number changes may harbour oncogenes 
and TSGs with roles in development of primary GBMs.
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Ô-5-3-4 GBM/S2532
GBM/S2532 had loss at 17pl3-12, implicating the TP53 gene, with gains at 13ql4- 
31.3, spanning the RBI locus. Two discrete losses at 9q34 and 16pl3.3-13.2 
respectively implicated TSCl and TSC2, which might imply an association with 
tuberous sclerosis type 1. Thus, despite losses corresponding to the TP53 locus, 
GBM/S2532 does not conform to any of the prevailing astrocytoma progression 
pathways. There were 6 additional regions of gain and 9 of loss, most of them at 
novel locations that were frequently altered in other tumours. The most frequent gains 
were at 13q in which 11 other tumours gained at 2 discrete loci (13q21-22, gained in 8 
other tumours, and 13q33-34, gained in 5 others), and Ip in which 7 other tumours 
gained, 4 of them within a small locus at lp22. Other than losses at 16ql 1.2, 19p and 
19q that have already been highlighted, other frequently deleted novel loci in this 
tumour were at 10q25-26 in which 10 tumours were deleted with 5 spanning this 
locus, 14q31-32 (also lost in 5 others) and 17q24-24 that was deleted in 6 other 
tumours. These frequently altered loci may harbour important oncogenes and TSGs 
respectively.
6-5-3-5 GBM/S2409
This tumour gained at 9p21-23 (which was the only gain recorded), and lost at lp36 
and 22ql 1-13. The gain of 9p21-23, spanning the CDKN2A/2B locus at 9p21, is 
unusual since this locus is usually deleted in high grade-astrocytomas. However the 
losses at Ip and 22q could implicate TP73 and NF2 respectively. There are in addition 
3 regions of novel loss -  all discrete deletions, at 10pl5 (which is spanned by 7 other 
tumours), 10q26 (similarly deleted in 3 other tumours, with 5 others having 
larger/spanning deletions), and 14q31-32 (similarly discretely deleted in 4 other 
tumours with a fifth tumours spanning). These interesting regions may harbour 
important TSGs. Clinical data suggested that this tumour was a primary GBM. The 
gain at 9p21 might suggest a different mechanism of involvement of this locus in this 
astrocytoma or the presence of an entirely different candidate oncogene in this region. 
The combination of -Ip and -22q in pathogenesis of this tumour would suggest 
involvement of the pathway to secondary glioblastomas.
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6-5-3-6 GBM/C 1719m
GBM/C1719m gained in only one locus of genes with established roles in 
astrocytomas. The discrete gain at 7p22 could implicate either PDGFA or PMS2 (or 
both) and a deletion at 17pl3 possibly implicating the TP53 gene. These were the 
only aberration implicating any of the genes with established roles in sporadic 
astrocytomas. However, cytogenetic analyses found alterations, all of them deletions 
in 3 regions with established astrocytoma associations. The losses at 9q34, 17ql 1.2 
and 22ql2.2 could implicate TSCl, NFl and NF2 genes all of which have established 
roles in syndrome with which astrocytomas are associated. In addition, there were 20 
regions of novel gains and 3 of losses. No clinical data could be found on the tumour 
category for GBM/C 1917/m. The alterations in region of genes with established roles 
in astrocytomas could place GBM/C 1719/m in the category of secondary GBM.
6-5-4 Tumours with 3 CNAs at loci implicating genes with roles in 
development o f  sporadic astrocytomas
6-5-4-1 GBM/C 1760m
GBM/C 1760/m, if considered based on the loss of lOq and 9p, respectively spanning 
the loci of PTEN and CDKN2AandCDKN2B, and gains corresponding to EGFR, 
would fit in the category of primary GBM. This would be in agreement with clinical 
data on the category of this tumour. However, the amplification PDGFA or /and 
possibly PMS2 could place it in the category of secondary GBMs. Presumably it 
would be in the subgroup of astrocytomas with concurrent EGFR and PDGFA 
amplification. This tumour has additionally gained the lp36 region and 19ql3.3 and 
has loss at the 16pl3 locus, which could implicate TSC2 in its pathogenesis. There 
are additionally 18 regions of novel copy number gain and 2 of loss, the latter being at 
16ql 1.2-22 and lOp.
6-5-4-2 GBM/S 1926m
GBM/S1926 had discrete gains at 7pl2 and 7p22, with the possibility of involvement
of PMS2 or PDGFA in the latter locus. Uncharacteristically, it also had a discrete gain
at 17pl3, which could suggest a gain-of-function aberration at the TP53 locus. There
were no losses in any of the regions of genes with established roles in astrocytomas,
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irrespective of category (whether sporadic or associated with established hereditary 
syndromes). Thus, the distribution of CNAs in this tumour does not correspond with 
any of the existing model pathways for progression to GBMs. This would suggest that 
alternative pathways might exist. However, there were 8 additional regions of novel 
gains and 3 of loss. The 3 regions of novel loss were at lq ll-21  (seen in 3 other 
tumours), 9ql 1-21 (6 others), and 16ql 1.2-12.2, a discrete region that is deleted in 10 
other tumours in this study. One or more of these novel regions of loss could harbour 
TSGs that may have contributed to pathogenesis of this GBM.
6-5-4-3 GBM/S2126
This tumour had the largest number of aberrations in the study. Almost all 
chromosome arms were affected except 2p, 6p, 12p, 18 (p/q), and 20q. The 
combinations of CNAs -Ip, +PMS2, +APC, +CDKN2A, +12q, -PTEN, -TSC2, -19q 
and -NF2 would more likely suggest the possibility of this tumour being a secondary 
GBM. In fact, clinical data obtained indicated that it was a primary GBM. The gain 
corresponding to the CDKN2A locus is uncharacteristic for this locus in high 
malignancy grade astrocytomas. If the CDKN2AandCDKN2B are involved in the 
tumour they may be operating under different mechanisms, perhaps with implications 
on prognosis. Alternatively it may be that gene(s) other than those usually implicated 
in astrocytomas in this location are responsible for pathogenesis of this tumour.
Ô-5-4-4 GBM/S2687m
GBM/S2687 is a recurrent glioblastoma whose original category could not be 
established. Cytogenetic analyses revealed gains, possibly of EGFR (7pl2), PDGFA 
or PMS2 (7p22) and deletion, presumably of PTEN (-lOq). These alterations suggest 
that GBM/S2687 might have been a primary glioblastoma. However, amplification at 
the locus of PMS2, which is a mismatch repair (MMR) gene, might imply that the 
patient was susceptible to other genetic disease such as Turcot’s syndrome, for 
example, and associated malignancies. Indeed, the large deletion at 16p could 
implicate the TSC2 gene, another gene with established roles in syndromes with 
astrocytoma association. If this were the case, this tumour would also fit the category 
of a secondary GBM.
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6-5-4-S GBM/S 1575
This tumour gained at regions corresponding to loci of EGFR and CDK4/MDM2, and 
lost at loci of PTEN. These CNAs would suggest that this tumour is a primary GBM. 
This is in agreement with the clinical categorization of this tumour. However, this 
tumour had copy number gains at the locus of PMSl, and deletions at 16p 13.3-13.2 
(implicating the TSC2 gene) and 19ql2. There were also 4 regions of novel gains and 
6 of loss. Most of these were discrete alterations that could point to oncogenes and 
TSGs with roles in development of this primary GBM.
6-5-4-Ô GBM/S3044
GBM/S3044 had accumulated very many CNAs, with at least 13 gain-CNAs and 14 
of loss, covering most of the chromosome arms. It was not possible to obtain clinical 
data on the category for this tumour. However, it was deleted at 17pl3 (implicating 
TP53) and at Ip and 19q, and had gained at loci implicating EGFR and 
CDK4/MDM2. There were additional gains at loci implicating PMSl and APC, and 
losses at loci of TSCl, TSC2 and NF2. Deletions of TP53 with concurrent loss of Ip 
and 19q would suggest that this tumour was a progressive GBM, presumably one with 
the potential for a better prognosis. This pattern would suggest that GBM/S3044 
could be of the progressive type.
6-5-5 Tumours with CNAs at 4 loci o f genes with established roles in 
development o f  sporadic astrocytomas
6-5-5-1 GBM/S 1595m
Remarkably this tumour had aberrations implicating 4 genes with established roles in 
pathogenesis of sporadic astrocytomas and 5 other genes with equally well- 
established roles in syndromes associated with astrocytomas. In addition there were 
also discrete deletions at Ip and 19q, a combination that has been associated with 
tumour prognosis both in oligodendrogliomas, mixed oligo-astrocytomas, and other 
gliomas. The combinations of CNAs, which include +EGFR, +CDK4/MDM2, +APC, 
-TP53, -Ip, -19q, -TSCl/2, -NFl/2 would more likely suggest the possibility of it 
being a secondary GBM. In fact, clinical data obtained indicated that it was a primary
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GBM, which is of interest considering the apparent wide-ranging involvement of loci 
of genes with roles in hereditary syndromes with astrocytoma association and those 
that have specifically been associated with sporadic astrocytomas. Another equally 
interesting observation is the gain corresponding to the locus of RB, which is 
uncharacteristic for this gene in high malignancy grade astrocytomas. If it is involved 
in the pathogenesis of this tumour then it may be operating under different 
mechanisms, perhaps with implications on prognosis. Alternatively it may be that 
another gene at this locus is responsible for pathogenesis of this tumour.
Ô-5-5-2 GBM/S 1625
GBM/S 1625 has the classical combination of alterations, +7 (spanning 7p22 and 
7pl2) implicating EGFR and PDGFA/PMS2), +12ql4-ql5 (implicating 
CDK4/MDM2), and -lOq (implicating PTEN), that could place it in the category of a 
primary GBM. This is in agreement with clinical data on the category of this tumour. 
However, the probable involvement of PDGFR (or of PMS2) in 7p22 could have also 
placed this tumour in the category of a secondary GBM. Additional gains at 5q21-q22 
(implicating APC) and 7q, which were the only other CHR regions gained, would 
suggest that other oncogenes with roles in pathogenesis of astrocytomas might be 
located in these chromosome arms. In addition, there were other regions of copy 
number loss. Other than the entire loss of 10 (p/q), novel discrete losses were at 2q35- 
37 in which 5 other tumours lost with only one spanning this locus. The second loss 
was at 13q33-34 in which 4 other tumours also lost. Interestingly, the same set of 
tumours (except one; /C l60) lost at both loci.
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6-5-6 Tumour with 5 CNAs at loci implicating genes with roles in 
development o f  sporadic astrocytomas
6-5-6-1 GBM /S2858
GBM/S2858 with its combination of CNAs involving +7pl2, +PDGFA/PMS2, 
+12ql4-ql5, -CDKN2AandCDKN2B, and -17pl3 fits into either category of GBM. 
However, the clinical data categorizes it as a primary GBM, which raises issues with 
the probable roles of losses at 9q34, 17ql 1.2 and 22ql2.2 (implicating TSCl, NFl, 
and NF2), three established astrocytoma susceptibility syndrome genes in the 
pathogenesis of this primary glioblastoma.
6-6 Deletions at Ip and 19q
Combined deletions at lp/19q are probably the most relevant prognostic genetic 
predictors in grade 2 and 3 oligodendrogliomas (van den Bent et al., 2006; Caimcross 
et al., 2006). The combination is also predictive of chemosensitivity in low-grade 
astrocytomas (Kujas et al., 2005; Hoang-Xuan et al., 2005) and high-grade 
oligodendrogliomas (Caimcross et al., 1998). As a result, many studies are aiming to 
establish whether similar benefits can be derived in patients with high-grade 
astrocytomas. In this current study, losses at Ip were clustered at 2 regions, 
respectively centred at Ip34.1-p35.3 (in 5 cases) and at Ip36.1-p36.23 (in 8 cases). 
This is in agreement with other studies that have reported losses at Ip in astrocytomas 
ranging from 20-30% (Barbashina et al., 2005). The data could suggest that these 
regions harbour at least two genes that could be involved in pathogenesis of 
astrocytomas. Similarly, allelic loss of chromosome 19q is observed frequently in 
gliomas, and it has been suggested that terminal or interstitial deletions occur 
predominantly in astrocytomas and glioblastomas whereas tumours with an 
oligodendroglial component appear to lose the entire long arm of chromosome 19 
(von Deimling et al., 1994). Chromosome 19 was one of the most frequently altered 
in high-grade astrocytomas in this study. Of the 11 tumours with CNAs in the 19q- 
arm, 4 (-37%) had extensive deletions in the q-arm, demonstrating that extensive 
losses in the 19q-arm occurs in a sizeable proportion of astrocytomas of high 
malignancy grade.
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Although no genes have yet been confirmed, allelic losses on CHRs Ip and 19q have 
emerged as potentially important determinants of prognosis and response to therapy in 
gliomas in general, but in particular oligodendrogliomas (Caimcross et al., 1998; 
Jaeckle et al., 2006). In the study published by Kujas et al., in 2005, it was shown that 
in low-grade gliomas, the lp/19q deletion is more predictive of survival than even the 
histological subtype (i.e., oligodendroglioma, astrocytoma or oligoastrocytoma). 
However, several other equally recent studies have reported that the site and extent of 
deletion, and the grade of the tumour may be important factors (Ngo et al., 2007; 
Idbaih et al., 2005). The study by Idbaih and colleagues, reporting large-scale 
genomic analysis by array CGH in 2005, showed 2 clearly distinct patterns of Ip 
deletion in gliomas. Deletions of the whole of Ip, when associated with whole 19q 
deletions, were related to typical oligodendroglial morphology and good prognosis. 
More relevant to the current study Idbaih and co-workers also studied 35 cases of 
glioblastoma multiforme, of which two had a loss of the whole of Ip, fifteen had a 
loss of lp36 and eighteen had no loss on Ip. In these patients the loss of lp36 was 
associated with significantly worse prognosis (P=0.01). The molecular mechanisms 
that underlie the association between lp/19q loss and chemosensitivity remain 
unknown because the genes targeted by lp/19q deletions have not been identified.
Three recent randomized phase-3 trials failed to show a significant benefit of adjuvant
chemotherapy in grade 3 oligodendrogliomas and oligoastrocytomas in cases of
lp/19q-deleted tumours and in those with no deletion at these loci. The lp/19q loss
identifies a favourable prognostic sub-group of oligodendroglial tumours, with a
median survival longer than 8 years compared to 2 years (Jenkins et al., 2001;
European Organization for the Research and Treatment of Cancer 26951) and 2.8
years (Kros et al., 2006; Radiation Therapy Oncology Group 94-02) for tumours
without lp/19q loss, independent of treatment. The progression-free survival after
radiotherapy-only in patients harbouring lp/19q loss tumours is also much better (van
den Bent et al., 2006 (EORTC); Caimcross et al., 2006 (RTOG). A very recent review
of progress in treatment of gliomas (Idbaih, 2007) confirms that in
oligodendrogliomas the detection of lp/19q deletions has strong implications for
prognosis although this has not yet translated into success in targeted treatment.
In the current study of sporadic astrocytomas, Ip deletions in all 9 tumours were
discrete, which would be in agreement with findings of Idbaih and co-workers. Most 
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of our tumours with discrete deletions at lp36 (n=8) also had deletions of 19q (n=6) 
of which 4 (50%) involved the entire 19q arm.
The next section considers whether any of the moleeular data from the current study 
show any eorrelation with survival.
6-7 Survival o f  patients investigated in this study
Survival data were available for 26 (-80%) out of 32 patients in the study, of which 5 
had WHO grade III astrocytomas (figure 6-6) and 21 had glioblastomas (figure 6-7). 
Ten patients (2 with anaplastie astroeytomas and 8, glioblastomas) died within three 
months following initial diagnosis and treatment. This would suggest that this group 
of patients presented with advanced disease at diagnosis or/and had iatrogenic causes 
of mortality.
The majority of patients in this study were relatively young, mostly in middle age. 
From table 6-2 it can be seen that the ten patients already mentioned who survived 
three months or less had a mean age of 51.5 (median age about 49) and the eight who 
survived between 4 and 11 months have a mean age of 49.75 (median age about 45). 
The eight who survived twelve months or more were not signifieantly younger (mean 
45.75, median age about 44.
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Table 6-2 - Survival data for 26 patients with high malignancy grade 
astrocytomas
Tumour ID Grade A ge/sex Survival (m onths)
1. A A /C 545 III 38/M 2
2 . A A /S2614 III 40/F 13
3. A A /S2706 III 38/F 59
4. A A /S2721 III 46/M 1
5. A A /2745 III 31/M 18
6 . G BM /S 11 IV 53/M 1
7. GBM /C 160 IV 40/M 19
8 . GBM /C 1397 IV 37/M 3
9. G BM /C 1510 IV 55/M 40
10. GBM /S 1575 IV 71/F 2
11. G BM /S 1595 IV 68/F 18
12. GBM /C 1612* IV 44/M 8
12. GBM /C 1724* IV 44/M 8
13. G BM /S 1706 IV 47/M 44
14 G B M /C I719 IV 69/F 2
15. GBM /C 1752 IV 44/M 7
16. GBM /C 1760 IV 57/F 2
17. G BM /S2051 IV 44/M 1
18 G BM /S2093 IV 55/M 11
19. G B M /S2650 IV 44/M 11
2 0 . G B M /S2126 IV 64/M 10
21 G BM /C 2394 IV 47/M 17
22 G B M /S2409 IV 41/F 5
23 G B M /S2532 IV 50/M 2
24 G BM /C2685 IV 44/M 11
25 G B M /S2687 IV 48/M 3
26 G B M /S2848 IV 46/M 7
AA = anaplastic astrocytoma (W HO grade III), GBM = glioblastom a multiforme
grade IV), S = solid/biopsy & C = cell cultures, respectively representing abbreviations for
216
Cytogenetic Analysis of DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
Chapter 6 Discussion
the source o f  D N A , which was used in the CGH experiments in this study. M =m ale, F = 
female. Survival data is in months after initial diagnosis *Tumour specim ens o f  one patient
Patient survival is known to depend on several other factors, for example, intracranial 
site/location of a tumour, extent of surgery, and the mode and dose of radiotherapy 
administered. Clinical data relating to most of these parameters were not available for 
this study, which made it difficult to be more specific about their possible role in 
these early deaths, or generally the overall outcomes. The CGH data from these 10 
patients were very variable. But the most frequent chromosomal aberrations involved 
gains of CHR 7p in 5 patients (50%), CHR 13 in 5 patients (50%), and CHR 7q in 4 
patients (40%). Meanwhile, the most commonly deleted regions were at 16p and 19p 
each in 5 patients (50%), and Ip, lOq, 16q, 17p, 19q, and 22q, each in 4 patients 
(40%) who died within three months of diagnosis. The rest of this section will divide 
the patients into those with anaplastic astrocytomas (5 with survival data) and those 
with GBM (20 patients).
The median post-treatment survival of patients with anaplastic astrocytomas has been
reported as 3 - 5 years (Surawicz et al., 1998; Sant et al., 2003). Recent improvements
in surgical access and extent of resection, in addition to more accurately targeted
radiotherapy, may have resulted in modest improvement in survival of patients
diagnosed with glioblastoma multiforme. The median post-treatment survival is
currently around 12 months (Brandes et al., 2004; Mitchell et al., 2004). Therefore, it
appears that a fair proportion of glioblastoma patients now survive for 1 -2 years after
diagnosis. Nevertheless many studies and reviews continue to report an overall
duration of survival of less than 1 year for glioblastoma. In this study, only one out of
3 patients (33%) with anaplastic astrocytoma, a female aged 38 years, survived for
approximately 5 years (see figure 6-6). Two other patients with AAs survived for 13
and 18 months respectively. This was far below the expected median survival for this
grade of astrocytoma. Except for the possibility of iatrogenic causes of death, which
could have accounted for the death of two patients with AAs who died within three
months of diagnosis, the short duration of survival in four of the five patients with
AAs would suggest that they might have had tumours with more aggressive molecular
characteristics, or that they died of other causes. The CNAs found in these patients are
shown in figure 6-6. Indeed AS2745 had 8 discrete gains, which included three that
. 217
Cytogenetic Analysis o f  DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
Chapter 6 Discussion
are located on similar chromosome arms in AS2614 (3p, 61 and 13q) and 9 losses, 
one of which (16qll.2) is common to both tumours. These regions could harbour 
genes that modify the biological character of astrocytomas, perhaps conferring an 
aggressive phenotype. The patient who survived 18 months did have discrete deletion 
of lp36 and large (whole) deletion of 19q, but the possible role of these is unknown
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A summary of chromosome abnormalities with 
tumours arranged according to duration of survival 
of the patients (months) following initial diagnosis
219
Cytogenetic Analysis of DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
Chapter 6 Discussion
Figure 6-7
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Figure 6-7 shows survival data for 20* patients with GBMs - a summary o f chromosomal 
abnormalities with the tumours arranged according to the duration o f survival o f the patient after 
initial diagnosis.
* The tumour GBM/C1724 and GBM/C1612 are the same patient, while data on the survival 
were unavailable for 5 from the cateeorv o f unknown GBMs.
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Explanation for Figure 6-7- Survival data of 20"^  patients with GBMs 
A summary o f  chromosome abnormalities with the tumours arranged according to the 
duration o f survival o f the patient after diagnosis/initial treatment. The duration o f 
survival (months) is in the top row. As elsewhere in the thesis AA stands for  
anaplastic astrocytoma, GBM: glioblastoma multiforme, C: cell culture, S: 
solid/biopsy, and ‘m ’ indicates that CGH was obtained from mda-amplified DNA. Red 
shading is used to show chromosome arms that bore losses covering the entire 
chromosome or very large segments, while rose (pink) identifies short segmental 
losses in a CHR arm, ‘sea-green ’ identifies gains o f whole CHR or large portions, 
and ‘light green ’ represents patchy gain over limited segments o f  a CHR arm. Grey 
shaded circles indicate CHR-arms in which losses and gains were reported (i.e., in 
different band regions o f the same arm)
* The tumours GBM/C1724 and GBM/C1612 are the same patient, while data on the 
survival were unavailable for 5 patients from the category o f  unknown GBMs.
Continuation o f  text...
The overall survival in this cohort was roughly as expected for glioblastoma patients. 
The five GBM patients who survived >12 months (in fact 17/12 or more months) had 
an average of just 4 CHR-arm involvement per tumour (range 0-17), with one female 
aged ages 68 (GBM/S 1595/m), who had aberrations involving 17 CHR-arms 
surviving for 18 months. This contrasts remarkably with the survival 8 patients who 
survived between 4 -1 1  months, who on average had CNAs in 10 -  12 CHR arms per 
person. The tumours of the 17 patients who are known to have survived 11 months or 
less had between them a total of 192 CHR arm involvements, giving an average, of 11 
CHR arm aberrations per tumour.
In the light of the findings of Idbaih it is of interest to look at any correlation of 
survival and deletion of lp36. Of the eight patients whose tumours show loss in this 
region the median time of survival was between 3 and 5 month whereas in the 13 
patients without this specific change the median survival was 8 months. However five 
very short-term survivors (<4 months) had other changes in Ip. The median survival 
for 10 GBM patients with no changes on Ip was 11 months. These data are consistent
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with the findings of Idbaih and coworkers although the numbers are too small to draw 
firm conclusions.
6-7-3 Long-term glioblastoma survivors
Two (10%) out of 20 patients with glioblastoma in this series survived for 3 or more 
years. In the context of glioblastoma multiforme a patient is considered to be in the 
category of long-term survivors if the survival outcome is at least three years (Scott et 
al., 1999; Burton et al., 2002). Although our series is quite small in comparison, the 
finding of 3-year survival of -10% is somewhat in agreement with that of Sant and 
colleagues (2003), who investigated management outcomes of 6,513 ‘adulf 
glioblastoma multiforme patients in a recent EUROCARE study, except that the 
higher proportion of survivors (11%; range 2 -  11%) in their series was attributed to 
patients aged 1 5 -1 8  years -  by far a much younger age group of patients than those 
in this series. This data indicates a higher proportion of glioblastoma survivors than 
currently thought possible (Senger et al., 2003; McLendon and Halperin, 2003). This 
would either validate the view that there has been some improvement in current 
management practices for glioblastoma, or/and that a fair proportion of glioblastoma 
subgroups may possess molecular markers responsible for long-term survival.
On the basis of molecular cytogenetic alterations observed by metaphase CGH 
(figures 6-7) a general observation that is striking from these two long-term survivors 
(LTSs) is the relatively small number of copy number alterations that were reported in 
their tumours.
From these CGH results, the two LTSs shared no common aberration. GBM/C 1510 
had gains at several minimum common region of overlap (MCROs) on CHR 7 (p & 
q), and losses at 9q34, proximal 16q, and 19p, while GBM/C 1706 had gains at 13q21 
and the entire X-CHR. Neither tumour showed a loss at lp36
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6-8 DNA Copy Number Aberrations implicating genes o f  syndromes 
with astrocytoma associations
As already mentioned, DNA copy number aberrations implicating several loci of well 
known syndrome-genes, such as those for tuberous sclerosis and neurofibromatosis, 
were found at a frequency similar to, and in some cases higher than at well known 
loci like those of PTEN, TP53, CDKN2AandCDKN2B and RBI. The latter are 
considered as the major contributors to pathogenesis of sporadic astrocytomas while 
the former group have established roles in astrocytomas associated with hereditary 
/familial syndromes. Hereditary astrocytomas are believed to account for ~5% of 
astrocytomas, the majority being pilocytic, benign, WHO grade 1, astrocytomas. 
Although generally well circumscribed and progress slowly, NFl-associated pilocytic 
astrocytomas (NFl-PA) occasionally behave as aggressive tumours (Tada et al.,
2003), suggesting that certain aberrations associated with the NFl gene are capable of 
causing malignant transformation. The low expression of NF2 gene in hereditary 
astrocytomas (Weber et al., 1996; Watkins et al., 1996) and of the TSCl/2 genes 
(Weber et al., 2007), implicates these genes in pathogenesis of sporadic astrocytomas. 
Although the evidence in each case directly relates to hereditary astrocytomas, it 
would seem to provide indirect evidence for sporadic astrocytomas that have LOH at 
these loci. Further evidence pointing to a possible role of these genes in sporadic 
astrocytomas is implied by:
1. Occurrence of glioblastomas in association with congenital syndromes, for 
example, the NFl/2 (Lee et al., 2006; Kruger et al., 2007) and TSCl/2 
(Malmgren et al., 1984; Al-Saleem et al., 1998; Senatus et al., 2005)
2. Involvement in tumours of other glial cell types e.g., ependymomas (Zheng et 
al., 2000)
3. And, in addition they have been implicated in pathogenesis of sporadic 
tumours of other cell-types and organs; for example, the NFl/2 genes in 
colorectal cancer (Rustgi et al., 1994/1995; Cacev et al., 2005), and the 
TSCl/2 genes in cancers of the bladder and other sites (Knowles et al., 2003; 
Adachi et al., 2003; Rosner et al., 2006).
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It seems of interest that past studies failed to establish a clear association between 
these genes and sporadic astrocytomas. Indeed, despite the good overall agreement 
between metaphase and array CGH data in this study, there were notable 
discrepancies in regions harbouring the TSCl/2 in 3 tumours (showing alterations in 
the metaphases) among the small group investigated by these two procedures. This 
renders the data somewhat inconclusive on the possible role of the TSCl/2 genes in 
these tumours and the study in general. The question of the adequacy of either/or both
CGH procedures (metaphase and 1MB arrays) for investigating aberrations in the 
chromosome regions that harbour these genes has been raised by several other 
observations. A genomic array similar to the ones used in this study also failed to 
detect established deletions of the TSC2 gene in 2 samples (Michaelet et al., 1997; 
Ekong et al., 2004). Among other possible explanations, the failure to validate 
previously established deletion, by Ekong and co-workers, one reason would be that 
the genomic arrays were not sensitive enough to detect the aberrations in the TSC2 
region possibly because of polymorphism in the repetitive sequences not fully 
suppressed by COTl DNA (for example, see Radon et al., 2006). This problem may 
be overcome eventually by using arrays containing only genuinely single copy 
sequences.
Therefore, while the CGH methodologies measure the relative DNA copy number of 
one test genome compared to a reference, they overlook its absolute DNA ploidy state 
and the distribution of common repeats across the genome, which can impair data 
interpretation (Carter et al., 2002; Mantripragada et al., 2004; Fiegler et al., 2007), 
and are also insensitive to balanced rearrangements such as inversions and reciprocal 
translocations. Although segmental duplications and structural polymorphism are 
common to many chromosomes, in general chromosomes 9, 16, 17 and 22, which 
harbour the genes for NFl/2 and TSCl/2 are known to have relatively higher 
percentages of repetitive sequences and segmental duplications, as well as being 
structurally polymorphic within the substantive euchromatic regions (Humphray et 
al., 2004; Martin et al., 2004; Mantripragada et al., 2003/2004; Zody et al., 2006). It 
would therefore require the use of more specific and elaborate methodologies to 
search for aberrations at the loci of these genes. On the other hand, it is possible that
some other genes, located in the vicinity of the well-known hereditary-astrocytoma
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associated genes, are the ones that are altered and responsible for sporadic 
astrocytomas. However, no alternative candidate TSGs have so far been identified, 
and the search continues both in glial tumours and tumours of other sites that have 
been found to show frequent LOH in the regions of these genes (for example, Ho- 
Keung et ah, 1998; Knowles et ah, 2003; Suarez-Merino et ah, 2005; de Stahl et ah,
2005).
6-9 So, why is it that genetic studies o f  sporadic astrocytomas have so 
far failed to find evidence firmly implicating some well-known 
syndrome-genes, in particular the N F l/2  and TSC l/2?
This concern is also at the centre of this current study; the two key issues arising 
from it are: 1) whether genes implicated in established syndromes (with astrocytoma 
association) contribute to development of sporadic astrocytomas, and 2) why, in spite 
of frequent findings of LOH (and in some cases, apparently reduced gene expression), 
that studies of sporadic astrocytomas have so far failed completely to find evidence 
firmly implicating some well known syndrome genes in the pathogenesis of sporadic 
astrocytomas.
There may be several possible explanations. LOH does undoubtedly occur in some 
sporadic astrocytomas but may be quite uncommon and may be overestimated by 
CGH approach. This problem should be solved by better arrays, including SNP 
arrays, and by recognizing the essential need to have normal DNA from the patient -  
a need emphasized by recent recognition of the extent of normal copy number 
variation of large segments (Redon et al., 2006). However, if the LOH is genuine and 
important, another explanation is haploinsufficiency of genes implicated.
6-9-1 The role o f  haploinsufficiency
Based on the evidence of LOH it may be that these TSGs can contribute to 
astrocytomas via haploinsufficiency rather than the canonical two-hit hypothesis. 
Several investigators now believe that this may be the case (for example, Gutman et 
al., 1999; Paige AJW, 2003; Barbashina et al., 2005). However the associations of 
haploinsufficiency and tumour occurrence requires cautious interpretation due to 
strain-specific variations (Hawes et al., 2007).
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6-10 An Illustration o f Probable Molecular Pathways o f  some GBM  
Observed in this Study.
It has been generally aecepted that glioblastomas are distinguishable from anaplastic 
astrocytoma by, among other possibilities, primarily, deletion of lOq (Somerville et 
ai., 1998; Fults et al., 1998; Kleihues and Cavenee, 2000; Furuta et ah, 2004), which 
is thought to implicate the gene for phosphatase and tensin homolog (PTEN) at 
10q23.3. Based just on this premise our panel of glioblastomas can be categorized 
into at least three subgroups. 1) Those with deletions of lOq spanning the locus for 
PTEN - possibly the category that conforms to the current definition, 2) those with 
deletions of lOq but in which the PTEN locus is apparently spared, and 3) 
histologically confirmed glioblastomas that did not show copy number alterations 
anywhere in chromosome 10. As far as the status of the PTEN locus, as determined 
by metaphase CGH is concerned, the latter two categories appear to be at variance 
with the prevailing moleeular definition of a glioblastoma. This would suggest that 
alternative molecular endpoints exist for some categories of glioblastoma multiforme. 
However it is important to keep in mind that deletions of the PTEN gene may have 
occurred but could be too small for detection using the method of metaphase CGH. 
Indeed array CGH of GBM/C 1724 found deletions of PTEN which where not 
revealed by the metaphase CGH experiment. On balance, the finding of a region of 
loss or gain in a specific clone for which a prior hypothesis exists is therefore a firmer 
result than the failure to find one (Sue Povey, personal communication).
This study observed 2 regions that were at the centre of most deletions, or minimum 
common region of deletions (MCRD) in the lOp-arm. These were located respectively 
at 10pll.21 and lOpl 1.22-pl 1.23. Similarly there were three MCRD in the lOq-arm 
centred at 10q21.2-q21.3, 10q23.1-q23.3 (encompassing the locus for PTEN), and 
10q25.1-q26.2. These 5 most commonly deleted regions on chromosome 10 might 
harbour TSGs that may constitute different molecular pathways (perhaps endpoints) 
for some categories of glioblastoma multiforme (for details, please refer back to the 
section on CNAs of CHR 10 in Results Chapter 3).
Similarly, inactivation of TP53 is considered a key factor in early transformation of 
astrocytomas along the pathway to secondary GBMs (Jin et al., 2000; Fulci et al.,
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2002; Wang et al., 2004). TP53 is highly homologous to TP73 and the two genes are 
considered to be functionally similar (Benard et al., 2003). MDM2 is normally bound 
to TP53, rendering both of them inactive (Issaeva et al., 2004; Arva et al., 2005). 
Amplification of MDM2, which results in free, ‘unbound’ MDM2 is considered to be 
a primary molecular mechanism for bypassing tumour suppressor functions of TP53 
(Cameo et al., 2000; Yu et al., 2003). Thus, the three genes, TP53, TP73 and MDM2, 
may have critical roles in early tumour development in some categories of astrocytic 
tumours. Data from this study appear to suggest that there may be alternative 
mechanisms for bypassing p53 tumour suppressor functions in glioblastomas. A 
comparison of the pattern of CNAs in loci implicating TP53, TP73 and MDM2 found 
a total of 14 tumours with CNAs implicating one or more of these loci (Table 6-3), 
with another 18 revealing no CNAs in any of the above loci (see figure 6-3 for a 
detailed plot of CNAs).
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Table 6-3 shows CNAs in loci of 3 genes: TP53 and two others that may have roles in 
astrocytoma oncogenesis. An empty box signifies that no CNAs were observed in a 
corresponding gene locus, circles filled with either “tan” or “green” colours 
(respectively representing loss and gain) identify loci implicated in copy number 
aberrations. The CHR region harbouring TP53 and TP73 were deleted, while that of 
MDM2 was gained.
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Gains of the region containing the locus for MDM2 implicated it in the development 
of 3 out of 14 cases (-21%) in which the above three genes are implicated. On the 
other hand the CHR region containing the TP53 locus was deleted alone in 3 cases 
(21%) and that of TP73 in 2 cases (14%). Probable cooperation of regions of all three 
genes, accounting for the majority in which more than one of three genes was 
implicated, was observed in 4 (28.6%) cases. Cooperation between regions 
harbouring TP73 and MDM2 occurred in one instance (7%), while loci corresponding 
to TP53 and TP73 were jointly deleted in 1 case (7%). From previous work (Biemat 
et al., 1997; Ghimenti et al., 2003) it has been suggested that deletion of TP53 and 
amplification of MDM2 are alternative mechanisms rarely found in the same tumours. 
In this series there are 4 cases of gain of the region harbouring the MDM2 without 
apparent loss of TP53, and similarly 4 cases of loss of TP53 without obvious gain of 
MDM2. There are four tumours where there is apparent loss of TP53 and gain of 
MDM2. In these 4 cases, and indeed in four others, there is also a loss of regions 
containing TP73. This might suggest involvement of different genes. The respective 
regions implicated here harbour multiple genes of interest, in particular the region to 
which the MDM2 gene is mapped, at I2ql3-ql5 (Fischer et al., 1996; Reifenberger et 
al., 1996; Nakahara et al., 2004). On the other hand, the same genes may be involved, 
with some acting via different mechanism, which could have implications on 
prognosis. However, irrespective of the operational mechanisms, or the specific 
combinations of genes that might be implicated, this possibility further implies 
existence of subgroups within this category of astrocytic tumours.
Thus, considering the probable involvement of these three genes that are believed to
have critical early roles in transforming a subcategory of tumours of astrocytic origin,
this study appears to identify at least 7 subgroups of high-grade astrocytic tumours six
of which are within this subcategory alone. It is likely that epigenetic mechanisms
may account for some cases, which would further point to additional subgroups. That
aside, this study suggests that some astrocytomas do not have gross structural
alterations involving the chromosome regions harbouring loci of the genes for TP53,
TP73, and MDM2, which in this study amounts to 21 (-65%) tumours. It is possible
of course that some of the tumours could have small deletions or amplifications, or
indeed point mutations in these regions. However since major structural changes are
an extremely common basis for the evolution of tumours, it is certainly possible that
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these tumours have arisen by different meehanisms. This suggests that other initiating 
genes may be responsible for tumour development in this latter group, which would 
also imply additional subeategories. Eleven of the 21 tumours that do not appear to 
have gross alterations of TP53, TP73 and MDM2, had copy number aberrations 
suggesting deletions at several other gene loei, of which at least 19 may harbour 
tumour suppressor genes that could have contributed to tumour initiation in this set of 
astroeytomas. Please refer to figure 6-3 for details.
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6-11 CONCLUSIONS
There are striking differences between primary and secondary glioblastomas with 
respect to clinical manifestations as well as genetic aberrations (Ohgaki and Kleihues, 
2007). For example, there are differences in age distribution of patients, with the 
mean age of primary GBM patients being ~60 years, whereas patients with secondary 
GBM are on average -45 years (Ohgaki et ak, 2004; Ohgaki & Kleihues, 2005). 
There is also gender bias; primary GBMs develop more frequently in men (M:F 
ration, 1:33), whereas secondary GBMs are more frequent in females (M:F ratio, 0:65 
(Ohgaki et al., 2004)). In terms of survival, the median survival of secondary GBM 
patients (7.8 months) is marginally better than of patients with primary GBMs (4.7 
months) (Ohgaki & Kleihues (2007). However, this difference is considered largely 
due to the younger age of patients with secondary GBMs (Kleihues et al., 2004). 
Other than age, which is a consistent predictive factor of longer survival of GBM 
patients, multivariate analyses have so far showed no significant differences in 
survival of patients with primary and secondary glioblastomas (Ohgaki et al., 2004; 
Ohgaki & Kleihues, 2005). This seems to emphasize a need for a better understanding 
of the clinical manifestations and the associated molecular pathogeneses, for the 
respective sub groups of tumours, so as to design effective targeted molecular 
therapies. The work described in this thesis has been one small step in this complex 
process. The results have shown considerable agreement with some established 
previous findings for example gains on chromosomes 7 and 12 and losses on 
chromosome 10. There was also some agreement with less well established previous 
findings for example fewer chromosome aberrations in tumours from patients who 
survived longer and some suggestion of a worse prognosis for tumours showing loss 
in the lp36 region
As noted previously, one of several additional observations from this study is that loci 
of almost all the genes currently implicated in familial/astrocytoma susceptibility 
syndromes, such as the genes for tuberous sclerosis and neurofibromatosis, are 
predominantly implicated in sporadic astrocytomas investigated in this study. This 
would suggest that these genes (or others thereabout) despite several of them not 
featuring in current models, could have contributed to pathogenesis of these sporadic
astrocytomas. Regrettably, because of the limited access to micro-arrays these
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metaphase CGH data could not be adequately compared with the microarray in some 
of the regions of genes that we would be interested to investigate further, i.e., at 9q34 
(TSCl), 16pl3 (TSC2), 17qll.2 (NFl) and 22ql2 (NF2). These genes (and regions) 
have been frequently investigated in the past and no definite role in sporadic 
astrocytomas has been found (refs, as indicated previously). Indeed, this study found a 
discrepancy involving the TSC2 region in one tumour; the convincing loss of 16pl3 
in 1724 that was not confirmed on microarray. This would appear to support the 
earlier findings of other investigators mentioned above. However, equally, the 
discrepancy in this study involving the TSC2 region would appear to east some doubt 
on the sensitivity of mieroarrays in investigation of this region. Ekong et al., in 2004 
published a paper in which a mieroarray failed to detect established deletions of 69 kb 
and 136 kb (Michalet et al., 1997) in two samples they examined. Results obtained for 
the cosmids in the TSC2 region were inconsistent and indicated either a deletion for 
all the clones including those known to be undeleted, or normal ratios for all clones 
including the deleted ones. The spurious results found in this region may be attributed 
to the fact that it is known to have a high density of repeat elements and duplications 
(Sampson et al., 1997; Bailey et al., 2002). Furthermore, labelling artifacts are known 
to cause wide variation of fluorescence ratio in heteroehromatic pericentromerie 
regions (1,9, 16) and GC-rieh regions for example on chromosomes Ipter, 16,19 and 
22. These limitations of the CGH procedures could account for discrepancies 
observed between metaphase and microarray CGH in some of the chromosome 
regions, for example at 9q34 (in 1510), 16pl3 (in 1612 and 1724), and 19pl3 (in 
1510 and 1612) that were highlighted by this study. In spite of these difficulties of 
interpretation the data in this study which suggest loss in the regions implicated in 
hereditary astrocytoma syndromes are too strong to be dismissed.
An additional issue that arises from these data is the very diverse nature of aberrations
revealed by metaphase CGH in a relatively small sample of high-grade sporadic
astrocytomas (Table 6-1; Figure 6-3). While a number of these aberrations are typical
of changes that have long been associated with various grades of astrocytomas,
several others are largely unreported in the literature on astrocytomas. This could
raise issues concerning the cellular and molecular basis of glioblastomas. The cell of
origin of secondary glioblastomas may be somewhat straightforward, as it would be
inferred from the histological diagnosis of a preceding, lower grade tumour that 
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would have progressed or recurred. However, with regards to primary glioblastomas, 
a rapidly developing subgroup of tumours, which are believed to constitute 
approximately 90% of glioblastomas, the anaplastic histology obscures the normal 
morphology, creating uncertainties with defining the cellular origins of such tumours. 
While there is no disputing the fact that astrocytes could contribute to a significant 
proportion of primary glioblastomas, it seems that the assumption of an astrocyte as 
the inevitable cell o f origin may be in some doubt. This view is illustrated by the case 
of glioblastomas arising from oligodendrocytes. Moreover, reliance on GFAP 
immunohistochemistry for resolving uncertainty with the diagnosis following 
anaplastic histology seems unspecific. This examination appears not to be entirely 
specific to astrocytes (Walz and Lang, 1998; Wittowski W et al., 1998), and is also 
uninformative for subgroups of astrocytes and/or glioblastomas (Reifenberger et al., 
1987; Walz Wolfgang, 2000; Chronwall et al., 2000; Riemenschneider et al., 2004).
Secondary glioblastomas arising from oligodendrocytes might be expected to retain 
some characteristic histological features suggestive of the cell of origin (Ghimenti et 
al., 2003). However, the fact that oligodendrocytes give rise to secondary 
glioblastomas strongly suggests that this cell type could give rise to primary 
glioblastomas, perhaps with little if any distinguishing histological features. If the 
histologies of primary glioblastomas that arise from astrocytes and oligodendrocytes 
are similar, then it is probable that other glial cell types can give rise to primary 
glioblastomas with apparently similar histological features. A considerable fraction of 
gliomas show ambiguous histological features that make their classification into 
oligodendroglial or astrocytic difficult, and immunohistochemical or molecular 
markers for unequivocally distinguishing glioblastomas that have arisen from 
oligodendrogliomas and astrocytomas are not available (Riemenschneider et al.,
2004). Even more interesting is the observation that some glioblastomas display 
neoplastic neuronal elements (Fung et al., 2004; Galli et al., 2004). All these add to 
the implication that other neuroepithelial cells may constitute significant parts of the 
anaplastic, neoplastic histology especially of primary glioblastomas. Further still, 
some glioblastomas have neoplastic mesenchymal features in them (Reis et al., 2000; 
Bertrand et al., 2002; Alatakis et al., 2005; Orimo A and Weinberg R, 2006; 
Bimbaum et al., 2007), which suggest that eellular elements traditionally considered 
extrinsic to the neuroepithelial domain could be involved in glioma pathogenesis. It
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seems therefore probable that other neuroepithelial cell types such as ependymal cells 
and cells destined to form neuronal structures, and even other non-neuroepithelial cell 
types (e.g., mesenchymal /mesodermal derivatives) might have the potential to give 
rise to some categories of primary glioblastomas through mesenchymal-epithelial 
transitions (Orimo A, & Weinberg R, 2005).
Additional support is inferred from profiles of pilocytic astrocytomas. Within the 
established category o f astrocytes, the genetic profiles of pilocytic astrocytomas 
(WHO Grade 1) are clearly different from those of diffuse infiltrating astrocytomas 
(WHO Grades II -  IV). However, it has been observed that a small proportion of 
pilocytic astrocytomas progress to glioblastomas (von Deimling et al., 1993; 
Figueiredo et al., 2003; Luyken et al., 2003; Lubansu et al., 2004). This important 
observation suggests that cells with genetic profiles typically associated with pilocytic 
growths have the potential to develop into glioblastomas. Primary glioblastomas are 
by far the most prevalent o f ‘astrocytic’ CNS tumours. They develop rapidly, most 
patients typically presenting within ~3 months of onset of symptoms, and with highly 
anaplastic tumour histology. What proportion of this rapidly developing category of 
astrocytic tumours might arise from the diverse and varied cell-types mentioned 
above cannot be precisely ascertained at the moment. While it is true that the changes 
which influence origin or progression of the tumour presumably arise as random 
events which confer some proliferative advantage and thus are selected and may come 
to dominate the tumour, it is nevertheless likely that differences in the original 
molecular backgrounds of cells from which astrocytomas develop could account for 
some diversity in molecular profiles that characterise astrocytomas.
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6-12 FUTURE DIRECTIONS
This study has produced a broad-brush picture of a large number of tumours. The 
laboratory procedures that were used allow for genome-wide detection of aberrations 
in the range o f 1 -20 Mb. This leaves a diagnostic gap for any alterations in the range 
of 1-900 Kb. There is also the possibility that some genes could have been affected by 
point mutation, epigenetic silencing and balanced rearrangements, all of which would 
have also escaped detection by these methods. As explained previously, both methods 
are limited in their scope to detect aberrations in regions with high prevalence of 
repetitive DNA sequences (for example, the long interspersed nuclear elements 
(LINE) and short interspersed nuclear elements (SINE). In order to further 
characterize these tumours, it would now require use of more precise tools.
Overall, the study has identified at least 83 regions of recurrent copy number 
alterations, each shared by a significant number (minimum 3) from a panel of 26 
informative high-grade astrocytomas (see in the appendix). Thirty-eight of these are 
regions of loss, while 45 were of recurrent gains. The low resolution of the techniques 
used, together with the large number of genes located within these regions, make it 
difficult to identify candidate genes. First it would be necessary to investigate the 
remaining tumours using genomic arrays, as was the case for the small number in the 
current study, allowing identification of the genes implicated in regions identified. 
Indeed ideally all tumours would be studied again with one of the more recent 
genomic chips, either a tiling path array or a SNP chip, allowing a more detailed 
evaluation of LOH. Particularly interesting would be those samples, which have few 
but definite chromosome aberrations. For the difficult chromosomal regions already 
discussed, customised arrays (for example exon-specific) might be useful. 
Quantitative Fluorescent (QF) 5-plex PCR (QF-PCR) of DNA using microsatellite 
markers might also be helpful for some of these regions.
Having established gene dosage as far as possible there would then be several ways to
proceed from this point. As large-scale sequencing becomes cheaper there would
certainly be some need for this. Perhaps more immediately, gene expression profiling,
for example, using cDNA and appropriate arrays (Pollack et al., 2002; Ruano et al.,
2006) would allow the identification of overexpressed (target) genes whose aberrant
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expression could suggest involvement in the pathogenesis of the tumours. Additional 
methods would include quantitative real-time PCR of any candidate genes e.g., those 
with established roles in sporadic astrocytomas such as EGFR, PDGFA, 
CDKN2A/2B, PTEN, RBI, TP53, genes with roles in hereditary syndromes, i.e., 
NFl/2, TSCl/2, and any other genes of interest identified from genomic array CGH 
data. This would help to answer the question of whether there are other pathways to 
oncogenesis, which do not include loss of any of these genes, or whether small 
deletions have been missed. This could also help to explain the apparent low 
frequency of loss on 9p, 13q, and 17p in this study in spite of previous findings of loss 
of CDKN2A, RBI, and TP53, in astrocytomas.
The issue of the genes with established roles in hereditary syndromes with 
astrocytoma association, but which have not been implicated in sporadic 
astrocytomas, has been of particular interest in this study. It is possible that these 
genes are not mutated in sporadic astrocytomas as apparently shown by numerous 
past studies. However significantly reduced gene expression in the absence of 
demonstrable mutations of the genes might support the hypothesis that they could 
contribute to sporadic astrocytomas via haploinsufficiency. Furthermore, studies of 
these regions by the mieroarrays described above might help to identify alternative 
candidate TSGs in these frequently altered regions.
In addition to these general possibilities some particular tumours are of interest.
The tumour GBM/C1724 has already been further investigated by microarray CGH 
and M-FISH, and several findings here would be worth pursuing. There are three 
areas that would warrant further investigation. The first, is the dramatic gain of 
material in 4p, shown both in the original (GBM/C1612) and in the recurrent tumour 
CGH, which microarray has shown to represent a region of ~31 Mb. Secondly, array 
appeared to show several translocation breakpoints in CHRs 1, 8 and 11, while the 
MFISH of the same tumour revealed numerous translocations, with 4 of them 
(der(8)t(8;22), der(8)t(8;12), der(9)t(9;ll) and der(X)t(16;X)t(17;X)) recurring with a 
higher frequently.
Chromosome 1 had 3 possible translocation breakpoints, at 1 36.32 flanked by RP4-
731G4 and RP11-204L3, and the other, respectively, at 1 150.75 -  1 152.88 (flanked
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by RP11-422P24 and RPl 1-17216), and 1_160.96 -  1_164.74 (flanked by RPl l -  
541J2 and RP4-702J19). Other possible breakpoints (details in the results ehapter) 
were on 8q and l ip.  These (and similar ones in other tumours) would need to be 
characterized further in the hope of identify possible fusion genes. However, the 
overwhelmingly large number and diversity of chromosomes in each cell of 1724 may 
indicate genomic instability. Finally for this particular tumour, it would also be 
interesting to confirm and define regions where there is apparent loss of a single 
clone, for example on distal 6q, and alterations in a few scattered outliers in several of 
the tumours investigated by array (detailed in appendix 4).
Two of the patients with Grade IV malignancy at diagnosis survived for more than 
three years, and their tumours were also investigated by mieroarrays. Although one of 
them showed little (or no DNA) in the sample, these tumours would also be worth 
further study. Finally, in any study designed in future it would be a great advantage to 
have more access to clinical information and histology. Microdissection of the 
tumours would be essential and a parallel DNA sample (probably blood) from each 
patient would be highly desirable.
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Ipl 1-ql 1; 7p22-q36; I 2 q l 3 - q l 5
lp22; 6p25; 6q22; 7 p 2 I-p l4 ;  7q2I; 7q22-q32; 9p24; l l q l 4 ;  
12q l5-q2I;  13q22-q21; 2 0 p l2 -p l  1.2; 2 1 q l  1.1
h
Ip22-p21; lq31; 2q23-q21; 3p l2 ;  3 q l l . l - q l 3 ;  4q l3-q28;  4q31-  
q32; 5q l2-q23;  5q31-q32; 6 q l l -q 2 3 ;  7 p 2 1 - p l l . l ;  7 q l l .2 -q 3 2 ;  
8q22; 9p21; I l p l 4 - p l 2 ;  H q l4 -q 2 2 ;  12pl 1.2-pl 1.1; 12ql4-q21;  
13q21-q22  
9p23-p21
I p 3 1 -p l3 ;3 p l2 ;3 q 2 1 -q 2 7 ;  13ql4-qT l;  18ql 1 .2 -q l2 ,2 1 q l  1.2
2q35-q37; 10pl5-q26; 13q33-q34  
7 p 3 6 3 p 3 3 :  1 q 12; l ^ Î L G q T  1 _ | ; | l q  1 ï - q  12; f2q\i^qÏ3
Ip36.3-p31; lq l2 ;  4 p l6 ;  5p l5 .3 ;  8p23-p l2;  9 q l  l-ql_2; 9q34; lOplSnql 1.2; 10q2l;  
10q24-q25; l l q l 2 ;  12q24.1-q24.3;  14q31-q32; 1 5 q l l -q l3 ;  1 6 p l3 .3 -q l l .2 ;  ! 
16q23-q24; 1 7 p l 3 - p l l . l :  17q21; 17q23-q25; 1 9 p l3 .3 -q l3 .43 ;  2 0 q l2 -q l3 .2 ;  : 
; 21 q22; 22p 13-q 13; X p 2 2 . 3 - p 2 1 ; X p l  1.4 -q2 1 ; X q 2 1 ; Xq22-q28  
: 1 p36.3; 1 Opl 5 ; l0 q 2 6 .2 ;  14 q 3 1 -qT2'; 22q Î iJ-qT f
1 p 3 1 ; 4 q 26-q 31.1; 7p22-q36; 12q 14-q 15; 20p 13-q 12
5 p l5 .3 -p l5 .2 ;  5 p l5 .1 -p l3 ;  5q l4-q23;  6 q l2 ;  7p21-ql 1.2; 7q22-  
q36; 1 2 p l l . l - q l 2 ;  12ql4-q21; 18q26
Iq43-q44; 4q34; 5q35; 7 p l5 -p l  1.2; 7p22-p21; 7q21; U q23-q24;  
12pl3; 15q26; 16pl l . l - q l 2 .1 ;  17pl3;  2 0 p l 3 - p l 2  
2p25; 3p26; 5 p l5 .3 -p l3 .2 ;  7 p l3 -q H .2 ; 'T p 2 3 - p 2 2 ;  T îq 2 1 ;  
13q32-q34; 15q26; 18q22-q23
lp36jT 2p25-p24; 3p26; 3q28-29; 4pl6; 4q34;“ ^ 5 . 3
9q34; ( lOpll .2-q  11.2; 10q25-q26; l l p l 5 ;  i l p l l . l - q l 3 ;  14q31-q32; 16pl3 .3 -  
p l3 .1 ;  16pl 1.1-ql 1.2; 16q24; 17 p l3 -p l2 ;  17q24-q25; 1 9 p l3 .3 -q l l ;  19q l3 .11-  
q l3 .4 1 ;X p 2 2 .3 -q 2 8
5 q 3 J ;'9 '^ -q Ï 2 ; 1 Op i ] :q 2 6 ; # 2 q  H .2 -ÿÎ3T X l^ 2 .3-q28  
Ip36.2-p33; 9p21-p l2 ;  9q34; T0q24-q26; I l q l 2 - q l 3 ;  16pl3 .3 -p l  1.1; 17plT-  
p l l . 2 ;  1 7 p l l . l -q 2 1 ;  17q22-q25; 19p l3 .3 -p l  1.1; 19q l3 .2 -q l3 .3 ;  20 q l  1 .2-ql3.1;  
22q 11.1 -q 13; X p 2 2 .1 -p22.3; X p  11.2-q 11 ; Xq26
" l p I 2 - q 2 1 ; 9 q l l - q 2 1 ;  1 6 p l l . l - q l 2 . 2 ; X p 2 I ; X p n T q 2 ~  ~
10pl5-q26; 17q21; Xp22.3-q28
6 q ll.l-q 2 2 ; 9p23-pl2; 10pl4-q25; I6pl3.3
6q ll.l-q 2 2 ;9 p 2 3 -p l2 ; 10pl4-q25; 16pl3.3
111
lp36.3; 2p25-p24; 3p26; 3q28-29; 4pl6; 4q34; 5pl5.3  
7p22-q36 ;
18p ll.3; 18q22-q23; 1 *
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9 q l3 .3 ,2 0 p l3 -p l2 ;2 0 p ll.2 -q ll.2 ;2 0 q l3 .2 ;2 1 q 2 2  ,
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IIOU! ID
c/2
<0<J
CO
O
u
u
>-
OC<
a
S2093*#
GBM/C160*#
GBM/C1510#
GBM/C1706*#
GBM/C1752*#
GBM/C16l2/mda#
GBM/CI724#
GBM/C1724/mda
GBM/S2687/mda
18q23
Mctaphase CXjM data
None
Array CGI I data
f u t f  tiflD
pN one
7pl5;7pl3;7q21;7q22-q32
2q37
{ " ^ 4 ;  Ï6^T 2l^l9pÎ3j::plY
The gain at 18q23, reported by metaphase CGH, 
was unsupported in the array. Instead, the array i
revealed gain of 3 clones on 7p two of which !
contain EGFR sequences. There is slight 
I underrepresentation of the entire CHR 10V  —  * —— —  — - - __  —  j
Essentially normal; the apparent loss reported by j 
metaphase CGH was not substantiated.
13q21;Xp22.1-q28 
I 9ql2
' 3p26^pl4; 3 p l 2 - q n 3 ;  T q 2 ¥ ;” Tpl5T2-plT;
6p25-q26; 7p22-q35; 8p22-q24.3; 21qll.2- 
, q21;Xp22.3-ql2;Xql3-q28 
^Ip22; 4pl57l-pll; 5pl4-pl2; 8pll.2-q24.3; 
9pl2-q33;21qll.l-q22
None
None
2p 25-q l7 ;  4q21-q22; 4q28-q35, 10pl5-q26,  
1 3 q l l -q 3 4 ,  1 4 q l l . l - q l 2 ;  16pl3.3;  1 ^ 1 1 . 2 ;  
19pl3.3;  19pl3.2
"2q35-q37; lTq22-q25; 13q32-q34; 14q24:q3l;  
I6p l3 .3 -q 24
CHR 7 is slightly overrepresented throughout, 
CHR 10 slightly underrepresented throughout, 
while losses reported by metaphase CGH on 9q, 
_ 19p ^e not substantiated. _ _ _ _ _ _ _
Essentially normal
Essentially normal
-J
I Ip31-p l3;  Iq22-q23, 4 p l5 .3 -p l2 ;  8 p l l . 2 -  
q24.3; 9p 13-q 11: 9q 13-q34; 21 q 11 -q22
5 p l 5 .3 ; 7 p 2 2 - q l l . 2 ;  7q21-q36
lllpn.2-5TT; Hq22-q25; 13q21-q22; 13q33- 
q34; 14q21-q24; 16pl3.3-q23 
TOplS-pll.l; 10q21-q24; 15q21-q23; 16pl3.2- 
pl2;Xp22.1-q28
Several clones are prominently deleted between 
85-90 MB, (corresponding to 10q23) and at 115- 
120 MB (corresponding to 10q25-q26). Details 
discussed in Chapter 4
The set clones deleted in CHR 10 of 1612 were 
also deleted in 1724. In CHR 17, a few clones 
were underrepresented around 10MB, 
corresponding to the location o f T P 5 3 . ______
*, Tumours that had <3 CNAs (copy number alterations) in the autosomes (n=5); #, tumours that were further investigated by array CGH (n=7)
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With the exception o f  7 tumours, all 33 gained and/or lost at three separate chromosome regions. Each o f  the 8 tumours showed either gains or 
losses only and generally had fewer CNAs. Three had no gains: AA24 showed three loss-CNAs, G B M /Sll lost in 10 separate regions, while 
GBM/C160 only lost at 2q37. Six remaining tumours had no losses overall; o f these 4 gained in only one region (GBM/S2093; 18q23), 
GBM/S2848; Xp22.3-q28, GBM/C1752; 9q l2 , and GBM/C2394; Xp22.2-q27 while two lost in two regions, GBM/C1706 at 13q21 and Xp22.1- 
q28; and GBM/C2685 at 1 5 q ll.2 -q l2  and X p22.2-ql2 respectively. Bold font, regions that are markedly gained or lost; light green colour 
shading, tumours with 0-3 CNAs in autosomes; Gray-shaded areas, regions o f  (or bordering) heterochromatin. a+ and a- (respectively 
representing gains and losses), show specific alterations revealed by array CGH which were unreported in the metaphase experiments.
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A p p en d ix  2: 
in vestiga ted
Copy number losses: 
MCRO 
1 6 q l l . l  
16p l3 .3 -p l3 .2  
19pl3 .2-p l3 .3  
19pl3.13  
19pl3 .12-p l3 .r  
22q l3 .2 -q l3 .3 2  
2 2q l2 .2 -q l3 .2  
10q25.1-q26.12 
lOplI-21  
1 0 q l l .2 1 -q l l .2 2  
16pl3 .3-p l2 .2  
,J 9 q l3 .2 -q l3 .4 2  
■ i0 p l l .2 3 -p l2 .2  
lGq23.l-q23.33  
19ql3 .11-ql2 .13  
9q34.1-q34.2 
lGq21.1-q21.3 
17pl3 .1-pl3 .3  
19ql2
22q ll .2 1 -q l2 .1
Ip34.1-p35.3
2q35-q37.3
lGpl2.31-pl5.1
14q24.1-q32.32
16ql2 .2-ql3
1 7 p l l .2 -p l2
lp 3 6 .1-36.23
lq l2
13q33.1-q34 
, 1 5 q l l . l - q l 2  
' 16q22.3-q24.2 
I lq l2 .2 -q l3 .1  
17q21.1 
2Gql 2-q 13.2 
9 p l2 -p l3 .2  
13ql3 .3-q l4 .12  _ 
1 7 q l l .2 -q l2  
17q22-q23
Recurrent regions of overlap of CNAs in a panel of 26 tumours
I------
!
[___
I __
.23________ 3 p l2
Frequency % Copy number gains: 
MCRO 
7pl3-14.1  
7pl5 .1 -p l5 .3
7q2 2 _____
7q31
7q21
13q21.l-q21.33  
Ipl3.2-p31.2  
12ql4.3-q21.2  
lp22  
5q23.3 
2p24.3-p25.3 
3p25.3-p26.3 
4q26-q27 
5pl5 .2-pl5 .33  
5ql4-q21.2  
7p22.1-p22.3 
13q21-q22 
13q33.1-q33.33 
2q22-q23 
2q31.2-q31.3
Frequency %
5G
5G
50
19
4pl4-p l5 .1  
5q21.2-q22.2 
6p25.1-p25.2  
6 q l2  
6q22  
8q22-q23  
9p24.2-q24.3  
Hq23.2-q24.3  
15q25.1-q26.2 
1 8 p ll .3 2  
2Gpl3
21q ll .2 -q21 .2
 21q22.13-q22.2
4q22-q24  
4 q l l -q l3 .3  
6 q l5 -q l6 .2  
8p23.3
12pl3.32-pl3.33  
20pl2 .32-p l2 .3  
3ql3 .11-q l3 .12  
9p21.1-p21.3 
9ql3-q33.3  
lp l5 .5  
Iql4 .1-ql4 .3
Appendix 2: A list o f  84 MCRO (minimum common regions o f  overlap) o f  CNAs
observed in at least 3 out o f  26 high-grade astrocytomas investigated in this study.
Cytogenetic Analysis of DNA Copy Number Aberrations in High Malignancy Grade astrocytomas
A ppendix 2
Frequencies are expressed as a percentage. The chromosomal regions in which the most 
frequent losses are found implicate loci o f  probable tumour suppressor genes, D N A  
repair genes, and landscapers that may be involved in the pathogenesis o f  astrocytomas. 
In som e cases m assive deletions span the entire chromosom e arm or the whole 
chrom osom e. Chromosome studies have revealed many deletions, which point to the 
presence o f  tumour suppressor genes or D N A  repair genes at corresponding regions. 
For som e exam ples, see Appendix 3.
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Number of Informative
tumours
Frequently altered chromosome region Genes o f  Interest
Total
N=34 p/q
Chr.l 15 15/8
Gains
Ip l3 .2 -p 31 .2 (lp 22),lq 31
Cases
8(7), 2
Chr.2 I 15 7/11 2q21.1-q33.3 (2q22-q23; 2q31.2-q31.1) 6(5;5)
rhri : n I , /A 3p25.3-p26.3,3pl2,3ql3.1MI3.12, 6,5,5,
; 3q25.31-q25.33,3q29 2 ,1
Chr.4 : 12 8/10 4p l4-p l5 .3 ,4q 22-q 24,4q 26-q 27  5 ,5 ,7
Chr.5 14 8/10 5 p l5 .2 -p l5 .3 3 ,5pl l-p l4 .3 ,5 q l4 -q 2 3 , 6 ,2 ,6 ,
5q21.2-q22.2,5q23.3 5,3
Chr.6 : 10 5/7 6 p 2 5 .1 -p 2 5 .3 ,6 q l2 ,6 q l5 -q l6 .2 ,6 q 2 2 6,5,4,
Chr.7 : 17 11/15 7 p l3 -p l4 ,7 p l5 .1 -p l5 .3 ,7 q 2 1 ,7 q 2 2 ,7 q 3 1
Chr.8 : 10 111
Chr.9 : 22 13/14
Chr.lO 14 12/12
8p23.3,8q22-q23 (8q22) 
9p21.1-p21.3,9p24.2-p24.3  
10pl5.1-pl5.3
4,7(3)
Losses
Ip31.3-p36.3(lp35.1-p35.3), lq l2 .
2p24.3-p25.3(2p25),2q35-q37.2(2q37) 
3pl4-p21,3q26.3  
4pl6.2-p l6 .3 ,4q21.1-q21.3  
5q 15.33,5q35.1 
6 q ll.l-q 2 2  
None 
8pl2-p23
3 ,5  9p21.1-p21.3,9q34.11-q34.2
2  1 0 p l l .2 1 ,1 0 p ll.2 2 .p l 1 .2 3 ,10q21.2-q21.3,10q23.1-
q23.3,10q25.1-q26.1
Chr.l 1 12 7/12 l lp l5 .5 ,  I lq l4 -q l4 .3 , Hq23.2-q24.3 3,3,5 I lp l5 .2 -p l5 .5 , l l p l 2 - q l l ,  I lq l2 .2 -q l3 .1
Loss
8(6), 5 EPHB2, PAX7, BMP8B, MAP3K6, WNT2B
6(6), 6(6) D D X l, NM l, 1GFBP5, PAX3, ERBB4, PM Sl, NEURODl
1 , 1
1 , 1
M SH l, RARB, R O BO l, E1F4, EPH3 TP73
SL1T2, PROM1/CD133, FGFR3, M S X l, NKX3-2, BAPX, NKX6, 
PRGFC, VEGF/KDR, SM A D l, EGF, EMCN
PC4, SEMA5A, GTF2H2, FST, ISL l, CCNH, CDC25C, EFNA5, 
NEUROGl, FGF, PDGFR
VEGF, EPH7, FIG, CCNC, PEX7, C D K 11, HE Y2, ATXN, 
TNFA1P3, M AP3K5,0L1G3, NMBR, BLBP, TCF21
HOXA1, HO XA13, PDGF, EGFR, RAC 1, GBAS, PHKG1, 
HGF/SF, HGFRMET, P13K, FRA7G, N-WASPAVASL, SMO
1 SCA/BHLH.2, N R G l, NKX3-1, CCNE2, E2F5
3  _ CDKN2AandCDKN2B, IFN B l, MTAP, DM RTAl, S C A lA l, 
PTCH, ASTN2, F lB C D l, T SC l, A B L l, DAPKl
9,8,6,8,
10
2,2,4
PTEN/M M ACl/SLlTl, PAX2, MGMT, NKX6-2, V A X l, SUFU
T F llH l, ASCL3, M Y O D l, ESPIO, HRAS, FLJ23311, MAP4K2, 
VEGFB, PAX6, CD44, CCND, C T N N D l, PRG2andSLC43A
Number of Informative
tumours
Frequently altered chromosome region Genes of Interest
Total
N=34
Chr,
arm
p/q
Chr. 12 12 6/8
Gains
12pl3.32-pl3.33, 12pll-pl2,12ql4.3-
q21.2
Chr. 13 18 18
Chr. 14 7 7
Chr. 15 9 9
Chr. 16 19 14/13
Chr. 17 17 10/9
Chr. 18 9 5/6
Chr. 19 15 13/11
13ql3.3-ql4.12,13q21.1-q22.3(13q21.1- 3,9(8), 
q21.3), I3q33.2-q33.3 4
None 
15q26 
None 
17pl3.3 
18pll,3, 18q22.2 
19ql3.31-ql3.33
Cases Losses Loss
4,2,8 ; 12q24.1-q24.3 2
13ql3-ql4,13q33.1-q33.3 3,5
14q24.2-q32.33(14q31 -q32.32) 7(7)
15q ll.l-q ll.l2 ,15q21.2-q22.32 5, 1
MGSTl, NTF3, GAPD, CDKNIB*, EN02, CDK2, CDK4, MDM2, 
SAS, BRAP, MAPKAPK9, GRF2H3, BCL2L14*
N/A
N/A
LATSl, IBPFl, CDK6, RBI, DDX26
TlFl, NKX2-9, MAP4K5, BMP5, V-AKT/AKTl, MLH3*, 
CDC42BPB, PTPNI, SELIL*, SERP1NA2*
CRABPl, NEOl, FES, MESPl
16pl3.2-pl3.3,16pl2.3-pl3.12, 12,9, MRPL28, AXINI, TSC2, MLCK, LOC440374, RABL2, MAP3K7,
16qlL2, 16qll.2-ql2, 16q23.3-q24.1 13,6,5 AR1D3A, FRA16D, CDKIO, MMP2*, FANCA*, STYWOBU*
5,5
17pl2-pl3,17q21.1,17q24.1-q25.1 7,4,6
N/A
o  Chr.20 10 6/6 20pl2.1-pl2.3,20pl3,20qll.3-ql3.2 6,5,2
m
X
^  Chr.21 7 7 21qll.2-q2L2,21q22.13-q22.2 3,6
CD
O,
a .
< Chr.22 12 12 None N/A
None
19pl3.2-pl3.3, 19pl3.2-pl3.3
20ql3.2,20ql2-ql3.11
21q22.12-q22.13
22qll.21-ql2.1,22ql2.3-ql3.32
TP53, E1F4A1, HES7, NEUR0D2, ERBB2, GFAP, BRCAl, 1G135, 
HOXB, CDK3, MAP2K6, SYMl, SYNSl, MRC2*
RAB31,SMAD7, DCC.l
, Q NHLH2, CDKN2D, ELAV2, CCNE, SERTADl, TGFBl, NTF5, 
APC2*, BAX*, ELSPBPl*
4  2  NXIl, SOX12/SOX20, NKX2-2, CDC25andC20orf25, SMOX, E2F, 
CHD5/CHD6, BCAS4, MYBL2, MMP9*
SIOOB, 0L1G2, GRIKI, H2B, WDRandSH3BGR, RUNXl
NF2, HGFL (MGC17330), KREMEN1, L1MK2, CHEK2, BCR, 
BCL2L13*
Legend for appendix 3:
Genes that are listed in table 6.4 participate in various cellular functions, for example 
proliferation, control o f  the cell cycle and apoptosis, while others have been included 
because o f  known crucial roles in neurogenesis. * Genes with M M R (or caretaker) 
functions (genes belonging to one o f  two categories known to protect cells from  
chromosomal instability). Aberrations in these genes com m only predispose cells to 
m alignancy. Table 6.5: summarizes the frequencies o f  occurrence o f  D N A  copy 
number alterations in regions that harbour established mismatch repair (MMR) 
(mutators) in this study.
A ppendix 4
Appendix 4  - Clones altered in G BM /C160
CHR position Clone Fluorescence ratio Matching genes (locus)
(Mb) (Mean)
Test/Ref Control
CHRl 25 CTB-14E10 2.09,2.25 No record
CHR2 89.77 RP11-316G9 0.70,0.75 1.07 None
CHR5 131 CTB-104P14 2.04,2.00 0.99 SLC22A4 (5q23.3)
CHR5 175.8 CTB-87L24 1.30,1.32 0.97 RNF44 (5q35.2); ETEA (5q35.2)
CHR6 32.5 RP1-93N13 1.27,1.24 0.69 None
CHR6 169 RP1-137D17 1.78,1.99 N/A None; clone mapped to 6q27
CHR7 98.5 RP4-550A13 1.27,1.35 0.96 ARPClA(7q22.1)
*CHR8 16.29 RP11-19N21 1.25,1.22 0.97 6 genes, 5 of  them clustered at
CHR19 13.14
CHR19 48.48
CHR19 52.4
CHRll 118.8 CTD-3245B9 1.90,1.93 0.86
CHR12 133.3 CTC-221K18 1.68,1.66 0.61
CHR14 19.74 RP11-2F9 0.54,0.56 1.80
CHR14 105.12 CTC-820M16 1.22,1.23 1.21
CHRl 5 99.4 RAP11-299G20 1.31,1.24 0.87
CHRl6 69.95 RP11-296110 0.65,0.67 1.06
CHR19 9.10 CTC-2547N9 1.44,1.46 N/A
CHRl 9 9.10 CTC-444D3 1.62,1.63 1.04
CTC-250114
CTC-490G23
CTC-483111
1.65,1.52
1.88,1.97
2.07,2.17
0.87
1.11
0.88
11.55 (CDKNIC, KCNQl, 
SLC22A18, SLC22A1LS, 
PHLDA2), and the other at 11.54 
(KCNQl DN)
N/a; some STS mapped to CHR-X 
N/a; clone not in NCBI registry 
N/a
No record 
No record
4 genes, 3 clustered at 16q22.1 
(EXOSC6, MGC34761, PDPR), 
and one at 16q22 (AARS)
No record
6 genes, 6 clustered at 19pl3.2 
(OR7D4, 0R7G 1,0R1M 1,  
OR7D2, OR7G2, OR7G3), and 
oneat 19pl3 (ZNF317)
4 genes, 3 of  them clustered at 
19pl3.13 (BTBD14B, STXIO, 
IER2), and one: CACNAIA and 
19pl3.2-pl3.1.
5 genes, 4 all mapped to 19ql3.2 
(PSG4, PSG5, PSG9, PRVl), and 
one: MGC4766 at 19q 13.31.
3 genes, 2 are mapped to 19q 13.32 
(SAEl, CCDC9), and one (BBC3) 
is at 19ql3.3-ql3.4
XI
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Appendix 4  - Clones altered in G BM /C1510
CHR position Clone Fluorescence ratio Matching genes (locus)
(Mb) (Mean)
Test/Ref Control
CHR5_ 14.54 RP1-29-29012 0.59,0.59 1.36 None
CHR6_32.58 RP1-93N13 0.71,0.68 0.70 None
CHR7_38.01 RP11-121A8 1.30 1.01 S T A R D 3N L (7p l4-p l3 )
CHR7_86.75 CTB-1137N13 1.28 1.01 Clone not found in NCBI Clone 
Registry
CH R7_123.39 RP5-902E20 1.30 1.04 None
CHR7_ 136.51 RP11-8P6 1.30 n/a Mapped to CHR 18, & X; No 
genes
CHR9_65.21 RP11-265B8 *0.48 0.97 3 genes found: FXN at 9q l3 -
(1/2) (0.96) q 2 1.1, others (PRKACG & 
P1P5K1B) are both at 9q 13
CHRl 1_118.80 CTD-3245B9 1.33,1.35 0.86 N/a; some STS mapped to CHR-X
C H R 12_133.30 CTC-221K18 1.25,1.25 0.61 N/a; clone not in NCBI registry
CHRl 5_ 19.74 RP11-2F9 0.52,0.52 1.80 N/a
CHR16_69.95 RPl 1-296110 0.71,0.70 1.01 4  genes, 3 clustered at 16q22.1 
(FXOSC6, MGC34761, PDPR), 
and one at 16q22 (AARS)
CHR17_43.73 RP5-1169K15 0.65,0.66 1.06 M A P3K 14(17q21)
CHR19_8.58 CTD-2547N9 1.27,1.34 0.84 N/a
Xll
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Appendix 4  - C lones altered in G BM /C 1706  
CHR position Clone
(Mb)
CHRl 0.25 
CHR1J72.12  
CHR2 89.77
CTB-14E10
RP5-1045J21
RP11-316G9
1.65
1.48
0.71
CHR2 190.07 CTC-444N24 1.30
CHR5 69.35 RP11-497H16 0.72
CHR5_110.12 
CHR5 127.68
CTC-534K6
CTC-352M6
1.43
1.37
CH R5131.68  
CHR6 32.58 
CHRl 1 118 .80  
CHRl2 37.92
CTB-104P14
RP1-93N13
CTD-3245B9
RP11-462G12
1.51 
0.79
1.51 
1.22
CHR12 133.30 
CHRl 5 1 9 .7 4  
CHR16 69.95
CTC-221K18 
RP11-2F9 
RPl 1-296110
1.45
0.72
0.71
CHR17_43.73 RP11-374N3 0.71
CHR19_5.06 
CHR19 8.58 
CHRl9 9.10
CTC-482H14
CTD-2547N9
CTC-444D3
1.49
1.52
1.52
CHR19_13.14 CTC-250114 1.44
CHR19_33.30 CTD-2043116 1.24
CHRl9 44.45 CTC-246B18 1.35
CHRl9 48.48 CTC-490G23 1.38
CHR19 52.40 CTC-483111 1.48
Fluorescence ratio 
(Mean)
Test/Ref Control 
0.48 
0.92 
1.19
0.66
1.20
0.91
1.05
0.89
1.20
0.80
1.01
0.66
1.03
1.12
0.82
0.83
0.54
1.05
0.76
0.82
0.95
0.96
0.84
Matching genes (locus)
None
N/A; mapped to Iq23.3-lq24.3 
N/a; mapped to multiple CHRs: 2, 
4, 12 and X
5 genes, 3 mapped to 19ql3.4 
(ZNF272, ZNF304, ZNF264) and
2 to 19ql3.43 (ZNF543, AURKC). 
N/a; multiple mappings; 6p25, 
5ql2, 5p
N/a; mapped to 5ql3-5q 14 
FBN2 (5q23-q31); at least one 
STS of the primary CHR 5 Contig. 
was mapped to CHR-X 
SLC22A4 (5q23.3)
N/a
N/a; some STS mapped to CHR-X
ADCY9(16pl3.3);anSTS
mapped to CHR 3
N/a; clone not in NCBI registry
N/a
4 genes, 3 clustered at 16q22.1 
(EXOSC6, MGC34761, PDPR), 
and one at 16q22 (AARS)
N/a; multiple mappings, also on 
C H R ll
JMJD2B(19pl3.3)
N/a
6 genes, 6 clustered at 19pl3.2 
(0R 7D 4,0R 7G 1,0R 1M 1,  
OR7D2, OR7G2, OR7G3), and 
oneat 19pl3 (ZNF317)
4 genes, 3 o f  them clustered at 
19pl3.13 (BTBD14B, STXIO, 
IER2), and one: CACNAIA and 
19pl3.2-pl3.1.
N/a; multiple ePCR mapping, also 
on CHR 14
6 genes, 3 mapped to 19ql3.13 
(IL28A, 1L28B, 1L29) and 3 at 
19ql3.2 (FLJ10211,LRFN1, 
GMFG)
5 genes, 4 all mapped to 19ql3.2 
(PSG4, PSG5, PSG9, PRVl), and 
one: MGC4766 at 19q 13.31.
3 genes, 2 are mapped to 19q 13.32 
(SAEl, CCDC9), and one (BBC3) 
is at 19ql3.3-ql3.4
Xlll
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Appendix 4  - Clones altered in G BM /C1752  
CHR position Clone Fluorescence ratio
(Mb)
CHR2 89.71 RP11-316G9
(Mean)
Test/Ref
0.71
Control
1.19
CHR2 180.28 RP11-391P1 1J3 1.00
CHR2 190.07 CTC-444N24 1.26 0.66
CHR2 205.07 RP11-507C18 1.25 0.83
CHR4 133.92 RP11-149A7 1.39 0.65
CHR5 10.40 CTD-2274H20 1.30 0.60
CHR5 55.38 RP11-412L4 0.78 0.93
CHR5 69.35 RP11-497H16 0.78 1.20
CHR5_127.68 CTC-352M6 1.29 1.05
C H R 5 1 3 1 .6 8 CTB-104P14 1.34 0.89
CHR6 20.14 RPl 1-86017 1.33 0.83
CHR7 103.76 RP11-148A10 1.25 0.87
CHR 10 45.52 RPl 1-432113 1.25 0.99
CHRIO 64.09 RP11-13A2 1.39 0.86
CHRIO 126.73 RP13-238F13 1.28 0.91
CHRl 1 1 1 8 .8 0 CTD-3245B9 1.49 0.80
C H R ll 123.88 RP11-485A5 1.48 1.01
CHR12_52.53 RP11-96P3 1.78 0.78
CHR12 95.62 RP11-74K11 0.80 1.12
CHR12 133.30 CTC-221K18 1.53 0.66
CHR15_46.71 RPl 1-485010 1.45 0.76
C H R l6 49.48 RP11-305A7 0.77 0.99
CHRl 6 69.95 RPl 1-296110 0.72 1.09
CHR17 69.53 RP11-144K9 1.25 0.74
CHR18 41.77 RP11-486C18 1.32 0.81
CHR19 8.58 CTD-2547N9 1.50 0.54
CHR19_9.10 CTC-444D3 1.33 1.05
CHR19_13.14 CTC-250114 1.29 0.76
C H R l9 40.95 RP11-38C1 1.24 0.60
CHR19 54.60 RPl 1-521120 1.36 0.85
CHR22 45.36 CTA-29F11 1.25 0.91
CHR-X 0.54 CTB-98C4 1.23 0.63
Matching genes (locus)
N/a; multiple mapping, also on
CHRs 4, 12, and X
N/a
5 genes, 3 mapped to 19ql3.4  
(ZNF272, ZNF304, ZNF264) and
2 to 19ql3.43 (ZNF543, AURKC). 
N/a
N/a; mapped by FISH to 
“4q28.3b” and 4q27 
N/a; mapped to 5 p l5 -5 p l4  
N/a; mapped to CHR 5 & 1 2  
N/A; multiple mapping, to 6p25, 
5 q l2 , 5p
FBN2 (5q23-q31 ); at least one 
STS o f  the primary CHR 5 Contig. 
was mapped to CHR-X  
SLC22A4 (5q23.3)
N/a
N/a
0R 13A 1 (lO ql 1.21); also mapped 
on CHR 12 
ZNF365 (10q21.2)
3 genes: 2 (C10orfl21 & LHPP) 
mapped to 10q26.13, and OAT is 
at 10q26
N/a; some STS mapped to CHR-X
N/a
N/a
PLXNCl (12q23.3)
N/a; clone not in NCBI registry
3 genes: Cep 152 (15q21.1) while 
CRH & RaLP are mapped to 
15q21.1-q21.2
N/a; mapped to 16ql2.1
4 genes, 3 clustered at 16q22.1 
(EXOSC6, M GC34761, PDPR), 
and one at 16q22 (AARS)
N/a
N/a
N/a
6 genes, 6 clustered at 19pl3.2  
(O R 7 D 4 ,O R 7 G l,O R lM l, 
OR7D2, OR7G2, OR7G3), and 
one at 19p 13 (ZNF317)
4 genes, 3 o f  them clustered at 
19pl3.13 (BTBD14B, STXIO, 
1ER2), and one: CA CNAIA and 
19p l3 .2-p l3 .1 .
N/a
N/a; also mapped to CHR 6 
2 genes: C22orf4 (22q l3 .3) and 
CERK 
(22q 13.31).
N o record
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CHR-X 2.22 RP11-457M 7 0.80 0.94
CHR-X 10.66 RP1-27C22 1.89 0.74
CHR-X J 4 9 .1 9 GS1-225F9 0.80 N/a
N/a; multiple mapping to X, Y and 
CHR 5
2 genes; AMELX (Xp22.31-p22.1) 
and ARHGAP6 (Xp22.3)
No record
XV
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Appendix 4  - C lones altered in G BM /S2093  
CHR position Clone
(Mb)
Fluorescence ratio 
(Mean) 
Test/Ref
CHRl 0.25 CTB-14E10 1.51
CHRl 9.80 RP4-575L21 0.73
CHRl 28.40 RP4-669K10 0.74
CHRl 69.54 RP5-944F13 1.29
C H R l l  12.68 RP11-31F15 0.72
CHRl 221.18 RPl 1-100E13 0.76
CHR4 162.05 RP11-502F14 1.38
CHR5 14.54 RPl-29012 0.64
CHR5 69.35 RP11-497H16 0.65
CHR5 110.12 CTC-534K6 1.42
CHR5 131.68 CTB-104P14 1.44
CHR6 32.58 RP1-93N13 1.28
CHR6_ 155.24 RP1-66H9 0.75
CHR6 169.36 RP1-137D17 1.55
CHR7 54.43 RP11-449G3 3 J *
CHR7 54.85 RP5-1091E12 5.02
CHR7 55.01 RP11-339F13 3.99
CHR8_132.15 RP11-4C17 0.77
CHR9_6.65 RP11-106A1 0.68
CHR9 23.46 RP11-495L19 0.68
CHR9 27.50 RP11-27J8 0.64
CHRIO 12.01 RP11-401F24 0.64
CHRIO 
CHRl o’
29.17
"45.98
RP11-478H13
RP11-534N5
0.67
0.67
CHRIO 
CHRl o ’
74.10 
j o  1.92
RP11-326F3
RP11-724N1
0.67
0.68
CHRIO 133.73 RP11-45A17 0.71
CHRll
C H R lf
C H R ll’
CHR12]
14.09 
118.80 
133.06 
j  13.06
RP11-502G22
CTD-3245B9
RP11-545G18
RP11-495K9
0.76
1.44
0.77
0.76
CHR12 
CHRl 3’ 
CHR 14
113.30
103.35
21.45
CTC-221K18
RP11-502J9
RP11-98N22
1.27
0.79
0.73
CHR14 22^5 RPl 1-29813 0.71
Control
0.48
1.07
0.97
0.78
0.99
1.04 
0.68 
0.99 
1.20
0.91
0.89
1.20
1.20
0.75
0.81
1.00
1.05
0.82
1.21
0.92
1.17
1.22
0.95
1.12
1.05
1.01
1.08
0.87
0.84
N/a
0.87
0.66
0.78
0.75
1.18
Matching genes (locus)
No record
UBE4B (lp36.3); also maps to 
CHR 12
5 genes, 4 o f  which map to lp35.3 
(MGC45806, SECP43, TAP 12, 
LOC85028) and one (CHCl) maps 
to lp36.1
N/a; clone maps to Ip31.2-lp32.1 
N/a; clone maps to Ipl3.1-lpl3.3,  
and also to CHR 12 
FLJ38993 (lq42.12)
N/a
N/a
N/a; multiple mappings: 6p25, 
5ql2, 5p
N/a; mapped to 5ql3-5ql4  
SLC22A4 (5q23.3)
None
N/a; also maps to CHR 2 
N/a; clone mapped to 6q27 
N/a
EGFR (7pl2)
EGFR (7pl2); FISH maps clone to
7pll .2 -p l2
N/a
GLDC (9p22); also maps to CHR 
12
*ePCR maps this clone to CHR-X 
3 genes, all mapped to 9p21.2 
(C9orf72, IFNK, MOBKL2B)
3 genes 2 (C10orf47 & ECHDC3) 
mapped to 10pl4, and UPF2 
mapped to 10pl4-pl3  
N/a
KIAA0592 (lOql 1.1); sequence
also maps to CHR 12
N/a
CNN M2 (10q24.33); sequence also 
mapped to CHR 19 
BN1P3 (10q26.3); clone also maps 
to CHR-X 
SPONl ( l lp l5 .2 )
N/a; some STS mapped to CHR-X 
N/a
SFRS8 (12q24.33); also maps to 
CHRs 13, 5, and 12 
N/a; clone not in NCBI registry 
N/a
2 genes both mapped to 14ql 1.2 
(OR4K17, OR4N5)
8 genes: one (SKBl) mapped to 
14ql 1.2-q21, and 7 all clustered 
atl4q 11.2 (ACIN1, Cl4orf94, 
RBM23, PSMB5, C14orf93,
XVI
Cytogenetic Analysis o f DNA Copy Number Aberrations in High Malignancy Grade Astrocytomas
A ppendix 4
CHR14 32.89 RP11-500A9 0.76 0.97
CHRl 5 19.74 RP11-2F9 0.55 1.03
CHR15 20.57 RPl 1-13024 0.76 1.45
CHR15_38.64 RP11-532F12 0.74 0.81
CHR15_82.77 RPl 1-565012 0.77 1.03
CHR16_0.21 CTB-12114 0.75 0.84
CHR16 11.99 R P11-31011 0.68 0.93
CHR16 16.10 CTD-2504F3 0.73 1.15
CHR16 22.61 RP11-105B19 0.73 1.03
CHR16_29.73 RP11-74E23 0.76 1.04
CHR16_69.95 RPl 1-296110 0.57 1.39
C H R 1 7 7 .5 2 RP11-199F11 0.75 1.12
C H R l7 29.20 RP11-229K15 0.78 1.12
CHRl 7 39.93 RP11-156E6 0.78 1.15
CHR17 43.73 RP11-334N3 0.69
C H R l7 80.04 RP11-525L23 0.75
CHR17 81.23 RPl 1-567016 0.72
CHR19 5.06 CTC-482H14 1.47
CHR19 13.72 RP11-285H8 0.73
CHR19 38.17 RP11-298M 15 0.69
CHR19_52.40 CTC-4831H 1.41
CHR19_52.98 CTD-2571L23 0.71
CHRl 9 54.05 CTD-2639E6 0.72
CHR20 30.95
CHR20 45.13
RP5-857M 17
R P3-337018
0.78
0.75
N/a
0.93
0.77
0.83
0.91
1.09
0.84
0.72
0.91
1.13
1.22
CDH24, JUB)
* This clone is mapped to CHR 12 
in the NCBI clone registry 
N/a 
N/a
7 genes: GCHFR mapped to 15ql5, 
while all six others are at 15ql5.1  
(PPP1R14D, FLJ10579, FLJ10634, 
RAD51, SPINTI, ZFYVE19) 
SPC 18(15q25.3)
N o record found in the NCBI cone
registry
N/a
ABCCl (16p l3 .1 )
N/a; also mapped to CHR 5 
N/a; mapped to 16pl 1.2 
4 genes, 3 clustered at 16q22.1 
(EXOSC6, M GC34761, PDPR), 
and one at 16q22 (AARS)
4 genes including TP53, FLJ10385, 
FLJ46675, which are all mapped to 
17pl3.1, and one - EFNB3 -  which 
maps to 17p l3 .1-p l 1.2
N/a
6 genes o f  which only ACLY maps 
to 17ql2-q21, while 5 others are all 
clustered at 17q21.2 (SC65, 
M G C20781, K L H L l0, KLHLl 1, 
FKBPIO, DK FZP434H 0115)
N/a
N/a
TBCD (17q25.3)
JM JD 2B (19pl3.3)
N/a; clone also maps to CHR 5 
N/a
3 genes, 2 are mapped to 19q 13.32 
(SA E l, CCDC9), and one (BBC3) 
is at 19q l3 .3 -q l3 .4
5 genes, FLJ40321 mapped at 
19q 13.32, the others at 19ql3.3  
(CRX, GLTSCR2, EHD2, SEPW l) 
10 genes o f  which 2 are mapped to 
19q l3 .3 -q l3 .4  (BAX, 19ql3.3- 
q l3 .4 ), 2 others are mapped to 
19ql3.3 (DHDH, G Y S l), another 2 
mapped to 19q 13.33 (DHRSIO, 
PLEKHA4). 4 remaining genes are 
mapped variously, PPP1R15A at 
19q l3 .2 ,N U C B l at 
19q l3 .2 -q l3 .4 , BCAT2 at 19ql3, 
andTULP2 atl9q  13.1
3 genes, ID l mapped to 20q l 1, 
while BCL2L1 & COX4I2 are both 
a t2 0 q ll.2 1
8 genes, one (PPGB) mapped to 
20q l3 .1; 2 mapped to 20q l2-q l3 .1  
(PT El, PLTP) and all remaining 
five mapped to 20q l3 .12  
(C 20orfl65, NEURL2, ZSWIM3,
X V ll
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C20orfl61,ZSW IM l).
CHR22 38.36 CTA-229A8 0.78 0.95 2 genes: GPR24 (22qI3.2) and
MKLl
22ql3
CHR22 39.70 RP11-422A16 0.78 1.08 EP300 (22ql3.2)
CHR22 40.60 CTA-250D10 0.77 0.99 7 genes: NAGA at 2 2 q ll, SREBF2
at 22qI3, TNFRSF13C at 22ql3.1- 
ql3.31, and 4 at 22ql3.2  
(LOCI 50368, MGC26816, SEPT3, 
C22orfl8)
CHR-X 43.55 RP1 1-386N14 0.79 1.13 2 genes: DUSP21 at Xpl 1.4-pl 1.23
and UTX at Xpl 1.2
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Appendix 4 -  Sample clones altered in CHRl of GBMs 1612 and 1724
Fluorescence ratio 
(Mean)
CHR position Clone Fluorescence Ratios
(Mb) (Test/Ref)
1612 1724 CTRL
CHRl 66.89 RP11-412F21 1.07 1.22 1.09
CHR1J42.71 RP11-326G21 1.24 1.40 1.06
CHR1_225.32 RP4-799G3 1.28 1.03 0.92
CHRl 232.19 RPl 1-50911 1.24 1.19 0.96
CHRl 44.17 RPl 1-184116 1.04 1.25 0.98
CHRl 217.78 RP11-528D17 0.72 1.00 0.92
CHRl 221.18 RP11-1000E13 0.65 0.93 0.94
Matching genes (locus)
N/a: work abandoned 
PD E4D IP(lql2)
N/a; mapped to lq42.11- 
lq42.3
2 genes: CHSl (lq42.1- 
q42.2) & GNG4 
(lq42.3)
2 genes: SIAT6 () & 
JMJD2A(lp34.2-p34.1). 
STS(s) from this clone also 
map to CHR 7 
N/a
No record o f this clone in 
NCBI clone registry
Appendix 4 -  CHR2
CHR position 
(Mb)
CHR2 89.12
Clone
RPl 1-294120
Fluorescence ratio 
(Mean)
Fluorescence Ratios 
(Test/Ref)
1612 1724 CTRL
0.61 0.77 1.15
CHR2 89.77 RP11-316G9 0.50 0.73 1.12
CHR2 131.89 RP11-209H16 0.63 0.76 0.99
CHR2 206.40 RP11-325M10 0.63 0.79 0.99
CHR2 241.01 RP11-299H21 1.82 0.84 1.05
CHR2 22.62 RPl 1-368018 0.68 0.74 1.01
CHR2 130.68 RP11-32C20 0.66 0.77 1.11
Matching genes (locus)
N/a: clone is mapped to 
CHR 19 on the NCBI clone 
registry
N/a; STSs from this clone 
also map to CHRs 4, 12 & X 
2 genes: ARHGEF4 (2q22) 
& PLEKHB2 
(2q21.1)
ALS2CR19 (2q33.3)
2 genes, both mapped to 
2 q ll.2  (RNF149, C2orf29) 
N/a
N/a; The clone is mapped to 
q214.3. a STS from this 
clone also maps to CHR 7
XIX
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Appendix 4 -  CHR3
CHR position 
(Mb)
CHR3 52.52
CHR3_65.15 
CHR3_86.93 
CHR3_144.73 
CHR3_153.04 
CHR3_170.37 
CHR3_194.55 
CHR3 195.53
Clone
RP11-447A21
Fluorescence ratio 
(Mean)
Fluorescence Ratios 
(Test/Ref)
1612 1724 CTRL
0.74 0.94 1.07
RP11-88H12 1.34 1.00 0.97
RP11-81P15 1.34 1.03 0.96
RP11-165M11 1.35 1.02 0,95
RPl 1-64013 0.78 1.08 0.94
RP11-141C22 1.46 1.04 1.00
RP11-552A14 0.73 0.90 1.04
RP11-279P10 1.35 1.04 1.04
Matching genes (locus)
5 genes of which FBI is 
mapped to 3p21 and the 
other four (NS, SPC 12, AD- 
017, NEK4) are all clustered 
at3p21.1
BAIAPl (3pl4.1)
FLJ38507 (3pl2.1)
SLC9A9 (3q24)
N/a
N/a; clone mapped to 3q26.1 
N/a
3 genes all mapped to 3q29 
(LRRC15,GP5, AFURSl); 
some STSs map to multiple 
chromosomes, i.e. CHRl 2 
and 14.
Appendix 4 -  CHR4
CHR position 
(Mb)
Clone
Fluorescence ratio 
(Mean) 
Fluorescence Ratios 
(Test/Ref)
Matching genes (locus)
1612 1724 CTRL
CHR4 1.16 RP11-296G16 0.66 0.72 0.98 N/a
CHR4 8.11 RP11-338K13 0.67 0.81 0.96 3 genes: LOC389199 
(4pl6.1), AFAP (4pl6), 
ABLIM2 (4pl6-pl5).
CHR4 13.65 RP11-341G5 1.34 1.68 0.98 N/a
CHR4~ 20.51 RP11-362J17 1.35 1.61 0.95 KCNIP4(4p 15.31)
CHR4’ 57.71 RP1 1-355L4 0.69 0.78 0.95 N/a; mapped to 4ql2; one 
STS additionally maps to 
CHR 12
CHR4 62.67 RPl 1-2417 1.26 0.89 0.97 LPHN3 (4ql3.1)
CHR4”jlO .13 RP11-75N20 0.64 0.78 1.04 2 genes both o f which map 
to 4q25 (AGXT2L1, 
COL25A1)
CHR4 117.87 RP11-55L3 0.65 0.75 0.94 N/a
CHR4 190.10 RP11-347K3 0.63 0.69 0.96 N/a
XX
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Appendix 4 -  CHR5
Fluorescence ratio 
(Mean)
CHR position Clone Fluorescence Ratios Matching genes (locus)
(Mb)
1612
(Test/Ref)
1724 CTRL
CHR5 14.54 RPl-29012 0.58 0.63 1.36 N/a
CHR5 17.69 RP11-556F3 0.69 0.83 1.03 ; N/a
CHR5 73.82 RPl 1-97L2 1.00 1.31 1.01 N/a; mapped to 5ql2-5ql3  
(FISH)
CHR5 79.26 RP11-30D15 1.35 1.04 0.95 N/a
CHR5_84.95 CTC-480C2 1.22 0.97 0.95 N/a; mapped to 5ql2-5q 13 
(FLpter)
CHR5_104.21 RP11-275K4 0.78 0.82 0.93 N/a
CHR5 110.16 RP3-502L6 *1.54 1.30 0.95 CTNND2 (5pl5.2)
CHR5_145.25 CTC-370H24 0.76 1.09 0.98 2 genes both mapped at 5q32 
(MGC21644,SH3RF2)
CHR5_178.48 RP11-281015 1.44 1.03 1.05 4 genes to of which (GRM6, 
ZNF354C) are mapped at 
5q32, while two others 
(ZNF454,FLJ21628) are 
mapped at 5q32.3
Appendix 4 -  CHR6
CHR position 
(Mb)
CHR6 32.58 
CHR6 79.51
CHR6_96.94 
CHR6 155.95
Clone
RP1-93N13
RP11-173D14
**RP11-4D24
RP11-100E6
Fluorescence ratio 
(Mean) 
Fluorescence Ratios 
(Test/Ref)
1612
1.70
0.66
1724
1.35
1.18
CTRL
0.70
1.10
0.69 1.07 0.97
0.90 0.75 1.11
Matching genes (locus)
N/a
2 genes: IRAKIBPl (6ql4- 
ql5), PHIP
(6ql4); some STSs also map 
to X-CHR.
All STSs map to CHR 4 
NOT 6!
STEF/TIAM2 (T cell 
invasion & metastasis 2); 
Clone could affect RAC 
pathway
XXI
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Appendix 4 -  CHR7
CHR position 
(Mb)
Clone
Fluorescence ratio 
(Mean) 
Fluorescence Ratios 
(Test/Ref)
Matching genes (locus)
1612 1724 CTRL
CHR7 38.01 RP11-121A8 1.41 1.11 1.01 STARD3NL(7pl4-pl)
CHR7~ 66.89 RP11-358M3 1.25 0.87 1.09 N/a
CHR7]'80.75 RPl 1-28121 1.37 1.04 1.05 N/a; some o f the STSs map 
to CHR 1
CHR7 83.31 RP11-313H6 1.33 0.78 1.07 N/a
CHR7 '90.22 RP5-1084H12 1.29 0.93 0.98 N/a
CHR7 113.81 RP11-126C19 1.39 1.02 1.15 : N/a
CHR7’ 118.47 RP11-105B19 1.31 1.31 1.10 N/a
CHR7] 125.91 **RP11-21K15 1.41 1.10 1.01 N/a; Problem clone -  all 
STSs map to CHR5 & one 
additionally maps to X- 
CHR
CHR7 140.71 RP11-5894A10 0.97 0.86 0.96 3 genes: FLJl0842,
FLJ40852 & SSBPl 
(single-stranded DNA- 
binding protein 1), all 
mapped to (7q34)
Appendix 4 -  CHRIO
Fluorescence ratio 
(Mean)
CHR position Clone Fluorescence Ratios Matching genes (locus)
(Mb)
1612
(Test/Ref)
1724 CTRL
CHR10_49.26 RP11-13E1 0.58 0.84 1.03 FRMPD2(10q 11.22)
CHR10_74.10 RP11-326F3 0.67 1.12 0.99 N/a
CHR10_85.79 RP11-219F10 0.54 0.78 1.04 N/a
CHR10 89.83 RP11-380G5 0.02 0.32 1.01 PTEN(10q23.3)
CHR10 89.75 RP11-165M8 O il 0.32 0.93 2 clones both mapped to 
10q23.31 (CFLPl, ATADl)
CHRIO 90.66 RPl 1-30415 0.33 0.54 1.06 2 genes both mapped to 
10q23.31 (ANKRD22, 
L1PL3)
CHRIO 117.10 RP11-338L11 0.09 0.33 1.00 ATRNLl (10q26)
X X l l
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Appendix 4 -  CHRl 1
CHR position Clone
Appendix 4 -  CHR 12
CHR position 
(Mb)
CHR12 72.12 
CHRl2 78.00 
CHRl 2 111.95
Clone
RP11-181D11
RP11-202G24
RP11-162P23
Fluorescence ratio 
(Mean) 
Fluorescence Ratios
(Mb) (Test/Ref)
1612 1724 CTRL
CHRll 22.56 RP11-34N19 1.39 1.01 0.95
CHRll 30.73 RPl 1-30208 0.92 0.74 1.04
CHRll _46.37 RP11-164L18 0.69 0.90 0.84
CHRll 61.45 RP11-286N22 0.87 0.78 0.91
CHRll 83.65 RP11-118L6 1.05 0.79 1.01
CHRll 126.44 RPll-432122 0.98 0.72 0.97
CHRll 128.53 RP11-264E20 0.94 0.59 1.04
CHRll 131.54 PAC1064E20 0.94 0.69 1.01
Fluorescence ratio 
(Mean) 
Fluorescence Ratios 
(Test/Ref)
Matching genes (locus)
N/a
N/a
N/a; one STS additionally 
maps to CHR 12 
9 genes: DDBl (1 lq l2 -  
ql3), SYT7 
(I lq l2 -q l3 .1 ), 
M G C :13379(llql3.1), 
and all remaining six are 
mapped to 11 q 12 
(MGC20446,FLJ32771, 
DKFZP586B1621, 
HSPC196, FLJ20487, 
FLJl2529)
N/a
N/a
N/a
No record at the NCBI 
clone registry
Matching genes (locus)
1612 1724 CTRL
1.30 0.87 0.92 N/a
1.05 0.72 1.02 N/a
0.75 1.03 1.10 3 genes: ALDH2 
(12q24.2), ACAD 10 
(12q24.12),BRAP(12q24)
Appendix 4 -  CHR 13
CHR position 
(Mb)
Clone
Fluorescence ratio 
(Mean) 
Fluorescence Ratios 
(Test/Ref)
Matching genes (locus)
1612 1724 CTRL
CHR13 26.01 RP11-570F6 0.66 0.77 0.92 WASF3 (13ql2)
CHR13_56.65 RP11-279F15 0.91 1.22 0.78 FLJ40296(13q21.1)
CHRl 3 69.26 RPl 1-43615 0.70 0.76 1.11 KLHLl (13q21)
CHR13 113.86 RP11-245B11 0.64 0.87 0.85 RASA3 (13q34)
CHR13 106.65 RP11-232K11 1.3 0.87 N/a
X X I11
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Appendix 4 -  CHR14
CHR position 
(Mb)
CHR14 22.55
Clone
RP11-468E2
Fluorescence ratio 
(Mean) 
Fluorescence Ratios 
(Test/Ref)
1612
0.65
1724
0.86
CTRL
0.96
CHR14 36.33 RP11-138H18 0.70 0.81 1.10
CHR14 50.38 RP11-463J10 0.62 0.80 1.04
CHR14 67.41 RP11-204K16 0.71 0.91 0.99
CHR14 87.82 RP11-79J20 0.67 0.79 0.96
CHR14 96.07 RP11-76E12 0.65 0.77 0.98
CHR14 99.29 **RP11-94D19 1.80 1.29 1.02
Matching genes (locus)
16 genes: NRL (14ql l . l -  
q ll.2 ) , REC8L1 
(14ql 1.2-ql2), and all 14 
other are clustered at 
14qll.2  (ISGF3G,TM9SF1, 
LOC161247, C14orf20, 
C14orfl23,C14orfl22, 
PCK2, RNF31, PSMEl, 
PSME2, IP04, WDR23, 
LOC90668, CPNE6) 
TTC6(14q21.1) 
NlD2(14q21-q22), 
C14orfl66(14q22.1), GNG2 
(14q21)
RAD51L1 (14q23-q24.2) 
N/a; mapped to 14q32.1 
N/a
N/a; Problem clone-  
mapped to 3pl4, and several 
clones additionally map to 
CHR-X
Appendix 4 -  CHR 16
Fluorescence ratio 
(Mean)
CHR position Clone Fluorescence Ratios
(Mb) (Test/Ref)
1612 1724 CTR
CHRl 6 1 1 .9 9 RPl 1-31011 0.89 0.75 0.97
CHR16_22.61 RP11-105B19 0.89 0.70
CHR16_47.71 RP11-523L20 0.71 0.81 0.95
CHRl6 49.48 RP11-452G23 0.99 0.82 1.01
CHR16 53.70 RP11-357N13 0.90 0.70 1.03
CHR16 68.22 RP11-76H6 0.92 0.69 0.93
CHRl 6 69.95 RPl 1-296110 0.68 0.65 1.01
Matching genes (locus)
N/a
N/a; one STS additionally
maps at CHR5
N/a
N/a; mapped to 16q 12.1. 
Some STSs additionally map 
to CHR-X 
FTO(16ql2.2)
N/a
4 clones: AARS (16q22) and 
three clustered at 16q22.1 
(EX0SC6, MGC34761, 
PDPR)
X XIV
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Appendix 4 - CHR17
CHR position 
(Mb)
*CHR17 7.518
CHR17 7.52
CH R177.65  
CHR17 8.49
CHRl 7 9 .5 4  
CHR17 10.15
Clone
RPl 1-31011
RP11-404G1
RP11-12H18
RP11-208F13 
RPl 1-40109
Fluorescence ratio 
(Mean) 
Fluorescence Ratios 
(Test/Ref)
17241612
0.42
0.39
0.39
0.52
0.39
0.44
0.58
0.49
0.55
0.65
0.61
0.60
CTRL
0.85
0.96
0.97
0.98
0.93
1.05
Matching genes (locus)
Location o f TP53 in relation 
to clones found in this array 
slide (plate)
N/a; Problem clone -  all 
STSs mapped to CHR 5 and 
none to this chromosome 
FLJ46675 (17pl3.1)
2 genes: FLJ32734 
(17pl3.1)and MYHIO 
(17pl3)
N/a
2 genes: MYH8 (17pl3.1)
and MYH13
(17pl3)
M A P2K 4(17pll.2)CHRl 7 12.02 RPl 1-471L13
*The shaded row shows the CHR position of TP53 in relation to clones that are present 
in this array slide.
Appendix 4 -  CHRl8
CHR position 
(Mb)
Clone
Fluorescence ratio 
(Mean) 
Fluorescence Ratios 
(Test/Ref)
Matching genes (locus)
1612 1724 CTRL
CHRl 8 6.84 RP11-109E24 1.29 1.30 1.00 ATP8A1 (4pl4-pl2), 
problem clone -  mapped 
entirely to CHR 4
CHRl 8 30.51 RP11-19F9 0.72 1.01 1.01 ; N/a
CHRl 8][35.34 RP11-108G3 0.72 1.01 0.79 N/a; Problem clone -  
mapped to CHR 11 and -X
CHRl 8 54.39 RP11-383D22 1.29 1.04 0.97 WDR7(18q21.1-q22)
CHRl 8'[75.59 **RP11-16L7 0.93 1.03 1.02 N/a; Problem clone all STSs 
mapped to CHR7
XXV
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Appendix 4 -  CHR 19
Fluorescence ratio 
(Mean)
CHR position Clone Fluorescence Ratios
(Mb) (Test/Ref)
1612 1724 CTRL
CHR19_8.58 CTD-2547N9 0.72 1.19 0.84
CHR19_36.92 CTC-416D1 0.69 1.06 0.91
CHR19_52.98 CTD-2571L23 0.68 1.12 0.88
CHR19_58.14 RP11-44L20 1.28 1.19 1.09
CHR19_59.39 CTD-2337J16 1.21 1.14 1.07
CHR19 59.94 RP5-1060P11 1.32 1.30 0.93
Matching genes (locus)
N/a
N/a
5 genes, FLJ40321 mapped 
at 19q 13.32, the others at 
19ql3.3 (CRX, GLTSCR2, 
EHD2, SEPWl)
N/a; mapped to 19ql3.41b 
3 genes all mapped to 
19ql3.4 (L1LRB5, 
L1LRB3,1LT8)
7 genes: K1R2DL5 mapped 
to 19pl3.3, and 6 
remaining all clustered at 
19ql3.4 (K1R2DL2, 
K1R2DL4, K1R2DS1, 
K1R2DS2, K1R2DS3, 
K1R2DS5)
Appendix 4 -  CHR22
CHR position 
(Mb)
CHR22 21.47 
CHR22 24.21
Clone
RP11-50L23
CTA-390B3
Fluorescence ratio 
(Mean)
Fluorescence Ratios 
(Test/Ref)
1612 1724 CTRL
0.71 0.78
0.69 1.04
1.07
0.83
Matching genes (locus)
N/a; Reported as 
“Redundant” 
MFNG (22ql2)
XXVI
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Appendix 5 - Sample list (N=135) of known polymorphic and "dodgy" clones
Cancer 2B6 NONSG6 D8 RP11-444B5
CTB-31C16 NONSG6E9 RP11-446P9
CTC-490G23 NONSG7A3 RP11-451G1
CTC-820M16 ÎNONSC7D6 
GTC-963K6 iNONSC7E4
RP11-455J20
RP11-457E6
iCTD-2337J16 ^NONSG8D3 = RP11-209H16 RP11-46G20
NONSC12A12 INONSG8F3 RP11-478K18
NONSC12A3 NONSG9D5 RP11-484P7
NONSC14A5 = RP11-462G12 NONSG9D6 RP11-489K4
NONSG15G12 RP11-105G19 RP11-497H16
NONSG16G6 RP11-10N17 RP11-505G12
NONSG16D7 RP11-11408 RP11-52G8
N0NSG1A3 RP11-11N15 RP11-543G4
NONSG24A3 = RP1-29012 RP11-11N16 RP11-551B22
NONSG24D1 RP11-12D3 RP11-557N21
NONSG27A1 RP11-13E1 RP11-6G14
NONSC29B9 RP11-142A12 RP1-171F15
NONSG29E10 RP11-144K9 RP1-179P12
NONSG2B11 RP11-147L13 RP11-84H6
NONSG2H4 RP11-164L18 RPl 1-87012
NONSG32E12 RP11-209H16 RP11-94E2
NQNSG32E8 RP11-220N20 RP11-96B2
NONSG32G1 RP11-229G4 RP1-215P15
nonsc35B9 RP11-23N11 RP1-29012
nonsc35F4 RP11-23N2 RP1-93N13
nonsc35H1 RP11-24H13 RP5-1060P11
nonsc35H6 RP11-24I19 RP5-1108M17
nonsc38B3 RP11-25F15 RP5-1109K10
NONSG3A10 RP11-270H4 SGI 1Mb BAG1A1
NONSG3B12 RP11-279F15 %C1 1Mb BAG2G10
nonsc40A2 RP11-285F23 SG10BAG-1Mbset-1G5
nonsc40E5 RP11-292F22 SG20BAG 1Mb setA4
nonsc40F10 RP11-296110 SG20BAG_1 Mb_setB2
nonsc41A3 RP11-2F9 SG20PAG 1Mb setD3
nonsc41F1 RP11-305D15 SG6BAG1Mbset1A6
nonsc43D9 RP11-312H1 SG6BAG1Mbset1B8
NONSG4G12 RP11-316G9 SG6PAG1Mbset1B4
NONSG4E7 RPl 1-324110 SGOBAGMbset 1E9
NONSG4F4 RP11-326G21 telomereAl
NONSG5G8 RP11-328M22 telomereB2
NONSG5E12 RP11-32G20 telomereB3
NONSG5G8 iRP11-368N21 telomereGI
NONSG5H5 RP11-374N3 telomereG4
1NONSG6A6 RP11-386L3 telomereG2
NONSG6D5 RPl 1-424011 telomereG4
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APPENDIX 6: ABBREVIATIONS 
~ An estimate, ‘approximation’
>
3’ UTR
A148T
A2B5
AA/C
AA/S
AAs
ABCBI
ABII
ABLI
Add/add
AKT
ALL
ANKRD22
APC
ARID3A
ARL6
ARL7
ARPs
AS
ASCL2
ASCL3
ASTN/ASTNI,-2
ATRNLl
AXINI
BA
BAG
BCAS4L
BCAS4
BCR
BHLH
More than
3 prime untranslated region
Alanine to threonine substitution at codon 148
Monoclonal antibody
Anaplastic astrocytoma/cell culture (sample)
Anaplastic astrocytoma/solid (sample) or biopsy 
Anaplastic astrocytoma(s)
ATP-binding cassette, sub-family B (MDR/TAP), member I 
Abl-interactor 1
V-abl, Abelson murine leukaemia viral oncogene homolog I 
Added (in a translocation)
V-akt murine thymoma viral oncogene homolog (I, 2 and 3)
Acute lymphocytic leukaemia
Ankyrin repeat domain containing 22
Adenomatosis polyposis coli
AT rich interactive domain 3A BRIGHT-like
ADP-ribosylation factor 6
ADP-ribosylation factor 7
Astrocyte restricted precursor
Angelman syndrome
Achaete-Scute complex homolog-like 2 family member 
Achaete-scute complex like 3 
Astrotactins/astrotactin I, -2 
Attractin-like 1
AxinI (a negative regulator o f the wingless-type member I
Brodmann areas
Bacterial active chromosome
Breast carcinoma amplified sequence 4 like
Breast carcinoma amplified sequence 4
Chromosome 22 breakpoint cluster region
Basic helix-loop-helix
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BlNl
Encoding bridging integrator 1 (initially identified 
interacting protein with features o f a tumor suppressor).
BLBP Brain lipid binding protein
BMP4 Bone morphogenetic protein 4
BMP5/BMP5.1 Bone morphogenetic protein 5
BMP8B Bone morphogenetic protein, member 8B
BNGF Nerve growth factor
bp Base pair(s)
BRAP BRCAl associated protein
BRCAl Encoding breast cancer 1, early onset.
BRCA2 Encoding breast cancer 2, early onset.
C9orfl57 Chromosome 9 open reading frame 157
C9orf96 Chromosome 9 open reading frame 96
CCNC Cyclin C
CCND Cyclin D
CCNDl Cyclin D1
CCNE Cyclin E
CCNE2 Cyclin E 2
CCNH Cyclin H
CD44
CDCIO
CDC25A
CDC25BandC20orf29
CDC25C
CDC42
CDC42BPB
CDKIO
CDK ll
CDK2
CDK3
CDK4
CDK6
CD44 antigen (homing function and Indian blood group system) 
Cell division cycle 10 
Cell division cycle 25A
Cell division cycle 25B and chromosome 20 open reading frame 29 
Cell division cycle 25C 
Cell division cycle 42 
CDC42 binding protein B 
Cyclin-dependent kinase (CDC2-like) 10 
Cyclin dependent kinase (CDC2-like) 11 
Cyclin dependent kinase 2 
Cyclin dependent kinase 3 
Cyclin dependent kinase 4 
Cyclin dependent kinase 6
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CDKNIB
CDKN2AandCDKN2B
CDKN2D
CDKs
cDNA
CFLPl
CGH
CHD6/CHD5
CHEK2
CHR
CIN
CKI
CKIT/c-KIT/c-Kit
CLK
C-MET
CML
CMTIA
CMTIB
C-MYC
CNAs
CNS
COR
Cot-1
CpG
CRABP/CRABPl
CRDs
CSEIL
CSF
CSPG4/NG2
CT
Cyclin dependent kinase lB/p27/KlPl 
Cyclin-dependent kinase 2A and cyclin-dependent kinase 2B 
Cyclin dependent kinase 2D  
Cyclin-dependent kinases
Cmplementary DNA (originally made from RNA transcript)
Cofilin pseudogene
Comparative genomic hybridisation
Chromodomain DNA binding protein 6
Checkpoint homolog 2
Chromosome
Chromosomal instability
CDK inhibitor
C-kit (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog)
CDC-like kinase 1 
Cellular MET (gene)
Chronic myeloid leukaemia 
Charcot-Marie-Tooth disease types 1A 
Charcot-Marie-Tooth disease types lAB  
Cellular MYC
(DNA) copy number aberration(s) (or alteration(s)
Central nervous system 
Cut off range
Human placental DNA, used to suppress cross hybridisation to 
repetitive DNA
Cytosine and guanine enriched regions in a chromosome 
Cellular retinoic acid binding protein/CRBPl 
Common regions o f deletion 
Chromosome segregation 1-like 
Cerebrospinal fluid
Chondroitin sulfate proteoglycan 4/neurogranin 
Computed tomography
XXX
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C-terminal
CTNNBl
DAPI
dATP
DBSs
DBX2
DCC
DCC.l
DCC/DCC.l
dCTP
DDXl
DDX26
del
dGTP
DMBTl
DMRTAl
DMs
DMSO
DMA
dNTP
DOP-PCR
DPP
dTTP
DTX3L/BBAP
dUTP
E1/E2
E2F
E2F1
E2F2
E2F5
EcoRI
EDTA
Carboxyl-terminal 
Catenin B1
4,6-diamidino-phenylindole 
Deoxyadenine triphosphate 
DMA-binding sites
Encoding developing brain homeobox 2.
Deleted in colon cancer
Deleted in colon cancer
Deleted in colon cancer genes
Deoxy cytosine triphosphate
DEAD (Asp-Glu-Ala-Asp) box polypeptide
DEAD box protein
Deletion
Deoxyguanine triphosphaste 
Deleted in malignant brain tumours-1
Methylthioadenosine phosphorylase (MTAP) and DBRT-like 1 
Double minute(s)
Dimethyl sulfoxide 
Deoxyribonucleic acid 
Deoxynucleoside(s) triphosphate(s)
Degenerate oligonucleotide primed PCR
Decapentaplegic
Deoxytymine triphosphate
Deltex 3-like or B-lymphoma- and BAL-associated protein 
Deoxyuracil triphosphate
Hypothetical end-point in developmental pathways of astrocytomas
Eukaryotic transcription initiation factors, member 2
Transcription factor E2F1
E2F transcription factor 2
E2F5 transcription factor
(Strain of) escherichia coli (restriction enzyme) 1
Ethylene-diamino-tetra-acetic acid (anticoagulant, protease inhibitor,
inhibits PCR reaction, washing solution
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EFNA
EFNA2
EFNA5
EFNB3
EGF/EGFR
EIF4
EIF4A1
EIF4A-II
ELAV2
EMCN
EMX2
ENl
EN2
ENCR
EN02
EPH3
EPHA7
ERBB2/Erbb2
ERBB4
ERPs
ESP 10
ESR
Et OH
F-IO(HAM),
ECS
FES
FGF
FGFR3
Fgfr3-
Fgfr3+)
FGR
FIBCDl
FIG
Ephrin-A
Ephrin-A2
Ephrin-A5
EphrinB3
Epidermal growth factor /receptor 
Eukaryotic translation initiation factor 4 
Eukaryotic initiation factor 4, A1 
Eukaryotic transcription initiation factors 
Embryonic lethal, abnormal vision 2 
Endomucin-like sialoprotein 
Mammalian homolog o f empty spiracles 2 
Engrailed 
Engrailed-2
European Network o f Cancer Registries 
Neural enolase 2 gamma 
Ephrin receptor 3 
Ephrin A7
V-erb-b erythroblastic leukaemia viral oncogene homolog 2 
V-erb-a erythroblastic leukaemia viral oncogene homolog 4 
Ependymal restricted cells
Hypothetical protein LOC441583.1 (similar to radixin
Estrogen receptor 1
Ethyl alcohol
Nutrient Mixture
Fetal calf serum
Feline sarcoma viral homolog
Fibroblast growth factor
Fibroblast growth factor receptor 3
Fibroblast growth factor receptor type three (negative)
Fibroblast growth factor receptor type three (positive) 
Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog 
Fibrinogen C domain containing 1 
Fused in glioma
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FISH
FLJl 0385
FLJ23311
FLJ40296
FLJ45721
FLJ46675
FRA16D
FRA3B
FRA7G
FST
FRP
GO
G1
G2
GABl
GAPD
GBAS
GBMs
GBX2
GDP
GFAP
GFOCs
GFPs
GLI
GLTSCRl
GLTSCR2
GOIs
Grb2
GRIKl
GRN
GRPs
GTF2H2
GTF2H3
Fluorescence(or fluorescence) in situ hybridisation
Codes for similar to WDR79 domain containing
E2F-related hypothetical protein
Hypothetical protein FLJ40296
Codes hypothetical protein (often o f the same name!)
Codes for similar to dynein 
Fragile site 
Fragile site 3B 
Fragile site 7G 
Follistatin
Fluorescence ratio profile(s)
Growth arrest (resting) phase o f mitotic cell cycle 
Resting state (phase)
Second growth
G-protein receptor binding 2 associated binding protein 1 
Glyceraldehydes-3-phosphate dehydrogenase 
Glioblastoma amplified sequence 
Glioblastoma multiforme(s)
Homeobox gene (a vasoactive intestinal peptide receptor)
Glycerophosphodiester phopsphodiesterase domain containing
Glial fibrillary acidic protein
Gliofibrillary oligodendrocytes
GTPase-fusion proteins
Glioma-associated oncogene homolog 1
Glioma tumour suppressor candidate region, genes 1
Glioma tumour suppressor candidate region, genes 2
Gene(s) o f  interest
Encoding growth factor receptor-bound protein 2.
Glutamate receptor, ionotrophic, kinase 1 
Granulin
Glial restricted precursors
General transcription factor 11, polypeptide 2
General transcription factor 2 H, polypeptide 3
XXXlll
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GTP
GTPase
GUKl
Gy
H&  E
H2B
HBSS
HCMV
HDAC4
HDACs
HDLBP
HES7
HEY2
HGAs
HGF/SF
HLH
HMG
HMGAs
HNPCCl
FrNPCC2
HNPP
HOXA
HOXAl
HOXA13
HOXB
HOXD
HPE
HRAS
H-ras
HSR
hTERT
lARC
Guanine triphosphaste 
GTPase activating protein 
Guanylate kinase 1 
Gray (unit o f radiation)
Haematoxyline and eosin 
H2B histone family, member S 
Hank’s Balanced Salts 
Human cytomegalovirus
Histone deacetylase C4 (a component o f the p53-dependent DNA- 
damage response)
Histone deacetylases
High-density lipoprotein binding protein
Hairy/enhancer o f split, homolog 7
Hairy/enhancer o f split related with YRPW motif 2
High-grade astrocytomas
Hepatocyte growth factor/scatter factor
Helix-loop-helix
High malignancy grade
High malignancy grade astrocytomas
Hereditary nonpolyposis colorectal cancer type 1
Hereditary nonpolyposis colorectal cancer type 2
Hereditary neuropathies with liability to pressure palsies
Homeobox genes
Homeobox A1
Homeobox A13
Homeobox class B genes
Homeobox D
Holoprosencephaly
Harvey rat sarcoma viral oncogene homolog 
Ras-viral oncogene homolog 
Homogeneous staining region 
Catalytic subunit o f the telomerase enzyme 
International Agency for Research on Cancer
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IC D -0
ICH
IDs
ids.(image format)
IFI35
IFITMl
IFNBl
IGF
IGFBP2
IGFBP5
Igl
IPFI
IPW
IRS3
ISH
ISLl
Kb
KCNIP4
Ki-67/MIB
KPS
KREMENI
KRT8
EATS 2
LDHA
EGA
EGII
EIMK2
EMGAs
EN2
EOC440374 
Log (log)
International classification of disease for oncology 
Institute o f Child Health 
Imprinting defects
File format for storage and processing o f image data using QUIPs 
software
Interferon induced protein 35 
Interferon induced transmembrane protein I 
Interferon, beta polypeptide I 
Insulin growth factor
Insulin-like growth factor receptor binding protein 2
Insulin-like growth factor binding protein 5
Immunoglobulin light chain, lambda
Insulin promoter factor I
Imprinted gene in the PWS region gene
HRBE, encoding HIV-1 Rev binding protein-like.
In situ hybridisation
Motor neuron-specific Islet-1 transcription factors 
Kilo (10^) bases (nucleoside)
Potassium voltage-gated (Kv) channel interacting protein 4
MK167, encodes antigen identified by nomoclonal antibody Ki-67
Kamofsky performance score
Kringle containing transmembrane protein I
Keratin 8
Earge tumour suppressor, homolog 2 
Eactate dehydrogenase A 
Eow-grade astrocytoma(s)
Eeucine-rich gene glioma activated-1 
Encdes receptors for WNT/catenin-signaling pathways 
Eow malignancy grade astrocytomas 
Eiquid nitrogen
Encoding similar to RAB43, member o f  Ras oncogene family 
Eogarithm
XXXV
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LOH
LRP
LTSs
M (phase)
MAGEL2
MAP2K6
MAP3K
MAP3K6
MAP3K7
MAP4K2
MAP4K5
MAPKAP5
MB (Mb)
MC4-R
mCGH
MCRD
MCRO
MDA
MDM2
MESPl
MFISH
MGC17330
MGMT
MGSTl
MIF
MIN
MIST
MKRN3
Ml (ml)
Pg
pi
MLCK
Loss of heterozygosity
Low density lipoprotein-related protein 1
Long-term survivors
Mitosis
Melanoma antigen-like gene 2
Mitogen-activated protein kinase kinase 6
Mitogen-activated protein kinase kinase kinase 5
Mitogen-activated protein kinase kinase kinase 6
Mitogen-activated protein kinase kinase kinase 7
Mitogen-activated protein kinase kinase kinase kinase 2
Mitogen-activated protein kinase kinase kinase kinase 5
Mitogen-activated protein kinase-activated protein kinase 5
Million bases
Melanocortin 4 receptor
Metaphase comparative genomic hybridisation
Minimum common regions o f deletion
Minimum common regions of overlap
Multiple displacement amplification
Murine double minute 2
Mesodermal posterior I
Multi-colour/multiplex fluorescent/fluorescence in situ hyb.
Hepatocyte growth factor-like
O-6-methylguanine DNA methyl transferase
Microsomal glutathione S-transferase I
Macrophage migration inhibitory factor
Microsatellite instability
Mast cell immmunoreceptor transducer
Makorin ring finger protein
Millilitre
Microgram
Licrolitre
Myosin light chain kinase
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MLH3
MM (mM)
MMR
MNOPs
MPAG
MPE600
MRC
MRC BR05
MRI
mRNA
MRPL28
MSHl
MSH2
MSH2
MSXl
MTAP
mTOR
MYBL2
MYCN
MYODl
NBCCS
NCBI
NEOl
NEOROD
NEURODl
NEUROD2
NEUROG
NEUROGl
NFl
NF2
MUTE homolog 3 
Millimolar 
Mismatch repair
Motomeuron-oligodendrocyte precursors 
Malignant primary adult-onset glioma
Breast cancer cell line o f known cytogenetic abnormalities, supplied 
by Vysis and used as positive control in CGH experiments 
Medical research council
Multi-centre din. trial (MRC Brain Tumour Working Party, 2001 
Magnetic resonance imaging 
Messenger RNA
Mitochondrial ribosomal protein L28 
MutL homolog 1 
MutS homolog 2
Muscle segment homeobox homolog 2 
Muscle segment homeobox 1 homolog 
Methylthioadenosine phosphorylase 
Mammalian target o f rapamycin
V-myb, the myeloblastosis viral oncogene related (avian)-like 2
V-myc myelobl. viral oncogene related, neuroblastoma derived
Myogenic factor 3
Nevoid basal cell syndrome
National Centre for Bio Informatics (USA)
Neogenin homolog 1 
Neurogenin
Neurogenin differentiation 1 
Neurogenic differentiation factor 2 
Neurogenin 
Neurogenin 1
Neurofibromatosis 1 (gene)
Neurofibromatosis 2 (bilateral acoustic neuroma)
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ng
NHLH
NHLH2
NHS
NIDI
NIN
Nkx2.2
NKX2-9
NKX3-1
NKX3-2
NKX6-1
NKXX2.2
NMBR
NME3/DR-nm23
NME4andDECR2
NMI
NNMT
NOG
NP-40
NPPB
NRG!
NRP
NRPl
NSC
Nt
NTF3
NTF5
N-WASP
N-WASP/WASL
NXTl
02A
0LIG2
0LIG3
Nanogram (10’ grams)
Nascient helix-ioop-helix 
Nascient helix-loop-helix 2 
National health service 
Entactin or nidogen 
Nucleotide instability
NK2 related transcription factor, members 2 
NK2 transcription factor related, locus 9 
NK3 transcription initiation factor, locus 1 
NK3 transcription factor related, locus 2 
NK6 transcription factor related, locus 1 
NK2 transcription factor related, locus 2 
Neuromedin B receptor 
Non-metastatic cell 3
NME23-H4, encoding non-metastatic cells 4, protein expressed in 
N-myc and ST AT interactor 
Nicotinamide N-methyltransferase 
Noggin
Nonindet P-40 (cell lysis buffer)
Natriuretic peptide precursor B 
Neuregulin 1
Neuron restricted precursors 
Neuropilin 1 
Neural stem cell 
Nucleotide 
Neurotrophin 3 
Neurotrophin 5
Neural Wiscott-Aldrich Syndrome 
Wiscott-Aldrich syndrome-like 
Neurotrophin factor 2 (NFT2) -  like export factor 1 
Oligodendrocyte type-2 astrocyte precursors 
Oligodendrocyte lineage transcription factor 2 
Oligodendrocyte transcription factor 3
XXXVI11
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pl6INK4A, pl4ARF
p27KIPl/p27
p53
PAHs
p-arm
PAX2
PAX3
PAX6
PAX7
PBS buffer
PC4
PCR
PCV
PDCDl
PDGF
PDGFC
PDGFR
PDGFRA
PER7
PFS
PGYI
PHKGl
PI3K
PIK3CA
PKDl
PMSl
PMS2
PP2A
pRB
PRG2andSLC43A3
PROMl
PTCH
Alias of CDKN2AandCDKN2B
CDKNIB, encoding cy cl in-dependent kinase inhibitor IB (Kipl) 
P53 protein
Polyaromatic hydrocarbons
The short arm of a chromosome
Paired box 2
Paired box 3
Paired box 6
Paired box 7
Phosphate-buffered-saline
Activated RNA polymerase II transcription factor 4
Polymerase chain reaction
Procabazine, cisplatin, and vincristine
Programmed cell death gene
Platelet derived growth factor
Platelet derived growth factor C
Platelet derived growth factor receptor
Platelet derived growth factor receptor-a
Peroxismal biogenesis factor 7
Progression-free survival
P-glycoprotein 1
Phosphorylase kinase gamma 1
Phosphoinositide-3-kinase (3 catalytic subunits, alpha/beta/gamma
Phosphoinositide-3-kinase, catalytic, alpha polypeptide
Encoding polycystic kidney disease 1 (autosomal dominant)
Postmeiotic segregation increased 1
Postmeiotic segregation increased 2
Protein phosphatase 2A
Retinoblastoma protein
For proteiglycan 2 and solute carrier 43, member 3 polypeptide 
Prominin 1
Human homolog o f patched
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PTEN/MMACl
PTN
PTPNl
PVCs
PWS
PWS/AS-SRO
QALY
q-arm
QIAgen
QUIPS
RACl
Ran
RARB
Ras
Ras-GTP
RBI
RBLl (pl07) 
R B L 2(pl30)
RC2
Rheb
RNA
ROBOl
RP11-61G19
RT
RT
RTK
RUNXl and R U N X l.l 
S
S-lOOb
S-lOOb
Phosphatase and tensin homolog/mutated in multiple adeno Ca 1 
Pleiotrophin
Protein tyrosine phosphatase, non-receptor type 1 
Polyvinyl chrlorides 
Prader-Willi syndrome
PWS/Angelman syndrome-smallest region o f overlap
Quality adjusted life year
The long arm of a chromosome
Brand-name of a scientific company manufacturing ‘quantitative 
image appliances’
Quantitative Image Processing System
Encoding ras-related C3 botulinum toxin substrate 1 (rho family, 
small GTP binding protein R ad )
Encoding v-raf-1 murine leukaemia viral oncogene homolog 1 
Retinoic acid receptor, beta 
Member o f Ras oncogene family
Ras-GTPase activating protein SH3 domain-binding protein 
Retinoblastoma 1 
Retinoblastoma like 1 
Retinoblastoma like 2
RGN, encoding regucalcin (senescence marker protein-30)
Ras homolog enriched in brain 
Ribonucleic acid 
Roundabout, homolog 1 
BAG clone 
Radiotherapy 
Room temperature 
Receptor tyrosine kinase
Runt-related transcription factor 1 (acute myeloid leukaemia I) 
Synthesis (as o f DNA in mitotic phase of a cell cycle)
SI GO calcium binding protein, beta (neural)
SI GO calcium binding protein beta (neural)
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SAS
SCAl/ATXN
SCX/bHLH.2
SEER
SEGA
SEMA5A
SERPINE/GDNPF
SERTADl
SGZ
She
SHH
SIMl
SKY
SLC lA l
SLC2A3/GLUT-3
SLITI
SLIT2
SLIT3
SMADl
SMAD6
SMAD7
SMADs
SMO
SMOX
SNARE
SNURF-SNRPN
Sos
SOX12/SOX20
Sarcoma amplified sequence 
Spinocerebellar ataxia/ataxin
Scleraxis, the basic helix loop helix dimérisation region 2 
Surveillance, Epidemiology and End Results 
Subependymal giant cell ependymomas 
Semaphorin
Serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 2, or glial-derived neurite 
promoting factor, protease inhibitor 7 
SERTA domain containing 1 
Subgranular zone
Encoding 'Src homology 2 domain containing transforming prot.
Sonic hedgehog
Single-minded homolog 1
Spectral karyotyping
Solute carrier family 1, member 1
Solute carrier family 2 (facilitated glucose transporter), member 3 
Slit homolog 1 
Slit homolog 2 
Slit 3
Mothers against decapentaplegic homolog 1 
Mothers against decapentaplegic homolog 6 
Mothers against decapentaplegic (DPP) homolog 7 
Mothers against decapentaplegic (DPP) homologs 
Smothered
Hypothetical gene which codes for polyamide oxidases (Wang et al., 
2003) that may have roles in cell proliferation and survival 
Similar to RIKEN cDNA A030009B12 gene.
Small ribonucleoproteins-N-upstream reading frame-small
ribonucleoproteins-N
Son o f  sevenless homolog
SRY-BOX 12
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SPARC AADH, secreted protein, acidic, cysteine-rich
SSC Buffer made o f sodium chloride and sodium citrate
SUFU Suppressor o f fused
SV Subventricular
SV40 Simian virus 40
SV40 ER SV40 early region
SV40T Simian virus 40 large-T (oncoprotein)
SYMl Symphalangism 1
SYNSl Synostoses 1
T/t Translocation
TAB Tris-acetate-EDTA electrophoresis buffer
TCF21 Transcription factor 21 gene
TDGFl Teratocarcinoma-derived growth factor 1
TFIIHl Transcription factor 2H, member 1
TGF-b/TGFB Transforming growth factor (ligand) beta
TGFR-beta Transforming growth factor receptor-beta
TIFl Thyroid nuclear factor / thyroid transcription factor 1
T1MP3 Tissue inhibitors o f metalloproteinase 3
TNFAIP3 TNF alpha-induced protein 3
TNFSFII/OPGL TNF (ligand) superfamily, member 11/osteoporin
TOR Target of rapamycin
TP53 Tumour protein p53
TP53BP1 Tumour protein p53 binding protein, 1
TP73 Tumour protein 73
TSCl Tuberous sclerosis 1 (merlin) (gene)
TSC2 Tuberous sclerosis 2 (tuberin) (gene)
TSGs Tumour suppressor genes
TYRG3 Tyrosine-protein kinase receptor TYR03 precursor
UBE3A Ubiquitin 3E
UCL University College London
UNC-40 Uncoordinated (centrosome movement)-40 (deleted in colon Ca)
UNC-6 Uncoordinated (centrosome movement)-6
UPD Uniparental disomy
xlii
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UV
V
V-AKT/AKTl
VAXl
VEGF/ -alpha /  -beta 
VEGFR/KDR
VZ
WDR79
WHO
WHO grade I 
WHO grade II 
WMPCs 
WNT 
WNT2B
WRDandSHSBGR
XBF-2
ZNF33A
Ultra violet (light source)
Volts
Human homolog o f the murine thymoma viral oncogene
Ventral anterior homeobox 1
Vascular endothelial growth factor/ -alpha / -beta
Human homolog of the proto-oncogene c-kit (v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog, and vascular
endothelial growth factor receptor or kinase insert domain receptor
Ventricular zone
WD repeat domain 79
World Health Organisation
Pilocytic astrocytomas
Astrocytoma
White matter precursor cells 
Wingless type
Wingless-type MMTV integration site, member 2B 
SH3 domain binding glutamic acid rich protein 
Xenopus brain factor 2 
Zinc finger protein 33 A
xliii
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Tumour ID
<
g
c/5
<-J00O
3o
sn
GBM/S3044
GBM/S2848/mda*
GBM/C1397
GBM/1719/mda
GBM/S1575
GBM/C2394
GBM/C2685
Metaphase CGH data
None
I -osses
Ip33-pl3, Iq24-q31, 2q22-q24, 2q31-q32, 3q24-q25, 4pl5.1- 
pl4; 4ql3-q32; 5ql3; 5ql4-q23; 6ql l-q22; 7p21-pl2; 7q21; 
7q22-q31; llq l4 ;  12ql5-q21; 12q24.1-q24.3; 18qll.2-ql2
Xp22.3-q28
I lp22; 3p l2-p ll; 4q22-q24; 4q26-q27; 5ql4-q22; 9p24;
I 13q21-q31
I 2p ll.2-ql 1.2; 2 |^ p 24r3p d Y -p l f;lp 26-p 25T 3^ 8; 4 p l^  
I 4q ll-q l2 ; 4q34-q35; 5pl5.3; 6p25; 6q22; 8p23; 8q24.2- 
I  q24.3; 9p24-p23, 10pl5; llp l5 ;  llq24; I2pl3; 12q24.3;
I  13q34; 18pll.3; 18q22-q23; 20pl3; 21q22
Ip36.3-p36.1; 16pl3.3-p!3.2; 16qll.l-qllJ5; 16q24; 17pl3; 17q24- 
q25; 19pl3.3-pl2; 19q 13.3-q13.2; 22ql3; Xp22.3-q28
Ip36.3-p33; 2q37; 9ql2, 9q34; I0q25-q26; 13q34; 14q31-q32; 
15qll.2; 16qll.2; 17pl3-pl2; 17q24-q25; I9pl3.2-ql3.3; 20ql3.2; 
22^11.2-q 13; Xp22.3-q21 ; Xq21 -q28 
None
fp36.2^p32- T^Tîik q  13^42; 22p 13-qT3-1^2272Z^!7
Ip35-p34.3; 9q33-q34; 16pl3.2-pl 1.2; 17pl3- q24, 19pl3.3-pl2; | 
19q 12-q 13.3; 22q 11.2-q 13; Xp22.1 -p21 |
Ip31-p22; 2q21-q24; 2q37; 7p21-qll.2; 7q21-q32; 12ql3- 
q21; 18pll.3 
X^22.2-q27 ‘
None
*, Tumours that had <3 CNAs (copy number alterations) in the autosomes (n=5).
Iql2; 9q ll-q l3; lOpl 1.2-q 11.2; 10q21; 10q23; 10q26; 13ql l ; |  
15qll.2; 16pl3.3-pl3.2; 16ql 1.1-ql 1.2 j
None
■f5qlT2-qT2
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